[XLS] · Web viewWang X, et al. J Med Chem. 2013, 56(6), 2700-2704. T2001 PF 573228 869288-64-2 C22H20F3N5O3S PF-573228 is an ATP-competitive inhibitor of FAK with IC50 of 4 nM in

ID Name CAS FormulaT6739 Zoledronic Acid 118072-93-8 C5H10N2O7P2

T6737 Zaltoprofen 74711-43-6 C17H14O3S

T6694 Tamibarotene 94497-51-5 C22H25NO3

T6680 Staurosporine 62996-74-1 C28H26N4O3

T6671 Sirtinol 410536-97-9 C26H22N2O2

T6669 SH-4-54 1456632-40-8 C29H27F5N2O5S

T6644 Rolipram 61413-54-5 C16H21NO3

T6643 Ro 31-8220 Mesylate 138489-18-6 C25H23N5O2S.CH4O3S

T6620 Ospemifene 128607-22-7 C24H23ClO2

T6569 L-Mimosine 500-44-7 C8H10N2O4

T6558 KW-2478 819812-04-9 C30H42N2O9

T6537 HO-3867 1172133-28-6 C28H30F2N2O2

T6509 Galeterone 851983-85-2 C26H32N2O

T6501 Fludarabine Phosphate 75607-67-9 C10H13FN5O7P

T6485 Embelin 550-24-3 C17H26O4

T6483 EHT 1864 754240-09-0 C25H29Cl2F3N2O4S

T6433 CAY10505 1218777-13-9 C14H8FNO3S

T6410 Bexarotene 153559-49-0 C24H28O2

T6403 BAF312 (Siponimod) 1230487-00-9 C29H35F3N2O3

T6343 Geldanamycin 30562-34-6 C29H40N2O9

T6337 RepSox 446859-33-2 C17H13N5

T6329 INO-1001 3544-24-9 C7H8N2O

T6324 BIX02188 1094614-84-2 C25H24N4O2

T6321 477600-75-2 C16H20N6O

T6315 MLN8054 869363-13-3 C25H15ClF2N4O2

T6309 AZ 960 905586-69-8 C18H16F2N6

T6305 908112-43-6 C23H27F3N4O3

T6300 WP1130 856243-80-6 C19H18BrN3O

Tofacitinib (CP-690550,Tasocitinib)

SNX-2112 (PF-04928473)

T6278 Sotrastaurin 425637-18-9 C25H22N6O2

T6276 NU7441 (KU-57788) 503468-95-9 C25H19NO3S

T6275 803712-79-0 C20H19N3O.CH4O3S

T6271 Tipifarnib 192185-72-1 C27H22Cl2N4O

T6270 Trichostatin A (TSA) 58880-19-6 C17H22N2O3

T6266 PP2 172889-27-9 C15H16ClN5

T6254 Idasanutlin (RG-7388) 1229705-06-9 C31H29Cl2F2N3O4

T6240 827022-33-3 C24H29N7O2.C2H6O4S

T6239 827022-32-2 C24H29N7O2.HCl

T6235 388082-77-7 C29H26ClFN4O4S.2C7

T6233 Entinostat (MS-275) 209783-80-2 C21H20N4O3

T6230 Imatinib (STI571) 152459-95-5 C29H31N7O

T6228 Irinotecan 97682-44-5 C33H38N4O6

T6227 91599-74-5 C27H32ClN5O5

T6226 357166-30-4 C20H21N5O6.5/2H2O.2

T6225 Adenine hydrochloride 2922-28-3 C5H5N5.HCl

T6224 Iniparib (BSI-201) 160003-66-7 C7H5IN2O3

T6223 U0126-EtOH 1173097-76-1 C18H16N6S2.C2H6O

T6218 Selumetinib (AZD6244) 606143-52-6 C17H15BrClFN4O3

T6217 LFM-A13 244240-24-2 C11H8Br2N2O2

T6216 Abiraterone 154229-19-3 C24H31NO

T6215 Abiraterone Acetate 154229-18-2 C26H33NO2

T6212 Combretastatin A4 117048-59-6 C18H20O5

T6202 DAPT (GSI-IX) 208255-80-5 C23H26F2N2O4

T6199 LEE011 1211441-98-3 C23H30N8O

T6197 PJ34 344458-19-1 C17H17N3O2

T6189 PD0325901 391210-10-9 C16H14F3IN2O4

T6187 TDZD-8 327036-89-5 C10H10N2O2S

T6185 Gambogic Acid 2752-65-0 C38H44O8

Obatoclax Mesylate (GX15-070)

Palbociclib (PD0332991) IsethionatePalbociclib (PD-0332991) hydrochlorideLapatinib (GW-572016) Ditosylate

Benidipine hydrochloridePemetrexed Disodium Hydrate

T6184 252916-29-3 C18H18N2O3

T6173 BI 2536 755038-02-9 C28H39N7O3

T6170 Elesclomol (STA-4783) 488832-69-5 C19H20N4O2S2

T6168 ZSTK474 475110-96-4 C19H21F2N7O2

T6165 Bardoxolone Methyl 218600-53-4 C32H43NO4

T6154 SU11274 658084-23-2 C28H30CIN5O4S

T6136 Canertinib (CI-1033) 267243-28-7 C24H25ClFN5O3

T6131 Pimasertib (AS-703026) 1236699-92-5 C15H15FIN3O3

T6124 Mubritinib (TAK 165) 366017-09-6 C25H23F3N4O2

T6117 Tivantinib (ARQ 197) 905854-02-6 C23H19N3O2

T6116 Bleomycin Sulfate 9041-93-4 C55H85N17O25S4

T6110 YM201636 371942-69-7 C25H21N7O3

T6108 Ki16425 355025-24-0 C23H23ClN2O5S

T6100 Torin 2 1223001-51-1 C24H15F3N4O

T6092 AZD8931 (Sapitinib) 848942-61-0 C23H25ClFN5O3

T6090 Belnacasan (VX-765) 273404-37-8 C24H33ClN4O6

T6084 LY2603618 911222-45-2 C18H22BrN5O3

T6082 SSR128129E 848318-25-2 C18H15N2O4.Na

T6078 Saracatinib (AZD0530) 379231-04-6 C27H32ClN5O5

T6076 EPZ015666 1616391-65-1 C20H25N5O3

T6075 152044-54-7 C27H41NO6S

T6070 Rigosertib (ON-01910) 1225497-78-8 C21H24NNaO8S

T6066 SCH772984 942183-80-4 C33H33N9O2

T6061 LMK-235 1418033-25-6 C15H22N2O4

T6059 GSK343 1346704-33-3 C31H39N7O2

T6057 URMC-099 1229582-33-5 C27H27N5

T6052 GW441756 504433-23-2 C17H13N3O

T6047 LY2228820 862507-23-1 C24H29FN6.2CH4O3S

T6045 Torin 1 1222998-36-8 C35H28F3N5O2

TSU-68 (SU6668, Orantinib)

Epothilone B (EPO906, Patupilone)

T6037 E-64 66701-25-5 C15H27N5O5

T6030 XL388 1251156-08-7 C23H22FN3O4S

T6028 PF-477736 952021-60-2 C22H25N7O2

T6027 847499-27-8 C21H28BN3O5

T6024 1265229-25-1 C20H16N6O

T6023 Nutlin-3a 675576-98-4 C30H30Cl2N4O4

T6019 Volasertib (BI 6727) 755038-65-4 C34H50N8O3

T6017 OSI-906 (Linsitinib) 867160-71-2 C26H23N5O

T6016 Maraviroc 376348-65-1 C29H41F2N5O

T6014 FRAX597 1286739-19-2 C29H28ClN7OS

T6013 Z-VAD-FMK 187389-52-2 C22H30FN3O7

T6007 Birinapant 1260251-31-7 C42H56F2N8O6

T6006 128517-07-7 C24H36N4O6S2

T6005 Z-DEVD-FMK 210344-95-9 C30H41FN4O12

T6002 915087-33-1 C21H16F4N4O2S

T3695 Pepstatin 26305-03-3 C34H63N5O9

T3678 Entrectinib 1108743-60-7 C31H34F2N6O2

T3677 GSK2879552 1401966-69-5

T3664 THZ1 1604810-83-4 C₃₁H₂₈ClN₇O₂

T3661 ACY-241 1316215-12-9 C24H26ClN5O3

T3659 AZD3759 1626387-80-1 C22H23ClFN5O3

T3658 TAS-102 733030-01-8 C10H11F3N2O5·C9H11C

T3647 HTHQ 148081-72-5 C15H24O2

T3643 HMN-176 173529-10-7 C20H18N2O4S

T3634 1421373-66-1 C29H37N7O5S

T3633 LY3039478 1421438-81-4 C22H23F3N4O4

T3630 Relugolix 737789-87-6 C29H27F2N7O5S

T3626 Acalabrutinib 1420477-60-6 C26H23N7O2

T3623 Cobimetinib 934660-93-2 C21H21F3IN3O2

CEP-18770 (Delanzomib)CH5183284 (Debio-1347)

Romidepsin (FK228, Depsipeptide)

Enzalutamide (MDV3100)

C23H28N2O2

AZD-9291 mesylate

T3621 Brigatinib 1197953-54-0 C29H39ClN7O2P

T3615 Evofosfamide 918633-87-1

T3600 Licochalcone A 58749-22-7 C21H22O4

T3550 Ensartinib 1365267-27-1 C25H25Cl2FN5O3

T3549 CC-122 1015474-32-4

T3548 Epacadostat 1204669-58-8

T3441 Anlotinib 1058156-90-3 C23H22FN3O3

T3432 Cinobufagin 470-37-1 C26H34O6

T3419 Chelerythrine chloride 3895-92-9 C21H18ClNO4

T3418 Demethylzeylasteral 107316-88-1 C29H36O6

T3398 Icaritin 118525-40-9 C21H20O6

T3389 TRX818 1256037-58-7

T3380 Homoharringtonine 26833-87-4 C29H39NO9

T3356 50-76-0 C62 H86 N12 O16

T3353 Niraparib hydrochloride 1038915-64-8 C19H20N4O

T3352 XL413 1169558-38-6

T3339 Sophoridine 6882-68-4 C15H24N2O

T3338 Azd6738 1352226-88-0 C20H24N6O2S

T3330 22255-22-7 C17H18O3

T3318 Wogonoside 51059-44-0 C22H20O11

T3314 Perillyl alcohol 536-59-4 C10H16O

T3299 AT-406 1071992-57-8 C32H43N5O4

T3289 Amifostine 20537-88-6 C5H15N2O3PS

T3280 88416-50-6 CH10Cl2Na2O10P2

T3274 S49076 1265965-22-7 C22H22N4O4S

T3261 NVP-TNKS656 1419949-20-4 C27H34N4O5

T3260 3PO 13309-08-5 C13H10N2O

T3258 Ponesimod 854107-55-4 C23H25ClN2O4S

T3257 UNC0638 1255580-76-7 C30H47N5O2

C9H16Br2N5O4P

C14H14N4O3

C11H13BrFN7O4S

C16H11FNNa2O5P

Actinomycin D

C14H12ClN3O2

3,5,4'-Trimethoxystilbene

Disodium clodronate tetrahydrate

T3256 745017-94-1 C39H65N5O8

T3241 (R)-(+)-Limonene 5989-27-5 C10H16

T3218 Napabucasin 83280-65-3 C14H8O4

T3214 NS-398 123653-11-2 C13H18N2O5S

T3211 PKC-412(Midostaurin) 120685-11-2 C35H30N4O4

T3210 AZD-3965 1448671-31-5 C21H24F3N5O5S

T3209 AMG-337 1173699-31-4 C23H22FN7O3

T3207 Briciclib 865783-99-9 C19H23O10PS

T3205 UF010 537672-41-6 C11H15BrN2O

T3204 BML-210 537034-17-6 C20H25N3O2

T3201 WDR5-0103 890190-22-4 C21H25N3O4

T3200 DB07268 929007-72-7 C17H15N5O2

T3199 PTACH 848354-66-5 C20H26N2O2S2

T3196 GNF-7 839706-07-9 C28H24F3N7O2

T3195 CVT-313 199986-75-9 C20H28N6O3

T3193 937039-45-7 C20H25N3O2

T3190 PIK-inhibitors 371934-59-7 C19H17N5O2

T3188 NSC5844 140926-75-6 C20H16Cl2N4

T3186 161058-83-9

T3185 R112 575474-82-7 C16H13FN4O2

T3184 Kevetrin hydrochloride 66592-89-0 C5H10ClN3S

T3181 SW044248 522650-83-5 C22H23N5O2S

T3168 MN-64 92831-11-3 C18H16O2

T3157 COH29 1190932-38-7 C₂₂H₁₆N₂O₅S

T3153 MLN1117 1268454-23-4 C19H17N6O3

T3147 5108-96-3 C5H12N2S2

T3143 Mesterolone 1424-00-6 C20H32O2

T3137 13103-34-9 C30H44O3

T3130 1255-49-8 C28H36O3

MonoMethyl auristatin F (MMAF)

Pimelic diphenylamide 106

NU2058 C12H17N5O

Pyrrolidinedithiocarbamate ammonium(PDTC)

Boldenone UndecylenateTestosterone Phenylpropionate

T3129 Testosterone Enanthate 315-37-7 C26H40O3

T3122 (+)-Fangchinoline 436-77-1 C37H40N2O6

T3117 Marbofloxacin 115550-35-1 C17H19FN4O4

T3113 849217-64-7 C34H34F2N4O6

T3111 LY2835219 mesylate 1231930-82-7 C27H32F2N8.CH4O3S

T3109 SP600125 129-56-6 C14H8N2O

T3108 CUDC-101 1012054-59-9 C24H26N4O4

T3105 PFK-158 1462249-75-7 C18H11F3N2O

T3100 GSK J4 hydrochloride 1373423-53-0 C24H27N5O2.HCl

T3099 EPZ5676 1380288-87-8 C30H42N8O3

T3094 PS-1145 431898-65-6 C17H11ClN4O

T3090 Abietic Acid 514-10-3 C20H30O2

T3089 154-42-7 C5H5N5S

T3082 SGC0946 1561178-17-3 C28H40BrN7O4

T3081 EPZ004777 1338466-77-5 C28H41N7O4

T3080 Pyridone 6 457081-03-7 C18H16FN3O

T3079 GSK1838705A 1116235-97-2 C27H29FN8O3

T3078 SGI-1776 free base 1025065-69-3 C20H22F3N5O

T3077 SB216763 280744-09-4 C19H12N2O2Cl2

T3076 GLPG0634 analogue 1206101-20-3 C21H23N5O3S

T3075 FLI-06 313967-18-9 C25H30N2O5

T3074 CHIR98014 556813-39-9 C20H17Cl2N9O2

T3073 PF670462 950912-80-8 C19H22Cl2FN5

T3072 XL019 945755-56-6 C25H28N6O2

T3071 GZD824 1257628-77-5 C29H27F3N6O

T3070 GANT61 500579-04-4 C27H35N5

T3067 Tideglusib 865854-05-3 C19H14N2O2S

T3066 S-Ruxolitinib 1160597-27-2 C17H18N6

T3063 PD-173955 260415-63-2 C21H16Cl2N4OS

Foretinib (GSK1363089)

2-Amino-6-mercaptopurine

T3062 WIKI4 838818-26-1 C29H23N5O3S

T3061 PF06463922 1454846-35-5 C21H19FN6O2

T3060 105628-07-7 C14H18ClN3O2S

T3059 AP26113 1197958-12-5 C26H34ClN6O2P

T3058 SMI-4a 438190-29-5 C11H6F3NO2S

T3057 UNC1999 1431612-23-5 C33H43N7O2

T3048 10058-F4 403811-55-2 C12H11NOS2

T3047 SRT3109 1204707-71-0 C18H23F2N5O4S2

T3045 Salubrinal 405060-95-9 C21H17Cl3N4OS

T3043 1092939-17-7 C17H21N6O4P

T3042 NSC 42834 195371-52-9 C23H24N2O

T3041 ALK inhibitor 2 761438-38-4 C23H28ClN7O3S

T3032 VE-821 1232410-49-9 C18H16N4O3S

T3031 A-83-01 909910-43-6 C25H19N5S

T3025 Asiaticoside 16830-15-2 C48H78O19

T3024 Avitinib 1557267-42-1 C26H26FN7O2

T3017 Trenbolone acetate 10161-34-9 C20H24O3

T3015 763113-22-0 C24H23FN4O3

T3008 2348-82-5 C11H8O3

T3001 Honokiol 35354-74-6 C18H18O2

T3000 Magnolol 528-43-8 C18H18O2

T2996 Tetrandrine 518-34-3 C38H42N2O6

T2995 Chrysophanic Acid 481-74-3 C15H10O4

T2994 Cardamoni 19309-14-9 C16H14O4

T2993 Cordycepin 73-03-0 C10H13N5O3

T2992 Pinocembrin 480-39-7 C15H12O4

T2985 Gypenoside XLIX 94987-08-3 C52H86O21

T2970 Rotenone 83-79-4 C23H22O6

T2968 83-49-8 C24H40O4

Fasudil (HA-1077) hydrochloride

Ruxolitinib (INCB-18424) phosphate

Olaparib (AZD2281, Ku-0059436)2-Methoxy-1,4-naphthoquinone

Hyodeoxycholic acid (HDCA)

T2959 Ginsenoside Rh2 78214-33-2 C36H62O8

T2957 Arctigenin 7770-78-7 C21H24O6

T2947 Indole-3-carbinol 700-06-1 C9H9NO

T2939 Forskolin 66575-29-9 C22H34O7

T2937 6559-91-7 C21H20O8

T2925 Schizandrin B 61281-37-6 C23H28O6

T2923 Apremilast (CC-10004) 608141-41-9 C22H24N2O7S

T2921 6080-33-7 C19H24ClNO4

T2915 CDDO(Bardoxolone) 218600-44-3 C31H41NO4

T2911 Stevioside 57817-89-7 C38H60O18

T2898 Andrographolide 5508-58-7 C20H30O5

T2897 Shikonin 54952-43-1 C16H16O5

T2895 Lupeol 545-47-1 C30H50O

T2893 Muscone 541-91-3 C16H30O

T2879 Fisetin 528-48-3 C15H10O6

T2873 Ginsenoside Rg2 52286-74-5 C42H72O13

T2870 (+)-Matrine 519-02-8 C15H24N2O

T2869 Emodin 518-82-1 C15H10O5

T2865 Oleanolic Acid 508-02-1 C30H48O3

T2864 Lycopene 502-65-8 C40H56

T2863 p-Coumaric acid 501-98-4 C9H8O3

T2859 Biochanin A 491-80-5 C16H12O5

T2854 Forsythin 487-41-2 C27H34O11

T2853 Curcumol 4871-97-0 C15H24O2

T2851 Daphnetin 486-35-1 C9H6O4

T2847 Indigo 482-89-3 C16H10O2N2

T2846 Isoimperatorin 482-45-1 C16H14O4

T2842 Tangeretin 481-53-8 C20H20O7

T2834 Nobiletin 478-01-3 C21H22O8

4'-Demethylepipodophyllotoxin

Sinomenine hydrochloride

T2830 Betulinic acid 472-15-1 C30H48O3

T2827 Asiatic acid 464-92-6 C30H48O5

T2826 Asarylaldehyde 4460-86-0 C10H12O4

T2823 Crocin 42553-65-1 C44H64O24

T2818 Methyl Vanillate 3943-74-6 C9H10O4

T2816 7,8-Dihydroxyflavone 38183-03-8 C15H10O4

T2814 Cryptotanshinone 35825-57-1 C19H20O3

T2809 Fangchinoline 33889-68-8 C37H40N2O6

T2807 Caffeic Acid 331-39-5 C9H8O4

T2805 Chlorogenic Acid 327-97-9 C16H18O9

T2803 Monocrotaline 315-22-0 C16H23NO6

T2802 Nocodazole 31430-18-9 C14H11N3O3S

T2795 Laetrile 29883-15-6 C20H27NO11

T2792 Glucosamine sulfate 29031-19-4 C6H13NO5.H2SO4

T2782 Catharanthine 2468-21-5 C21H24N2O2

T2775 Baicalin 21967-41-9 C21H18O11

T2768 Saikosaponin A 20736-09-8 C42H68O13

T2764 19685-09-7 C20H16N2O5

T2759 Loganin 18524-94-2 C17H26O10

T2757 Myricetrin 17912-87-7 C21H20O12

T2751 Ginkgolide B 15291-77-7 C20H24O10

T2743 142880-36-2 C20H28N4O4

T2736 13114-29-9 C8H8Na2O5

T2734 Sennoside B 128-57-4 C42H38O20

T2730 Gossypol acetic acid 12542-36-8 C32H34O10

T2709 TAK901 934541-31-8 C28H32N4O3S

T2708 SL-327 305350-87-2 C16H12F3N3S

T2707 Pifithrin-α 63208-82-2 C16H18N2OS.HBr

T2706 Palomid 529 (P529) 914913-88-5 C24H22O6

10-Hydroxycamptothecin

Ilomastat (GM6001, Galardin)Sodium Demethylcantharidate

T2705 Mutant EGFR inhibitor 1421373-62-7 C27H30ClN7O2

T2704 MLN0905 1228960-69-7 C24H25F3N6S

T2702 IWP-2 686770-61-6 C22H18N4O2S3

T2699 BMS-777607 1025720-94-8 C25H19ClF2N4O4

T2697 KN-93 139298-40-1 C26H29ClN2O4S

T2696 1370261-97-4 C19H23N9O.HCl

T2695 TBB(NSC 231634) 17374-26-4 C6HBr4N3

T2694 KN-62 127191-97-3 C38H35N5O6S2

T2685 KU55933 587871-26-9 C21H17NO3S2

T2683 IWP-L6 1427782-89-5 C25H20N4O2S2

T2680 NVP-BVU972 1185763-69-2 C20H16N6

T2679 BMS-265246 582315-72-8 C18H17F2N3O2

T2677 Crenolanib 670220-88-9 C26H29N5O2

T2676 PF-04217903 956905-27-4 C19H16N8O

T2675 AS 602801 848344-36-5 C25H23N5O2S

T2674 GSK0660 1014691-61-2 C19H18N2O5S2

T2672 TG100-115 677297-51-7 C18H14N6O2

T2671 Regadenoson 313348-27-5 C15H18N8O5

T2670 ML167 1285702-20-6 C19H17N3O3

T2669 VE822 1232416-25-9 C24H25N5O3S

T2668 JNK-IN-8 1410880-22-6 C29H29N7O2

T2667 PIK75 372196-67-3 C16H14BrN5O4S.HCl

T2661 TGX-221 663619-89-4 C21H24N4O2

T2660 IC-87114 371242-69-2 C22H19N7O

T2659 GW2580 870483-87-7 C20H22N4O3

T2657 Elacridar 143664-11-3 C34H33N3O5

T2656 Fruquintinib 1194506-26-7 C21H19N3O5

T2655 CEP37440 1391712-60-9 C30H38ClN7O3

T2653 SB1317 1204918-72-8 C23H24N4O

PRT062607 (P505-15, BIIB057) hydrochloride

T2651 IWR-1-endo 1127442-82-3 C25H19N3O3

T2649 1271738-62-5 C18H25N5S2

T2647 INCB024360 analogue 914471-09-3 C9H7ClFN5O2

T2644 658084-64-1 C24H29N3O2

T2643 1271738-59-0 C18H25N5S2

T2642 PD173074 219580-11-7 C28H41N7O3

T2641 KRCA-0008 1472795-20-2 C30H37ClN8O4

T2640 DCC-2036 (Rebastinib) 1020172-07-9 C30H28FN7O3

T2639 LY2811376 1194044-20-6 C15H14F2N4S

T2638 1229236-86-5 C23H25ClFN7O

T2637 Exherin (ADH-1) 229971-81-7 C22H34N8O6S2

T2636 Decernotinib(VX-509) 944842-54-0 C18H19F3N6O

T2634 Ro3280 1062243-51-9 C27H35F2N7O3

T2632 A-1210477 1668553-26-1 C46H55N7O7S

T2630 Poziotinib (HM781-36B) 1092364-38-9 C23H21Cl2FN4O3

T2627 152946-68-4 C14H14Cl2N4OS

T2625 MK0752 471905-41-6 C21H21ClF2O4S

T2624 OSI 930 728033-96-3 C22H16F3N3O2S

T2623 PD 98059 167869-21-8 C16H13NO3

T2620 G-749 1457983-28-6 C25H25BrN6O2

T2619 CH5132799 1007207-67-1 C15H19N7O3S

T2618 LGK-974 1243244-14-5 C23H20N6O

T2617 SNS-314 Mesylate 1146618-41-8 C18H15ClN6OS2.CH4O

T2616 PIK-93 593960-11-3 C14H16ClN3O4S2

T2615 131740-09-5 C21H21Cl2NO5

T2611 CCT137690 1095382-05-0 C26H31BrN8O

T2610 BMS 599626 714971-09-2 C27H27FN8O3

T2609 Masitinib (AB1010) 790299-79-5 C28H30N6OS

T2608 CHIR-98014 252935-94-7 C20H17Cl2N9O2

MI-2 (Menin-MLL Inhibitor)

FK866 (APO866, Daporinad)MI-3 (Menin-MLL Inhibitor)

Gandotinib (LY2784544)

AG-337;Nolatrexed dihydrochloride

Flavopiridol (Alvocidib) hydrochloride

T2606 KN-93 Phosphate 1188890-41-6 C26H29ClN2O4S.H3PO

T2605 1025687-58-4 C23H24FN6O9P.2Na

T2603 CC-292 (AVL-292) 1202757-89-8 C22H22FN5O3

T2602 722544-51-6 C26H30FN7O3

T2600 133550-30-8 C17H14N2O3

T2598 Thymopentin 69558-55-0 C30H49N9O9

T2595 Lumacaftor(VX 809) 936727-05-8 C24H18F2N2O5

T2591 Veliparib (ABT-888) 912444-00-9 C13H16N4O

T2590 879085-55-9 C19H14Cl2N2O3S

T2586 849217-68-1 C28H24FN3O5

T2584 Octreotide Acetate 83150-76-9 C49H66N10O10S2

T2582 Apatinib 811803-05-1 C24H23N5O

T2581 Fluoxymesterone 76-43-7 C20H29FO3

T2576 649735-63-7 C22H24FN5O4

T2572 17-Methyltestosterone 58-18-4 C20H30O2

T2569 Chlorotrianisene 569-57-3 C23H21ClO3

T2566 Oxandrolone 53-39-4 C19H30O3

T2565 Hesperetin 520-33-2 C16H14O6

T2558 Cladribine 4291-63-8 C10H12ClN5O3

T2553 Etofenamate 30544-47-9 C18H18F3NO4

T2550 Tolmetin 26171-23-3 C15H15NO3

T2543 Cabazitaxel 183133-96-2 C45H57NO14

T2539 162359-56-0 C19H34ClNO2

T2538 Bimatoprost 155206-00-1 C25H37NO4

T2537 150915-40-5 C22H39ClN2O6S

T2531 Eprosartan Mesylate 144143-96-4 C23H24N2O4S.CH4O3S

T2527 Ulipristal acetate 126784-99-4 C30H37NO4

T2518 ARRY380 937265-83-3 C29H27N7O4S

T2517 891494-63-6 C15H18BrN7

R788 (Fostamatinib) Disodium

Barasertib (AZD1152-HQPA)AG-490 (Tyrphostin B42)

Vismodegib (GDC-0449)Cabozantinib (XL184, BMS-907351)

Brivanib Alaninate (BMS-582664)

Fingolimod (FTY720) hydrochloride

Tirofiban hydrochloride monohydrate

MK-8776 (SCH 900776)

T2516 Amuvatinib(MP470) 850879-09-3 C23H21N5O3S

T2514 Linifanib (ABT-869) 796967-16-3 C21H18FN5O

T2513 VX-702 745833-23-2 C19H12F4N4O2

T2512 726169-73-9 C23H20N6O

T2511 Plinabulin (NPI-2358) 714272-27-2 C19H20N4O2

T2510 700874-72-2 C22H19N5O

T2506 AZD5438 602306-29-6 C18H21N5O2S

T2505 S3I-201;NSC 74859 501919-59-1 C16H15NO7S

T2503 PAC1 315183-21-2 C23H28N4O2

T2501 289499-45-2 C24H27Cl3FN5O3

T2500 Cediranib (AZD2171) 288383-20-0 C25H27FN4O3

T2496 Semaxanib (SU5416) 194413-58-6 C15H14N2O

T2495 Lomeguatrib 192441-08-0 C10H8BrN5OS

T2494 Cilengitide 188968-51-6 C27H40N8O7

T2492 Perifosine (KRX-0401) 157716-52-4 C25H52NO4P

T2491 AZ5104 1421373-98-9 C27H31N7O2

T2490 AZD9291 1421373-65-0 C28H33N7O2

T2489 1316214-52-4 C24H27N5O3

T2488 BAY 87-2243 1227158-85-1 C26H26F3N7O2

T2485 1187594-09-7 C16H17N7O2S

T2484 AZD2461 1174043-16-3 C22H22FN3O3

T2483 1110813-31-4 C24H25ClFN5O2

T2482 AT13148 1056901-62-2 C17H16ClN3O

T2479 Tyrphostin 9 10537-47-0 C18H22N2O

T2477 UNBS-5162 956590-23-1 C17H18N4O3

T2475 KU0063794 938440-64-3 C25H31N5O4

T2474 KU-60019 925701-49-1 C30H33N3O5S

T2473 PLX4720 918505-84-7 C17H14ClF2N3O3S

T2472 CGI1746 910232-84-7 C34H37N5O4

Mocetinostat (MGCD0103)

Galunisertib (LY2157299)

Canertinib dihydrochloride

Rocilinostat (ACY-1215)

Baricitinib (LY3009104, INCB028050)

Dacomitinib (PF299804, PF299)

T2471 MK8745 885325-71-3 C20H19ClFN5OS

T2468 A 769662 844499-71-4 C20H12N2O3S

T2467 R406 free base 841290-80-0 C22H23FN6O5

T2466 Osu-03012 742112-33-0 C26H19F3N4O

T2465 PF-562271 717907-75-0 C21H20F3N7O3S

T2464 NSC319726 71555-25-4 C11H14N4S

T2463 ML141 71203-35-5 C22H21N3O3S

T2461 PIK-90 677338-12-4 C18H17N5O3

T2460 58753-54-1 C23H25NO.HCl

T2457 IRAK-1/4 Inhibitor 509093-47-4 C20H21N5O4

T2456 Tivozanib (AV-951) 475108-18-0 C22H19ClN4O5

T2454 LAQ824 (Dacinostat) 404951-53-7 C22H25N3O3

T2450 SANT-1 304909-07-7 C23H27N5

T2449 D 4476 301836-43-1 C23H18N4O3

T2446 KI8751 228559-41-9 C24H18F3N3O4

T2445 FG-2216 223387-75-5 C12H9ClN2O4

T2444 KNK437 218924-25-5 C13H11NO4

T2443 PD184352 (CI-1040) 212631-79-3 C17H14ClF2IN2O2

T2442 CPI-203 202591-23-9 C19H18ClN5OS

T2441 TAS-301 193620-69-8 C23H19NO3

T2440 IC261 186611-52-9 C18H17NO4

T2438 HMN214 173529-46-9 C22H20N2O5S

T2435 EPZ011989 1598383-40-4 C35H51N5O4

T2434 LY 303511 154447-38-8 C19H18N2O2

T2433 NU7026 154447-35-5 C17H15NO3

T2432 PD 169316 152121-53-4 C20H13FN4O2

T2430 PHOB 1429651-50-2 C17H18N2O4

T2429 GZD824 Dimesylate 1421783-64-3 C29H27F3N6O.2CH4O3

T2426 CEP-33779 1346168-57-7 C24H26N6O2S

ZM 39923 hydrochloride

T2425 KPT-185 1333151-73-7 C16H16F3N3O3

T2424 P22077 1247819-59-5 C12H7F2NO3S2

T2421 SKLB1002 1225451-84-2 C13H12N4O2S2

T2420 PHT-427 1191951-57-1 C20H31N3O2S2

T2419 BMS794833 1174046-72-0 C23H15ClF2N4O3

T2418 A66 1166227-08-2 C17H23N5O2S2

T2416 BIX02189 1094614-85-3 C27H28N4O2

T2415 PP121 1092788-83-4 C17H17N7

T2414 Torkinib (PP242) 1092351-67-1 C16H16N6O

T2413 FH535 108409-83-2 C13H10Cl2N2O4S

T2412 SRT1720 1001645-58-4 C25H24ClN7OS

T2410 Nedaplatin 95734-82-0 C2H8N2O3Pt

T2408 MK-2866 (GTx-024) 841205-47-8 C19H14F3N3O3

T2403 Bromfenac sodium 120638-55-3 C15H11BrNNaO3

T2400 Candesartan Cilexetil 145040-37-5 C33H34N6O6

T2399 Bortezomib (PS-341) 179324-69-7 C19H25BN4O4

T2398 540737-29-9 C22H28N6O8

T2396 Ramatroban 116649-85-5 C21H21FN2O4S

T2394 Pixantrone dimaleate 144675-97-8 C25H27N5O10

T2391 Camostat mesilate 59721-29-8 C21H26N4O8S

T2386 Pirfenidone 53179-13-8 C12H11NO

T2384 Pomalidomide 19171-19-8 C13H11N3O4

T2383 Panobinostat (LBH589) 404950-80-7 C21H23N3O2

T2382 918504-65-1 C23H18ClF2N3O3S

T2381 LY2835219 1231929-97-7 C27H32F2N8

T2380 BIBR 1532 321674-73-1 C21H17NO3

T2378 RGB-286638 free base 784210-88-4 C29H35N7O4

T2377 XL147 analogue 956958-53-5 C21H16N6O2S2

T2375 ZK-811752, BX-471 217645-70-0 C21H24ClFN4O3

Tofacitinib (CP-690550) Citrate

Vemurafenib (PLX4032, RG7204)

T2374 HTH-01-015 1613724-42-7 C26H28N8O

T2373 Vipadenant 442908-10-3 C16H15N7O

T2372 AP24534 Ponatinib 943319-70-8 C29H27F3N6O

T2369 1374640-70-6 C27H28F3N7O3

T2367 SKF-86002 72873-74-6 C16H12FN3S

T2366 Tipiracil hydrochloride 183204-72-0 C9H12Cl2N4O2

T2365 Pilaralisib (XL147) 934526-89-3 C25H25ClN6O4S

T2364 937263-43-9 C26H24N8O2

T2363 STF-31 724741-75-7 C23H25N3O3S

T2361 LY-2874455 1254473-64-7 C21H19Cl2N5O2

T2360 1187595-84-1 C16H20N7O6PS

T2359 ANA-12 219766-25-3 C22H21N3O3S

T2358 ENMD-2076 934353-76-1 C21H25N7

T2357 GSK-1059615 958852-01-2 C18H11N3O2S

T2356 Ro-3306 872573-93-8 C18H13N3OS2

T2354 UNC0631 1320288-19-4 C37H61N7O2

T2352 AMI-1 20324-87-2 C21H14N2Na2O9S2

T2349 BMS-754807 1001350-96-4 C23H24FN9O

T2348 GSK2334470 1227911-45-6 C25H34N8O

T2347 BLU9931 1538604-68-0 C26H22Cl2N4O3

T2346 Enasidenib 1446502-11-9 C19H17F6N7O

T2343 AS601245 345987-15-7 C20H16N6S

T2341 KW2449 1000669-72-6 C20H20N4O

T2339 ARN-509 956104-40-8 C21H15F4N5O2S

T2328 Radotinib 926037-48-1 C27H21F3N8O

T2327 Pelitinib (EKB-569) 257933-82-7 C24H23ClFN5O2

T2325 Neratinib(HKI-272) 698387-09-6 C30H29ClN6O3

T2322 Fimasartan(BR-A-657) 247257-48-3 C27H31N7OS

T2318 LCZ696 936623-90-4 C24H29N5O3.C24H29NO

Rociletinib (CO-1686, AVL-301)

Irbinitinib(ARRY-380; ONT-380)

Baricitinib (Phosphate)

T2315 1431368-48-7 C14H22Cl2N2

T2314 PF 431396 717906-29-1 C22H21F3N6O3S

T2313 MPI-0479605 1246529-32-7 C22H29N7O

T2310 CHIR-99021 252917-06-9 C22H18Cl2N8

T2309 Ganetespib (STA-9090) 888216-25-9 C20H20N4O3

T2308 HS-173 1276110-06-5 C21H18N4O4S

T2307 Icotinib Hydrochloride 1204313-51-8 C22H22ClN3O4

T2304 SP2509 1423715-09-6 C19H20ClN3O5S

T2303 Afatinib (BIBW2992) 439081-18-2 C24H25ClFN5O3

T2302 CNX-774 1202759-32-7 C26H22FN7O3

T2301 SB202190 (FHPI) 152121-30-7 C20H14N3OF

T2300 AZD1208 1204144-28-4 C21H21N3O2S

T2299 BMS-833923 1059734-66-5 C30H27N5O

T2297 PIK-294 900185-02-6 C28H23N7O2

T2295 SB590885 405554-55-4 C27H27N5O2

T2294 BG45 926259-99-6 C11H10N4O

T2293 SGX-523 1022150-57-7 C18H13N7S

T2288L 857876-30-3 C22H23N5O.2H3PO4

T2288 Motesanib (AMG-706) 453562-69-1 C22H23N5O

T2287 PIK-75 372196-77-5 C16H14BrN5O4S.HCl

T2286 BIIB-021 848695-25-0 C14H15ClN6O

T2283 PX-12 141400-58-0 C7H12N2S2

T2282 RPI-1 269730-03-2 C17H15NO4

T2281 GSK-2256098 1224887-10-8 C20H23ClN6O2

T2280 Endoxifen 112093-28-4 C25H27NO2

T2277 585543-15-3 C22H26FN3O2

T2274 SC 79 305834-79-1 C17H17ClN2O5

T2273 ITD-1 1099644-42-4 C27H29NO3

T2272 BPR1J-097 1327167-19-0 C27H28N6O3S

GSK-LSD1 dihydrochloride

Motesanib Diphosphate (AMG-706)

Losmapimod (GW856553X)

T2270 Trans-Tranilast 70806-55-2 C18H17NO5

T2269 50892-23-4 C14H14ClN3O2S

T2268 VER-49009 940289-57-6 C19H18ClN3O4

T2267 BQU57 1637739-82-2 C16H13F3N4O

T2266 1477949-42-0 C15H22N2O3

T2265 PI3K-IN-2 1225037-39-7 C17H20F3N7O2

T2263 VX661 1152311-62-0 C26H27F3N2O6

T2262 GHF-5074 749269-83-8 C16H11Cl2FO2

T2261 IM-12 1129669-05-1 C22H20FN3O2

T2260 GW9662 22978-25-2 C13H9ClN2O3

T2259 CX-4945 (Silmitasertib) 1009820-21-6 C19H12ClN3O2

T2258 VER-50589 747413-08-7 C19H17ClN2O5

T2255 SB743921 940929-33-9 C31H34Cl2N2O3

T2253 TCS PIM-1 1 491871-58-0 C18H11BrN2O2

T2250 DY-131 95167-41-2 C18H21N3O2

T2248 AS-605240 648450-29-7 C12H7N3O2S

T2247 KenPaullone 142273-20-9 C16H11BrN2O

T2246 LRRK2-IN-1 1234480-84-2 C31H38N8O3

T2245 CL-387785 (EKI-785) 194423-06-8 C18H13BrN4O

T2243 881202-45-5 C21H20N4

T2242 Wnt-C59 1243243-89-1 C25H21N3O

T2241 MLN8237(Alisertib) 1028486-01-2 C27H20ClFN4O4

T2240 GSK2578215A 1285515-21-0 C24H18FN3O2

T2237 ICG001 847591-62-2 C33H32N4O4

T2236 RU58841 154992-24-2 C17H18F3N3O3

T2235 915019-65-7 C30H23N5O

T2234 SC-202671 312917-14-9 C20H16N2OS

T2233 GW 4064 278779-30-9 C28H22Cl3NO4

T2231 113-38-2 C24H32O4

WY-14643 (Pirinixic Acid)

CAY10683 (SantacruzaMate A)

JNJ-26854165 (Serdemetan)

BEZ235 (NVP-BEZ235, Dactolisib)

17-Beta-Estradiol-3,17-Dipropionate

T2230 Paeoniflorin 23180-57-6 C23H28O11

T2225 4-Hydroxyantipyrine 1672-63-5 C11H12N2O2

T2221 Uridine 58-96-8 C9H12N2O6

T2220 2-Methoxyestradiol 362-07-2 C19H26O3

T2217 Cephalomannine 71610-00-9 C45H53NO14

T2215 Ferulic Acid 1135-24-6 C10H10O4

T2213 Terconazole 67915-31-5 C26H31Cl2N5O3

T2207 Adrenosterone 382-45-6 C19H24O3

T2205 652-37-9 C9H10N4O4

T2202 Lithocholic acid 434-13-9 C24H40O3

T2201 6112-76-1 C5H6N4OS

T2195 Epiandrosterone 481-29-8 C19H30O2

T2193 2-Chloropyrazine 14508-49-7 C4H3ClN2

T2179 Triptolide (PG490) 38748-32-2 C20H24O6

T2176 57-71-6 C4H7NO2

T2175 Apigenin 520-36-5 C15H10O5

T2174 Quercetin 117-39-5 C15H10O7

T2169 Zebularine 3690-10-6 C9H12N2O5

T2168 2-NP 65182-56-1 C14H10N2O

T2166 TWS119 601514-19-6 C18H14N4O2

T2160 Suramin Sodium Salt 129-46-4 C51H34N6Na6O23S6

T2159 CaMKP Inhibitor 52789-62-5 C10H12NNaO9S2

T2158 Nutlin-3 548472-68-0 C30H30Cl2N4O4

T2157 251456-60-7 C16H25N3O3

T2156 WP1066 857064-38-1 C17H14BrN3O

T2155 Thiazovivin 1226056-71-8 C15H13N5OS

T2154 MG-132 133407-82-6 C26H41N3O5

T2153 1NM-PP1 221244-14-0 C20H21N5

T2146 Fulvestrant 129453-61-8 C32H47F5O3S

Theophylline-7-acetic acid

6-Mercaptopurine monohydrate

2,3-Butanedione 2-Monoxime

Histone Deacetylase Inhibitor III

T2145 162635-04-3 C56H87NO16

T2144 Tacrolimus (FK506) 104987-11-3 C44H69NO12

T2140 Parthenolide 20554-84-1 C15H20O3

T2127 OF-1 919973-83-4 C17H18BrN3O4S

T2125 871700-17-3 C26H23FIN5O4

T2124 PJ34 hydrochloride 344458-15-7 C17H18ClN3O2

T2123 LY2109761 700874-71-1 C26H27N5O2

T2122 MLN2238(Ixazomib) 1072833-77-2 C14H19BCl2N2O4

T2120 1300031-49-5 C23H21N5O3

T2119 ABT-199 (GDC-0199) 1257044-40-8 C45H50ClN7O7S

T2118 SC-514 354812-17-2 C9H8N2OS2

T2116 AEE788 497839-62-0 C27H32N6

T2115 PLX-3397 1029044-16-3 C20H15ClF3N5

T2114 NVP-BEP800 847559-80-2 C21H23Cl2N5O2S

T2111 YM155 781661-94-7 C20H19BrN4O3

T2110 (+)-JQ-1 1268524-70-4 C23H25ClN4O2S

T2109 SD-208 627536-09-8 C17H10ClFN6

T2108 Andarine 401900-40-1 C19H18F3N3O6

T2107 NVP-ADW742 475489-15-7 C28H31N5O

T2106 WS6 1421227-53-3 C29H31F3N6O3

T2105 ABT888 hydrochloride 912445-05-7 C13H18Cl2N4O

T2103 SB715992(Ispinesib) 336113-53-2 C30H33ClN4O2

T2101 ABT-263 (Navitoclax) 923564-51-6 C47H55ClF3N5O6S3

T2100 CX5461 1138549-36-6 C27H27N7O2S

T2099 ABT-737 852808-04-9 C42H45ClN6O5S2

T2098 A77-01 607737-87-1 C18H14N4

T2094 827318-97-8 C26H30N6O3

T2090 CYT997 (Lexibulin) 917111-44-5 C24H30N6O2

T2085 PQ401 196868-63-0 C18H16ClN3O2

Temsirolimus (CCI-779, NSC 683864)

Trametinib (GSK1120212)

I-BET151 (GSK1210151A)

Danusertib (PHA-739358)

T2084 ETP46464 1345675-02-6 C30H22N4O2

T2083 PI3065 955977-50-1 C27H31FN6OS

T2082 CDK4-IN-1 1256963-02-6 C22H29ClN8

T2081 946518-60-1 C24H32Cl4N6OS

T2080 LCL161 1005342-46-0 C26H33FN4O3S

T2079 GSK126 1346574-57-9 C31H38N6O2

T2078 CUDC-907 1339928-25-4 C23H24N8O4S

T2077 MK1775 955365-80-7 C27H32N8O2

T2074 B-Raf inhibitor 1 1093100-40-3 C26H19ClN8

T2073 GSK-2636771 1372540-25-4 C22H22F3N3O3

T2070 CEP-32496 1188910-76-0 C24H22F3N5O5

T2068 LB-100 1026680-07-8 C13H20N2O4

T2066 Quizartinib (AC220) 950769-58-1 C29H32N6O4S

T2064 Semaxinib(SU 5416) 204005-46-9 C15H14N2O

T2063 AG18 118409-57-7 C10H6N2O2

T2059 Purvalanol A 212844-53-6 C19H25ClN6O

T2056 UNC0064-12 1430089-64-7 C19H24N8

T2055 WS3 1421227-52-2 C28H30F3N7O3

T2054 Altiratinib(DCC2701) 1345847-93-9 C26H21F3N4O4

T2052 KY02111 1118807-13-8 C18H17ClN2O3S

T2051 FLT3-IN-1 1370256-78-2 C25H27N7O3S2

T2050 PF-06447475 1527473-33-1 C17H15N5O

T2048 LY-364947 396129-53-6 C17H12N4

T2047 AG-1478 153436-53-4 C16H14ClN3O2

T2046 Nimorazole 6506-37-2 C9H14N4O3

T2045 WHI-P131 202475-60-3 C16H15N3O3

T2041 AG-1517;PD153035 153436-54-5 C16H14BrN3O2

T2040 OAC1 300586-90-7 C14H11N3O

T2039 GSK923295 1088965-37-0 C32H38ClN5O4

LY2409881 trihydrochloride

T2038 RG108 48208-26-0 C19H14N2O4

T2035 WHI-P258 21561-09-1 C16H15N3O2

T2033 BML-277 516480-79-8 C20H14ClN3O2

T2032 WHI-P180 211555-08-7 C16H15N3O3

T2029 Bohemine 189232-42-6 C18H24N6O

T2028 NG-52 212779-48-1 C16H19ClN6O

T2025 Chidamide 743420-02-2 C22H19FN4O2

T2023 MC1568 852475-26-4 C17H15FN2O3

T2022 CZC-54252 1191911-27-9 C22H25ClN6O4S

T2019 OAC2 6019-39-2 C15H12N2O

T2018 Apilimod 541550-19-0 C23H26N6O2

T2016 MLN9708 1201902-80-8 C20H23BCl2N2O9

T2015 Fexaramine 574013-66-4 C32H36N2O3

T2012 Oclacitinib 1208319-26-9 C15H23N5O2S

T2011 RKI-1313 1342276-76-9 C17H16N4O2S

T2009 SB-3CT 292605-14-2 C15H14O3S2

T2008 LY294002 154447-36-6 C19H17NO3

T2003 Isx 9 832115-62-5 C11H10N2O2S

T2001 PF 573228 869288-64-2 C22H20F3N5O3S

T2000 AM095 1345614-59-6 C27H23N2NaO5

T1999 GDC-0032 1282512-48-4 C24H28N8O2

T1998 CHS 828 200484-11-3 C19H22ClN5O

T1996 1073154-85-4 C20H21F3N8O3S

T1995 936091-26-8 C27H36N6O3S

T1994 GDC-0941 957054-30-7 C23H27N7O3S2

T1992 Mertansine 139504-50-0 C35H48ClN3O10S

T1991 193000-39-4 C22H19ClFN3O2

T1989 747412-49-3 C26H31N3O5

T1988 1201438-56-3 C22H17ClN6O

Defactinib (VS-6063, PF-04554878)Fedratinib (SAR302503, TG101348)

ZM 323881 hydrochlorideLuminespib (AUY-922, NVP-AUY922)Duvelisib (IPI-145, INK1197)

T1986L Atopaxar Hydrobromide 474550-69-1 C29H39BrFN3O5

T1985 WHI-P154 211555-04-3 C16H14BrN3O3

T1983 CAY10603 1045792-66-2 C22H30N4O6

T1980 HA14-1 65673-63-4 C17H17BrN2O5

T1979 AVN944 297730-17-7 C25H27N5O5

T1977 BML-275 866405-64-3 C24H25N5O

T1976 RN486 1242156-23-5 C35H35FN6O3

T1975 BGJ398 (NVP-BGJ398) 872511-34-7 C26H31Cl2N7O3

T1974 PH797804 586379-66-0 C22H19BrF2N2O3

T1973 PFI-4 900305-37-5 C21H24N4O3

T1972 GSK 5959 901245-65-6 C22H26N4O3

T1971 WAY-262611 1123231-07-1 C20H22N4

T1967 AZD3463 1356962-20-3 C24H25ClN6O

T1966 Tubastatin A BASE 1252003-15-8 C20H21N3O2

T1965 Bikinin 188011-69-0 C9H9BrN2O3

T1963 1029712-80-8 C23H17FN6O

T1962 ASP 3026 1097917-15-1 C29H40N8O3S

T1961 AZD2014 1009298-59-2 C25H30N6O3

T1958 AZ20 1233339-22-4 C21H24N4O3S

T1957 AZD2858 486424-20-8 C21H23N7O3S

T1955 SB225002 182498-32-4 C13H10BrN3O4

T1953 L-779,450 303727-31-3 C20H14ClN3O

T1952 1032350-13-2 C25H23Cl2N5O

T1950 PND-1186 1061353-68-1 C25H26F3N5O3

T1949 CZC24832 1159824-67-5 C15H17FN6O2S

T1948 AZD4547 1035270-39-3 C26H33N5O3

T1947 BS-181 1092443-52-1 C22H32N6

T1945 GNE7915 1351761-44-8 C19H21F4N5O3

T1944 LDN-214117 1627503-67-6 C25H29N3O3

INCB28060(Capmatinib)

MK-2206 dihydrochloride

T1943 ML347 1062368-49-3 C22H16N4O

T1942 DMH1 1206711-16-1 C24H20N4O

T1941 GSK3787 188591-46-0 C15H12ClF3N2O3S

T1938 FLT3-IN-2 923562-23-6 C21H16ClF3N4

T1937 Spautin-1 1262888-28-7 C15H11F2N3

T1936 Alectinib 1256580-46-7 C30H34N4O2

T1935 LDN-193189 1062368-24-4 C25H22N6

T1934 Bay 11-7085 196309-76-9 C13H15NO2S

T1932 B-AP15 1009817-63-3 C22H17N3O6

T1930 JSH-23 749886-87-1 C16H20N2

T1929 Filgotinib (GLPG0634) 1206161-97-8 C21H23N5O3S

T1926 956697-53-3 C26H26F3N3O3

T1925 PLX647 873786-09-5 C21H17F3N4

T1924 LDN-57444 668467-91-2 C17H11Cl3N2O3

T1922 Pseudolaric Acid B 82508-31-4 C23H28O8

T1921 BYL-719(Alpelisib) 1217486-61-7 C19H22F3N5O2S

T1919 Tenovin-1 380315-80-0 C20H23N3O2S

T1918 TAE226 (NVP-TAE226) 761437-28-9 C23H25ClN6O3

T1917 6-BIO 667463-62-9 C16H10BrN3O2

T1916 1032754-93-0 C23H30N8O3S

T1914 K 02288 1431985-92-0 C20H20N2O4

T1912 Dinaciclib (SCH727965) 779353-01-4 C21H28N6O2

T1911 Afuresertib 1047644-62-1 C18H17Cl2FN4OS

T1908 MHY1485 326914-06-1 C17H21N7O4

T1906 1260907-17-2 C22H22ClN5O2

T1905 EPZ005687 1396772-26-1 C32H37N5O3

T1904 SGI-1027 1020149-73-8 C27H23N7O

T1903 1195765-45-7 C23H20F3N5O2S2

T1902 BAY 11-7082 19542-67-7 C10H9NO2S

LDE225 (NVP-LDE225,Erismodegib)

Apitolisib (GDC-0980, RG7422)

GSK-525762A(I-BET-762)

Dabrafenib (GSK2118436)

T1901 TG003 300801-52-9 C13H15NO2S

T1900 LDN212854 1432597-26-6 C25H22N6

T1898 RKI-1447 1342278-01-6 C16H14N4O2S

T1895 SKLB 610 1125780-41-7 C21H16F3N3O3

T1894 870281-82-6 C22H18FN7O

T1893 ML 161 423735-93-7 C17H17BrN2O2

T1891 NSC 405020 7497-07-6 C12H15Cl2NO

T1890 Pracinostat (SB939) 929016-96-6 C20H30N4O2

T1888 CI994 (Tacedinaline) 112522-64-2 C15H15N3O2

T1886 TAK632 1228591-30-7 C27H18F4N4O3S

T1881 AR-A014418 487021-52-3 C12H12N4O4S

T1879 5142-23-4 C6H7N5

T1878 XAV939 284028-89-3 C14H11F3N2OS

T1877 LH-846 639052-78-1 C16H13ClN2OS

T1876 Kobe0065 436133-68-5 C15H11ClF3N5O4S

T1873 Tenovin-3 1011301-27-1 C18H21N3OS

T1872 Fenretinide 65646-68-6 C26H33NO2

T1867 ATB 346 1226895-20-0 C21H19NO3S

T1862 PR-619 2645-32-1 C7H5N5S2

T1861 1086062-66-9 C25H17F2N5O3S

T1859 AZD8055 1009298-09-2 C25H31N5O4

T1857 TMP269 1314890-29-3 C25H21F3N4O3S

T1855 ZCL 278 587841-73-4 C21H19BrClN5O4S2

T1854 MS436 1395084-25-9 C18H17N5O3S

T1852 Belinostat (PXD101) 414864-00-9 C15H14N2O4S

T1851 ZM 336372 208260-29-1 C23H23N3O3

T1849 Momelotinib (CYT387) 1056634-68-4 C23H22N6O2

T1847 Necrostatin-1 4311-88-0 C13H13N3OS

T1845 B-Raf IN 1 950736-05-7 C29H24F3N5O

CAL-101 (Idelalisib, GS-1101)

3-Methyladenine (3-MA)

GSK2126458(Omipalisib)

T1844 KPT-330, (E)-RN 1421923-86-5 C17H11F6N7O

T1840 Isoindigotin 476-34-6 C16H10N2O2

T1838 INK 128 (MLN0128) 1224844-38-5 C15H15N7O

T1837 BX912 702674-56-4 C20H23BrN8O

T1836 AZD2932 883986-34-3 C24H25N5O4

T1835 Ibrutinib (PCI-32765) 936563-96-1 C25H24N6O2

T1834 CX-6258 1202916-90-2 C26H24ClN3O3

T1830 BX795 702675-74-9 C23H26IN7O2S

T1829 941678-49-5 C17H18N6

T1828 TTP 22 329907-28-0 C16H14N2O2S2

T1827 944396-07-0 C18H21F3N6O2

T1826 SAR245409 (XL765) 1349796-36-6 C31H29N5O6S

T1825 Picropodophyllin (PPP) 656820-32-5 C21H27N7O

T1821 CGK 733 905973-89-9 C23H18Cl3FN4O3S

T1819 Nexturastat A 1403783-31-2 C19H23N3O3

T1818 Tenovin-6 1011557-82-6 C25H34N4O2S

T1817 GNF-2 778270-11-4 C18H13F3N4O2

T1813 VGX-1027 6501-72-0 C11H11NO3

T1812 KX1-004 518058-84-9 C16H13FN2O2

T1811 WH-4-023 837422-57-8 C32H36N6O4

T1810 Purmorphamine 483367-10-8 C31H32N6O2

T1807 JW55 664993-53-7 C25H26N2O5

T1806 NLG919 1402836-58-1 C18H22N2O

T1803 GNF-5 778277-15-9 C20H17F3N4O3

T1801 SR9243 1613028-81-1 C31H32BrNO4S2

T1800 GW788388 452342-67-5 C25H23N5O2

T1798 RITA (NSC 652287) 213261-59-7 C14H12O3S2

T1797 1140909-48-3 C32H30FN3O10

T1795 Carfilzomib (PR-171) 868540-17-4 C40H57N5O7

(R)-Ruxolitinib (INCB018424)

BKM120 (NVP-BKM120, Buparlisib)

XL184(Cabozantinib malate)

T1792 755037-03-7 C21H15ClF4N4O3

T1791 LDK378(Ceritinib) 1032900-25-6 C28H36ClN5O3S

T1789 Obeticholic Acid 459789-99-2 C26H44O4

T1788 EPZ6438 1403254-99-8 C34H44N4O4

T1785 Palbociclib 571190-30-2 C24H29N7O2

T1784 Everolimus (RAD001) 159351-69-6 C53H83NO14

T1783 LXR623 875787-07-8 C21H12ClF5N2

T1780 Parecoxib 198470-84-7 C19H18N2O4S

T1779 912545-86-9 C28H28ClN3OS

T1778 902135-91-5 C16H18Cl3N5O2

T1777 Nintedanib (BIBF 1120) 656247-17-5 C31H33N5O4

T1776 Plerixafor 110078-46-1 C28H54N8

T1773 850140-73-7 C32H33ClFN5O11

T1772 Apoptosis Activator 2 79183-19-0 C15H9Cl2NO2

T1770 GNE9605 1536200-31-3 C17H20ClF4N7O

T1765 Erastin 571203-78-6 C30H31ClN4O4

T1764 SB203580 152121-47-6 C21H16FN3OS

T1763 SB525334 356559-20-1 C21H21N5

T1762 RGFP 966 1357389-11-7 C21H19FN4O

T1761 183322-45-4 C16H15BrClN3O2

T1759 OTSSP167 1431697-89-0 C25H28Cl2N4O2

T1758 ABT-751 (E7010) 141430-65-1 C18H17N3O4S

T1757 ML323 1572414-83-5 C23H24N6

T1755 LY2090314 603288-22-8 C28H25FN6O3

T1754 ZM306416 690206-97-4 C16H13ClFN3O2

T1753 D64131 74588-78-6 C16H13NO2

T1741 AZD1080 612487-72-6 C19H18N4O2

T1739 WZ811 55778-02-4 C18H18N4

T1738 480-18-2 C15H12O7

Regorafenib (BAY 73-4506)

Smoothened Agonist (SAG)AT 7519 hydrochloride salt

Afatinib (BIBW2992) Dimaleate

PD153035 hydrochloride

Taxifolin (Dihydroquercetin)

T1737 Genistein 446-72-0 C15H10O5

T1736 Apixaban 503612-47-3 C25H25N5O4

T1726 SB 431542 301836-41-9 C22H16N4O3

T1725 129830-38-2 C14H21N3O.2HCl

T1723 ADP 58-64-0 C10H15N5O10P2

T1721 2'-Deoxyuridine 951-78-0 C9H12N2O5

T1720 61618-27-7 C15H12NO3.H2O.Na

T1704 Diosmetin 520-34-3 C16H12O6

T1703 SN-38 86639-52-3 C22H20N2O5

T1692 2107-70-2 C11H14O4

T1688 80-92-2 C21H36O2

T1681 Aminophylline 317-34-0 2C7H8O2.C2H8N2

T1674 Nateglinide 105816-04-4 C19H27NO3

T1668 Vinblastine sulfate 143-67-9 C46H58N4O9·H2SO4

T1661 877399-52-5 C21H22Cl2FN5O

T1659 Melatonine 73-31-4 C13H16N2O2

T1656 Vandetanib (ZD6474) 443913-73-3 C22H24BrFN4O2

T1648 Vitamin E 59-02-9 C29H50O2

T1646 Famciclovir 104227-87-4 C14H19N5O4

T1645 Ramipril 87333-19-5 C23H32N2O5

T1643 Penciclovir 39809-25-1 C10H15N5O3

T1642 191732-72-6 C13H13N3O3

T1640 Ciprofloxacin 85721-33-1 C17H18FN3O3

T1639 Amlexanox 68302-57-8 C16H14N2O4

T1633 Beta-Carotene 7235-40-7 C40H56

T1625 98079-52-8 C17H20ClF2N3O3

T1622 Rosiglitazone maleate 155141-29-0 C18H19N3O3S.C4H4O4

T1621 220127-57-1 C29H31N7O.CH4SO3

T1620 Pazufloxacin Mesylate 163680-77-1 C16H15FN2O4.CH4O3S

Y-27632 dihydrochloride

Amfenac Sodium Monohydrate

3,4-Dimethoxyhydrocinnamic acid5Beta-Pregnane-3Alpha,20alpha-Diol

Crizotinib (PF-02341066)

Lenalidomide (CC-5013)

Lomefloxacin hydrochloride

Imatinib Mesylate (STI571)

T1615 Irbesartan 138402-11-6 C25H28N6O

T1611 Isotretinoin 4759-48-2 C20H28O2

T1606 Fasudil 103745-39-7 C14H17N3O2S

T1605 Enalapril 75847-73-3 C20H28N2O5

T1603 Glipizide 29094-61-9 C21H27N5O4S

T1602 Valerin 1069-66-5 C8H15NaO2

T1601 Lomustine 13010-47-4 C9H16ClN3O2

T1600 Doxifluridine 3094-09-5 C9H11FN2O5

T1596 Chlormadinone acetate 302-22-7 C23H29ClO4

T1592 Acetohydroxamic acid 546-88-3 C2H5NO2

T1591 10212-25-6 C9H12ClN3O4

T1590 Letrozole 112809-51-5 C17H11N5

T1587 Exemestane 107868-30-4 C20H24O2

T1586 Tenoxicam 59804-37-4 C13H11N3O4S2

T1583 149647-78-9 C14H20N2O3

T1582L Naproxen sodium 26159-34-2 C14H13NaO3

T1582 Naproxen 22204-53-1 C14H14O3

T1574 Etoricoxib 202409-33-4 C18H15ClN2O2S

T1570 Telmisartan 144701-48-4 C33H30N4O2

T1564 Cisplatin 15663-27-1 H6Cl2N2Pt

T1563 Nifuroxazide 965-52-6 C12H9N3O5

T1558 Resveratrol 501-36-0 C14H12O3

T1555 Diclofenac sodium 15307-79-6 C14H10Cl2NNaO2

T1549 82640-04-8 C28H28ClNO4S

T1548 8-Methoxypsoralen 298-81-7 C12H8O4

T1544 Olsalazine disodium 6054-98-4 C14H8N2Na2O6

T1541 Drospirenone 67392-87-4 C24H30O3

T1538 Melphalan 148-82-3 C13H18Cl2N2O2

T1537 Rapamycin (Sirolimus) 53123-88-9 C51H79NO13

Cyclocytidine hydrochloride

Vorinostat (SAHA, MK0683)

Raloxifene hydrochloride

T1536 Promestriene 39219-28-8 C22H32O2

T1535 Sodium Phenylbutyrate 1716-12-7 C10H11NaO2

T1527 Gliclazide 21187-98-4 C15H21N3O3S

T1524 Nilotinib (AMN-107) 641571-10-0 C28H22F3N7O

T1523 Teniposide 29767-20-2 C32H32O13S

T1521 Hydroxy Camptothecine 64439-81-2 C20H16N2O5

T1520 Aliskiren hemifumarate 173334-58-2 C30H53N3O6.1/2C4H4O

T1518 Benicar 144689-63-4 C29H30N6O6

T1516 Curcumin 458-37-7 C21H20O6

T1511 23541-50-6 C27H29NO10.HCl

T1508 Dacogen 2353-33-5 C8H12N4O4

T1507 Streptozocin 18883-66-4 C8H15N3O7

T1506 Vidarabine 5536-17-4 C10H13N5O4

T1501 Rifabutin 72559-06-9 C46H62N4O11

T1492 Gemifioxacin mesylate 210353-53-0 C19H24FN5O7S

T1489 Fosinopril sodium 88889-14-9 C30H45NO7P.Na

T1488 366-70-1 C12H19N3O.HCl

T1485 Methotrexate 59-05-2 C20H22N8O5

T1484L Perindopril erbumine 107133-36-8 C23H43N3O5

T1480 Danazol 17230-88-5 C22H27NO2

T1477 AICAR (Acadesine) 2627-69-2 C9H14N4O5

T1473 Trilostane 13647-35-3 C20H27NO3

T1468 Lornoxicam 70374-39-9 C13H10ClN3O4S2

T1467 Acemetacin 53164-05-9 C21H18ClNO6

T1464 Toremifene citrate 89778-27-8 C32H36ClNO8

T1462 Captopril 62571-86-2 C9H15NO3S

T1461 Candesartan 139481-59-7 C24H20N6O3

T1453 834-28-6 C10H16ClN5

T1452 Axitinib 319460-85-0 C22H18N4OS

Daunorubicin hydrochloride

Procarbazine hydrochloride

Phenformin hydrochloride

T1451 138199-71-0 C18H20FN3O4·1/2H2O

T1448L Dasatinib monohydrate 863127-77-9 C22H28ClN7O3S

T1448 Dasatinib 302962-49-8 C22H26ClN7O2S

T1444 Lomefloxacin 98079-51-7 C17H19F2N3O3

T1432 Phenylbutazone 50-33-9 C19H20N2O2

T1428 Trifluridine 70-00-8 C10H11F3N2O5

T1427 FOSFOSAL 6064-83-1 C7H7O6P

T1424 Ethynyl estradiol 57-63-6 C20H24O2

T1423 Hydroxytoluic acid 83-40-9 C8H8O3

T1421 Aceclofenac 89796-99-6 C16H13Cl2NO4

T1420 1642-54-2 C10H21N3O.C6H8O7

T1417 55-86-7 C5H12Cl3N

T1416 Zidovudine 30516-87-1 C10H13N5O4

T1415 Gemfibrozil 25812-30-0 C15H22O3

T1408 Capecitabine 154361-50-9 C15H22FN3O6

T1402 Fenofibric acid 42017-89-0 C17H15ClO4

T1401 3685-84-5 C12H16ClNO3.HCl

T1394 Ibuprofen 15687-27-1 C13H18O2

T1388 Fluconazole 86386-73-4 C13H12F2N6O

T1384 69-09-0 C17H19ClN2S.HCl

T1382 Griseofulvin 126-07-8 C17H17ClO6

T1378 17902-23-7 C8H9FN2O3

T1377 Methyldienedione 5173-46-6 C18H22O2

T1376 138564-58-6 C6H6N2S

T1368 Methyl protocatechuate 2150-43-8 C8H8O4

T1339 Mylosar 320-67-2 C8H12N4O5

T1338 Sucralfate 54182-58-0 C12H54Al16O75S8

T1337 57248-88-1 C3H9NNa2O7P2

T1330 Acitretin 55079-83-9 C21H26O3

Levofloxacin hydrochloride

Diethylcarbamazine citrateMechlorethamine hydrochloride

Meclofenoxate hydrochloride

Chlorpromazine hydrochloride

Tegafur (FT-207, NSC 148958)

2-Amino-5-methyl-3-thiophenecarbonitrile

Pamidronate disodium salt

T1325 Carprofen 53716-49-7 C15H12ClNO2

T1307 Carmofur 61422-45-5 C11H16FN3O3

T1306 Norfloxacin 70458-96-7 C16H18FN3O3

T1303 Auranofin 34031-32-8 C20H34AuO9PS

T1298 Clofibrate 637-07-0 C12H15ClO3

T1296 Aminopar 65-49-6 C7H7NO3

T1294 Fleroxacin 79660-72-3 C17H18F3N3O3

T1293 GATIFLOXACIN 112811-59-3 C19H22FN3O4

T1290 Oxiconazole nitrate 64211-46-7 C18H13Cl4N3O·HNO3

T1288 TTNPB (Arotinoid Acid) 71441-28-6 C24H28O2

T1285 Anethole trithione 532-11-6 C10H8OS3

T1280 Nepafenac 78281-72-8 C15H14N2O2

T1272 Cytarabine 147-94-4 C9H13N3O5

T1270 Vincristine sulfate 2068-78-2 C46H58N4O14S

T1261 Farlutin 71-58-9 C24H34O4

T1258 Nabumetone 42924-53-8 C15H16O2

T1257 Ubenimex 58970-76-6 C16H24N2O4

T1256 Caffeine 58-08-2 C8H10N4O2

T1250 52-24-4 C6H12N3PS

T1244 Celiprolol hydrochloride 57470-78-7 C20H33N3O4.HCl

T1241 Altretamine 645-05-6 C9H18N6

T1233 Oxolinic acid 14698-29-4 C13H11NO5

T1216 Diethylstilbestrol 56-53-1 C18H20O2

T1212 Toradol 74103-07-4 C19H24N2O6

T1210 Sodium etidronate 7414-83-7 C2H6Na2O7P2

T1209 Flunixin meglumin 42461-84-7 C21H28F3N3O7

T1207 Lovastatin 75330-75-5 C24H36O5

T1206 Amsacrine 51264-14-3 C21H19N3O3S

T1199 Mitotan 53-19-0 C14H10Cl4

Triethylenethiophosphoramide

T1193 Clomifene citrate 50-41-9 C32H36ClNO8

T1192 Protoporphyrin IX 553-12-8 C34H34N4O4

T1191L 68-89-3 C13H16N3NaO4S

T1185 Rofecoxib 162011-90-7 C17H14O4S

T1184 Rivaroxaban 366789-02-8 C19H18ClN3O5S

T1181 Gefitinib (ZD1839) 184475-35-2 C22H24ClFN4O3

T1178 Temozolomide 85622-93-1 C6H6N6O2

T1174 119413-54-6 C23H24ClN3O5

T1167 Cyproterone acetate 427-51-0 C24H29ClO4

T1166 Ellipticine 519-23-3 C17H14N2

T1158 63-92-3 C18H23Cl2NO

T1155 Mebendazole 31431-39-7 C16H13N3O3

T1149 Fenofibrate 49562-28-9 C20H21ClO4

T1144L 6108-05-0 C14H22N2O.HCl.H2O

T1140 10592-13-9 C22H24N2O8.HCl

T1133 Nimesulide 51803-78-2 C13H12N2O5S

T1123 (+)-Camptothecin 7689-03-4 C20H16N2O4

T1121 Podophyllotoxin 518-28-5 C22H22O8

T1120 Dacarbazine 4342-03-4 C6H10N6O

T1119 Rasagiline 136236-51-6 C12H13N

T1103 Aminoglutethimide 125-84-8 C13H16N2O2

T1099 Formestane 566-48-3 C19H26O3

T1095 Sparfloxacin 110871-86-8 C19H22F2N4O3

T1093 Adapalene 106685-40-9 C28H28O3

T1088 Repaglinide 135062-02-1 C27H36N2O4

T1087 124832-27-5 C13H20N6O4.HCl.XH2O

T1086 Vitamin D2 50-14-6 C28H44O

T1083L 5967-84-0 C7H8N4O2.H2O

T1083 Theophylline 58-55-9 C7H8N4O2

Sodium [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylamino]methan

Topotecan hydrochloride

Phenoxybenzamine hydrochloride

Lidocaine Hydrochloride hydrateDoxycycline hydrochloride

Valacyclovir hydrochloride

Theophylline monohydrate

T1080 2-Aminoethanethiol 60-23-1 C2H7NS

T1079 Metronidazole 443-48-1 C6H9N3O3

T1071 L-Adrenaline 51-43-4 C9H13NO3

T1060 Flumequine 42835-25-6 C14H12FNO3

T1058 Carboplatin 41575-94-4 C6H12N2O4Pt

T1057 Azilsartan 147403-03-0 C25H20N4O5

T1056 51-30-9 C11H18ClNO3

T1055 Ifosfamide 3778-73-2 C7H15Cl2N2O2P

T1051 Tretinoin 302-79-4 C20H28O2

T1048 Estradiol 50-28-2 C18H24O2

T1047 Epinephrine bitartrate 51-42-3 C13H19NO9

T1038 Fludarabine 21679-14-1 C10H12FN5O4

T1034 Docetaxel 114977-28-5 C43H53NO14

T1027 Luteolin 491-70-3 C15H10O6

T1025 1986-47-6 C9H11N.HCl

T1020 25316-40-9 C27H29NO11.HCl

T1011 Itraconazole 84625-61-6 C35H38Cl2N8O4

T1002 Etodolac 41340-25-4 C17H21NO3

T0987 Gimeracil 103766-25-2 C5H4ClNO2

T0986 Fluorocytosine 2022-85-7 C4H4FN3O

T0984 51-21-8 C4H3FN2O2

T0981 912-60-7 C22H23NO7.HCl.xH2O

T0980 Nifenazone 2139-47-1 C17H16N4O2

T0979 Dequalinium chloride 522-51-0 C30H40Cl2N4

T0975 Chloroambucil 305-03-3 C14H19Cl2NO2

T0974 Albamycinsodium 1476-53-5 C31H35N2NaO11

T0968 Paclitaxel 33069-62-4 C47H51NO14

T0964 Floxuridine 50-91-9 C9H11FN2O5

T0959 Ethopabate 59-06-3 C12H15NO4

Isoprenaline hydrochloride

Tranylcypromine (2-PCPA) hydrochlorideDoxorubicin hydrochloride

Fluorouracil (5-Fluoracil, 5-FU)Noscapine hydrochloride

T0949 Amstat 1197-18-8 C8H15NO2

T0942 69-05-6 C23H30CLN3O.2HCl

T0938 Thiabendazole 148-79-8 C10H7N3S

T0936 Aminophenazone 58-15-1 C13H17N3O

T0926 Azelaic acid 123-99-9 C9H16O4

T0923 Busulfan 55-98-1 C6H14O6S2

T0909L 3374-05-8 C12H11N2NaO3

T0909 Nalidixic acid 389-08-2 C12H12N2O3

T0907 Sulfasalazine 599-79-1 C18H14N4O5S

T0902 Ofloxacin 82419-36-1 C18H20FN3O4

T0890 Mefenamic acid 61-68-7 C15H15NO2

T0888 4-Biphenylacetic acid 5728-52-9 C14H12O2

T0881 6-Aminocaproic acid 60-32-2 C6H13NO2

T0875 Acetylcysteine 616-91-1 C5H9NO3S

T0867 Bufexamac 2438-72-4 C12H17NO3

T0859 Fenbufen 36330-85-5 C16H14O3

T0858 Flufenamic acid 530-78-9 C14H10F3NO2

T0856L 53-43-0 C19H28O2

T0856 853-23-6 C21H30O3

T0855 (R)-Naproxen 23979-41-1 C14H14O3

T0841 Bezafibrate 41859-67-0 C19H20ClNO4

T0839L (S)-(+)-Ketoprofen 22161-81-5 C16H14O3

T0839 Ketoprofen 22071-15-4 C16H14O3

T0838 Triclabendazole 68786-66-3 C14H9CI3N2OS

T0835 Tamoxifen citrate 54965-24-1 C32H37NO8

T0826 Meloxicam 71125-38-7 C14H13N3O4S2

T0825 Ebselen 60940-34-3 C13H9NOSe

T0824 Nonoxynol 26027-38-3 C28H50O8

T0812 318-98-9 C16H22ClNO2

Quinacrine dihydrochloride

Nalidixic acid sodium salt

DehydroepiandrosteroneDehydroepiandrosterone acetate

Propranolol hydrochloride

T0808 Diflunisal 22494-42-4 C13H8F2O3

T0805 Quinapril hydrochloride 82586-55-8 C25H31CIN2O5

T0800 Antrapurol 117-10-2 C14H8O4

T0798 Triamcinolone 124-94-7 C21H27FO6

T0795 Rutin 153-18-4 C27H30O16

T0784 TOLFENAMIC ACID 13710-19-5 C14H12ClNO2

T0778 Phenacetin 62-44-2 C10H13NO2

T0758 Piroxicam 36322-90-4 C15H13N3O4S

T0738 Urea 57-13-6 CH4N2O

T0737 L-Ornithine 70-26-8 C5H12N2O2

T0734 Antipyrine 60-80-0 C11H12N2O

T0726 132-69-4 C19H23N3O.HCl

T0724 Formononetin 485-72-3 C16H12O4

T0722 Ursolic acid 77-52-1 C30H48O3

T0718 Brivudine 69304-47-8 C11H13BrN2O5

T0717L Enoxacin 74011-58-8 C15H17FN4O3

T0717 84294-96-2 C15H17FN4O3·3/2H2O

T0714 Oxfendazole 53716-50-0 C15H13N3O3S

T0712 Suloctidil 54767-75-8 C20H35NOS

T0711 Niclosamide 50-65-7 C13H8Cl2N2O4

T0708 Oxaprozin 21256-18-8 C18H15NO3

T0707 6055-19-2 C7H17Cl2N2O2P·H2O

T0706 Lisinopril dihydrate 83915-83-7 C21H35N3O7

T0705 Triflusal 322-79-2 C10H7F3O4

T0704 Cyanoacetohydrazide 140-87-4 C3H5N3O

T0702 Gabapentin 60142-96-3 C9H17NO2

T0694 Pranlukast 103177-37-3 C27H23N5O4

T0693 Niflumic acid 4394-00-7 C13H9F3N2O2

T0688 Ganciclovir 82410-32-0 C9H13N5O4

Benzydamine hydrochloride

Enoxacin Sesquihydrate

Cyclophosphamide monohydrate

T0687 Simvastatin 79902-63-9 C25H38O5

T0681 Rifampicin 13292-46-1 C43H58N4O12

T0679 Ketoconazole 65277-42-1 C26H28Cl2N4O4

T0676 Hydroxyurea 127-07-1 CH4N2O2

T0651 N-Phenylbenzylamine 103-32-2 C13H13N

T0649 Salicylic acid 69-72-7 C7H6O3

T0646 Mesalamine 89-57-6 C7H7NO3

T0642 1771-18-2 C13H11NOS

T0639 Phenetidine 156-43-4 C8H11NO

T0625 Theobromine 83-67-0 C7H8N4O2

T0617 Nicotinamide-N-oxide 1986-81-8 C6H6N2O2

T0610 Piceatannol 10083-24-6 C14H12O4

T0602 Acridine 260-94-6 C13H9N

T0520 Lenvatinib (E7080) 417716-92-8 C21H19ClN4O4

T0506 Clotrimazole 23593-75-1 C22H17ClN2

T0498 Sasapyrine 552-94-3 C14H10O5

T0492 Dimethyl fumarate 624-49-7 C6H8O4

T0489 Flutamide 13311-84-7 C11H11F3N2O3

T0486L 100286-90-6 C33H39ClN4O6

T0486 136572-09-3 C33H45ClN4O9

T0484 Deracoxib 169590-41-4 C17H14F3N3O3S

T0477 Zileuton 111406-87-2 C11H12N2O2S

T0476 Abbolactone 52-01-7 C24H32O4S

T0468 Xylocaine 137-58-6 C14H22N2O

T0466 Celecoxib 169590-42-5 C17H14F3N3O2S

T0465 Ellagic acid 476-66-4 C14H6O8

T0463 Loxoprofen 68767-14-6 C15H18O3

T0459 Sulindac 38194-50-2 C20H17FO3S

T0458 Indometacin 53-86-1 C19H16ClNO4

2-Methoxyphenothiazine

Irinotecan HydrochlorideIrinotecan hydrochloride trihydrate

T0456 Cinchophen 132-60-5 C16H11NO2

T0451 Minoxidil 38304-91-5 C9H15N5O

T0449 Menadione 58-27-5 C11H8O2

T0448 Dexibuprofen 51146-56-6 C13H18O2

T0444L Econazole nitrate 24169-02-6 C18H15Cl3N2O.HNO3

T0444 Econazole 27220-47-9 C18H15Cl3N2O

T0443 SALICOSIDE 138-52-3 C13H18O7

T0441 Pasiniazid 2066-89-9 C13H14N4O4

T0438 Proflavine Hemisulfate 1811-28-5 C26H24N604S

T0436 Acexamic Acid 57-08-9 C8H15NO3

T0431 783355-60-2 C21H23N3O5

T0429 Glucosamine 3416-24-8 C6H13NO5

T0425L 149676-40-4 C17H20FN3O3.CH4O3S

T0425 Pefloxacin Mesylate 70458-95-6 C18H24FN3O6S

T0424 Bismuth subsalicylat 14882-18-9 C7H5BiO4

T0423 150-38-9 C10H13N2Na3O8

T0420 Pentetic Acid 67-43-6 C14H23N3O10

T0419 57-85-2 C22H32O3

T0393 Anastrozole 120511-73-1 C17H19N5

T0389 Dabigatran etexilate 211915-06-9 C34H41N7O5

T0384 Estradiol benzoate 50-50-0 C25H28O3

T0380 Bicalutamide 90357-06-5 C18H14F4N2O4S

T0374L Sunitinib 557795-19-4 C22H27FN4O2

T0374 Sunitinib Malate 341031-54-7 C26H33FN4O7

T0373L Erlotinib hydrochloride 183319-69-9 C22H23N3O4.HCl

T0373 Erlotinib 183321-74-6 C22H23N3O4

T0345 Estropipate 7280-37-7 C22H32N2O5S

T0344 Miconazole 22916-47-8 C18H14Cl4N2O

T0337 52-21-1 C23H30O6

PCI-24781 (Abexinostat)

Pefloxacin Mesylate Dihydrate

Edetate Trisodium

Testosterone propionate

Prednisolone-21-acetate

T0335 Sodium salicylate 54-21-7 C7H5NaO3

T0334 Rosiglitazone 122320-73-4 C18H19N3O3S

T0331 186826-86-8 C23H29ClFN3O4

T0321 Indoprofen 31842-01-0 C17H15NO3

T0320 Colchicine 64-86-8 C22H25NO6

T0319 Suxibuzone 27470-51-5 C24H26N2O6

T0308 Etidronate 2809-21-4 C2H8O7P2

T0297 Clofarabine 123318-82-1 C10H11ClFN5O3

T0291 Flurbiprofen 5104-49-4 C15H13FO2

T0289 Aminacrine 90-45-9 C13H10N2

T0288 Procodazole 23249-97-0 C10H10N2O2

T0285 Isoxicam 34552-84-6 C14H13N3O5S

T0274 Cinoxacin 28657-80-9 C12H10N2O5

T0272 Nilutamide 63612-50-0 C12H10F3N3O4

T0270 Hydrocortisone butyrate 13609-67-1 C25H36O6

T0264 Zomepirac Sodium 64092-48-4 C15H13ClNNaO3

T0263 6170-42-9 C16H20ClN3.HCl

T0260 Meclofenamate Sodium 6385-02-0 C14H10Cl2NNaO2

T0256 6080-58-6 C6H13Li3O11

T0251 Gemcitabine 95058-81-4 C9H11F2N3O4

T0250 93107-08-5 C17H18FN3O3·HCl

T0239 Lonidamine 50264-69-2 C15H10Cl2N2O2

T0228 Methyl hesperidin 11013-97-1 C29H36O15

T0221 Thioproline 444-27-9 C4H7NO2S

T0219 Valdecoxib 181695-72-7 C16H14N2O3S

T0215 Losartan potassium 124750-99-8 C22H22ClKN6O

T0214L 112529-15-4 C19H20N2O3S.HCl

T0213 Thalidomide 50-35-1 C13H10N2O4

T0212 Seratrodast 112665-43-7 C22H26O4

Moxifloxacin hydrochloride

Chloropyramine hydrochloride

Lithium citrate tribasic tetrahydrate

Ciprofloxacin hydrochloride

Pioglitazone hydrochloride

T0196 Diciofenac 15307-86-5 C14H11Cl2NO2

T0194 50-63-5 C18H26CLN3.2(H3PO4)

T0190 Vinorelbine 71486-22-1 C16H21N3O2

T0189L Pemetrexed disodium 150399-23-8 C20H19N5Na2O6

T0189 Pemetrexed acid 137281-23-3 C20H21N5O6

T0186 Docetaxel trihydrate 148408-66-6 C43H59NO17

T0184 Fenoprofen calcium 53746-45-5 C30H30CaO8

T0180 86541-74-4 C24H29ClN2O5

T0175 Amiloride hydrochloride 2016-88-8 C6H9Cl2N7O

T0167 Vinpocetine 42971-09-5 C22H26N2O2

T0164 Oxaliplatin 61825-94-3 C8H14N2O4Pt

T0158 70476-82-3 C22H30Cl2N4O6

T0155 Argatroban 74863-84-6 C23H36N6O5S

T0153 Oltipraz 64224-21-1 C8H6N2S3

T0152 Bosutinib 380843-75-4 C26H29Cl2N5O3

T0148 Calcium folinate 1492-18-8 C20H21CaN7O7

T0146 Vagistat 65899-73-2 C16H13Cl3N2OS

T0139 Toremifene 89778-26-7 C26H28ClNO

T0135 Estradiol valerate 979-32-8 C23H32O3

T0134 Imiquimod 99011-02-6 C14H16N4

T0132 Etoposide 33419-42-0 C29H32O13

T0131 Cepharanthine 481-49-2 C37H38N2O6

T0129 Sanguinarine chloride 5578-73-4 C20H14ClNO4

T0122 Bengenin 477-90-7 C14H16O9

T0120 Voriconazole 137234-62-9 C16H14F3N5O

T0097L Pazopanib 444731-52-6 C21H23N7O2S

T0095 3543-75-7 C16H21Cl2N3O2.HCl

T0093L Sorafenib 284461-73-0 C21H16ClF3N4O3

T0093 Sorafenib tosylate 475207-59-1 C21H16ClF3N4O3.C7H

Chloroquine diphosphate

Benazepril hydrochloride

Mitoxantrone hydrochloride

Bendamustine hydrochloride

T0079 Stanozolol 10418-03-8 C21H32N2O

T0078L 388082-78-8 C29H26ClFN4O4S·2(C7

T0078 Lapatinib 231277-92-2 C29H26ClFN4O4S

T0069 Uracil 66-22-8 C4H4N2O2

T0065 Acetaminophen 103-90-2 C8H9NO2

T0061 Clofibric acid 882-09-7 C10H11ClO3

T0058 Anovigam 938-73-8 C9H11NO2

T0057 Famprofazone 22881-35-2 C24H31N3O

T0055L 65513-72-6 C19H17ClN2O4·HCl

T0055 Glafenine 3820-67-5 C19H17ClN2O4

T0054 Disulfiram 97-77-8 C10H20N2S4

T0050 4-Aminoantipyrine 83-07-8 C11H13N3O

T0046 Arsenic oxide (3) 1327-53-3 As2O3

T0040 Quinestrol 152-43-2 C25H32O2

T0035 Dienestrol 84-17-3 C18H18O2

T0033 Miltefosine 58066-85-6 C21H46NO4P

T0022 Taurine 107-35-7 C2H7NO3S

T0020 6018-19-5 C7H6NNaO3.2H2O

T0018 614-39-1 C13H21N3O.HCl

T0014 cis-Anethol 104-46-1 C10H12O

T0012 Cinchonine 118-10-5 C19H22N2O

T0010 Mercaptopurine (6-MP) 50-44-2 C5H4N4S

T0009 Flubendazole 31430-15-6 C16H12FN3O3

T0005 Acetylsalicylic acid 50-78-2 C9H8O4

T0004 Salicylamide 65-45-2 C7H7NO2

T0002 Etamsylate 2624-44-4 C10H17NO5S

Lapatinib ditosylate monohydrate

Glafenine Hydrochloride

Sodium 4-aminosalicylate dihydrateProcainamide hydrochloride

MolWt Condition Diseases Indication272.09 FDA Approved Cancer Bone Metastases; Cortic

298.36 Approved Immunology

351.44 Approved Cancer Acute Promyelocytic Le

466.53 Clinic Cancer Arrhythmias; Cancer; Hy

394.47 N/A

610.59 N/A

275.34 Clinic Respiratory system/ CanAsthma; Glioma; Hiv-1 In

553.65 N/A

378.89 FDA Approved Other Dyspareunia

198.18 Clinic Cancer Cancer

574.66 Clinic Cancer Haematological malignan

464.55 N/A

388.55 Clinic Cancer Prostate cancer

365.21 FDA approved Cancer Chronic lymphocytic leu


581.47 Clinic Nervous system/ CancerAlzheimer's disease; Ca

289.28 N/A

348 FDA Approved Cancer Cutaneous T Cell Lymp

516.6 Clinic Immunology Multiple Sclerosis

560.64 Clinic Cancer Cancer; Herpes simplex v

287.32 N/A

136.15 Clinic Cancer Abdominal aortic aneurys

412.48 N/A

312.37 FDA Approved Endocrine system Rheumatoid Arthritis

476.86 Clinic Cancer Liver cancer; Solid tumo

354.36 N/A

464.48 Clinic Cancer Breast cancer; Cancer;


Chronic Rheumatoid Arthritis

438.48 Clinic Cancer Diffuse large B cell ly

413.49 N/A

413.49 Clinic Cancer Chronic Lymphocytic Leu

489.4 Clinic Cancer Acute myeloid leukaemia


301.77 N/A


573.66 Approved Cancer Breast Cancer



376.41 Clinic Cancer Breast Cancer

493.60 FDA Approved Cancer Acute Lymphoblastic Leu

586.68 FDA Approved Cancer Breast Cancer; Cervical

542.03 Approved Cardiovascular system Hypertension

516.42 FDA Approved Cancer Mesothelioma; Non-Small

171.59 N/A Cancer leukopenia

292.03 Clinic Cancer Brain Metastases; Breast

426.6 N/A

457.68 Clinic Cancer Non-Small Cell Lung Can

360 Clinic Cancer Cancer

349.51 FDA Approved Cancer Prostate Cancer


316.35 Clinic Cancer Fallopian tube cancer; O

432.46 Clinic Nervous system Alzheimer'S Disease

434.54 Clinic Cancer Breast cancer

295.34 N/A

482.19 Clinic Cancer Neurofibromatoses; Colo

222.26 Clinic Cancer Leukaemia


310.35 Clinic Cancer Hepatocellular Carcinom

521.66 Clinic Cancer Acute Myeloid Leukaemia


417.41 Clinic Immunology/ Cancer Inflammation; Solid tumo

505.69 Clinic Cancer Cancer; Inflammation; L


485.94 Clinic Cancer Breast cancer; Head and

431.20 Clinic Cancer Malignant Melanoma



1512.62 FDA Approved Cancer Breast Cancer; Head An

467.48 N/A


432.4 N/A

473.93 Clinic Cancer Colorectal cancer

509 Clinic Cardiovascular system Cardiovascular Disorders;

436.3 Clinic Cancer Non-small cell lung canc

346.31 N/A

542.03 Clinic Nervous system Alzheimer'S Disease; Br

383.44 Clinic Cancer Cancer; Haematological

507.68 Clinic Cancer Brain cancer; Breast can

473.47 Clinic Cancer Chronic Myelomonocytic

587.67 N/A

294.35 N/A

541.69 N/A

421.54 N/A

275.3 N/A

612.74 Clinic Cancer Ovarian cancer

607.62 N/A

357.41 Clinic Cancer Cancer; Cataracts

455.5 Clinic Cancer Cancer; Myeloproliferativ

419.48 Clinic Cancer Solid tumours

413.28 Clinic Cancer Non-Hodgkin's lymphoma

356.38 Clinic Cancer Solid Tumours



421.49 Clinic Cancer Adrenocortical carcinoma

513.67 FDA Approved Immunology Hypertriglyceridaemiahiv-

558.1 N/A

467.49 N/A

806.94 Clinic Cancer Chronic myelomonocytic

540.7 FDA Approved Cancer Cutaneous T Cell Lymph

668.66 N/A



560.64 Clinic Cancer Colorectal cancer; Non-sm

364.21 Clinic Cancer Acute myeloid leukaemia;

566.05 Clinic Cancer Acute lymphoblastic leuk

467.95 Clinic Cancer Multiple myeloma


0 FDA Approved Cancer Colorectal cancer

236.35 Clinic Cardiovascular system/ Atherosclerosis; Cancer;


595.71 FDA Approved Cancer Non-small cell lung canc

464.44 Clinic Cancer Acute lymphoblastic le

623.63 Clinic Cancer/ Nervous systemPain; Uterine leiomyoma

465.51 Clinic Cancer Chronic lymphocytic leu

531.32 FDA Approved Cancer Malignant melanoma


Clinic Cancer Glioblastoma; Leukaemia;

338.4 Clinic Cancer/ Endocrine syst Cancer; Rosacea; Skin d


286.11 Clinic Cancer Chronic lymphocytic leu

436.99 Clinic Cancer Malignant melanoma

407.44 Clinic Cancer Colorectal cancer; Gastri

442.55 Clinic Cancer/ Immunology Cancer, Cushing’s syndro


480.59 Clinic Cancer/ Immunology Autoimmune disorders; Ca

368.38 Clinic Cancer Hepatocellular carcinom

393.21Clinic Cancer Cancer; Solid tumours545.61 Approved Cancer Chronic myeloid leukaem

1255.44 Clinic Cancer Ewing's sarcoma

320.39 Clinic Cancer Fallopian tube cancer; O

289.06 Clinic Cancer Haematological malignan

248.36 N/A Cancer

412.51 Clinic Cancer Refractory Cancer

270.32 N/A Cancer Breast cancer

460.39 N/A Nervous system/ Canceranxiety, cancer

152.23 Clinic Cancer Glioblastoma; Glioma; Br

561.72 Clinic Cancer Head and neck cancer; O

214.22 FDA Approved Cancer Cytoprotective Adjuvant

360.92 Approved Endocrine Osteoporosis

438.13 Clinic Cancer Glioblastoma; Non-small

494.58 N/A

210.23 N/A Cancer

460.97 Clinic Immunology Multiple Sclerosis; Psoria

509.73 N/A

449.04

731.98 Clinic Cancer

136.23404 Clinic Cancer Breast Cancer; Lung Can

240.21 Clinic Cancer Colorectal Cancer; Gastr

314.36 Clinic Cancer



463.46 Clinic Cancer Gastric Cancer; Oesopha


271.15 N/A

339.43 N/A

383.44 N/A

321.33 N/A

390.56 N/A

547.53 N/A

400.47 Clinic Cardiovascular system Coronary Artery Restenos

339.43 N/A

347.37058 N/A

383.27 N/A


312.3 Clinic Immunology Allergic Rhinitis

179.67 N/A

421.52 N/A

264.32 N/A

420.44 Clinic Cancer Solid tumours

363.37 Clinic Cancer Endometrial cancer; Rena

164.29 N/A

304.47 Approved Endocrine system Hypoandrogenism

452.67 N/A Endocrine system muscle growth

420.58 Approved Endocrine system Hypoandrogenism

Gastric Cancer

400.59 FDA Approved Endocrine system Hypogonadism

608.72 N/A

362.36 FDA Approved Others Vet Drug

632.65 Clinic Cancer Breast Cancer; Gastric

602.70 Clinic Cancer Breast Cancer; Non-Smal

220.23 Clinic Immunology/ RespiratoryAllotransplant Rejection

434.49 Clinic Cancer Breast Cancer; Gastric


453.96 N/A

562.71 Clinic Cancer Acute Lymphoblastic Le

322.75 Clinic Cancer/ respiratory syst Cancer; Chronic obstructi

302.45 N/A


618.57 N/A

539.67 N/A

309.34 N/A

532.57 N/A

405.42 Clinic Cancer Acute Myeloid Leukaemi

371.22 N/A

425.50 Clinic Immunology Crohn's disease; Rheumatoi

438.52 N/A

486.31 N/A

410.32 N/A

444.53 Clinic Respiratory system Myelofibrosis; Polycytha

532.57 N/A

429.60 N/A

334.39 Clinic nervous system Alzheimer'S Disease; Pr

306.37 Approved Cardiovascular system Myelofibrosis; Polycytha

443.35 N/A

521.59 N/A

406.41 Clinic Cancer Non-Small Cell Lung Ca

327.83 Approved Cerebral Ischaemia; Ce


273.23 N/A

569.74 N/A

249.35 N/A

475.53 N/A

479.81 Clinic Cancer Relapse Multiple Myelo

404.36 FDA Approved Cardiovascular system Myelofibrosis; Polycytha

344.45 N/A

518.03 N/A

368.41 N/A

421.52 N/A

959.15 Clinic Metabolism Diabetic Foot


312.40 N/A

434.46 FDA Approved Cancer Ovarian Cancer

188.18 N/A

266.32 Clinic Metabolism Non-Alcoholic Fatty Live

266.32 Approved Immunology Fungal Infection

622.77 Approved Immunology/ Cancer Arthralgia; Neuralgia/ Co

254.24 Approved Immunology Inflammation

270.28 N/A

251.24 Clinic Cancer Leukaemia

256.25 Clinic Nervous system Shock

1047.23 N/A

394.43 N/A

392.58 N/A

Cerebrovascular system

622.87 N/A

372.41 Approved Cancer


410.51 Clinic Cancer/ Cardiovascular Cancer; Heart Failure; I

400.38 N/A

400.46 N/A

460.50 FDA Approved Immunology Plaque Psoriasis; Psoriati

365.85 Approved Metabolism

491.7 Clinic Cancer Cancer; Leukaemia; Soli


350.44 Approved Cancer/ Immunology Cancer; Hiv Infections

288.29 Clinic Cancer Bladder Urothelial Carc

426.73 N/A Endocrine system Acne

238.41 N/A

286.24 N/A

785.01 N/A

248.37 N/A Immunology/ Cancer Inflammation; Cancer


456.72 N/A Cancer Hepatitis B; Liver Cancer

536.89 Approved Cancer Health Care Product ; A

164.16 N/A Cancer

284.26 N/A

534.56 Approved Immunology Influenza; Fever

236.35 Clinic Others Chemothersapy Induced

178.14 Approved Cardiovascular system Thromboangiitis Oblitera

262.26 Clinic Cancer Brain Tumors With Ill-De

270.28 N/A

372.38 N/A

402.40 N/A

Lung Cancer; Colorectal Cancer

Rheumatism；Arthritis

Stomach Cancer

456.71 N/A

488.70 Approved Nervous system/ CardiovDepress; Coronary Heart

196.20 N/A

976.96 Approved Cancer Cancer

182.17 N/A

254.24 N/A

296.37 N/A Endocrine system Polycystic Ovary Syndr

608.72 N/A

180.16 Clinic Cancer/ Immunology Cancer; Psoriasis

354.32 Clinic Cancer Cancer; Glioblastoma

325.36 Clinic Others Snake Envenomation



277.25 Clinic Cancer Lung Cancer


446.37 Clinic Cancer/ Immunology Cancer; Hepatitis C; Hiv-

780.99 Approved Immunology Head Pain; Cough

364.36 Approved Cancer Cancers

390.38 Approved Immunology/ MetabolismInflammation; Diabetes

464.38 N/A

424.40 Clinic Cancer/ Respiratory systArrhythmias; Arterial Th

388.46 Clinic Cancer/ Metbolism Cancer; Chronic Obstruct


862.74 N/A


504.64 Clinic Cancer Haematological Maligna

335.35 N/A

367.30 N/A

406.43 Clinic Endocrine system Age-Related Macular De

Liver cancer, Esophagus cancer, Gastric carcinoma

520.03 N/A

486.56 N/A

466.60 N/A


501.04 N/A

429.91 Clinic Cancer/ Immunology Cancer; Inflammation; R

434.71 N/A

721.84 N/A

395.49 N/A

472.58 N/A

340.38 N/A




457.55 N/A

418.49 N/A

346.34 Clinic Respiratory system Asthma; Chronic Obstruct

390.35 FDA Approved Cardiovascular System Coronary Disorders

335.36 N/A

463.55 N/A

507.59 N/A

488.74 N/A

364.44 N/A

397.43 N/A

366.41 N/A


393.39 Approved Cancer Colorectal Cancer; Non-


372.46 Clinic Cancer Chronic Lymphocytic Le

409.44 N/A




375.55 N/A

523.67 N/A

609.12 N/A

553.59 Clinic Cancer Acute Lymphoblastic Leu


469.94 Clinic Cancer Myeloproliferative Disord

570.69 Clinic Cancer Malignant Melanoma; So

392.38 Clinic Immunology Rheumatoid Arthritis

543.61 N/A

850.04 N/A

491.34 Clinic Cancer Adenocarcinoma; Breast

357.26 Clinic Cancer Colorectal Cancer; Head

442.90 Clinic Nervous system/ CancerBreast Cancer; Cns Canc


267.28 N/A

521.41 clinic cancer Acute Myeloid Leukemia


396.44 Clinic Cancer Colorectal Cancer


389.88 N/A

438.30 Clinic Cancer Cute Myeloid Leukaemia

551.48 N/A

530.55 Clinic Cancer Breast Cancer; Glioma;

498.64 Approved Others Mastocytosis

486.31 N/A

599.03 N/A

624.42 Clinic Cardiovascular system Immune Thrombocytopen

423.44 Clinic Cancer Rheumatoid arthritis


294.30 N/A

679.56 Approved Cancer Immunocom Promise Caus

452.41 FDA Approved Cancer


421.30 FDA Approved Cancer Basal Cell Cancer

501.50 FDA Approved Cancer Renal Cancer; Thyroid C

1019.24 FDA Approved Endocrine system/ CanceAcromegaly; Intestinal O

397.48 FDA Approved Cancer Gastric Cancer

336.44 FDA Approved Endocrine system/ CancBreast Cancer; Delayed


302.45 FDA Approved Endocrine system Hypogonadism

380.86 FDA Approved Endocrine system/ Canc

306.44 FDA Approved Endocrine system Type 2 Diabetes Mellitus

302.27 Approved Immunology/ cardiovascuInflammatory; Hyperlipid

285.69 FDA Approved Cancer Chronic Lymphocytic Leu

369.34 Approved Others

257.28 FDA Approved Nervous system Pain( Non-Steroidal Anti


343.93 FDA Approved Immunology Multiple Sclerosis

415.57 FDA Approved Others Glaucoma; Hypotrichosis

495.07 FDA Approved Cardiovascular System Acute Coronary Syndromes

520.62 FDA Approved Cardiovascular system Essential Hypertension

475.62 FDA Approved Cancer/ Endocrine syst Contraception; Uterine



Cystic Fibrosis

Menopausal Symptoms; Estrogen Deficiency; And Prostate Cancer

Joint And Muscular Pain

447.51 Clinic Cancer Glioblastoma; Small Cel


404.30 Clinic Cardiovascular system Acute Coronary Syndrome

396.44 Clinic Cancer Bladder Cancer; Diffuse


369.42 Clinic Cardiovascular system Myelodysplastic Syndro

371.46 Clinic Cancer Cancer; Solid Tumours

365.36 Clinic

392.49 Clinic Cancer Haematological Malignan


450.51 Approved Cancer Ovarian Cancer

238.28 Clinic Cancer Cute Myeloid Leukaemia;

326.17 Clinic Cancer Cancer; Colorectal Canc

588.66 Clinic Cancer Glioblastoma; Head And

461.66 Clinic Cancer Glioma; Gynaecological

485.58 Clinic Cancer Non Small Cell Lung Can

499.61 Approved Cancer Non-Small Cell Lung Ca

433.50 Approved Cancer Multiple Myeloma


371.42 Approved Immunology Rheumatoid Arthritis




282.38 N/A

326.35 Clinic CANcer Lymphoma; Solid Tumou

465.54 N/A

547.67 N/A

413.83 clinic Cancer/ Immunology/ NeAlzheimer'S Disease; Can

579.69 N/A

431.91 N/A

360.39 N/A

470.45 Clinic Immunology Immune Thrombocytopen

460.45 Clinic Cancer Lymphoma; Solid Tumou


234.32 N/A

407.49 N/A

351.36 N/A

367.91 N/A

395.41 N/A

454.86 clinic cancer Renal Cancer


373.49 N/A

398.41 N/A

469.41 N/A

280.66 Clinic Cardiovascular system Anaemia



399.90 clinic cancer Cancer; Cystic Fibrosis;

357.40 clinic Others Reperfusion Injury

311.33 N/A


605.81 N/A

306.36 N/A

281.31 N/A

360.34 N/A

314.34 N/A

724.77 N/A

462.57 N/A

355.31 clinic cancer Acute Myeloid Leukaemia;

315.32 N/A

320.39 N/A

409.61 clinic cancer Cancer

468.84 N/A

393.53 N/A

440.54 N/A

319.36 N/A

308.34 N/A

361.20 N/A

506.22 clinic Cancer/ Metbolism/ ImmAmyotrophic Lateral Scle


389.33 Clinic Cancer Breast Cancer; Stress In

356.15 FDA Approved Immunology Cular Inflammation; Ocul

610.66 FDA Approved Endocrine system Hypertension

384.24 FDA Approved Cancer Mantle-Cell Lymphoma;

504.49 FDA Approved Immunology Rheumatoid Arthritis

416.47 Approved Immunology Allergic Rhinitis

557.21 Approved Cancer Non-Hodgkin'S Lympho


185.22 FDA Approved Respiratory system Ldiopathic Pulmonary Fib

273.24 FDA Approved Cancer Multiple Myeloma


489.92 FDA Approved Cancer Malignant Melanoma

506.59 Approved Cancer Breast Cancer; Non-Smal

331.36 N/A


448.52 Clinic Cancer Neoplasm Malignant

434.89 Clinic Nervous system Alzheimer'S Disease; End

468.55 N/A

321.34 Clinic Nervous system Parkinson'S Disease

532.56 FDA Approved Cardiovascular System Acute Lymphoblastic Le


297.35 N/A

279.12 FDA Approved Cancer Colorectal Cancer

541.02 Clinic Cancer Endometrial Cancer


423.53 clinic cancer Cancer; Ovarian Cancer


469.41 Approved Immunology Rheumatoid Arthritis

407.49 N/A

375.47 Clinic Cancer Breast Cancer; Hepatoce


351.45 N/A

635.93 N/A

348.45 N/A

461.49 Clinic Cancer Breast Cancer; Solid Tu

462.59 N/A

509.38 clinic cancer Cancer; Gastrointestinal


372.45 Clinic Immunology Inflammation; Ischaemia


477.43 Clinic Cancer Prostate Cancer

530.50 Approved Cancer Chronic Myeloid Leukae

467.92 Clinic Cancer Colorectal Cancer; Non-

557.04 Clinic cancer Breast Cancer

501.65 Approved Cardiovascular system Essential Hypertension;

915.98 Approved Cardiovascular system Heart Failure

289.24 N/A

506.50 N/A


465.34 Clinic Metabolism Type 2 Diabetes Mellitus


422.46 N/A


437.90 N/A

485.94 FDA Approved Cancer Non-Small Cell Lung Ca

499.50 N/A

331.34 N/A


473.57 Clinic Cancer Chronic Myeloid Leukae

489.53 N/A

453.54 clinic cancer Olid Tumours

214.22 N/A


569.44 Clinic Cancer Breast Cancer; Colorecta

373.46 Clinic Nervous system/ EndocrNon-Small Cell Lung Ca

488.74 N/A

318.76 Clinic Cancer Breast Cancer; Gastroint

188.32 Clinic Cancer Metastatic Cancer; Adv

297.31 N/A

414.89 clinic Cancer Meningioma; Pancreatic


383.46 Clinic Cardiovascular system Acute Coronary Syndro

364.78 N/A

415.52 N/A

516.62 N/A

327.33 Approved Immunology Allergic

323.80 Approved Cardiovascular system Plasma Lipid Modulation


334.30 N/A

278.35 N/A

411.38 N/A

520.50 Clinic Cancer Cystic Fibrosis

325.16 N/A

377.41 N/A

276.68 N/A

349.77 Clinic Cancer Cholangiocarcinoma

388.80 N/A

553.52 Clinic Cancer Hodgkin'S Disease; Non

367.20 N/A

311.38 N/A

257.27 N/A


571.00 N/A



379.45 N/A

518.92 Clinic Cancer B Cell Lymphoma; Brain

399.42 N/A

548.63 N/A

369.34 Clinic Endocrine system Acne; Alopecia

469.54 Clinic Immunology Influenza Virus Infection

332.42 N/A

542.84 N/A

384.52 FDA Approved Endocrine system Menopausal Syndrome;

480.46 Clinic Cardiovascular system Inflammation

204.23 Approved Immunology Pain And Fever

244.20 FDA Approved Cancer Colorectal cancer



194.19 Approved Cardiovascular system Thrombosis

532.46 FDA Approved Immunology Vaginal Yeast Infection

300.40 Approved Others Dietary Supplement

238.20 Approved Respiratory system

376.58 FDA Approved Metabolism Inborn Genetic Disorders

170.19 FDA Approved Cancer Acute Lymphoblastic Le

290.44 Clinic Nervous system Alzheimer'S Disease; Inf

114.53 N/A

360.40 Clinic Cancer Breast Cancer; Gastric C

101.11 N/A


302.24 Clinic Cardiovascular system Thromboembolism

228.20 N/A

222.24 N/A

318.33 N/A


377.32 N/A


307.39 N/A


311.36 N/A

475.62 Clinic cancer Cancer

331.41 N/A

606.77 FDA Approved Cancer Breast Cancer

Acute Monocytic Leukemia; Malignant Tumor

Chronic Obstructive Pulmonary Disease (Copd) Andasthma

1030.29 FDA Approved Cancer Mantle-Cell Lymphoma;

804.02 FDA Approved Immunology Allergic Conjunctivitis;


440.31 N/A


311.80 N/A

441.52 N/A


415.44 N/A

868.44 FDA Approved Cancer Non-Hodgkin'S Lympho

224.30 N/A

440.58 Clinic Cancer Glioblastoma; Solid Tum

417.81 Clinic Immunology Pigmented Villonodular S


443.26 Clinic Cancer Breast Cancer; Diffuse


352.75 clinic Immunology Psoriasis

441.36 Clinic Nervous system Cachexia

453.38 N/A

568.59 N/A


517.06 Clinic Cancer Breast Cancer; Colorect




286.33 N/A

474.55 Clinic Cancer Chronic Myeloid Leukaem

434.53 Clinic Cancer Glioblastoma; Multiple


470.52 N/A

506.64 N/A

440.97 N/A

594.43 N/A

500.63 Clinic Cancer Breast Cancer; Multiple

526.67 N/A

508.55 Clinic Cancer Diffuse Large B Cell L

500.60 Clinic Cancer Gynaecological Cancer;

478.94 N/A






186.17 N/A

388.89 N/A

364.45 N/A

569.58 N/A


376.86 N/A

537.66 N/A

305.33 N/A

272.30 N/A

315.75 clinic Cancer Human Papillomavirus In

226.23 Approved Cancer Head And Neck Cancer

297.31 clinic Immunology/ CardiovascuAllergic Asthma; Amyotro

360.21 N/A

237.26 N/A


334.33 N/A

281.31 N/A

363.80 N/A

297.31 Clinic Cancer/ Immunology Allergic Rhinitis; Brain C

340.42 clinic Cancer Cancer

346.81 N/A

390.41 Approved Cancer Peripheral T-Cell Lymp

314.31 N/A

504.39 N/A

236.27 N/A

418.49 Clinic Cancer Non-Hodgkin'S Lympho

517.12 Approved Cancer Multiple Myeloma

496.64 N/A

337.44 N/A

340.40 N/A

306.40 N/A


234.27 N/A

491.49 Clinic Others

478.47 clinic Cancer Cancer; Fibrosis; Sclero



510.49 Clinic Cancer Mesothelioma; Non-Small

524.68 Clinic Cancer/ Cardiovascular Essential Thrombocythae


738.29 Clinic Cancer Haematological Malignan

411.86 N/A

465.54 Clinic Cancer Pancreatic Cancer


608.54 clinic Cardiovascular system Acute Coronary Syndrom


446.50 N/A


477.51 Clinic Immunology/ Cancer Autoimmune Disorders; H

399.49 N/A

606.69 N/A

560.48 Clinic Cancer Bladder Cancer; Cholang

477.30 Clinic Nervous system/ RespiraChronic Obstructive Pulm

380.44 N/A

394.47 N/A

318.42 N/A

448.95 N/A

335.40 N/A

273.08 N/A

412.42 Clinic Cancer Glioblastoma; Hepatocel

580.74 Clinic Cancer B Cell Lymphoma; Solid

462.54 Clinic Cancer Diffuse Large B Cell Ly

412.51 N/A


352.14 Clinic Respiratory system Chronic Obstructive Pul

347.80 N/A


501.50 N/A

364.40 N/A

463.57 Clinic Cancer On-Small Cell Lung Canc

380.53 N/A

443.40 N/A

419.52 N/A

352.39 N/A

380.44 N/A

392.78 clinic Nervous system Alzheimer'S Disease; Can

416.83 N/A

271.26 N/A


406.48 N/A

249.33 N/A

419.39 N/A

240.34 N/A

425.50 Clinic Immunology Crohn'S Disease; Rheumat

485.50 Approved Cancer Basal Cell Cancer

382.38 Clinic Immunology Hypersensitivity; Inflamm

397.64 N/A

432.18 N/A


369.48 N/A

468.94 N/A

356.17 N/A

498.60 Clinic Cancer Breast Cancer; Endometr

352.38 N/A



387.39 N/A

423.90 Clinic Cancer Carcinoma; Haematologic

539.67 Clinic Cancer Cancer; Lymphoma; Soli

461.52 N/A


207.25 N/A

249.33 N/A

406.48 N/A

326.37 N/A

415.37 N/A

415.42 FDA Approved Cancer Chronic Lymphocytic Leu

361.23 N/A

260.16 N/A



554.52 clinic Cancer Cancer; Malignant Mela

308.31 Clinic Nervous system Alzheimer'S Disease; Ma

149.15 N/A


316.81 N/A

449.79 N/A

327.44 N/A

391.55 Clinic Cancer Peripheral T-Cell Lymph

365.45 Clinic Nervous system Pain

223.33 N/A

505.50 Clinic Cancer/ Respiratory Idiopathic Pulmonary Fi


514.52 N/A

584.89 N/A

383.42 N/A

318.35 FDA Approved Cancer Peripheral T-Cell Lymp

389.45 N/A

414.46 Clinic Cardiovascular system/ Essential Thrombocythaem

259.33 N/A

515.53 N/A

443.31 Clinic Cancer Iposarcoma

262.26 N/A

309.33 Clinic cancer Breast Cancer; Endometr

471.35 clinic Cancer Solid Tumours

447.49 N/A

440.50 FDA Approved Cancer Chronic Lymphocytic Le

461.94 Clinic cancer Acute Myeloid Leukaemi

591.47 clinic Cancer Solid Tumours

306.37 FDA Approved Cardiovascular System Myelofibrosis; Polycytha

330.42 N/A




555.84 N/A

341.40 N/A

454.63 N/A

374.32 N/A

205.21 N/A

284.29 N/A

568.67 N/A

520.62 N/A

434.48 N/A


418.37 N/A

626.62 N/A

425.48 N/A

292.37 N/A

635.59 FDA Approved Cancer Renal Cancer; Thyroid C


482.82 FDA Approved Cancer Colorectal Cancer; Gastr


420.63 Approved Metabolism Primary Biliary Cirrhosis

572.74 Clinic Cancer Non-Hodgkin'S Lymphom


958.22 FDA Approved Cardiovascular System Angiomyolipoma; Astrocyt

422.78 Clinic Cardiovascular system Atherosclerosis

370.42 Approved Nervous system Pain

490.06 N/A

418.71 Clinic cancer Chronic Lymphocytic Le

539.62 FDA Approved Cancer Idiopathic Pulmonary Fib

502.78 FDA Approved Others Stem Cell Mobilisation


306.14 N/A

449.83 N/A

547.04 Clinic cancer Multiple Myeloma; Solid

377.43 Clinic Cancer/ Endocrin/ ImmuCancer; Postmenopausal

343.42 N/A

362.40 N/A

396.67 N/A



384.48 N/A


333.74 N/A

251.28 N/A


290.36 N/A

304.25 N/A


459.50 FDA Approved Cardiovascular system Deep Vein Thrombosis;

384.39 Clinic Cancer Cancer; Wounds

320.26 Clinic Cardiovascular system/ Ngina Pectoris; Asthma;


228.20 N/A Cancer Cancers

295.27 Approved Immunology Chronic Rheumatoid Arthr

300.26 N/A

392.40 N/A

210.23 N/A

320.52 N/A

420.43 FDA Approved Respiratory system High Altitude Pulmonary

317.42 FDA Approved Metabolism Type 2 Diabetes Mellitus



232.28 Approved Cancer Prostate Cancer; Solid

475.31 FDA Approved Cancer Thyroid Cancer

430.71 FDA Approved Immunology Atopic Dermatitis

321.33 FDA Approved Immunology Herpes Simplex Virus Inf

416.51 FDA Approved Immunology Cardiovascular Disorders

253.26 FDA Approved Immunology Herpes Simplex Virus Inf

259.26 FDA Approved Cancer Mantle-Cell Lymphoma; M

331.34 FDA Approved Immunology Otitis Media

298.29 FDA Approved Immunology Aphthous Stomatitis

536.87 FDA Approved Respiratory system/ CanAsthma; Cancer; Heart D

387.81 FDA Approved Immunology Infectious Conjunctivitis


589.71 FDA Approved Cancer Acute Lymphoblastic Leu

414.40 Approved Immunology/ RespiratoryBacterial Infections; Le

Solid Tumors；Central Nervous System Tumors

428.54 FDA Approved Metabolism/ CardiovascuDiabetic Nephropathies;

300.44 FDA Approved Endocrine system Acne

291.37 Approved Others Cerebral Vasospasm

376.45 FDA Approved Cardiovascular system

445.54 FDA Approved Metabolism Diabetes Mellitus

166.20 FDA Approved Nervous system Epilepsy; Bipolar Disord

233.70 FDA Approved Cancer Glioblastoma


404.93 Approved Endocrine system Contraception

75.07 FDA Approved Immunology

261.66 Approved Cancer Acute Leukemia; Solid T



337.37 Approved Immunology Inflammatory

264.32 FDA Approved Cancer Cutaneous T Cell Lymp

252.24 FDA Approved Nervous system Migraine

230.27 FDA Approved Nervous system

358.84 Approved Immunology/ MetabolismAcute Pain; Ankylosing S

514.62 FDA Approved Cardiovascular system Cardiovascular Disorders

300.05 FDA Approved Cancer Cancer


228.24 Approved Others Oxydation

318.13 FDA Approved Immunology Inflammation; Pain

510.04 FDA Approved Endocrine system Osteoporosis; Postmeno

216.19 Approved Metabolism/ Cancer/ Im

346.20 FDA Approved Immunology Inflammatory Bowel Dis

366.49 FDA Approved Endocrine system Contraception

305.21 FDA Approved Immunology Liver Metastases

914.18 FDA Approved Cardiovascular system/ Coronary Artery Resteno

Hypertension; Diabeticnephropathy; And Some Types Of Chronic Heart Failure

Urinary Tract Infections

Migraine; Osteoarthritis; Kidney Stones; Rheumatoid Arthritis; Psoriatic Arthritis; Gout; Ankylosing Spondylitis; Menstrual Cramps; Tendinitis; And Bursitis

Colitis; Diarrhea

Psoriasis; Eczema; Vitiligo; And Somecutaneous Lymphomas

328.49 Clinic Others Hypospadias

186.18 FDA Approved Nervous system Cns Disorders; Neurodeg

323.42 Approved Metabolism Type 2 Diabetes

529.52 FDA Approved Cancer Chronic Myeloid Leukae


364.35 Approved Cancer Gastric Cancer; Hepatic

1219.60 FDA Approved Cardiovascular system Hypertension


368.39 Clinic Cancer/ Immunology Cancer; Inflammation

563.99 FDA Approved Immunology Leukemia

228.21 FDA Approved Cancer Acute Myeloid Leukaemia

265.22 FDA Approved Immunology Inflammatory

267.24 FDA Approved Immunology Herpes Simplex; Varicell

847.00 FDA Approved Immunology Mycobacterium Avium Co

485.49 Approved Respiratory system

586.65 FDA Approved Cardiovascular system Heart Failure; Hypertens

257.76 FDA Approved Cancer Hodgkin'S Lymphoma; Br

454.44 FDA Approved Cancer Cancers: Breast; Head An

441.61 FDA Approved Cardiovascular system Hypertension; Congestive

337.46 FDA Approved Endocrine system Endometriosis

258.24 Clinic Cancer Lymphocytic Leukaemia



415.82 Approved Immunology/ MetabolismOsteoarthritis; Rheumato




241.72 Withdrawn Metabolism

386.47 FDA Approved Cancer Renal Cancer

Acute Lymphocytic Leukemia (All); Hodgkin'S Lymphoma; Certainbrain Tumours

Chronic Bronchitis

Diabetic

370.38 FDA Approved Respiratory system Cystic Fibrosis-Associate

506.03 Approved Cancer Chronic Myeloid Leukem





218.10 Approved Immunology Arthrophlogosis

296.41 FDA Approved Endocrine system Contraception; Menopau

152.15 N/A

354.18 Approved Immunology Ankylosing Spondylitis; O

391.42 FDA Approved Immunology Filariasis

192.51 FDA Approved Immunology/ Cancer Mycosis Fungoides; Pros

267.24 FDA Approved Immunology Hiv-1 Infections

250.33 FDA Approved Metabolism

359.35 FDA Approved Cancer Breast Cancer; Colorecta

318.75 FDA Approved Cardiovascular system Hyperlipidaemia

294.17 Approved Nervous system Alzheimer'S Disease

206.28 FDA Approved Immunology/ Nervous syPain; Fever; Inflammatio

306.27 FDA Approved Immunology Fungal Infections

355.32 FDA Approved Cancer Solid Tumours

352.77 FDA Approved Immunology Tinea

200.17 Approved Cancer Cancers

270.37 N/A

138.19 N/A

168.15 N/A

244.20 FDA Approved Cancer Acute Myeloid Leukaemi

2086.75 FDA Approved Immunology Duodenal Ulcers

279.03 FDA Approved Cancer Cancer Metastases; Mali

326.43 FDA Approved Immunology Psoriasis

Rheumatoid Arthritis

Lower Lipid Levels

273.71 FDA Approved Nervous system Inflammatory

257.27 Withdrawn Cancer Cancer

319.34 FDA Approved Immunology Urinary Tract Infections

678.48 FDA Approved Immunology Rheumatic


153.14 Approved Immunology system/ EndTuberculosis; Ulcerative

369.34 Approved Immunology Bacterial Infections


492.14 FDA Approved Immunology Fungal Infections

348.48 N/A


254.28 FDA Approved Immunology Ocular Inflammation; Oc

243.22 FDA Approved Cancer Carcinomatous Meningiti

923.04 FDA Approved Cancer Acute Coronary Syndro

386.54 FDA Approved Endocrine system Contraception; Pain

228.29 FDA Approved Immunology Inflammation


194.19 FDA Approved Respiratory system Nervous System

189.22 FDA Approved Cancer Haematological Disorder


210.28 FDA Approved Cancer Ovarian Cancer

261.24 Approved Others Pesticide

268.35 FDA Approved Endocrine system

376.40 FDA Approved Nervous system Postoperative Pain In Inf

249.99 FDA Approved Cancer Cancer Metastases; Can


404.54 FDA Approved Cardiovascular system Cardiovascular Disease

393.46 Approved Cancer Acute Lymphoblastic Le

320.04 FDA Approved Cancer Adrenocortical Carcinom

Controlling The High Cholesterol And Triacylglyceride Level In The Blood

Gonorrheal Vaginitis; Atrophic Vaginitis; Menopausal Symptoms; Postpartum Lactation

598.10 Approved Endocrine system Female Infertility

562.67 Clinic Cancer Actinic Keratosis

333.34 Approved Immunology Pain; Inflammatory; Feve

314.36 FDA Approved Immunology/ Nervous syDental Pain; Dysmenorrho

435.88 FDA Approved Cardiovascular system Embolism; Stroke; Veno


194.15 FDA Approved Cancer Anaplastic Astrocytoma;

457.92 FDA Approved Cancer Cervical Cancer; Ovaria

416.94 Clinic Others Hot Flashes

246.31 N/A

340.30 FDA Approved Cancer Pheochromocytoma


360.83 FDA Approved Cardiovascular system Cardiovascular Disorders

288.82 Approved Cardiovascular system Ventricular Tachycardia



348.36 Clinic Cancer Ovarian Cancer; Renal C

414.41 FDA Approved Cancer Hpv


171.24 FDA Approved Nervous system Parkinson'S Disease

232.28 FDA Approved Cancer Early-Stage Breast Canc

302.41 Withdrawn Cancer Breast Cancer

392.40 FDA Approved Immunology Bacterial Infections; Pne

412.52 FDA Approved Endocrine system Acne Vulgaris


360.80 FDA Approved Immunology Cytomegalovirus Infectio

396.65 FDA Approved Metabolism

198.18 FDA Approved Respiratory system Bronchiectasis

180.16 FDA Approved Respiratory system Asthma; Chronic Obstruc

Ascariasis; Pinworm Disease; Hookworm Infections; Guinea Worm Infections; Hydatid Disease; And Giardia

Antibiotic(Lyme Disease; Chronic Prostatitis; Sinusitis; Pelvic Inflammatory Disease; Acne; Rosacea; And Rickettsial Infections)

Malignant Melanoma; Hodgkin'S Lymphoma; Sarcoma; And Islet Cell Carcinoma Of The Pancreas.

Vitamin D Deficiency

77.15 Approved Others Radiation Sickness

171.16 FDA Approved Immunology Bacterial Vaginosis

183.20 FDA Approved Immunology Anaphylaxis; Eye Disord

261.25 Withdrawn Others Vet Drug



247.72 FDA Approved Cardiovascular system/ Bradycardia; Heart Bloc

261.09 FDA Approved Cancer Pancreatic Cancer

300.44 FDA Approved Endocrine system/ CancAcne; Acne Vulgaris; Ac

272.38 FDA Approved Endocrine system Menopausal Syndrome

333.30 FDA Approved Immunology Anaphylaxis; Eye Disord


807.88 FDA Approved Cancer Head And Neck Cancer

286.24 Approved Immunology/ Cancer Inflammation; Allergy/ C

169.66 FDA Approved Cancer/ Cardiovascular Porphyria; Cardiovascul

579.99 FDA Approved Cancer Lymphoma

705.63 FDA Approved Immunology Mycoses

287.35 FDA Approved Immunology Inflammation

145.54 Approved Cancer Biliary Cancer; Breast

129.09 FDA Approved Cancer Anaplastic Astrocytoma;




527.59 Approved Immunology Bacterial Vaginosis; Vul


634.61 FDA Approved Immunology Antibiotic


246.19 FDA Approved Cancer/ Immunology Colorectal Cancer; Hepat

237.25 FDA Approved Others Vet Drug 200-205

Anal; Breast; Colorectal; Oesophageal; Stomach; Pancreatic And Skin Cancers

157.21 FDA Approved Endocrine system Menorrhagia

472.88 Approved/ Clinic Immunology/ Cancer Giardiasis; Cutaneous Le

201.25 FDA Approved Immunology Fungal Infection; Parasit

231.29 Approved Immunology Fever; Pain

188.22 FDA Approved Metabolism Acne; Melanosis; Rosac

246.30 FDA Approved Cancer Haematological Malignan

254.22 Approved Immunology Urinary Tract Infections


398.39 FDA Approved Immunology Rheumatoid Arthritis

361.37 FDA Approved Immunology Corneal Ulcer; Infectious

241.29 FDA Approved ENdocrine system Dysmenorrhoea

212.24 Approved Immunology Inflammatory; Pain

131.18 FDA Approved Cardiovascular system Bleeding Disorders

163.19 FDA Approved Respiratory system Poisoning; Chronic Obst

223.27 Approved Immunology Eczema; Neurodermatiti

254.28 Approved immunology


288.42 Approved Endocrine system Menopause; Polycystic

330.46 N/A

230.26 FDA Approved Immunology/ Nervous sy

361.82 Approved Cardiovascular system/


254.28 FDA Approved Nervous system Musculoskeletal Pain; Pa

359.66 Approved Others Vet Drug


351.40 FDA Approved Immunology Ankylosing Spondylitis; B

274.18 Clinic Nervous system Hearing Loss; Noise-Indu

514.69 FDA Approved Endocrine system Contraception

295.81 FDA Approved Cancer Haemangioma

Inflammatory

Migraine; Osteoarthritis; Kidney Stones; Rheumatoid Arthritis; Psoriatic Arthritis; Gout; Ankylosing Spondylitis; Menstrual Cramps; Tendinitis; And Bursitis

Hypertriglyceridemia； Hypercholesteremia



240.22 Approved Immunology Diarrhea



261.70 Approved Nervous system Migraine

179.22 Approved Immunology Fever; Pain

331.35 FDA Approved Immunology Non-Steroidal Anti-Infla

60.06 FDA Approved Immunology Helicobacter Infections

132.16 Approved Others Dietary Shortage

188.23 Approved Immunology Inflammatory; Fever


268.27 Approved Cancer Breast Cancer; Prostatic


333.14 Approved/ Clinic Immunology/ Cancer Herpes Zoster/ Pancreat


347.34 FDA Approved Immunology Bacterial Infection


337.56 Withdrawn Nervous system Vasodilat

327.12 FDA Approved Immunology Cestodes

293.32 FDA Approved Nervous system

279.10 FDA Approved Cancer Hematologic Malignancie


248.16 Approved Thrombus; Cerebral Infarc

99.09 Approved Nervous system Head Pain; Sleepiness

171.24 FDA Approved Nervous system Postherpetic Neuralgia

481.50 Approved Respiratory system Allergic Rhinitis; Asthma


255.23 FDA Approved Immunology Ocular Herpes Simplex

Eczema; Psoriasis; Arthritis; Allergies; Ulcerative Colitis; Lupus; Sympathetic Ophthalmia; Temporal Arteritis; Uveitis; Ocular Inflammation; Urushiol-Induced Contact Dermatitis; Aphthous Ulcers

Inflammatory Conditions Of The Mouth Andthroat

Osteoarthritis; Rheumatoid Arthritis

High Blood Pressure; Heart Failure; And After Heart Attacks

Cerebrovascular system

418.57 FDA Approved Metabolism Diabetic Cardiomyopathy;

822.94 FDA Approved Cancer Hepatocellular Carcinom

531.43 FDA Approved Immunology Mycoses

76.06 FDA Approved Cancer Cancer; Sickle Cell Ana

183.25 N/A

138.12 FDA Approved Immunology Fever Relief

153.14 FDA Approved Immunology Inflammatory Bowel Dis

229.30 N/A

137.18 N/A

180.16 Approved Cardiovascular system

138.12 N/A

244.24 Approved Cancer Leukemia

179.22 Clinic Cancer Colorectal Cancer; Glio

426.85 FDA Approved cancer Renal Cancer; Thyroid C






677.18 Approved Cancer Breast Cancer; Cervical


236.29 FDA Approved Respiratory system Asthma


234.34 FDA Approved Nervous system Depressant

381.37 FDA Approved Nervous system Acute Pain; Ankylosing S

302.19 Clinic Cancer Follicular Lymphoma


356.41 FDA Approved Immunology Trypanosomiasis

357.79 FDA Approved Nervous system Acute Pain

Arteriosclerosis; Certain Vascular Diseases; Angina Pectoris; And Hypertension

Fungal Infection

Inflammatory Disorders Such As Rheumatoid Arthritis Or Noninflammatory Disorders Such As Osteoarthritis

Colorectal Cancer

Heart Failure; Liver Scarring; Kidney Disease

249.26 Approved Metabolism Gout

209.25 FDA Approved Others Alopecia

172.18 FDA Approved Immunology Exanthema

206.28 Approved Immunology Back Pain; Dysmenorrhoea

444.70 FDA Approved Immunology Fungalinfection

381.68 FDA Approved Immunology Tinea Pedis


290.28 Approved Respiratory system Pulmonary Tuberculosis

516.57 Approved Immunology Topical Antiseptic

173.21 N/A


179.17 Approved Immunology Osteoarthritis

465.49 Approved Immunology Fungalinfection

429.46 Approved Immunology Bacterial Infections

362.09 FDA Approved Immunology Inflammatory

358.19 FDA Approved Cardiovascular system Atherosclerosis

393.35 N/A

344.49 FDA Approved Endocrine system Breast Cancer; Decreas


627.73 FDA Approved Cardiovascular system Deep Vein Thrombosis;

376.49 FDA Approved Endocrine system Menopausal Syndrome


398.47 FDA Approved Cancer Gastrointestinal Stroma

532.56 FDA Approved Cancer Gastrointestinal Stroma


393.44 FDA Approved Cancer Non-Small Cell Lung Can

436.56 FDA Approved Endocrine system Menopause

416.13 FDA Approved Immunology Oropharyngeal Candidias

402.48 Approved Immunology/ Cancer Inflammatory; Autoimmun

160.11 Clinic Metabolism Type 2 Diabetes Mellitus


437.89 FDA Approved Immunology Infectious Conjunctivitis;

281.31 Withdrawn Immunology

399.44 FDA Approved Metabolism Gout; Familial Mediterra

438.47 Approved Nervous system

206.03 FDA Approved Cancer Cancer Metastases; Can


244.26 FDA Approved Nervous system Musculoskeletal Pain

194.23 Approved Cancer Acute Leukemias And M


335.34 Withdrawn Immunology/ Nervous syInflammatory; Pain



432.55 FDA Approved Nervous system/ CancerAlzheimer'S Disease; Ang

313.71 Withdrawn Immunology

326.26 Approved Immunology/ Respiratory

318.14 FDA Approved Metabolism/ Endocrine

281.98 FDA Approved Nervous system Huntington'S Disease

263.20 FDA Approved Cancer Biliary Cancer; Bladder

367.8 FDA Approved Immunology Acute Sinusitis; Anthrax;

321.17 Approved Cancer Benign Prostatic Hyperpl

624.59 Approved Cardiovascular system Hypertension


314.36 FDA Approved Immunology Dysmenorrhoea; Osteoarth

461.01 FDA Approved Metabolism Diabetic Nephropathies;


258.23 FDA Approved Cancer Leprosy; Multiple Myelo

354.44 Approved Respiratory system Asthma

Inflammatory

Joint And Muscular Pain

Quinolone Antibiotic

Inflammatory

Allergic Conjunctivitis; Allergic Rhinitis; Bronchial Asthma

Joint; Muscular Pain; Arthritis And Dysmenorrhea

296.15 Approved Immunology Pain; Inflammation

515.87 FDA Approved Immunology Malaria

778.93 FDA Approved Cancer Breast cancer; Non-small


427.41 FDA Approved Cancer Mesothelioma; Non-Small

861.95 Clinic Endocrine system Hormone Refractory Pros

558.63 FDA Approved Immunology Rheumatoid Arthritis; Os


266.09 FDA Approved Cardiovascular system Hypertension; Congestive

350.45 Approved Cardiovascular system Cerebrovascular Disorde


517.40 FDA Approved Cancer Acute Myeloid Leukaemia

508.63 FDA Approved Cardiovascular system Arterial Thrombosis; He

226.34 Clinic Immunology/ Cancer Non-Alcoholic Fatty Live

530.45 FDA Approved Cancer Chronic Myeloid Leukae

511.51 FDA Approved Cancer Gastric Cancer; Pancrea

387.71 FDA Approved Immunology Fungalinfections


356.51 FDA Approved Endocrine system Contraception; Metrorrha

240.31 FDA Approved Cancer Actinic Keratosis; Basal

588.56 FDA Approved Cancer Small Cell Lung Cancer;

606.73 Approved Cancer Radiation-Induced Leuko

367.78 Approved Others Plaque; Malodor

328.27 Approved Immunology/ RespiratoryChronic Bronchitis

349.31 FDA Approved Immunology Aspergillosis; Candidiasi

437.52 FDA Approved Cancer Renal Cancer; Sarcoma

394.72 FDA Approved Cancer Breast Cancer; Cancer;



Pleural Mesothelioma; Non-Small Cell Lung Cancer.

328.49 FDA Approved Cardiovascular system Anaemia; Hereditary An

943.47 FDA Approved Cancer Breasr Cancer

581.06 FDA Approved Cancer Breasr Cancer

112.09 FDA Approved Cancer/ Digestive syste Cancer; Gastrointestinal

151.16 FDA Approved Nervous system Pain

214.65 Approved Cardiovascular system






203.24 Approved Immunology Pain And Fever


364.53 FDA Approved Cancer Breast Cancer; Prostate

266.34 FDA Approved Endocrine system Aenopausal

407.58 FDA Approved Cancer/ Immunology Cancer Metastases; Leis

125.15 Clinic Cancer/ Metbolism Prostate Cancer; Hepatic

211.15 Approved Respiratory system Extrapulmonary Tubereul

271.79 FDA Approved Cardiovascular system Cardiac Arrhythmias

148.20 Approved Cancer Leukopenia



313.29 Approved Immunology Worm Infection


137.14 Approved Immunology Pain; Fever

263.31 Approved Cardiovascular system Platelet Dysfunction

Hyperlipoproteinemia Type Iii

Acute Promyelocytic Leukemia

Pain; Fever; And Inflammation

Pathways Target ReceptorCell Cycle/Checkpoint Rho inhibitor Rho

Neuroscience COX inhibitor COX-1 , COX-2

Metabolism Retinoid Receptor agonisRARα , RARβ

Immunology/InflammatioPKC inhibitor PKCα , PKCη , PKCγ , P

Chromatin/Epigenetic Sirtuin inhibitor SIRT2 , SIRT1

JAK/STAT signaling STAT inhibitor STAT3 , STAT5

Metabolism PDE inhibitor PDE4

Immunology/InflammatioPKC inhibitor PKCα , PKCβ2 , PKCβ1

Endocrinology/ HormoneEstrogen/progestogen Recselective estrogen recep

Others Others Others

Cell Cycle/Checkpoint HSP (e.g. HSP90) inhibitHSP90

JAK/STAT signaling STAT inhibitor STAT3

Endocrinology/ HormoneAndrogen Receptor antagCYP17 , Androgen Recep

DNA Damage/DNA repaiDNA/RNA Synthesis inhibDNA polymerase α , DNA

Apoptosis IAP inhibitor 5-LO , mPGES-1 , XIAP

Cell Cycle/Checkpoint Rho inhibitor Rac1 , Rac1b , Rac2 , R

PI3K/Akt/mTOR signalin PI3K inhibitor PI3Kγ

Metabolism Retinoid Receptor inhibitRXR

GPCR/G Protein S1P Receptor modulatorS1P1 receptor , S1P5 rec

Cell Cycle/Checkpoint HSP inhibitor p185 , HSP90 (N-termina

Immunology/InflammatioTGF-beta/Smad inhibitorTGFβR1(ALK5)

DNA Damage/DNA RepaiPARP inhibitor PARP

MAPK Signaling MEK inhibitor MEK1/2/5;ERK1/5;JNK2

JAK/STAT Signaling JAK inhibitor JAK3 , JAK2 , JAK1 , R

Cell Cycle/Checkpoint Aurora Kinase inhibitor Aurora A , Aurora B , LC

JAK/STAT Signaling JAK inhibitor JAK2 , JAK2

Cell Cycle/Checkpoint HSP inhibitor HSP90α , HSP90β

Angiogenesis Bcr-Abl inhibitor DUB , Bcr-Abl

Immunology/InflammatioPKC inhibitor PKCθ , PKCβ1 , PKCα ,

DNA Damage/DNA RepaiDNA-PK inhibitor DNA-PK , mTOR , PI3K

Apoptosis Bcl-2 inhibitor Bcl-2

Metabolism Transferase inhibitor FTase

Chromatin/Epigenetic HDAC inhibitor HDAC

Angiogenesis Src inhibitor LCK , Fyn , EGFR , JAK

Apoptosis Mdm2 inhibitor Mdm2

Cell Cycle/Checkpoint CDK inhibitor CDK4/CyclinD3 , CDK4/C

Cell Cycle/Checkpoint CDK inhibitor CDK4/CyclinD3 , CDK4/C

Tyrosine Kinase/AdaptorHER2 inhibitor ErbB2 , EGFR , ErbB4 , c

Chromatin/Epigenetic HDAC inhibitor HDAC1 , HDAC3

Tyrosine Kinase/AdaptorPDGFR inhibitor PDGFR , c-Kit , v-Abl

DNA Damage/DNA RepaiTopoisomerase inhibitor Topo I

Angiogenesis Src inhibitor c-Src , LCK , c-YES , E

Metabolism DHFR inhibitor TS , TS , DHFR , DHFR

DNA Damage/DNA RepaiDNA/RNA Synthesis inhibDNA/RNA Synthesis

DNA Damage/DNA RepaiPARP inhibitor PARP1

MAPK Signaling MEK inhibitor MEK

MAPK Signaling MEK inhibitor MEK1

Angiogenesis BTK inhibitor BTK

Metabolism CYP inhibitor CYP17

Metabolism CYP inhibitor CYP17

Cell Cycle/Checkpoint Microtubule Associated inβ-tubulin

Proteases/Proteasome Gamma-secretase inhibitAβ , γ secretase(Aβ)

Cell Cycle/Checkpoint CDK inhibitor CDK4 , CDK6

Chromatin/Epigenetic PARP inhibitor PARP

MAPK Signaling MEK inhibitor MEK

PI3K/Akt/mTOR SignalinGSK-3 inhibitor GSK-3β

Apoptosis Bcl-2 inhibitor Bcl-w , Bcl-B , Mcl-1 , Bfl

Tyrosine Kinase/AdaptorVEGFR inhibitor PDGFRβ , FGFR1 , Flk1

Cell Cycle/Checkpoint PLK inhibitor PLK1 , PLK2 , PLK3 , PI

Cell Cycle/Checkpoint HSP activator HSP70

PI3K/Akt/mTOR SignalinPI3K inhibitor PI3Kδ , PI3Kα , PI3K , P

Immunology/InflammatioIκB/IKK inhibitor IKK

Tyrosine Kinase/Adaptorc-Met inhibitor Met , Flk1 , RON , FGFR

Tyrosine Kinase/AdaptorEGFR inhibitor EGFR , ErbB2

MAPK Signaling MEK inhibitor MEK1/2 (MM cell line)

Tyrosine Kinase/AdaptorHER2/ErbB2;EGFR/FGFRHER2/ErbB2;EGFR;FGF

Tyrosine Kinase/Adaptorc-Met inhibitor c-Met

DNA Damage/DNA RepaiDNA/RNA Synthesis inhibUT-SCC-19A

PI3K/Akt/mTOR SignalinPI3K inhibitor PIKfyve , p110α

GPCR/G Protein LPA Receptor antagonistLPA1 , LPA3 , LPA2

PI3K/Akt/mTOR SignalinmTOR inhibitor mTOR , ATM , ATR , DN

Tyrosine Kinase/AdaptorHER2 inhibitor ErbB2 , EGFR , ErbB3

Apoptosis Caspase inhibitor Caspase-4 , Caspase-1

Cell Cycle/Checkpoint Chk inhibitor Chk1

Angiogenesis FGFR inhibitor FGFR1

Angiogenesis Src inhibitor c-Src , LCK , c-YES , E

Chromatin/Epigenetic Histone MethyltransferasePRMT5

Cell Cycle/Checkpoint Microtubule Associated inTubulin

Cell Cycle/Checkpoint PLK inhibitor PLK1

MAPK Signaling ERK inhibitor ERK2 , ERK1 , MEK1

DNA Damage/DNA RepaiHDAC inhibitor HDAC5 , HDAC4

Chromatin/Epigenetic Histone MethyltransferaseEZH2 , EZH1

Others Others Abl1 , LRRK2 , MLK3 ,

Tyrosine Kinase/AdaptorTrk receptor inhibitor TrkA , CDK2 , C-Raf-1

MAPK Signaling p38 MAPK inhibitor p38α

PI3K/Akt/mTOR SignalinmTOR inhibitor mTORC1 , mTOR , DNA-

Proteases/Proteasome Cysteine Protease inhibitCysteine protease

PI3K/Akt/mTOR SignalinmTOR inhibitor mTORC1 , mTOR , mTOR

Cell Cycle/Checkpoint Chk inhibitor Chk1 , VEGFR2 , Fms ,

Proteases/Proteasome Proteasome inhibitor Chymotrypsin-like prote

Angiogenesis FGFR inhibitor FGFR2 , FGFR1 , FGFR

Apoptosis Mdm2 inhibitor p53/MDM2 interaction


Tyrosine Kinase/AdaptorIGF-1R inhibitor IGF-1R , Insulin Receptor

Microbiology & Virology CCR antagonist MIP-1α , RANTES , MIP-

Cell Cycle/Checkpoint PAK inhibitor PAK1 , PAK2 , PAK2 ,

Apoptosis Caspase inhibitor Pan-caspase

Apoptosis IAP inhibitor cIAP1 , XIAP

Cell Cycle/Checkpoint HDAC inhibitor HDAC1 , HDAC2

Apoptosis Caspase inhibitor Caspase-3

Endocrinology/ HormoneAndrogen Receptor antagAndrogen Receptor

Neuronal Signaling NMDAR inhibitor aspartic protease

Tyrosine kinase TRK Receptor inhibitor; ATrkA; TrkB; TrkC; ALK

Epigenetics Histone Demethylase Histone Demethylase

DNA Damage/ Repair; CelCDK inhibitor; CDK7

HDAC inhibitor; HDAC

PI3K/ Akt/ mTOR EGFR inhibitor; EGFR

Others lipid Others

Others microtubule nucleation Others

JAK/STAT Signaling; EGFR inhibitor L858R/T790M EGFR; Exo

Stem Cells/Wnt Notch inhibitor Notch

GPCR/G protein GnRH antagonist GnRH


MAPK/ERK Pathway MEK inhibitor; MEK1/2

Tyrosine Kinase/AdaptorALK inhibitor; ALK;


Other caspase caspase-3

Protein Tyrosine Kinase ALK inhibitor; ALK


Metabolism IDO1 inhibitor IDO1

JAK/STAT Signaling EGFR EGFR

Membrane Transporter/I ATPase inhibitor Na+/K+-ATPase

Tyrosine Kinase/AdaptorPKC inhibitor PKC

Metabolism UGT inhibitor UGT1A6; UGT2B7

JAK/STAT Signaling JAK; STAT inhibitor

Others Others OthersJAK/STAT Signaling STAT inhibitor STAT3

Immunology/InflammatioAntibiotics Other

DNA Damage & Repair PPAR inhibitor; PARP2; PARP1; V-PARP

DNA Damage & Repair; CeCDC7 kinase inhibitor CDC7 kinase

DNA Damage/DNA Repai DNA topoisomerase I inh DNA topoisomerase I (to

PI3K/Akt/mTOR Signalin ATR

PI3K/Akt; Wnt/β-catenin Others Others

Neuroscience GABAA GABAA


Apoptosis IAP antagonist; Apoptosis protein


TGF-beta/Smad

Tyrosine Kinase/AdaptorMET, AXL/MER, and FGFRMET, AXL/MER, and FGFR

DNA Damage/DNA repaiPARP Inhibitor

Others PFKFB3 inhibitor PFKFB3

GPCR/G protein LPL agonist S1P1

Cell Cycle/Checkpoint Histone methyltransferasG9a; GLP

JAK2; STAT3

ATM/ATR inhibitor

IL-1β, IL-6, and TNF-alfa inhibitorIL-1β, IL-6, and TNF-alfa

TNKS2

Cell Cycle/Checkpoint; Microtuble; tubulin; ADCsMicrotuble; tubulin; ADCs


JAK/STAT signaling STAT inhibitor STAT

Immunology/InflammatioCOX inhibitor COX-2

Immunology/InflammatioPKC inhibitor PKC isoforms (α, β, γ),

Membrane Transporter/I MCT inhibitor MCT1

Tyrosine Kinase/AdaptorMET inhibitor MET

Cell Cycle/Checkpoint CDK cyclin D1

Cell Cycle/Checkpoint HDAC HDAC


Cell Cycle/Checkpoint Histone methyltransferasWDR5

MAPK/ERK Pathway JNK JNK1


Tyrosine Kinase/AdaptorBcr-Abl Bcr-Abl

Cell Cycle/Checkpoint CDK CDK


PI3K/Akt/mTOR PI3K inhibitor PI3K

GPCR/G Protein CCR CCR1 agonist

CDK inhibitor; DNA topo CDK1;CDK2; DNA topois

Tyrosine Kinase/AdaptorSyk Syk

Apoptosis p53 activator MDM-2/p53

DNA Damage/DNA RepaiTopoisomerase Top I

Cell Cycle/Checkpoint PARP Tankyrase

RNR inhibitor; PARP inhiRNR; PARP

PI3K/ Akt/ mTOR p110 inhibitor; mTOR p110α, p110β, p110γ, p

Immunology/InflammatioNF-κB inhibitor NF-κB

Endocrinology/ HormoneAndrogen receptor agoniAndrogens receptor

Endocrinology/ HormoneAndrogen receptor agoniAndrogens receptor

Endocrinology/ HormoneAndrogen Receptor agonAndrogens receptor

Endocrinology/ HormoneAndrogen Receptor agonAndrogens receptor

Angiogenesis FAK inhibitor FAK

DNA Damage/DNA RepaiTopoisomerase inhibitor Topoisomerase II, Topoi

Tyrosine Kinase/Adaptorc-Met inhibitor Met , KDR , Tie-2 , VE

Cell cycle/Checkpoint CDK inhibitor CDK4;CDK6

MAPK Signaling JNK inhibitor JNK1,JNK2,Aurora A,T

Chromatin/Epigenetic HDAC inhibitor EGFR , HDAC , HDAC1

Others Others PFKFB3

Chromatin/Epigenetic Histone Demethylase inhiJMJD3

Chromatin/Epigenetic Histone MethyltransferaseDOT1L

NF-κB IκB/IKK inhibitor; IKK

Metabolism; Proteases/ PPAR activator; MMP inhiPPARα/γ; MMP-1

Chromatin/Epigenetic DNA Methyltransferase inDNMT1



JAK/STAT Signaling JAK inhibitor JAK1/JAK2/JAK3/Try2

Tyrosine Kinase/AdaptorTGF-beta/Smad inhibitor;ALK/insulin receptor/IG

JAK/STAT Signaling Pim inhibitor; FLT3 inhibiPim1; FLT3; Pim3;Pim2

PI3K/Akt/mTOR SignalinGSK-3 inhibitor GSK-3α;GSK-3β

JAK/STAT Signaling JAK inhibitor JAK1/2/3

Neuroscience; Protease Gamma-secretase inhibitNotch

PI3K/Akt/mTOR SignalingGSK-3 inhibitor;S6 KinaseGSK-3α/β;p70 S6K/c-Sr

Stem Cell CK inhibitor CK1ε

Tyrosine Kinase/AdaptorJAK inhibitor; PDGFR inhibJAK2;PDGFRβ;JAK1;FLT3

Angiogenesis Bcr-Abl inhibitor Abl

Stem Cell Hedgehog/Smoothened ReGLI1


JAK/STAT Signaling JAK inhibitor JAK1, JAK2

Angiogenesis Bcr-Abl inhibitor Bcr-Abl;Src

Stem Cell Wnt/beta-catenin inhibitoTNKS2

Immunology/InflammatioTGF-beta/Smad inhibito ROS1;ALLK;LTK;FER;F

Cell Cycle/Checkpoint ROCK inhibitor ROCK-II; PKA; PKG; PK

Tyrosine Kinase/AdaptorTGF-beta/Smad inhibitor;ALK;FER;ROS/ROS1

JAK/STAT Signaling Pim inhibitor Pim1

Chromatin/Epigenetic Histone MethyltransferaseEZH2;EZH1

Apoptosis c-myc inhibitor c-Myc-Max

Immunology/InflammatioCXCR antagonist CXCR2

Immunology/InflammatioeIF-2α inhibitor eIF2α

JAK/STAT Signaling JAK inhibitor JAK1/2

JAK/STAT Signaling JAK inhibitor Jak2; Jak2-V617F

Tyrosine Kinase/AdaptorTGF-beta/Smad inhibitorALK

PI3K/Akt/mTOR SignalinATM/ATR inhibitor ATR

Immunology/InflammatioTGF-beta/Smad inhibitorALK4/5/7

Immunology/InflammatioTGF-beta/Smad inhibitorTGF-β1;p38 MAPK

PI3K/ Akt/ mTOR EGFR Inhibitor EGFR

Endocrinology/ HormoneAndrogen Receptor agonAndrogen Receptor

Chromatin/Epigenetic PARP inhibitor PARP1/2

MAPK Signaling p38 MAPK inhibitor p38 MAPK;JNK

PI3K/Akt/mTOR SignalinAkt inhibitor;MEK inhibitoAkt-phosphorylation;ME

Immunology/InflammatioNF-κB inhibitor;p53 activNF-κB;p53;PPARγ

Membrane Transporter/I Calcium Channel inhibitoCalcium Channel

Tyrosine Kinase/AdaptorEGFR inhibitor;mTOR inhEGFR;mTOR

JAK/STAT Signaling STAT inhibitor STAT3

Immunology/InflammatioTNF-alpha inhibitor TNF-alpha


Metabolism PPAR activator PPAR-alpha

Apoptosis p53 activator p53;NAPDH

Metabolism Farnesoid X receptor antFarnesoid X receptor

Tyrosine Kinase/AdaptorEGFR inhibitor EGFR


Immunology/InflammatioNF-κB inhibitor;p53 activNF-κB;p53

GPCR/G Protein cAMP activator Adenylyl cyclase

DNA Damage/DNA RepaiTopoisomerase inhibitor Topoisomerase II

PI3K/Akt/mTOR SignalinATM/ATR inhibitor ATR

Metabolism PDE inhibitor PDE4; TNF-α


NF-κB Keap1-Nrf2 Nrf2

Immunology/InflammatioTLR inhibitor TLR2



PI3K/Akt/mTOR SignalinAkt inhibitor p-Akt

Proteases/Proteasome MMP inhibitor P-gp, MMP-9

Chromatin/Epigenetic Sirtuin activator Sirtuins

PI3K/Akt/mTOR SignalinGSK-3 inhibitor GSK3β

Neuroscience Opioid Receptor agonist κ-opioid receptor

Metabolism Dehydrogenase inhibitorDehydrogenase


Immunology/InflammatioROS ROS


Metabolism FAAH inhibitor; EGFR inhFAAH;EGFR

MAPK Signaling p38 MAPK inhibitor p38 MAPK

JAK/STAT Signaling JAK inhibitor JAK

Tyrosine Kinase/AdaptorsEGFR inhibitor; PKC inhiEGFR;PKA;PKC


Neuroscience COX inhibitor COX-1;COX-2

Others Notch-1 inhibitor Others

Proteases/Proteasome MMP inhibitor MMP

DNA Damage/DNA RepaiTopoisomerase inhibitor HIV-1;Eukaryotic topois


Neuroscience COX inhibitor COX-2


Stem Cell Wnt/beta-catenin activat wnt

Tyrosine Kinase/AdaptorTrk receptor inhibitor TrkB





Immunology/InflammatioTGF-beta/Smad inhibitorTGF-beta

Cell Cycle/Checkpoint Microtubule Associated inMicrotubules; Abl


Proteases/Proteasome MMP inhibitor MMP-3

Neuroscience AChR antagonist Nicotinic AChR

Neuroscience GABAR Agonist GABAR


DNA Damage/DNA RepaiTopoisomerase inhibitor Topoisomerase I


Immunology/InflammatioPKC inhibitor PKCα;PKCε

GPCR/G Protein PAFR antagonist PAFR

Proteases/Proteasome MMP inhibitor MMP-8/9/26/1


Tyrosine Kinase/AdaptorPDGFR inhibitor PDGFR


Cell Cycle/Checkpoint; Aurora Kinase inhibitor; JAurora A;Aurora B;JAK3

MAPK Signaling MEK inhibitor MEK1/2;AP-1;PKC

Apoptosis p53 inhibitor p53

PI3K/Akt/mTOR SignalinmTOR inhibitor mTORC1,mTORC2

Tyrosine Kinase/AdaptorEGFR inhibitor Mutated EGFR


Stem Cell Wnt/beta-catenin inhibitoWnt

Tyrosine Kinase/Adaptorc-Met inhibitor;TAM Recepc-Met;Axl;Ron;Tyro3;Mer

Neuroscience CaMK inhibitor CaMKII

Angiogenesis Syk inhibitor Syk;FGR;MLK1;YES;FLT3

Cell Cycle/Checkpoint CK inhibitor CK2

Neuroscience CaMK inhibitor CaMKI

PI3K/Akt/mTOR Signali ATM/ATR inhibitor; DNA-PATM;DNA-PK

Stem Cell Wnt/beta-catenin inhibitoPorcn


Cell Cycle/Checkpoint CDK inhibitor CDK1/CyclinB;CDK2/Cyc

Tyrosine Kinase/AdaptorPDGFR inhibitor PDGFRα/β


MAPK Signaling JNK inhibitor JNK

Metabolism PPAR agonist PPARβ/δ

PI3K/Akt/mTOR SignalinPI3K inhibitor PI3Kγ;PI3Kδ;PI3Kβ;PI3

GPCR/G Protein Adenosine Receptor AgoA2A adenosine receptor

Cell Cycle/Checkpoint CDK inhibitor CLK4;CLK1;CLK2;Dyrk1

PI3K/Akt/mTOR SignalinATM/ATR inhibitor ATR/ATM

MAPK Signaling JNK inhibitor JNK3;JNK1;JNK2;Kit;M

PI3K/Akt/mTOR SignalinPI3K inhibitor; DNA-PK inDNA-PK; p110α/p110β/p

PI3K/Akt/mTOR SignalinPI3K inhibitor PI3Kδ;PI3Kγ;PI3Kα;PI3

PI3K/Akt/mTOR SignalinPI3K inhibitor PI3Kβ, PI3Kγ, PI3Kδ

Tyrosine Kinase/Adaptorc-FMS inhibitor c-Fms kinase

Membrane Transporter/I BCRP inhibitor BCRP/P-gp

Tyrosine Kinase/AdaptorVEGFR inhibitor VEGFR

Immunology/InflammatioTGF-beta/Smad inhibitorFAK/ALK

Cell Cycle/Checkpoint; CDK inhibitor; JAK inhibitFLT3, JAK2, and CDKs


Chromatin/Epigenetic Histone MethyltransferaseMenin-MLL

Metabolism IDO inhibitor IDO1

Metabolism Transferase inhibitor NMPRTase

Chromatin/Epigenetic Histone MethyltransferaseMenin-MLL

Tyrosine Kinase/AdaptorFGFR inhibitor; VEGFR inhFGFR1;VEGFR2;c-Src;

Immunology/InflammatioTGF-beta/Smad inhibitorALK;Ack

Angiogenesis Bcr-Abl inhibitor Abl1;FLT3;KDR;Tie-2;Ly

Neuroscience; Protease BACE inhibitor;Beta amylBACE1; Beta Amyloid;

Tyrosine Kinase/AdaptorJAK inhibitor; FLT3 inhibJAK2(V617F);FLT3;JAK


JAK/STAT Signaling JAK inhibitor JAK3


Apoptosis Bcl-2 inhibitor Bcl-2;MCL-1

Tyrosine Kinase/AdaptorHER2 inhibitor HER1;HER2;HER4

DNA Damage/DNA RepaiThymidylate synthase inhThymidylate synthase

Neuroscience; Protease Gamma-secretase inhibitgamma-secretase;Beta A

Tyrosine Kinase/AdaptorCSF-1R inhibitor;c-Kit inhFLT1/KDR/CSF-1R/LCK/C

MAPK Signaling MEK inhibitor MEK1

Angiogenesis FLT3 inhibitor FLT3;Mer;Aurora B;RET

PI3K/Akt/mTOR SignalinPI3K inhibitor; mTOR inhiPI3Kα/β/δ/γ, mTOR

Stem Cell Wnt/beta-catenin inhibitoPorcn

Cell Cycle/Checkpoint Aurora Kinase inhibitor Aurora C;Aurora A;Auror

PI3K/Akt/mTOR SignalinPI3K inhibitor; DNA-PK inp110γ;PI4KIIIβ;p110α;

Cell Cycle/Checkpoint CDK inhibitor CDK1,2,4,6

Cell Cycle/Checkpoint Aurora Kinase inhibitor Aurora A/B/C

Tyrosine Kinase/AdaptorHER2 inhibitor; MEK inhiHER1/HER2/HER4/MEK

Tyrosine Kinase/Adaptorc-Kit inhibitor; PDGFR inhKit;Lyn B;PDGFRα;PDG

PI3K/Akt/mTOR SignalinGSK-3 inhibitor GSK-3α/β

Neuroscience CaMK inhibitor CaMKII

Angiogenesis Syk inhibitor Syk

Angiogenesis BTK inhibitor; Src inhibit BTK;YES;c-Src

Cell Cycle/Checkpoint Aurora Kinase inhibitor Aurora B/Aurora A

Tyrosine Kinase/AdaptorEGFR inhibitor; JAK inhibEGFR;JAK2;ErbB2

Endocrinology/ HormoneEstrogen/Progestogen ReEstrogen/Progestogen re

Membrane Transporter/I CFTR modulator CFTR

Chromatin/Epigenetic PARP inhibitor PARP1, PARP2

Stem Cell Hedgehog/Smoothened ReHedgehog/Smoothened R

Tyrosine Kinase/AdaptorVEGFR inhibitor VEGFR1,2,3

Endocrinology/ HormoneSomatostatin receptor Somatostatin receptor

Tyrosine Kinase/AdaptorVEGFR inhibitor VEGFR2;Ret;c-kit;c-Src;

Endocrinology/ HormoneAndrogen Receptor AgonAndrogen Receptor

Tyrosine Kinase/AdaptorVEGFR inhibitor VEGFR2;Flk1;FGFR1;V


Endocrinology/ HormoneEstrogen/Progestogen ReEstrogen/progestogen R

Endocrinology/ HormoneAndrogen Receptor AgonAndrogen Receptor

Immunology/InflammatioTGF-beta/Smad inhibitorTGF-beta/Smad; Histami

DNA Damage/DNA RepaiDNA/RNA Synthesis inhibAdenosine deaminase

Neuroscience COX inhibitor Prostaglandin G/H synth

Neuroscience COX inhibitor COX-1,COX-2

Cell Cycle/Checkpoint Microtubule Associated inMicrotubule/Tubulin

GPCR/G Protein S1P Receptor antagonistS1P receptor

Immunology/InflammatioPGE2 inhibitor PGE2, PGF2

Membrane Transporter/I Integrin antagonist integrin IIb/IIIa

Angiogenesis; Endocrin RAAS inhibitor; ACE inhibAT1 receptor

Endocrinology/ HormoneProgesterone receptor mProgesterone receptor

Tyrosine Kinase/AdaptorEGFR inhibitor; HER2 inhEGFR/HER2/p95-HER2

Cell Cycle/Checkpoint CDK inhibitor Chk1;CDK2;Chk2

Tyrosine Kinase/Adaptorc-Kit inhibitor; PDGFR inhc-Kit;PDGFRα;FLT3

Tyrosine Kinase/AdaptorVEGFR inhibitor VEGFR1/FLT1;VEGFR2/K

MAPK Signaling p38 MAPK inhibitor p38α

Chromatin/Epigenetic HDAC inhibitor HDAC1;HDAC2;HDAC11


Immunology/InflammatioTGF-beta/Smad inhibitorTβRI

Cell Cycle/Checkpoint CDK inhibitor CDK2;CDK1;CDK9


Apoptosis; Proteases/Pr Caspase activator Procaspase-3

Tyrosine Kinase/AdaptorEGFR inhibitor; HER2 inhEGFR, ErbB2

Tyrosine Kinase/AdaptorVEGFR inhibitor VEGFR3/FLT4;c-Kit;V

Tyrosine Kinase/AdaptorVEGFR inhibitor VEGFR2/Flk1

Chromatin/Epigenetic DNA Methyltransferase inO6-alkylguanine-DNA-alk

Cell Cycle/Checkpoint Integrin inhibitor αvβ3 receptor;αvβ5 recep

PI3K/Akt/mTOR SignalinAkt inhibitor Akt

Tyrosine Kinase/AdaptorEGFR inhibitor; IGF-1R iEGFR;ErbB4;ACK1;BLK;


Chromatin/Epigenetic HDAC inhibitor HDAC6/2/3/1;HDAC8/7/5/4

Angiogenesis HIF inhibitor HIF-1

JAK/STAT Signaling JAK inhibitor JAK1;JAK2;TYK2;JAK3


Tyrosine Kinase/AdaptorEGFR inhibitor; HER2 inhEGFR/ErbB2/ErbB4

PI3K/Akt/mTOR SignalinAkt inhibitor; ROCK inhibPKA;ROCK2;ROCK1;p70S

Tyrosine Kinase/AdaptorPDGFR inhibitor; EGFR inPDGFR;EGFR

Immunology/InflammatioCXCR antagonist CXCL

PI3K/Akt/mTOR SignalinmTOR inhibitor mTORC1/2

PI3K/Akt/mTOR SignalinATM/ATR inhibitor ATM

MAPK Signaling Raf inhibitor


B-Raf

Cell Cycle/Checkpoint Aurora Kinase inhibitor Aurora A;Aurora B

PI3K/Akt/mTOR SignalinAMPK activator AMPK

Angiogenesis Syk inhibitor Syk

PI3K/Akt/mTOR SignalinPDK inhibitor PDK-1

Angiogenesis FAK inhibitor FAK;PYK2;CDK2/CDK3/

Apoptosis Mdm2 inhibitor;p53 acivamutant P53r175

Cell Cycle/Checkpoint Rho inhibitor cdc42

PI3K/Akt/mTOR SignalinPI3K inhibitor PI3Kα/γ/δ/β

Tyrosine Kinase/AdaptorJAK inhibitor; EGFR inhibTGM2;JAK3;EGFR;JAK1

Tyrosine Kinase/AdaptorIRAK inhibitor IRAK-1/4

Tyrosine Kinase/Adaptorc-Met inhibitor; VEGFR inc-MET;VEGFR1/2/3


Stem Cell Hedgehog/Smoothened ReSmoothened receptor

Metabolism Casein Kinase inhibitor CK1from Schizosacchar

Tyrosine Kinase/AdaptorVEGFR inhibitor VEGFR2;c-Kit;PDGFRα

Angiogenesis HIF inhibitor PDH2

Cell Cycle/Checkpoint HSP inhibitor HSP105;HSP72;HSP40

MAPK Signaling MEK inhibitor MEK1/2

Chromatin/Epigenetic BET bromodomain inhibitBRD4

Cell Cycle/Checkpoint PKC inhibitor PKC

Stem Cell CK inhibitor CK1


Chromatin/Epigenetic Histone MethyltransferaseEZH2

PI3K/Akt/mTOR SignalinmTOR inhibitor mTOR

DNA Damage/DNA RepairDNA-PK inhibitor; ATM/ATDNA-PK;PI3K;ATM/ATR

MAPK Signaling p38 MAPK inhibitor p38

Chromatin/Epigenetic HDAC inhibitor HDAC6;HDAC3;HDAC8;

Angiogenesis Bcr-Abl inhibitor Bcr-Abl(WT); Bcr-Abl(T31


Membrane Transporter/I CRM1 inhibitor CRM1

Ubiquitination DUB inhibitor USP7;USP47;USP2 core

Tyrosine Kinase/AdaptorVEGFR inhibitor VEGFR2

PI3K/Akt/mTOR SignalinAkt inhibitor; PDK inhibit Akt, PDK-1

Tyrosine Kinase/Adaptorc-Met inhibitor; VEGFR inMet/VEGFR2

PI3K/Akt/mTOR SignalinPI3K inhibitor PI3Kα/β/δ;C2β

MAPK Signaling MEK inhibitor MEK5/ERK5/TGFβ/MEK1

Tyrosine Kinase/AdaptorPDGFR inhibitor;DNA-PK DGFR, Hck, mTOR, VEGF


Stem Cell; Metabolism Wnt/beta-catenin inhibitoWnt/β-catenin;PPARγ;P

Chromatin/Epigenetic Sirtuin inhibitor SIRT1

DNA Damage/DNA RepaiDNA/RNA Synthesis inhibDNA Synthesis



Angiogenesis; Endocrin RAAS antagonist;ACE inhAng II receptor

Proteases/Proteasome Protease inhibitor 20S proteasome

JAK/STAT Signaling JAK inhibitor JAK1/2/3

Angiogenesis TXA2 receptor antagonisTXA2 receptor; CRTh2


Membrane Transporter/I Sodium Channel inhibitoepithelial sodium channe

Immunology/InflammatioTGF-beta/Smad inhibitorTGF-β

Apoptosis TNF-alpha inhibitor TNF-α

Chromatin/Epigenetic HDAC inhibitor HDACs

MAPK Signaling Raf inhibitor B-Raf;C-Raf;ACK1;SRM

Cell Cycle/Checkpoint CDK inhibitor CDK4, CDK6

DNA Damage/DNA RepaiTelomerase inhibitor telomerase

Cell Cycle/Checkpoint CDK inhibitor cyclin T1-CDK9/cyclin

PI3K/Akt/mTOR SignalinPI3K inhibitor PI3Kα/δ/γ

Immunology/InflammatioCCR inhibitor CCR1

PI3K/Akt/mTOR SignalinPI3K inhibitor NUAK1;NUAK2

GPCR/G Protein Adenosine Receptor Adenosine Receptor

Tyrosine Kinase/AdaptorVEGFR inhibitor Abl, PDGFRα, VEGFR2,

Tyrosine Kinase/AdaptorEGFR inhibitor Mutant EGFR


DNA Damage/DNA RepaiDNA/RNA Synthesis inhibNucleoside antimetabolit


Tyrosine Kinase/AdaptorHER2 inhibitor HER2

Metabolism GLUT inhibitor GLUT1

Tyrosine Kinase/AdaptorFGFR inhibitor; VEGFR inFGFR2/FGFR1/FGFR3/

JAK/STAT Signaling JAK inhibitor JAK1;JAK2;TYK2;JAK3

Tyrosine Kinase/AdaptorTrk receptor inhibitor TrkB

Cell Cycle/Checkpoint Aurora Kinase inhibitor Aurora A;FLT3/RET/VE

PI3K/Akt/mTOR SignalinPI3K inhibitor; mTOR inhiPI3Kα/β/δ/γ;mTOR

Cell Cycle/Checkpoint; CDK inhibitor CDK1;PKCδ;SGK;ERK

Chromatin/Epigenetic Histone MethyltransferaseG9a

Chromatin/Epigenetic Histone Methyltransferaseyeast Hmt1p;human PR

Tyrosine Kinase/AdaptorIGF-1R Antagonist; c-MET IGF-1R; Insulin Recepto

PI3K/Akt/mTOR SignalinPDK inhibitor PDK-1

Tyrosine Kinase/AdaptorFGFR inhibitor FGFR4

Metabolism Dehydrogenase inhibitorIDH2

MAPK Signaling JNK inhibitor hJNK1;hJNK2;hJNK3

Tyrosine Kinase/AdaptorFLT3 inhibitor FLT3;Abl

Endocrinology/ HormoneAndrogen Receptor inhibiAndrogen Receptor; GAB

Tyrosine Kinase/AdaptorBcr-Abl inhibitor Bcr-Abl

Tyrosine Kinase/AdaptorEGFR inhibitor; Src inhibEGFR/Src/MEK/ErbB2

Tyrosine Kinase/AdaptorEGFR inhibitor; HER2 inhEGFR;HER2;KDR

Angiogenesis AGTR antagonist AGTR1

Angiogenesis; Endocrin RAAS inhibitor; ACE inhibRAAS

Chromatin/Epigenetic Histone Demethylase inhiLSD1

Angiogenesis FAK inhibitor FAK;PYK2

Cell Cycle/Checkpoint Kinesin inhibitor Mps1


Cell Cycle/Checkpoint HSP inhibitor HSP90/HSP72

PI3K/Akt/mTOR SignalinPI3K inhibitor PI3Kα

Tyrosine Kinase/AdaptorEGFR inhibitor EGFR and EGFR mutant

Chromatin/Epigenetic Histone Demethylase inhiLSD1



MAPK Signaling p38 MAPK inhibitor p38α/β

JAK/STAT Signaling Pim inhibitor Pim1,2,3

GPCR/G Protein Hedgehog/Smoothened aSmoothened

PI3K/Akt/mTOR SignalinPI3K inhibitor p110δ;p110γ;p110β

MAPK Signaling Raf inhibitor B-Raf

Chromatin/Epigenetic HDAC inhibitor HDAC3/1/2/6

Tyrosine Kinase/Adaptorc-Met inhibitor; Raf inhib c-Met;B-Raf/C-Raf/Abl/p

Tyrosine Kinase/AdaptorVEGFR inhibitor VEGFR1;VEGFR2;VEGFR


PI3K/Akt/mTOR SignalinPI3K inhibitor; DNA-PK inDNA-PK;p110α;p110γ;p1

Cell Cycle/Checkpoint HSP inhibitor HSP90

Immunology/InflammatioImmunologic Factors Thioredoxin-1

Tyrosine Kinase/Adaptorc-Met inhibitor; RET inhibRET, MET, DCDB2, CTN

Tyrosine Kinase/AdaptorFAK inhibitor FAK

Endocrinology/ HormoneEstrogen/Progestogen ReEstrogen Receptor/ERR

MAPK Signaling p38 MAPK inhibitor p38α/p38β

PI3K/Akt/mTOR SignalinAkt activator Akt

Immunology/InflammatioTGF-beta/Smad inhibitorTGF-β Receptor

Tyrosine Kinase/AdaptorFLT3 inhibitor FLT3

Angiogenesis AGTR antagonist Angiotensin Receptor

Metabolism PPAR activator PPARα

Cell Cycle/Checkpoint HSP inhibitor HSP90β

MAPK Signaling Raf inhibitor Ral

Chromatin/Epigenetic HDAC inhibitor HDAC2;HDAC6;HDAC4

PI3K/Akt/mTOR SignalinAkt inhibitor; S6 Kinase ipPKB,pS6

Membrane Transporter/I CFTR modulator VFTR

Neuroscience; Protease Gamma-secretase modulagamma-secretase;Beta A


Metabolism PPAR antagonist PPARα, PPARγ, PPARδ

Metabolism Casein Kinase inhibitor CK2

Cell Cycle/Checkpoint HSP inhibitor HSP90

Cell Cycle/Checkpoint Kinesin inhibitor KSP

JAK/STAT Signaling Pim inhibitor Pim-1

Endocrinology/ HormoneEstrogen/Progestogen ReERRβ/γ

PI3K/Akt/mTOR SignalinPI3K inhibitor p110α, p110β, p110δ, P

Cell Cycle/Checkpoint CDK inhibitor

Neuroscience LRRK2 inhibitor DCLK1;LRRK2;DCLK2


Apoptosis p53 activator; E3 ligase ip53;HDM2;Mdm2

Stem Cell Wnt/beta-catenin inhibitoPorcupine

Cell Cycle/Checkpoint Aurora Kinase inhibitor Aurora A, Aurora B

Neuroscience LRRK2 inhibitor LRRK2

Stem Cell Wnt/beta-catenin inhibitoCBP



MAPK Signaling JNK inhibitor JNK3/2

Metabolism FXR agonist Farnesoid X receptor

Endocrinology/ HormoneEstrogen/Progestogen Reestrogen receptor

CDK1/2/5


Neuroscience COX Prostaglandin G/H synth

DNA Damage/DNA RepaiDNA Synthesis LSm6

Cell Cycle/Checkpoint HIF inhibitor; Microtubule


Angiogenesis FGFR inhibitor FGFR1

Microbiology & Virology Antibiotic 14-α Demethylase

Endocrinology/ HormoneAndrogen Receptor antagandrogenic receptor

Others adenosine receptor antagOthers

Metabolism; Vitamin Farnesoid X receptor;VDFXR,PXR;VD receptor

DNA Damage/DNA RepaiPRPP Amidotransferase inPRPP Amidotransferase

Endocrinology/ HormoneAndrogen Receptor agonAndrogen/progestogen R

Cell Cycle/Checkpoint CDK inhibitor CDK2


PI3K/Akt/mTOR SignalinAkt inhibitor Akt

Metabolism CYP inhibitor CYP2C9

Chromatin/Epigenetic Sirtuin inhibitor Sirtuin;Src;PKC;PI3Kγ

Chromatin/Epigenetic DNA Methyltransferase inDNA methyltransferase;

JAK/STAT Signaling STAT activator STAT1


Neuroscience P2 Receptor inhibitor P2Y Receptor

Neuroscience CaMK inhibitor CaMKP

Apoptosis Mdm2 inhibitor;p53 inhibiMDM2/p53


JAK/STAT Signaling JAK inhibitor; STAT inhibJAK2;STAT3

Cell Cycle/Checkpoint ROCK inhibitor ROCK

Proteases/Proteasome Proteases inhibitor Proteases

Tyrosine Kinase/AdaptorSrc inhibitor Src Family Kinase

Endocrinology/ HormoneEstrogen/Progestogen ReEstrogen/progestogen Re

HIF-1α, HIF-2α;Microtubule depolymerization


PI3K/Akt/mTOR SignalinmTOR inhibitor FKBP1A

Ubiquitination E3 Ligase activator MDM2, p53

Chromatin/Epigenetic BET bromodomain inhibitBRPF1B;BRPF2

MAPK Signaling MEK inhibitor MEK1, MEK2


Immunology/InflammatioTGF-beta/Smad inhibitorTGF-β receptor type I/II

Proteases/Proteasome Proteasome inhibitor 20S proteasome

Chromatin/Epigenetic BET bromodomain inhibitBRD2, BRD3, BRD4


Immunology/InflammatioIκB/IKK inhibitor; CDK inhIKK2;CDK2/CyclinA

Tyrosine Kinase/AdaptorEGFR inhibitor; Bcr-Abl inEGFR/c-Abl/FLT1/c-Src

Tyrosine Kinase/Adaptorc-Kit inhibitor; FLT3 inhibKit;CSF-1R;FLT3

Cell Cycle/Checkpoint HSP inhibitor HSP90β

Apoptosis Survivin Survivin

Chromatin/Epigenetic Epigenetic Reader DomainBRD4

Immunology/InflammatioTGF-beta/Smad inhibitorALK5


Tyrosine Kinase/AdaptorIGF-1R inhibitor IGF-1R

Immunology/InflammatioIκB/IKK inhibitor IκB kinase;EBP1

Chromatin/Epigenetic PARP inhibitor PARP1, PARP2

Cell Cycle/Checkpoint Kinesin inhibitor kinesin spindle protein (

Apoptosis Bcl-2 inhibitor Bcl-2/Bcl-Xl/Bcl-w

DNA Damage/DNA RepaiDNA/RNA Synthesis inhibA375;MIA PaCa-2



Cell Cycle/Checkpoint Aurora Kinase inhibitor Aurora A;Abl;RET;TrkA

Cell Cycle/Checkpoint Microtubule Associated inβ-tubulin

Tyrosine Kinase/AdaptorIGF-1R inhibitor IGF-1R

PI3K/Akt/mTOR SignalinATM/ATR inhibitor; mTOR ATR/ATM;mTOR/DNA-P

PI3K/Akt/mTOR SignalinPI3K inhibitor p110δ

Cell Cycle/Checkpoint CDK inhibitor CDK4/Cyclin D1

Immunology/InflammatioIκB/IKK inhibitor IKK2

Apoptosis IAP inhibitor cIAP;XIAP


Chromatin/Epigenetic HDAC inhibitor HDAC1/2/3/10;PI3Kα/β/δ

Cell Cycle/Checkpoint Wee1 inhibitor Wee1

MAPK Signaling Raf inhibitor B-Raf

PI3K/Akt/mTOR SignalinPI3K inhibitor PI3Kβ

MAPK Signaling Raf inhibitor B-Raf/C-Raf;c-Kit;LCK;

Enzyme PP2A inhibitor PP2A




Cell Cycle/Checkpoint CDK inhibitor Cdc2/CyclinB;CDK2/Cycl


Immunology/InflammatioIκB/IKK inhibitor IκB kinase;EBP1

Tyrosine Kinase/Adaptorc-Met inhibitor; Tie-2 inh c-MET/TIE-2/VEGFR




Immunology/InflammatioTGF-beta/Smad inhibitor;TGFβRI;RIPK2;CK1δ;TG

Tyrosine Kinase/AdaptorEGFR inhibitor; HER2 inhEGFR/HER2/PDGFR

Microbiology & Virology Antiparasitic Antiparasitic



Stem Cell iPSCs oct4

Cell Cycle/Checkpoint Kinesin inhibitor CENP-E

Chromatin/Epigenetic Histone MethyltransferaseDNA methyltransferase

Tyrosine Kinase/AdaptorEGFR, JAK inhibitor EGFR, JAK3

Cell Cycle/Checkpoint CDK inhibitor ChK2

Tyrosine Kinase/AdaptorsEGFR inhibitor; CDK inhiEGFR; CDK2

Cell Cycle/Checkpoint CDK inhibitor CDK

Cell Cycle/Checkpoint CDK inhibitor Cdc28p


Chromatin/Epigenetic HDAC inhibitor HD1-A/B


Stem Cell iPSCs oct4

Immunology/InflammatioIL inhibitor IL12/IL23

Proteases/Proteasome Proteasome inhibitor 20S proteasome

Metabolism Farnesoid X receptor agoFarnesoid X receptor (F

JAK/STAT Signaling JAK inhibitor JAKs

Cell Cycle/Checkpoint ROCK inhibitor ROCK1, ROCK2

Proteases/Proteasome MMP inhibitor MMP-2/MMP-9

PI3K/Akt/mTOR SignalinPI3K inhibitor p110α, p110β, p110δ

Stem Cell Wnt/beta-catenin inhibitoWnt/β-catenin


GPCR/G Protein LPL inhibitor LPA1 receptor


Metabolism NAMPT inhibitor NAMPT


Tyrosine Kinase/AdaptorJAK inhibitor; FLT3 inhibiJAK2/FLT3/RET

PI3K/Akt/mTOR SignalinPI3K inhibitor PI3Kα/δ;p110β/p110γ


Tyrosine Kinase/AdaptorVEGFR inhibitor VEGFR2

Cell Cycle/Checkpoint HSP inhibitor HSP90α, HSP90β

PI3K/Akt/mTOR SignalinPI3K-δ/PI3K-γ inhibitor PI3K-δ/PI3K-γ

Angiogenesis Thrombin antagonist PAR-1

JAK/STAT Signaling JAK inhibitor; EGFR inhibJAK3; VEGFR/EGFR

Chromatin/Epigenetic HDAC inhibitor HDAC6


Metabolism Dehydrogenase inhibitorIMPDH

PI3K/Akt/mTOR SignalinAMPK inhibitor AMPK



MAPK Signaling p38 MAPK inhibitor p38α/p38β

Cell Cycle/Checkpoint BET bromodomain BRPF1

Cell Cycle/Checkpoint BET bromodomain BRPF1

Stem Cell Wnt/beta-catenin agonistβ-catenin



PI3K/Akt/mTOR SignalinGSK-3 inhibitor GSK-3/Shaggy-like kinas



PI3K/Akt/mTOR SignalinmTOR inhibitor;S6 KinasemTOR/P-Akt (S473)/pS6

PI3K/Akt/mTOR SignalinATM/ATR inhibitor; mTORATR;mTOR

PI3K/Akt/mTOR SignalinGSK-3 inhibitor GSK3

GPCR/G Protein CXCR antagonist CXCR2

MAPK Signaling Raf inhibitor Raf

PI3K/Akt/mTOR SignalinAkt inhibitor Akt1,2,3


PI3K/Akt/mTOR SignalinPI3K inhibitor PI3Kγ;PI3Kβ;PI3Kδ


Cell Cycle/Checkpoint CDK inhibitor CDK7

Neuroscience LRRK2 inhibitor leucine-rich repeat kinas

Tyrosine Kinase/AdaptorTGF-beta/Smad inhibitorALK2

Tyrosine Kinase/AdaptorTGF-beta/Smad inhibitorALK1/ALK2

Tyrosine Kinase/AdaptorTGF-beta/Smad inhibitorALK1/2/3

Metabolism PPAR inhibitor PPARδ




Tyrosine Kinase/AdaptorTGF-beta/Smad inhibitorALK2/3

Immunology/InflammatioIκB/IKK inhibitor IκBα phosphorylation

Proteases/Proteasome; UDUB inhibitor USP14/UCHL5

Immunology/InflammatioNF-κB inhibitor NF-ΚB

JAK/STAT Signaling JAK inhibitor; Tyk inhibit JAK1/JAK2/JAK3/Tyk2

Stem Cell Hedgehog/Smoothened ReHedgehog/Smoothened R

Tyrosine Kinase/AdaptorFMS inhibitor; c-Kit inhibc-FMS/c-KIT

Proteases/Proteasome; UDUB inhibitor UCH-L1,UCH-L3

MAPK Signaling p38 MAPK inhibitor p38

PI3K/Akt/mTOR SignalinPI3K inhibitor PI3Kα


Angiogenesis FAK inhibitor FAK/Pyk2

PI3K/Akt/mTOR SignalingGSK-3 inhibitor; Tyk inhibGSK-3α/β; TYK;CDK1/2/4

PI3K/Akt/mTOR SignalinPI3K inhibitor p110α

Tyrosine Kinase/AdaptorTGF-beta/Smad inhibitorALK1/2/3/6

Cell Cycle/Checkpoint CDK inhibitor CDK2/5/1/9

PI3K/Akt/mTOR SignalinAkt inhibitor Akt1/2/3

PI3K/Akt/mTOR SignalinmTOR activator mTOR

Chromatin/Epigenetic Epigenetic Reader DomainBET proteins


Chromatin/Epigenetic DNA Methyltransferase inDNMT1/3A/3B

MAPK Signaling Raf inhibitor B-raf, C-raf

Immunology/InflammatioIκB/IKK inhibitor IκBα phosphorylation

Cell Cycle/Checkpoint CDK inhibitor CLK1/2/4

Tyrosine Kinase/AdaptorTGF-beta/Smad inhibitorALK2

Cell Cycle/Checkpoint ROCK inhibitor ROCK1/2

Tyrosine Kinase/AdaptorVEGFR inhibitor VEGFR/FGFR/PDGFR

PI3K/Akt/mTOR SignalinPI3K inhibitor; mTOR inhiPI3Kα/β/δ/γ, mTOR

Angiogenesis PAR inhibitor PAR1

Proteases/Proteasome MMP inhibitor MT1-MMP

Chromatin/Epigenetic HDAC inhibitor HDAC1/3/4/5/9/10


MAPK Signaling Raf inhibitor B-Raf, C-Raf

PI3K/Akt/mTOR SignalinGSK-3 inhibitor GSK3β

PI3K/Akt/mTOR SignalinPI3K inhibitor PI3K

Stem Cell Wnt/beta-catenin inhibitoTNKS1/2

Stem Cell CK inhibitor CK1

MAPK Signaling Raf inhibitor Ras-Raf

Chromatin/Epigenetic Sirtuin inhibitor Sirt2

Metabolism RXR/RAR agonist RAR/RAX


Ubiquitination DUB inhibitor JOSD2

PI3K/Akt/mTOR SignalinPI3K inhibitor; mTOR inhip110α/β/δ/γ, mTORC1/2



Cell Cycle/Checkpoint Rho inhibitor Cdc42 GTPase

Cell Cycle/Checkpoint BET bromodomain BRD4 bromodomain


MAPK Signaling Raf inhibitor C-Raf

JAK/STAT Signaling JAK inhibitor JAK1/JAK2/JAK3

Apoptosis TNF-alpha inhibitor TNF-α

MAPK Signaling Raf inhibitor B-Raf/C-Raf

Tyrosine Kinase/AdaptorBcr-Abl inhibitor XPO1, CRM1

DNA Damage/DNA RepaiDNA Synthesis inhibitor DNA Polymerase


PI3K/Akt/mTOR SignalinPDK inhibitor PDE1

Tyrosine Kinase/AdaptorVEGFR inhibitor PDGFRβ/VEGFR2/Flt-3


JAK/STAT Signaling Pim inhibitor Pim1/2/3

PI3K/Akt/mTOR SignalingPDK inhibitor;c-Kit inhibi PDE1/TBK1;c-kit;CDK2;

JAK/STAT Signaling JAK inhibitor JAK1/2

Cell Cycle/Checkpoint CK inhibitor CK2

PI3K/Akt/mTOR SignalinPI3K inhibitor p110α, p110β, p110δ

PI3K/Akt/mTOR SignalinPI3K inhibitor; mTOR inhip110α/β/δ/γ, mTOR

GPCR/G Protein Adenosine receptor antaghuman A3 adenosine rece

PI3K/Akt/mTOR SignalinATM/ATR inhibitor ATM/ATR


Apoptosis p53 activator; sirtuin inhip53;Sirt1/2/3

Angiogenesis Bcr-Abl inhibitor Bcr-Abl

Immunology/InflammatioIL inhibitor IL-1β, TNF-α, IL-10

Tyrosine Kinase/AdaptorSrc inhibitor Src-PTK

Angiogenesis Src inhibitor Src/LCK

Stem Cell Hedgehog/Smoothened ReSmoothened

Chromatin/Epigenetic PARP inhibitor TNKS1/2;PARP

Metabolism IDO inhibitor IDO

Tyrosine Kinase/AdaptorBcr-Abl inhibitor Abl

Enzyme LXR agonist LXR



Tyrosine Kinase/AdaptorVEGFR inhibitor VEGFR3/FLT4

Proteases/Proteasome Protease inhibitor Proteasome

Tyrosine Kinase/AdaptorVEGFR inhibitor; PDGFR inVEGFR1/2/3;PDGFRβ;FG

Tyrosine Kinase/AdaptorTGF-beta/Smad inhibitor;ALK,IR, IGF-1R

Metabolism Farnesoid X receptor FXR


Cell Cycle/Checkpoint CDK inhibitor CDKs;EGFR;PDGFR;VE


Enzyme LXR agonist LXR


Stem Cell Hedgehog/Smoothened ReSmoothened

Cell Cycle/Checkpoint CDK inhibitor CDK1/2/4/6/9

Tyrosine Kinase/AdaptorVEGFR inhibitor VEGFR/FGFR/PDGFR

GPCR/G Protein CXCR antagonist CXCR

Tyrosine Kinase/AdaptorEGFR inhibitor; HER2 inhEGFR;EGFR mutant for

Apoptosis; Proteases/Pr Caspase activator Caspase-3


Metabolism Ferroptosis activator Ferroptosis

MAPK Signaling p38 MAPK inhibitor p38 MAPK; PKB




PI3K/Akt/mTOR SignalinMELK inhibitor MELK

Cell Cycle/Checkpoint Microtubule Associated inmicrotubule/tublin

Ubiquitination DUB inhibitor USP1-UAF1


Tyrosine Kinase/AdaptorVEGFR inhibitor VEGFR1/Src/Abl

Cell Cycle/Checkpoint Microtubule Associated intubulin polymerization


GPCR/G Protein CXCR antagonist CXCR4

GPCR/G Protein; NeurosAdrenergic Receptor antaβ-adrenergic receptor;Be

DNA Damage/DNA RepaiTopoisomerase inhibitor; Topoisomerase II; EGFR

Angiogenesis Factor Xa inhibitor Factor Xa

Immunology/InflammatioTGF-beta/Smad inhibitorALK4/7/5

Cell Cycle/Checkpoint ROCK inhibitor ROCK1,ROCK2


DNA Damage/DNA RepaiDNA Synthesis inhibitor Thymidylate synthase;U

Neuroscience COX inhibitor COX-1,COX-2

Tyrosine Kinase/AdaptorTrk receptor agonist TrkB receptor

DNA Damage/DNA RepaiTopoisomerase inhibitor DNA topoisomerase I

Enzyme Aromatase inhibitor Aromatase

Endocrinology/ HormoneEstrogen/Progestogen ReEstrogen receptor

Metabolism; GPCR/G ProtPDE inhibitor; AdenosinePDE; Adenosine recept

Membrane Transporter/I Potassium Channel inhibPotassium Channel ;PP

Cell Cycle/Checkpoint Microtubule Associated intublin chain;MRP1

Tyrosine Kinase/AdaptorTGF-beta/Smad inhibitor;ALK ;c-MET

Endocrinology/ HormoneMelatonin receptor agonimelatonin receptor;MPO;

Tyrosine Kinase/AdaptorVEGFR antagonist; EGFR VEGFR2/EGFR

Cell Cycle/Checkpoint; VPKC inhibitor; SEC14-likGST P, GST omega-1, GS

DNA Damage/DNA Repair;Antiviral HSV;DNA polymerase

Angiogenesis; Endocrin RAAS inhibitor; ACE inhibACE;ChE

DNA Damage/DNA RepaiDNA synthesis inhibitor; DNA polymerase;Thymidi

Immunology/InflammatioTNF-alpha inhibitor; CadhTNF-α;Cadherin-5;Prost

DNA Damage/DNA Repair;Topoisomerase Inhibitor Topoisomerase II , Topo

Immunology/InflammatioProtein S100 antagonist; Protein S100;FGFR1;IL-

Vitamin VA VA


Metabolism PPAR agonist PPAR

Tyrosine Kinase/AdaptorBcr-Abl inhibitor;c-kit in v-Abl; c-Kit; PDGFR


Angiogenesis AGTR inhibitor;TranscripAGTR1;Transcription fac

Metabolism RXR/RAR inhibitor RAR

Tyrosine Kinase/AdaptorROCK-II, PKA, PKG, PKROCK-II, PKA, PKG, PK

Angiogenesis; Endocrin RAAS inhibitor; ACE inhibMRP1;ACE

Membrane Transporter/I PPAR agonist; ABC inhibPPARγ;ABCC

Chromatin/Epigenetic; NGABAR;HDAC inhibitor GABAR;HDAC2, HDAC9

DNA Damage/DNA RepaiDNA Alkylating Stathmin-4;DNA Alkylati

DNA Damage/DNA RepaiNucleoside antimetabolitthymidine phosphorylase

Endocrinology/ HormoneAndrogen Receptor antagAndrogen receptor


DNA Damage/DNA RepaiDNA/RNA Synthesis inhibDNA/RNA synthesis

Endocrinology/ HormoneAromatase Inhibitor Aromatase



Chromatin/Epigenetic HDAC inhibitor HDAC1, HDAC2, HDAC3




Angiogenesis; Endocrin RAAS inhibitor; ACE inhiACE;PPAR gamma

Apoptosis; DNA Damage;Caspase activator;DNA/RCaspase3, caspase9;con

JAK/STAT Signaling STAT inhibitor STAT1/3/5

Chromatin/Epigenetic; UbHDAC activator;DNA SynthSirt1,2;DNA;Prostagland

Neuroscience Sodium Channel inhibitor;Sodium channel; PLA2

Endocrinology/ HormoneEstrogen/Progestogen ReEstrogen Receptor ;AO

Others DNA photosenstizing DNA

Microbiology & Virology Antibiotic; COX inhibitor; Prostaglandin G/H synth

Endocrinology/ HormoneProgesterone receptor agProgesterone receptor; A

DNA Damage/DNA RepaiDNA Alkylating DNA

PI3K/Akt/mTOR SignalingmTOR inhibitor;FGFR inhimTOR;FGFR 2;FKBP1A



Tyrosine Kinase/AdaptorPotassium Channel inhibABCC;Potassium Channe

Tyrosine Kinase/AdaptorBcr-Abl inhibitor;Mast/st Bcr-Abl ;Mast/stem cell


DNA Damage/DNA RepaiTopoisomerase inhibitor DNA topoisomerase I

Angiogenesis; Endocrin RAAS inhibitor; ACE inhibrenin

Angiogenesis; Endocrin RAAS inhibitor; ACE inhibRAAS

Immunology/InflammatioNF-κB inhibitor KEAP1-Nrf2

DNA Damage/DNA Repair;Topoisomerase inhibitor Topoisomerase II

Chromatin/Epigenetic DNA Methyltransferase inDNA Methyltransferase

DNA Damage/DNA Repair;Antibiotic; DNA alkylatio DNA alkylation

DNA Damage/DNA Repair;Antiviral;DNA/RNA SyntheDNA polymerase, ;DNA

DNA Damage/DNA Repair;Antibiotic; DNA/RNA SynthRNA polymerase ;Endop

DNA Damage/DNA RepaiTopoisomerase inhibitor;Topoisomerase II ;DNA

Angiogenesis; Endocrin RAAS inhibitor; ACE inhibACE

DNA Damage/DNA RepaiDNA Synthesis inhibitor DNA

Enzyme DHFR inhibitor DHFR

Angiogenesis; Endocrin RAAS inhibitor; ACE inhibACE;MRP1;ChE

Endocrinology/ HormoneC-C motif 2 inhibitor;G C-C motif 2;GNRHR;Estro


Endocrinology/ HormoneEstrogen receptor allosteHSD3B;Estrogen recepto



Endocrinology/ HormoneEstrogen/Progestogen REstrogen Receptor

Endocrinology/ HormoneCollagenase inhibitor;hy 72 kDa type IV collag

Angiogenesis; Endocrin RAAS inhibitor; ACE inhibAT1 receptor

PI3K/Akt/mTOR SignalinAMPK activator;PotassiuAMPK;Potassium Chann

Tyrosine Kinase/Adaptorc-Kit inhibitor; PDGFR inc-Kit;PDGFRβ;VEGFR1

DNA Damage/DNA RepaiDNA gyrase inhibitor;TopDNA gyrase;topoisomeras

Tyrosine Kinase/AdaptorBcr-Abl inhibitor;EPHA anAbl, Lck, Yes, Fyn;EPHA

Tyrosine Kinase/AdaptorSrc inhibitor;Abl inhibito Src;Abl, Lck, Yes, Fyn;c

DNA Damage/DNA RepaiTopoisomerase inhibitor Topoisomerase II, IV


DNA Damage/DNA RepaiDNA/RNA Synthesis inhibiThymidylate synthase;D

Microbiology & Virology; Antibiotic; COX inhibitor Prostaglandin G/H synth

Endocrinology/ HormoneEstrogen/Progestogen ReEstrogen Receptor


Neuroscience COX COX

Neuroscience COX inhibitor ALOX5;Prostaglandin G/H


DNA Damage/DNA Repair;Reverse Transcriptase inReverse Transcriptase, T

Metabolism PPAR agonist PPARα

DNA Damage/DNA RepaiDNA/RNA Synthesis inhibThymidylate synthase

Metabolism; Proteases/ MMP inhibitor;PPAR agonMMP;PPARα

Neuroscience COX inhibitor;ALOX5 inhiProstaglandin G/H synt

Angiogenesis; MetabolisThrombomodulin;PPAR actCFTR;Thrombomodulin;PP


Neuroscience Histamine Receptor antaHistamine H1 receptor;P

Cell Cycle/Checkpoint Microtubule Associated inTubulin chain

DNA Damage/DNA RepaiDNA/RNA Synthesis inhibDNA Synthesis



Apoptosis; GPCR/G ProtApoptosis inducer;AdenoAdenosine A2a receptor

Chromatin/Epigenetic DNA Methyltransferase inDNA Methyltransferase

Others Others Pepsin, FGF2, PGF, Fibr

Metabolism HAP antagonist FPPS;HAP

Metabolism RXR/RAR inhibitor RAR, RXR


DNA Damage/DNA RepaiDNA/RNA Synthesis inhibDNA/RNA


Immunology/InflammatioNF-κB inhibitor PRDX5;NF-κB kinase


Neuroscience; ImmunoloNF-κB inhibitor;COX inhibMPO;NF-κB kinase;ALOX5

DNA Damage/DNA RepaiDNA gyrase inhibitor;TopDNA gyrase;Topoisomeras

DNA Damage/DNA RepaiTopoisomerase inhibitor Topoisomerase IV

Microbiology & Virology Antibiotic 14-α Demethylase;LSS

Metabolism RXR/RAR agonist RARβ;RARα;RARγ



DNA Damage/DNA RepaiDNA Synthesis inhibitor DNA polymerase beta

Cell Cycle/Checkpoint Microtubule Associated inMRAP;Microtubules

Endocrinology/ HormoneEstrogen/Progestogen ReEstrogen receptor;Proge

Neuroscience COX inhibitor;MPO inhibiCOX1, COX2;MPO

Proteases/Proteasome Protease inhibitor APN;LTA4H

Metabolism; GPCR/G ProAdenosine receptor antagAdenosine receptor A;P


GPCR/G Protein Adrenergic Receptor antβ-adrenergic receptor

DNA Damage/DNA RepaiDNA Alkylating DNA Alkylating




Metabolism HAP antagonist HAP


Chromatin/Epigenetic; MHDAC inhibitor;HMG-CoA rHDAC2;HMG-CoA reducta

DNA Damage/DNA RepaiPotassium Channel inhibiPotassium Channel;topoi

Immunology/InflammatioImmunologic Factors Adrenodoxin


Others Chelator Ferritin light chain


Neuroscience COX inhibitor;Elastin;MRPProstaglandin G/H synth


Tyrosine Kinase/AdaptorEGFR antagonist EGFR





GPCR/G Protein Adrenergic Receptor antaAdrenergic Receptor;Cal

Cell Cycle/Checkpoint Microtubule Associated inTubulin alpha-1A chain,

Metabolism; Proteases/ MMP inhibitor;PPAR agonMMP;PPAR alpha

Tyrosine Kinase/AdaptorEGFR inhibitor; Sodium CEGFR;Sodium channel




Cell Cycle/Checkpoint Microtubule Associated inMicrotubule/Tubulin;Topo

DNA Damage/DNA RepaiDNA Synthesis inhibitor DNA polymerase beta

Apoptosis; Metabolism Bcl-2 activator; MAO inhiBcl-2;MAO-B, MAO-A

Endocrinology/ HormoneAromatase Inhibitor Aromatase

Endocrinology/ HormoneAromatase Inhibitor Type I steroidal aromata

DNA Damage/DNA Repair;DNA gyrase inhibitor;TopDNA gyrase;Topoisomeras

Metabolism RXR/RAR agonist RXR, RAR

Membrane Transporter/I Potassium Channel inhibPotassium Channel ;PP

Microbiology & Virology Antibiotic DNA polymerase

DNA Damage/DNA RepairDNA synthesis inhibitor; DNA Polymerase ;VD3 re

Chromatin/Epigenetic; GAdenosine Receptor antaAdenosine receptor;HD

Metabolism; GPCR/G ProtPDE inhibitors;HDAC actiPDE;HDAC2; Adenosine

Others Cystine Cleavage;NPYR2Cystine;NPYR2;Somatost

Metabolism; MicrobiologyHydrogenase inhibitor; AnFe hydrogenase 1;NADPH

GPCR/G Protein Adrenergic Receptor antPAH;TNF;Adrenergic rec


DNA Damage/DNA RepaiDNA Synthesis inhibitor DNA alkylation


GPCR/G Protein CAMP PDE activator;PI3KCAMP PDE;PI3K ;Adrener


Metabolism RXR/RAR agonist RXR, RAR

Endocrinology/ HormoneAndrogen Receptor agoniAndrogen Receptor ;Estr

GPCR/G Protein Adrenergic Receptor antAdrenergic Receptor;PA

DNA Damage/DNA RepairDNA synthesis inhibitor;SDNA Synthsis ;STAT1

Cell Cycle/Checkpoint Bcl-2 inhibitor; MicrotubuBcl-2;Tubulin chain

Immunology/InflammatioTNF-alpha inhibitor, IL inTNF-α, IL-6, NF-κB, AP-

Chromatin/Epigenetic; MHistone Demethylase inhiMAO;Histone Demethyla



Neuroscience; Metaboli RXR/RAR;COX inhibitor RXR-alpha;Prostaglandi

Enzyme Dehydrogenase inhibitorDihydropyrimidine dehy

DNA Damage/DNA Repair;Antibiotic; DNA/RNA SyntDNA synthesis

DNA Damage/DNA Repair;HIV Integrase;DNA/RNA SHIV Integrase;RNA synth

Neuroscience Opioid Receptor Opioid alkaloid


Tyrosine Kinase/AdaptorPKC inhibitor PKC


DNA Damage/DNA RepaiTopoisomerase inhibitor; Topoisomerase I, DNA gy

Cell Cycle/Checkpoint Bcl-2 inhibitor; MicrotubuBcl-2;Tubulin chain, Mic

DNA Damage/DNA RepaiDNA/RNA Synthesis inhibThymidylate synthase

Metabolism Folate metabolism Folate metabolism

Angiogenesis Plasminogen inhibitor Plasminogen

DNA Damage/DNA RepaiDNA interaction; HistaminDNA;Histamine N-methyl

Cell Cycle/Checkpoint Microtubule Associated inβ-Tubulin


DNA Damage/DNA RepaiDNA synthesis inhibitor;TDNA polymerase I;ThxR




Immunology/InflammatioNF-κB inhibitor;COX inhibProstaglandin G/H synth

DNA Damage/DNA RepaiTopoisomerase inhibitor Topoisomerase



Angiogenesis Plasminogen inhibitor Plasminogen activator

Neuroscience; ImmunoloNF-κB inhibitor;GluR actiNF-KB;ACY1; Glutamate r

Neuroscience COX inhibitor IFN-α

Neuroscience COX inhibitor COX1;COX2


Endocrinology/ HormoneGABAR agonist; AndrogenGABA-A receptor;Androge

Endocrinology/ HormoneAndrogen Receptor agonAndrogen receptor



Neuroscience COX inhibitor;MRP inhibiCOX1, COX2;MRAP 4

Neuroscience MRP inhibitor;COX inhibiMRAP4; Prostaglandin G


Endocrinology/ HormoneEstrogen/Progestogen ReEstrogen/progestogen R




Neuroscience; GPCR/G p5-HT receptor antagonist5-HT receptor;Adrenergic




Neuroscience COX inhibitor;Glucocorti Prostaglandin G/H syntha

Enzyme AKR AKR

Neuroscience COX inhibitor; Calcium CProstaglandin G/H synth

Neuroscience COX inhibitor COX1


Enzyme Carbonic anhydrase, betArginase-1, CA 2, Caten

Amino Acids & Building Amino Acids and DerivatOrnithine aminotransfera





Microbiology & Virology Antiviral HSV-1,VZV


DNA Damage/DNA Repair;DNA gyrase inhibitor;TopDNA gyrase;Topoisomeras

Cell Cycle/Checkpoint Microtubule Associated inTubulin chain;Glucose up

Angiogenesis Antiplatelet aggregation iAntiplatelet-aggregation

JAK/STAT Signaling; UbiqSTAT inhibitor; AutophagSTAT3; Autophagy


DNA Damage/DNA RepaiDNA;MRP inhibitor DNA;MRP1

Angiogenesis; Endocrin RAAS inhibitor;ACE inhibACE;MRP1

Angiogenesis; MetabolisTXA2 antagonist;PDE inhPDE;TXA2R

PI3K/Akt/mTOR SignalinGSK-3 inhibitor GSK-3

Membrane Transporter/I Adenosine receptor agoniAdenosine receptor ;Ca

Immunology/InflammatioCysLTR antagonist; TNF-alCysLTR,TNF,IL-5, NF-kB,

Metabolism Chloride channel inducer;Chloride channel protei

DNA Damage/DNA Repair;Antiviral;DNA/RNA SyntheDNA polymerase inhibito

Metabolism MRP inhibitor; HMG-CoA RMRP1; HMG-CoA Reductas

DNA Damage/DNA Repair;Antibiotic; DNA/RNA SyntDNA/RNA Synthesis inhib

Microbiology & Virology Antifungal; Hydroxylase 14-α Demethylase;17-hyd


Cell Cycle/Checkpoint Microtubule Assosiated inTubulin polymerization


Neuroscience; ImmunoloNF-κB inhibitor;PPAR agoNF-κB kinase;PPAR gam



Metabolism; GPCR/G ProAdenosine receptor antagAdenosine receptor ;PD

Metabolism c-Myc inhibitor c-myc

Angiogenesis Syk inhibitor;IκB/IKK inhiSyk;IκB/IKK

Others Intermediates Others

Tyrosine Kinase/AdaptorVEGFR inhibitor VEGFR2/KDR;VEGFR3/



Immunology/InflammatioNF-κB inhibitor KEAP1-Nrf2




Neuroscience COX COX2

Metabolism; Neuroscien 5-Lipoxygenase inhibitor;5-Lipoxygenase;Prostagl

Endocrinology/ HormoneAndrogen Receptor antagAndrogen Receptor ;Calc

Membrane Transporter/I EGFR inhibitor;Sodium ChEGFR;Sodium channel

Neuroscience COX inhibitor PDPK;COX2

Enzyme; Metabolism; CelCasein Kinase inhibitor;CSYK, Casein kinase II



Neuroscience COX inhibitor;PPAR agonProstaglandin G/H syn


Membrane Transporter/I COX inhibitor; Potassiu Prostaglandin G/H synth

Angiogenesis; Vitamin Prothrombin activator;VKProthrombin;VK

Neuroscience; AngiogensPlasminogen inhibitor;PPplasminogen;PPARγ; Pros


Microbiology & Virology Antifungal 14-α Demethylase


Neuroscience NADPH;COX inhibitor CP;NADPH;Prostaglandi

Angiogenesis; DNA DamaProthrombin;VB;DNA mutProthrombin;QacR, LfrR

Neuroscience COX inhibitor;Amino AcidProstaglandin G/H synth

Chromatin/Epigenetic HDAC inhibitor HDAC1HDAC3/HDAC6/H

Proteases/Proteasome; MMP antagonist;NF-κB inhMMP 9; NF-κB p100;IFγ;


DNA Damage/DNA RepaiTopoisomerase inhibitor DNA topoisomerase IV

Neuroscience COX inhibitor prostaglandin G/H Synth

Others Chelator metal ion

Others Chelator Heavy metal ion

Endocrinology/ HormoneAndrogen receptor agoniAndrogens receptor;CO


Angiogenesis Thrombin inhibitor Thrombin



Tyrosine Kinase/AdaptorRTK inhibitor;RTK inhibitKit, FLT3, c-Kit ; PDG

Tyrosine Kinase/Adaptorc-Kit inhibitor; PDGFR inc-Kit;PDGFRβ;VEGFR2


Tyrosine Kinase/AdaptorEGFR antagonist EGFR


Microbiology & Virology Potassium Channel inhibitPotassium Channel ;iNO

Endocrinology/ HormoneGlucocorticoid Receptor Glucocorticoid Receptor

Neuroscience; ImmunoloNF-κB inhibitor;COX NF-κB;Prostaglandin G/H




Cell Cycle/Checkpoint Microtubule Associated inTubulin beta chain


Membrane Transporter/I ATPase inhibitor; HAP anV-type proton ATPase ca

DNA Damage/DNA RepaiRNA Synthesis Ribonucleotide reductas

Neuroscience COX inhibitor;MRP inhibiProstaglandin G/H synt

Microbiology & Virology Antibacterial Others




Endocrinology/ HormoneAndrogen Receptor antagAndrogen receptor

Endocrinology/ HormoneGlucocorticoid Receptor Glucocorticoid Receptor

Neuroscience COX Prostaglandin D2 recepto

Neuroscience Histamine Receptor ant Histamine H1 receptor;


Neuroscience; PI3K/Akt GluR potentiator; GSK-3 iGluR 3;GSK-3B; IMPA

DNA Damage/DNA Repair;UMP-CMP kinase inhibitorUMP-CMP kinase;Autoph

DNA Damage/DNA RepaiTopoisomerase inhibitor;DNA topoisomerase II, I

Enzyme Hexokinase inhibitor hexokinase

PI3K/Akt/mTOR SignalinAkt inhibitor;PKC inhibitoAkt;PKC

Membrane Transporter/I Annexin A Annexin A5




Neuroscience; ImmunoloNF-κB inhibitor;TNF inhi NF-κB;TNF;Protein cereb

Angiogenesis; Neurosci TXA2 Receptor antagonisTXA2R;Prostaglandin G/


Ubiquitination; PI3K/Akt Autophagy inhibitor;ATMAutophagy;ATM

Cell Cycle/Checkpoint Microtubule Associated inTubulin beta chain

Metabolism; Enzyme DHFR inhibitor TS, DHFR,GARFT and

Enzyme; Metabolism DHFR inhibitor TS;DHFR;GART;PURH

Apoptosis; Cell Cycle/ChBcl-2 inhibitor; Microtubu



Angiogenesis Plasminogen inhibitor Plasminogen activator;

Immunology/InflammatioNF-κB inhibitor;PDE inhibNF-κB;PDE;Sodium chan

DNA Damage/DNA RepaiDNA Synthesis inhibitor DNA Synthesis


Angiogenesis Prothrombin inhibitor Prothrombin

DNA Damage/DNA Repair;Reverse Transcriptase inReverse Transcriptase

MAPK Signaling; TyrosinMAPK inhibitor;Src inhibiMAPKK2, MAPKKK2;ABL1,

Vitamin VB TS;VB


Endocrinology/ HormoneEstrogen/Progestogen REstrogen Receptor


Immunology/InflammatioTLR agonist TLR-7, 8

DNA Damage/DNA RepairTopoisomerase inhibitor;Topoisomerase II; MRP


Angiogenesis Egr-1 inhibitor;VEGF inhiEgr-1;VEGF

MAPK Signaling; ImmunoNO agonist;TNF-alpha inhibNO, TNF-α, IL-1β, and I


Tyrosine Kinase/AdaptorVEGFR inhibitor VEGFR1,2,3

DNA Damage/DNA RepaiDNA damage DNA damage

Tyrosine Kinase/AdaptorRaf inhibitor, VEGFR inhiRaf-1, B-Raf, VEGFR2

Tyrosine Kinase/AdaptorPDGFR inhibitor; Raf inhiPDGFRβ, B-raf, RAF-1, F

Bcl-2; Tubulin beta-1 chain

Endocrinology/ HormoneAndrogen Receptor agonAndrogen receptor



DNA Damage/DNA RepaiRNA synthesis RNA

Neuroscience COX inhibitor COX1, COX2



Neuroscience COX prostaglandin G/H Synth



Metabolism Dehydrogenase inhibitorALDH1;DBH





PI3K/Akt/mTOR SignalinAkt inhibitor; PI3K inhibi Akt, PI3K, PKC

Metabolism Lipid LDL,VLDL

Immunology/InflammatioNF-κB inhibitor; ROS inhiFree radical scavengers

Membrane Transporter/IoChE inhibitor;DNA MethylChE;DNA (cytosine-5)-me


Membrane Transporter/I Calmodulin inhibitor;SodCalmodulin;Sodium chan

DNA Damage/DNA RepairDehydrogenase inhibito IMPDH;HPRT

Cell Cycle/Checkpoint Microtubule Associated inmicrotubulin

Immunology/InflammatioCOX COX1, COX2


Angiogenesis TpoR agonist Thrombopoiesis

Bioactivity

Zaltoprofen is an inhibitor of Cox-1 and Cox-2 for treatment of arthritis.

Sirtinol is a specific SIRT1 and SIRT2 inhibitor with IC50 of 131 μM and 38 μM, respectively.

Rolipram is a PDE4 inhibitor and an anti-inflammatory agent.

L-Mimosine is a non-protein amino acid, and acts as an iron chelator.

KW-2478 is a nonansamycin HSP90 inhibitor with IC50 of 3.8 nM. Phase 1.

HO-3867, an analog of curcumin, is a selective STAT3 inhibitor.

CAY10505 is dehydroxyl of AS-252424, which is a PI3Kγ inhibitor with IC50 of 33 nM.

Zoledronic acid induces apoptosis in osteoclasts by inhibiting enzymes of the mevalonate pathway and preventing the isoprenylation of small GTP-binding proteins such as Ras and Rho.

Tamibarotene is a synthetic retinoic acid receptor (RAR) agonist with high specificity for RARα and RARβ over RARγ.Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM). Phase 3.

SH-4-54 is a potent STAT inhibitor with KD of 300 nM and 464 nM for STAT3 and STAT5, respectively.

Ro 31-8220 is a pan-PKC inhibitor with IC50 of 5 nM, 24 nM, 14 nM, 27 nM, and 24 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, and PKC-ε, respectively, and also shows potent inhibition against MAPKAP-K1b, MSK1, GSK3β and S6K1.Ospemifene is a non-hormonal selective estrogen receptor modulator (SERM), used for the treatment of dyspareunia.

Galeterone is a selective CYP17 inhibitor and androgen receptor (AR) antagonist with IC50 of 300 nM and 384 nM, respectively, and is a potent inhibitor of human prostate tumor growth. Phase 2.Fludarabine Phosphate is an analogue of adenosine and deoxyadenosine, which is able to compete with dATP for incorporation into DNA and inhibit DNA synthesis.Embelin, a quinone isolated from the Japanese Ardisia herb, is an inhibitor of X-linked inhibitor of apoptosis (XIAP) with IC50 of 4.1 uM.EHT 1864 is a potent Rac family GTPase inhibitor with Kd of 40 nM, 50 nM, 60 nM and 250 nM for Rac1, Rac1b, Rac2 and Rac3, respectively.

Bexarotene is a retinoid specifically selective for retinoid X receptors, used as an oral antineoplastic agent in the treatment of cutaneous T-cell lymphoma.BAF312 (Siponimod) is a next-generation S1P receptor modulator, selective for S1P1 and S1P5 receptors with EC50 of 0.39 nM and 0.98 nM, exhibits >1000-fold selectivity over S1P2, S1P3 and S1P4 receptors. Phase 3.Geldanamycin is a natural existing HSP90 inhibitor with Kd of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.RepSox is a potent and selective inhibitor of the TGFβR-1/ALK5 with IC50 of 23 nM and 4 nM for ATP binding to ALK5 and ALK5 autophosphorylation, respectively.INO-1001 is a potent inhibitor of PARP with IC50 of <50 nM in CHO cells and a mediator of oxidant-induced myocyte dysfunction during reperfusion. Phase 2.BIX02188 is a selective inhibitor of MEK5 with IC50 of 4.3 nM, also inhibits ERK5 catalytic activity with IC50 of 810 nM, and does not inhibit closely related kinases MEK1, MEK2, ERK2, and JNK2.Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM. It is more than 40-fold selective for Aurora A than Aurora B. Phase 1.AZ 960 is a novel ATP competitive JAK2 inhibitor with IC50 and Ki of <3 nM and 0.45 nM, 3-fold selectivity of AZ960 for JAK2 over JAK3.SNX-2112 (PF-04928473) selectively binds to the ATP pocket of HSP90α and HSP90β with Ka of 30 nM and 30 nM, uniformly more potent than 17-AAG.Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT).

Idasanutlin (RG-7388) is a potent and selective p53-MDM2 inhibitor with IC50 of 6 nM.

LEE011 is an orally available, and highly specific CDK4/6 inhibitor. Phase 3.

Sotrastaurin is a potent and selective pan-PKC inhibitor, mostly for PKCθ with Ki of 0.22 nM; inactive to PKCζ. Phase 2.NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits PI3K with IC50 of 5 μM.Obatoclax (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.Tipifarnib (R115777) is a potent and specific farnesyltransferase (FTase) inhibitor with IC50 of 0.6 nM, its anti-proliferative effects are most prominent in H-ras or N-ras mutant cells. Phase 3.Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM – HDAC8 is the only known member of the HDAC-family that is not affected by TSA.PP2, a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.

Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.Palbociclib (PD-0332991) HCl is a highly selective inhibitor of?CDK4/6?with?IC50?of 11 nM/16 nM respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.Lapatinib Ditosylate (GW572016, GW2016) is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively.Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM, compared with HDACs 4, 6, 8, and 10. Phase 3.Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively.Irinotecan is a topoisomerase I inhibitor for LoVo cells and HT-29 cells with IC50 of 15.8 μM and 5.17 μM, respectively.Benidipine HCl is a hydrochloride salt form of benidipine which is a dihydropyridine calcium channel blocker.Pemetrexed Disodium Hydrate is a novel antifolate and antimetabolite for TS, DHFR and GARFT with Ki of 1.3 nM, 7.2 nM and 65 nM, respectively.Adenine HCl is a hydrochloride salt form of adenine which is a purine derivative and a nucleobase with a variety of roles in biochemistry.Iniparib (BSI-201) is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC). Phase 3.U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059.Selumetinib (AZD6244) is a potent, highly selective MEK1 inhibitor with IC50 of 14 nM, also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Phase 3.LFM-A13 is a specific Bruton's tyrosine kinase (BTK) with IC50 of 2.5 μM, >100-fold selectivity over other protein kinases including JAK1, JAK2, HCK, EGFR,and IRK.Abiraterone (CB-7598) is a potent steroidal cytochrome P450 17alpha-hydroxylase-17,20-lyase (CYP17) inhibitor with an IC50 at 4 nM.Abiraterone Acetate is an acetate salt form of Abiraterone which is a steroidal cytochrome CYP17 inhibitor with IC50 of 72 nM.Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.DAPT (GSI-IX) is a novel γ-secretase inhibitor, which inhibits Aβ production with IC50 of 20 nM in HEK 293 cells.

PJ34 HCl is the hydrochloride salt of PJ34, which is a PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2.PD0325901 (PD325901) is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.TDZD-8 is a non-ATP competitive GSK-3β inhibitor with IC50 of 2 μM; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC.Gambogic Acid activates caspases with EC50 of 0.78-1.64 uM and competitively inhibits Bcl-XL, Bcl-2, Bcl-W, Bcl-B, Bfl-1 and Mcl-1 with IC50 of 1.47, 1.21, 2.02, 0.66, 1.06 and 0.79 uM, respectively.

ZSTK474 inhibits class I PI3K isoforms with IC50 of 37 nM, mostly PI3Kδ. Phase1/2.

LY2603618 is a selective Chk1 inhibitor with potential anti-tumor activity. Phase 2.

Epothilone B is a Taxol-like microtubule-stabilizing agent with EC0.01 of 1.8 μM. Phase 2.

SCH772984 is a novel, specific inhibitor of ERK1/2 with IC50 of 4 nM and 1 nM, respectively.

TSU-68 (SU6668, Orantinib) has greatest potency against PDGFR autophosphorylation with Ki of 8 nM, but also strongly inhibits Flk-1 and FGFR1 trans-phosphorylation, little activity against IGF-1R, Met, Src, Lck, Zap70, Abl and CDK2; does not inhibit EGFR. Phase 3.BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Bardoxolone Methyl is an IKK inhibitor, showing potent proapoptotic and anti-inflammatory activities. Phase 3.SU11274 is a selective Met inhibitor with IC50 of 10 nM, no effects on PGDFRβ, EGFR or Tie2.Canertinib (CI-1033) is a pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, no activity to PDGFR, FGFR, InsR, PKC, or CDK1/2/4. Phase 3.Pimasertib (AS-703026) is a highly selective, potent, ATP non-competitive allosteric inhibitor of MEK1/2 with IC50 of 5 nM-2 μM in MM cell lines. Phase 2.Mubritinib (TAK-165) is a potent inhibitor of HER2/ErbB2 with IC50 of 6 nM; no activity to EGFR, FGFR, PDGFR, JAK1, Src and Blk. Phase 1.Tivantinib (ARQ 197) is the first non-ATP-competitive c-Met inhibitor with Ki of 0.355 μM, little activity to Ron, and no inhibition to EGFR, InsR, PDGFRα or FGFR1/4. Phase 3.Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.YM201636 is a selective PIKfyve inhibitor with IC50 of 33 nM, less potent to p110α and insensitive to Fabl (yeast orthologue).Ki16425 is a competitive, potent and reversible antagonist to LPA1, LPA2 and LPA3 with Ki of 0.34 μM, 6.5 μM and 0.93 μM, respectively, shows no activity at LPA4, LPA5, LPA6.Torin 2 is a potent and selective mTOR inhibitor with IC50 of 0.25 nM; 800-fold greater selectivity for mTOR than PI3K and improved pharmacokinetic properties. Inhibition of ATM/ATR/DNA-PK with EC50 of 28 nM/35 nM/118 nM, respectively.AZD8931 is a reversible, ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4 nM, 3 nM and 4 nM, more potent than Gefitinib or Lapatinib against NSCLC cell, 100-fold more selective for the ErbB family than MNK1 and Flt. Phase 2.Belnacasan (VX-765) is a potent and selective inhibitor of caspase-1 with Ki of 0.8 nM. Phase 2.

SSR128129E is an orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs.Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.EPZ015666 is a potent, selective and orally bioavailable PRMT5 inhibitor with Ki of 5 nM, >20,000-fold selectivity over other PMTs.

Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Phase 3.

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.GSK343 is a potent and selective EZH2 inhibitor with IC50 of 4 nM, showing 60 fold selectivity against EZH1, and >1000 fold selectivity against other histone methyltransferases.URMC-099 is an orally bioavailable, brain penetrant mixed lineage kinase (MLK) inhibitor with IC50 of 19 nM, 42 nM, 14 nM, and 150 nM, for MLK1, MLK2, MLK3, and DLK, respectively, and also inhibits LRRK2 activity with IC50 of 11 nM.GW441756 is a potent, selective inhibitor of TrkA with IC50 of 2 nM, with very little activity to c-Raf1 and CDK2.LY2228820 is a novel and potent inhibitor of p38 MAPK with IC50 of 7 nM, does not alter p38 MAPK activation. Phase 1/2.Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM; exhibits 1000-fold selectivity for mTOR than PI3K.

E-64 is an irreversible and selective cysteine protease inhibitor with IC50 of 9 nM for papain.

Enzalutamide (MDV3100) is an androgen-receptor (AR) antagonist with IC50 of 36 nM.

XL388 is a highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.PF-477736 is a selective, potent and ATP-competitive Chk1 inhibitor with Ki of 0.49 nM and also inhibits VEGFR2, Aurora-A, FGFR3, Flt3, Fms (CSF1R), Ret and Yes. It shows ~100-fold selectivity for Chk1 than Chk2. Phase 1.CEP-18770 (Delanzomib) is an orally active inhibitor of the chymotrypsin-like activity of proteasome with IC50 of 3.8 nM, with only marginal inhibition of the tryptic and peptidylglutamyl activities of the proteosome. Phase 1/2.CH5183284 is a selective and orally available FGFR inhibitor with IC50 of 9.3 nM, 7.6 nM, 22 nM, and 290 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. Phase 1.Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM.Volasertib (BI 6727) is a highly potent Plk1 inhibitor with IC50 of 0.87 nM. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Phase 3.OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R with IC50 of 35 nM; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.Maraviroc is a CCR5 antagonist for MIP-1α, MIP-1β and RANTES with IC50 of 3.3 nM, 7.2 nM and 5.2 nM, respectively.FRAX597 is a potent, ATP-competitive inhibitor of group I PAKs with IC50 of 8 nM, 13 nM, and 19 nM for PAK1, PAK2, and PAK3, respectively.Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis.Birinapant is a SMAC mimetic antagonist, mostly to cIAP1 with Kd of <1 nM, less potent to XIAP. Phase 2.Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM, respectively.Z-DEVD-FMK is a specific, irreversible Caspase-3 inhibitor, and also shows potent inhibition on caspase-6, caspase-7, caspase-8, and caspase-10.

Pepstatin is a potent inhibitor of aspartyl proteases; inhibits the aspartic proteases cathepsin D, pepsin, and renin.Entrectinib is an inhibitor of TrkA (IC50 = 1.7 nM), TrkB (IC50 = 0.1 nM), and TrkC (IC50 = 0.1 nM), as well as C-ros oncogene 1 (ROS1; IC50 = 0.2 nM) and anaplastic lymphoma kinase (ALK; IC50 = 1.6 nM). Entrectinib blocks proliferation of ALK-dependent cell lines, including those with L1196M or C1156Y resistance mutations, and inhibits ALK‐dependent signaling. It GSK2879552 is a selective, orally bioavailable, irreversible, mechanism-based inactivator of lysine-specific demethylase 1 (LSD1)/corepressor, with potential antineoplastic activity.THZ1 is a novel selective and potent covalent CDK7 inhibitor with IC50(binding affinity) of 3.2 nM; inhibits Jurkat cell's proliferation with IC50 of 50 nM.ACY-241, also known as Citarinostat, is a potent, selective and orally available histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon oral administration, ACY-241 inhibits the activity of HDACs; this results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene AZD3759 is a potent, oral active, central nervous system-penetrant, EGFR inhibitor. At Km ATP concentrations, the IC50 values were 0.3, 0.2, and 0.2 nM for EGFR TK wild-type, L858R mutant, and Exon 19Del enzymes, respectively.TAS-102 is an investigational drug candidate for metastatic colorectal cancer. It contains trifluridine (TFT) and Tipiracil hydrochloride (TTP) in a molar ratio of 2:1.HTHQ, which is a hydroquinone monoalkyl ether, is a potent anti-oxidative agent, even at low dose levels. HTHQ is found to be a potent anti-lipid-peroxidative compound and its antioxidation activity to be extremely elevated in biological systems, such as that of liver microsomes via the generation of stable free radicals.HMN-176 is an active metabolite of the synthetic antitumor compound HMN-214. HMN-176 shows potent cytotoxicity toward various human tumor cell lines, and in mitotic cells, it causes cell cycle arrest at M phase through the destruction of spindle polar bodies, followed by the induction of DNA fragmentation. However, no direct interactions of HMN-176 with tubulin are AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors. AZD9291 is highly active in preclinical models and is well tolerated in animal models. It inhibits both activating and resistant EGFR mutations while sparing the normal form LY3039478 a orally bioavailable, novel small molecule Notch inhibitor with an IC50 of ~1nM in most of the tumor cell lines tested. LY3039478 potently inhibits mutant Notch receptor activity. In a xenograft tumor model, LY3039478 inhibited N1ICD cleavage and expression of Notch-regulated genes in the tumor microenvironment. LY3039478 is being investigated in Phase I.Relugolix is a novel, non-peptide, orally active gonadotropin-releasing hormone (GnRH) antagonist with IC50 of 0.33 nM in the presence of 40% fetal bovine serum, TAK-385 possesses higher affinity and potent antagonistic activity compared with TAK-013.Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream Cobimetinib is a selective inhibitor of mitogen-activated protein kinase kinase (MEK) with IC50 value of 0.9 nM

Cinobufagin is a specific Na+/K+-ATPase inhibitor. About as active as ouabain.

Brigatinib is an investigational cancer medicine showing promise in clinical trials as a potential treatment for certain types of lung cancer.Brigatinib is a highly potent and selective investigational ALK inhibitor with mean IC50 value ＜ 100 nM in Ba/F3 cells.Evofosfamide, also known as TH-302, is a hypoxia-activated prodrug consisting of a 2-nitroimidazole phosphoramidate conjugate with potential antineoplastic activity. The 2-nitroimidazole moiety of hypoxia-activated prodrug TH-302 acts as a hypoxic trigger, releasing the DNA-alkylating dibromo isophosphoramide mustard moiety within hypoxic regions of Licochalcone A exhibits potent antimalarial activity via and might be developed into a new antimalarial drug. Licochalcone A had anti-tumor activity in all cell lines tested and enhanced the effect of paclitaxel and vinblastine chemotherapy. Licochalcone A induced apoptosis in MCF-7 and HL-60 cell lines, as demonstrated by cleavage of PARP, the substrate of ICE-like proteases. Licochalcone A exhibits a strong antileishmanial activity ,that appropriate substituted chalcones

Ensartinib, also known as X-396, is an orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplastic activity. Upon oral administration, X-396 binds to and inhibits ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated signaling and CC-122 is an orally available pleiotropic pathway modulator with potential antineoplastic activity. CC-122 mimics an interferon response and has antitumor activity in DLBCL CC-122 binds Cereblon (CRBN) and promotes degradation of Aiolos and Ikaros in diffuse large B-cell lymphoma (DLBCL) and T cells in vitro, in vivo, and in patients, resulting in both cell Epacadostat, also known as INCB024360 or INCB24360, is an orally available hydroxyamidine and inhibitor of indoleamine 2,3-dioxygenase (IDO1), with potential immunomodulating and antineoplastic activities. INCB024360 targets and binds to IDO1, an enzyme responsible for the oxidation of tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine in Anlotinib is a EGFR inhibitor extracted from patent 2015185012 A1, compound 1，which can be used to treat non-small cell lung cancer.

Cell-permeable inhibitor of protein kinase C (IC50 = 660 nM); competitive with respect to the phosphate acceptor and non-competitive with respect to ATP. Has a wide range of biological activities, including antiplatelet, anti-inflammatory, antibacterial and antitumor effects. Activates MAPK pathways, independent of PKC inhibition. Inhibits binding of BclXL to Bak (IC50 = Demethylzeylasteral has strong immunosuppressive activity, can be used in the fields of organ transplantation and autoimmune disorders. The risk of elevated serum concentrations of estradiol due to the inhibition of estradiol glucuronidation by Demethylzeylasteral. Demethylzeylasteral increases both activation and inactivation time constants of Ca(2+) Icaritin has hormone regulation activity and cardiovascular function improvement activity. Icaritin has anticancer activity, can induce S phase arrest and apoptosis, inhibit ENKL cell proliferation. Icaritin has anti-multiple myeloma activity, mainly mediated by inhibiting IL-6/JAK2/STAT3 signaling. Icaritin at low concentration (4 or 8 μmol/L) can promote rat

TRX-818 is an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry (VM) activities. Although the exact multiple mechanisms of action through which this agent exerts its effects have yet to be fully elucidated, TRX-818, upon oral administration appears to induce cancer cell apoptosis and inhibits cancer cell proliferation. This agent also prevents tumor cell VM by blocking the formation of vasculogenic-like tubular structures through an as of yet undetermined mechanism of action.Homoharringtonine is an alkaloid inhibitor of protein synthesis with activity in myeloid malignancies. It might have clinical activity in some patients with myelodysplastic syndrome . Homoharringtonine enhances the paracellular permeability of Caco-2 cell monolayers by modulating the protein expression and localization of claudin isoforms. Homoharringtonine has Dactinomycin D (Actinomycin D; Oncostatin K) is the most significant member of actinomycines, which are a class of polypeptide antibiotics isolated from soil bacteria of the genus Streptomyces.Niraparib, also know as MK-4827, is an inhibitor of poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity. MK4827 inhibits PARP activity, enhancing the accumulation of DNA strand breaks and promoting genomic instability and apoptosis. The PARP family of proteins detect and repair single strand DNA breaks by the base-excision repair (BER) XL-413 is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity. CDC7 kinase inhibitor BMS-863233 binds to and inhibits the activity of CDC7, which may result in the inhibition of DNA replication and mitosis, the induction of tumor cell apoptosis, and the inhibition of tumor cell proliferation in CDC7-overexpressing Sophoridine, a natural anticancer drug, has been used in China for decades. A series of novel N-substituted sophoridinic acid derivatives were synthesized and evaluated for their cytotoxicity with 1 as the lead. The structure-activity relationship indicated that introduction of an aliphatic acyl on the nitrogen atom might significantly enhance the anticancer activity. Among the AZD6738 is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. Phase 1/2.

3,5,4'-Trimethoxystilbene, a natural methoxylated analog of resveratrol, inhibits breast cancer cell invasiveness by downregulation of PI3K/Akt and Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.Wogonoside acts as a positive allosteric modulator of the benzodiazepine siteof the GABAA receptor.Perillyl alcohol (POH) is a natural substance called a monoterpene, isolated from the essential oils of lavender,peppermint, spearmint, cherries, celery seeds, and several other plants. Laboratory evidence suggests that it interferes with the replication of dividing cells. POH has shown antitumor activity against a range of cancer types including pancreatic, lung, colon, and AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins(IAP), inhibits progression of human ovarian cancer binding to XIAP-BIR3, cIAP1-BIR3 and cIAP2-BIR3 with Ki of 66.4 nM, 1.9 nM, and 5.1 nM, 50- to 100-fold higher affinities than the Smac AVPI peptide. Phase 1.Amifostine is a cytoprotective adjuvant used in cancer chemotherapy and radiotherapy involving DNA-binding chemotherapeutic agents.Clodronic acid(INN) orclodronate disodium(USAN) is a first generation (non-nitrogenous)?bisphosphonate. It is an anti-osteoporotic drug approved for the prevention and treatment of?osteoporosis?in post-menopausal women and men to reduce vertebral fractures,hyperparathyroidism,hypercalcemia?in malignancy,multiple myeloma?and fracture S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3. S49076 potently blocked cellular phosphorylation of MET, AXL, and FGFRs and inhibited downstream signaling in vitro and in vivo. In cell models, S49076 inhibited the proliferation of MET- and FGFR2-dependent gastric cancer cells, blocked MET-driven migration of lung carcinoma cells, and NVP-TNKS656(TNKS-656) is a highly potent, selective, and orally active TNKS2 inhibitor with IC50 of 6 nM; > 300 fold selectivity against PARP1 and PARP2.PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase) inhibitor, reduces glycolytic flux and suppresses glucose uptake. Inhibits endothelial cell proliferation and causes G2/M cell cycle arrest in vitro. Attenuates vessel sprouting and tumor growth in vivo. Amplifies the antiangiogenic effect of VEGFR blockade.3PO may be useful agents in combination with other Ponesimod(ACT-128800) is an orally active, selective sphingosine-1-phosphate receptor 1 (S1P1) immunomodulator.UNC0638 is an inhibitor of?protein lysine methyltransferases G9a(IC50<15 nM) and GLP(IC50=19 nM) with excellent potency and selectivity over a wide range of epigenetic and non-epigenetic targets.

N/A

Napabucasin is an orally available Stat3 and cancer cell stemness inhibitor.

COX-2 inhibitor and anti-inflammatory agent

BML-210 is the novel HDAC inhibitor, and its mechanism of action has not been characterized.

DB07268 is a potent and selective JNK1 inhibitor with an IC50 value of 9 nM.

GNF-7 inhibits Bcr-Abl WT and Bcr-Abl T315I with IC50 of 133 nM and 61 nM, respectively.

It is a pan PI3K inhibitors,an analog of PI-103.

Mesterolone is an orally applicable androgen and dihydrotestosterone (DHT) derivative.

Monomethyl auristatin F is an antimitotic agentwhich inhibits cell division by blocking the polymerisation of tubulin

PKC412(Midostaurin; CGP41231; CGP41251) is a broad spectrum protein kinase inhibitor; inhibits conventional PKC isoforms (α, β, γ), PDFRβ, VEGFR2, Syk, PKCη, Flk-1, Flt3, Cdk1/B, PKA, c-Kit, c-Fgr, c-Src, VEGFR1 and EGFR.AZD3965 is a selective inhibitor of monocarboxylate transporter 1 (MCT1) with a binding affinity of 1.6 nM, is 6 fold selective over MCT2 and does not inhibit MCT4 at 10 μM.AMG-337 is a potent and highly selective small molecule ATP-competitive MET kinase inhibitor. AMG 337 inhibits MET kinase activity with an IC50 of < 5nM in enzymatic assays.Briciclib is a small molecule that suppresses cyclin D1 accumulation in cancer cells.

UF010 is a potent and selective HADC inhibitor with IC50 ~0.06 μM, 0.1 μM, 0.5 μM and 1.5 μM for HDACs 3, 2, 1 and 8, respectively. It has > 6-fold selectivity over other HDACs.

WDR5-0103 is a potent and selective WD repeat-containing protein 5 (WDR5) antagonist with Kd of 450 nM.

PTACH (NCH-51) is a SAHA-based novel inhibitor of human HDAC. PTACH exerts potent growth inhibition against various human cancer cells, with EC50 values ranging from 1 to 10 μM.

CVT-313(NG-26) is a potent, selective, reversible, and ATP-competitive inhibitor of CDK2 (IC50 = 0.5 uM for Cdk2/A and Cdk2/E; 4.2 uM for Cdk1/B; 215 uM for Cdk4/D1).Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I HDAC (HDAC 1, 2, and 3, with IC50 values of 150 nM , 760nM, and 370 nM, respectively), demonstrating no activity against class II HDACs.

NSC5844 (RE640) is a bisquinoline compound with C-C chemokine receptor type 1 (CCR1)-agonistic properties.NU2058 is a potent CDK inhibitor that has CDK2 IC(50)=17 microM and CDK1 IC(50)=26 microM. Inhibits growth of human tumor cells in vitro (mean GI50 = 13 μM). Also inhibits DNA topoisomerase II ATPase activity (IC50 = 300 μM).R112 is an ATP-competitive inhibitor of Syk kinase with a Ki of 96 nM. R112 inhibits Syk kinase activity with an IC50 of 226 nM.Kevetrin hydrochloride is a small molecule and activator of the tumor suppressor protein p53, with potential antineoplastic activity.SW044248 is a novel noncanonical Top1 inhibitor with a pattern of selective toxicity for NSCLC cells.MN-64 is a inhibitor of tankyrases, showed 6 nM potency against tankyrase 1, isoenzyme selectivity, and Wnt signaling inhibition.COH29 is an orally available, aromatically substituted thiazole and inhibitor of the human ribonucleotide reductase (RNR), with potential antineoplastic activity. Upon oral administration, the RNR inhibitor COH29 binds to the ligand-binding pocket of the RNR M2 subunit (hRRM2) near the C-terminal tail. This blocks the interaction between the hRRM1 and hRRM2 subunits MLN1117 (INK1117) is a p110 inhibitor which inhibits p110α, p110β, p110γ, p110δ with IC50 of 15 nM, 4.5μM, 1.9μM, 13.39μM respectively.Pyrrolidinedithiocarbamate ammonium is a selective NF-κB inhibitor, inhibits translation of nitric oxide synthase mRNA to prevent induction.

Boldenone undecylenate(Equipoise) is a synthetic steroid which has a similar effect as the natural steroid testosterone; it is frequently used in veterinary medicine, though it is also used in humans.Testosterone Phenylpropionate has an active life of 4-5 day. Release time-wise, it is directly in the middle of the Propionate (short) and Cypionate (long) versions of Testosterone.

Marbofloxacin is a potent antibiotic inhibiting bacterial DNA replication.

FLI-06 is a novel inhibitor of Notch signaling with EC50 of 2.3 μM.

Testosterone Enanthate is a long-acting intramuscular form of the androgen testosterone. Testosterone inhibits gonadotropin secretion from the pituitary gland and ablates estrogen production in the ovaries, thereby decreasing endogenous estrogen levels.Extracted from Stephania tetrandra S. Moore;Store the product in sealed,cool and dry condition

Foretinib (GSK1363089) is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met and KDR with IC50 of 0.4 nM and 0.9 nM. Less potent against Ron, Flt-1/3/4, Kit, PDGFRα/β and Tie-2, and little activity to FGFR1 and EGFR. Phase 2.LY2835219 is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.SP600125 is a broad-spectrum JNK inhibitor for JNK1, JNK2 and JNK3 with IC50 of 40 nM, 40 nM and 90 nM, respectively; 10-fold greater selectivity against MKK4, 25-fold greater selectivity against MKK3, MKK6, PKB, and PKCα, and 100-fold selectivity against ERK2, p38, Chk1, EGFR etc.CUDC-101 is a potent multi-targeted inhibitor against HDAC, EGFR and HER2 with IC50 of 4.4 nM, 2.4 nM, and 15.7 nM, and inhibits class I/II HDACs, but not class III, Sir-type HDACs. Phase 1.PFK-158 is a potent and selective inhibitor of PFKFB3 that is currently being investigated in a phase I study in patients with advanced solid malignancies.GSK J4 HCl is a cell permeable prodrug of GSK J1, which is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM in a cell-free assay and inactive against a panel of demethylases of the JMJ family.EPZ-5676 is an S-adenosyl methionine (SAM) competitive inhibitor of protein methyltransferase DOT1L with Ki of 80 pM, demonstrating >37,000-fold selectivity against all other PMTs tested, inhibits H3K79 methylation in tumor. Phase 1.PS-1145 is a specific IKK inhibitor with IC50 of 88 nM.

Abietic acid is the primary component of resin acid, is the primary irritant in pine wood and resin, isolated from rosin (via isomerization) and is the most abundant of several closely related organic acids that constitute most of rosin, the solid portion of the oleoresin of coniferous trees.Thioguanine, a purine antimetabolite, inhibits DNMT1 activity through ubiquitin-targeted degradation, used in the treatment of acute lymphoblastic leukemia, autoimmune disorders (e.g., Crohn's disease, rheumatoid arthritis) and organ transplant recipients.SGC0946 is a highly potent and selective DOT1L methyltransferase inhibitor with IC50 of 0.3 nM; selectively kill mixed lineage leukaemia cells.EPZ004777 is a potent, selective DOT1L inhibitor with IC50 of 0.4 nM.

Pyridone 6(CMP 6) is a potent and selective inhibitor of JAK1 (IC50=15 nM, murine JAK1), JAK2 (IC50=1 nM), JAK3 (Ki=5 nM), and Tyk2 (IC50=1 nM); displaying significantly weaker affinities (130 nM to 10 mM) for other protein tyrosine kinases.GSK1838705A is a potent IGF-1R inhibitor with IC50 of 2.0 nM, modestly potent to IR and ALK with IC50 of 1.6 nM and 0.5 nM, respectively, and little activity to other protein kinases.SGI-1776 free base is a novel ATP competitive inhibitor of Pim1 with IC50 of 7 nM in a cell-free assay, 50- and 10-fold selective versus Pim2 and Pim3, also potent to Flt3 and haspin. Phase 1.SB216763 is a potent and selective GSK-3 inhibitor with IC50 of 34.3 nM for GSK-3α and equally effective at inhibiting human GSK-3β.GLPG0634 analogue is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively. Phase 2.

CHIR 98014 is a potent GSK-3α/β inhibitor with IC50 of 0.65 nM/0.58 nM in cell-free assays, with the ability to distinguish GSK-3 from its closest homologs Cdc2 and ERK2.PF-670462 is a potent (IC50 = 7.7 ± 2.2 nM) and selective (>30-fold with respect to 42 additional kinases) inhibitor of CK1ε in isolated enzyme preparations.XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, exhibiting >50-fold selectivity over JAK1, JAK3 and TYK2. Phase 1.GZD824 is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.GANT61 is an inhibitor for GLI1 as well as GLI2-induced transcription, inhibits hedgehog with IC50 of 5 μM in GLI1 expressing HEK293T cell, displays selectivity over other pathways, such as TNF and glucocorticoid receptor gene transactivation.Tideglusib is an irreversible, non ATP-competitive GSK-3β inhibitor with IC50 of 60 nM in a cell-free assay; fails to inhibit kinases with a Cys homologous to Cys-199 located in the active site. Phase 2.Ruxolitinib (INCB018424) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3.PD173955 is a potent Bcr-Abl inhibitor with IC50 of 1-2 nM, also inhibiting Src activity with IC50 of 22 nM.

ALK inhibitor 2 is a novel and selective inhibitor for the ALK kinase.

Extracted from Pigs bile;Suitability:alcohol;Store the product in sealed,cool and dry condition

WIKI4 is a novel Tankyrase inhibitor with IC50 of 15 nM for TNKS2, and leads to inhibition of Wnt/beta-catenin signaling.PF-06463922 is a potent, dual ALK/ROS1 inhibitor with Ki of <0.02 nM, <0.07 nM, and 0.7 nM for ROS1, ALK (WT), and ALK (L1196M), respectively. Phase 1.Fasudil hydrochloride(HA-1077; AT-877) is a potent inhibitor of ROCK-II, PKA, PKG, PKC, and MLCK with Ki of 0.33 μM, 1.6 μM, 1.6 μM, 3.3 μM and 36 μM, respectively.AP26113 is a potent ALK inhibitor with IC50 of 0.62 nM in a cell-free assay, demonstrated ability overcome Crizotinib resistance mediated by a L1196M mutation. Phase 2.SMI-4a is a potent inhibitor of Pim1 with IC50 of 17 nM, modestly potent to Pim-2, does not significantly inhibit any other serine/threonine- or tyrosine-kinases.UNC1999 is a potent, orally bioavailable and selective inhibitor of EZH2 and EZH1 with IC50 of 2 nM and 45 nM in cell-free assays, respectively, showing >1000-fold selectivity over a broad range of epigenetic and non-epigenetic targets.10058-F4 is a cell-permeable thiazolidinone that specificallly inhibits the c-Myc-Max interaction and prevents transactivation of c-Myc target gene expression; induces cell-cycle arrest and apoptosis.SRT3109 is a CXCR2 ligand for use in the treatment of chemokine mediated diseases and conditions.Salubrinal is a selective inhibitor of eukaryotic translation initiation factor 2 subunit α (eIF2α) dephosphorylation.Ruxolitinib phosphate(INCB018424 phosphate) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3.NSC 42834(JAK2 Inhibitor V, Z3), a novel specific inhibitor of Jak2, inhibits Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity.

VE-821 is a potent and selective ATP competitive inhibitor of ATR with Ki/IC50 of 13 nM/26 nM.A 83-01 is a selective inhibitor of TGF-β type I receptor ALK5 kinase, type I activin/nodal receptor ALK4 and type I nodal receptor ALK7 with IC50 values of 12 nM, 45 nM and 7.5 nM, respectively.Asiaticoside (Madecassol) is the active chemical component of the plant Centella asiatica. Asiaticoside is used to study potential treatments for wounds and burns.Avitinib, also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. Upon oral administration, avitinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the drug-resistant T790M EGFR mutant, which prevents signaling mediated Trenbolone acetate (TBA; RU1697; Finaplix) is a synthetic androgen steroid with anabolic properties.Olaparib (AZD2281, KU0059436) is a potent PARP inhibitor with IC50 of 5 and 1 nM for PARP-1and PARP-2, respectively.Lawsone (2-hydroxy-1,4-naphthoquinone), also known as hennotannic acid, is a red-orange dye present in the leaves of the henna plant (Lawsonia inermis) as well as in the flower of water hyacinth (Eichhornia crassipes).Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation.Magnolol is isomeric to honokiol (sc-202653). Magnolol is an anxiolytic,anti-thrombotic and antibacterial. . Inhibitor of nitric oxide (NO) and TNF-α production in LPS-activated macrophages by the suppression of inducible nitric oxide synthase(iNOS; NOSTetrandrine, a bis-benzylisoquinoline alkaloid derived from Stephania tetrandra, is a calcium channel blocker.Extracted from Rheum palmatum L.;Suitability:Boiling ethanol,benzene,chloroform,ether,acetic acid and acetone;Store the product in sealed,cool and dry conditionCardamomin (also known as cardamonin) is a chalconoid that has been isolated from several plants including Alpinia katsumadai and Alpinia conchigera. It has received growing attention from the scientific community due to the expectations toward its benefits to human health.Cordycepin is a purine nucleoside antimetabolite and antibiotic isolated from the fungus Cordyceps militaris with potential antineoplastic activity. Extracted?from?Cordyceps;Store?the?product?in?sealed,?cool?and?dry?conditionPinocembrin is a flavanone, a type of flavonoid. It is an antioxidant found in damiana, honey, fingerroot, and propolis.Extracted from whole herb of Gynostemsma pentaphyllum(Thunb.)Mak.;Store the product in sealed, cool and dry conditionRotenone is an odorless, colorless, crystalline ketonic chemical compound used as a broad-spectrum insecticide, piscicide, and pesticide. It occurs naturally in the seeds and stems of several plants, such as the jicama vine plant, and the roots of several members of Fabaceae. It was the first described member of the family of chemical compounds known as rotenoids.

Muscone is an organic compound that is the primary contributor to the odor of musk.

Extracted from Rhus succedanea L;Store the product in sealed, cool and dry condition.

Ginsenoside Rg2 may have properties that inhibit or prevent the growth of tumors.

Nobiletin is an inhibitor of ERK with in a concentration-dependent manner .

Ginsenoside Rh2, an extract of red Panax ginseng, is a potent anti-inflammatory and anticancer drug. Extracted from Panax ginseng C. A. Mey.;Store the product in sealed,cool and dry conditionArctigenin is a lignan found in certain plants of the Asteraceae; it has shown antiviral and anticancer effects in glass; it is the aglycone of arctiin.Indole-3-Carbinol is a naturally occurring, orally available cleavage product of the glucosinolate glucobrassicanin, a natural compound present in a wide variety of plant food substances including members of the family Cruciferae with antioxidant and potential chemopreventive properties.Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.4'-demethylepipodophyllotoxin is a key intermediate compounds for the preparation of podophyllotoxin-type anti-cancer drugs.Schisandrin B(Wuweizisu-B) is a dibenzocyclooctadiene derivative isolated from Fructus Schisandrae, has been shown to produce antioxidant effect on rodent liver and heart.Apremilast (CC-10004) is a potent and orally active PDE4 and TNF-α inhibitor with IC50 of 74 nM and 77 nM, respectively.Extracted from Sinomenium Acutum Rehderett Wilson;Store the product in sealed, cool and dry conditionCDDO is a synthetic oleanane triterpenoid that blocks the cellular synthesis of inducible nitric oxide synthase and inducible COX-2 in INF-γ-activated mouse macrophages with an IC50 value of 0.4 nM. By suppressing reactive oxygen and nitrogen species (ROS/RNS) formation, it promotes the cellular control of ROS/RNS levels that would lead to DNA damage A nantural,noncaloric sweetener with a potency 300 times more than that of regular sucrose. Exhibits transepithelial p-aminohippurate transport via organic anion transport system interference.Andrographolide(Andrographis) is an irreversible antagonist of NF-κB and prevents in vitro T cell activation; displays antiviral, antiinflammatory, antiapoptotic, and antihyperglycemic properties.Alkannin is a natural dye that is obtained from the extracts of plants from the borage family Alkanna tinctoria that are found in the south of France. The dye is used as a food coloring and in cosmetics. It is used as a red-brown food additive in regions such as Australia.Lupeol is a pentacyclic triterpene that has anti-inflammatory and antioxidant activity. Murine skin studies report that Lupeol inhibits the cutaneous toxicity induced by benzoyl peroxide. Lupeol has been shown to regulate NF-κB and PI3K/Akt pathways,indu

Matrine is an alkaloid found in plants from the Sophora genus. It has a variety of pharmacological effects, including anti-cancer effects, and action as a kappa opioid receptor and ?-receptor agonist.Emodin is a naturally occurring anthraquinone present in the roots and barks of numerous plants; exerts antiproliferative effects in cancer cells that are regulated by different signaling pathways.Oleanolic Acid is a naturally occurring triterpenoid found in garlic and Phytolacca Americana. Exhibits strong anti-HIV activity. Mechanism of action is the induction of iNOS and of Cyclooxygenase 2Extracted from Papaya fruit, marigold flower petals;Store the product in sealed, cool and dry condition.Actions Hydroxycinnamic acid found in many fruits and vegetables. Other Notes :Predominantly trans isomer. Packaging: 1,5,10,25 g in poly bottleBiochanin A, an O-methylated isoflavone from Trifolium pratense, inhibits protein tyrosine kinase (PTK) of epidermal growth factor receptor with IC50 values of 91.5 μM.Extracted from Forsythia suspensa;Suitability:The mixed solvent of chloroform and methanol,DMSO;Store the product in sealed,cool and dry conditionCurcumol is a pure monomer isolated from Rhizoma Curcumaeis with antitumor activities. Extracted from Curcuma zedoaria(Berg.)Rose;Store the product in sealed,cool and dry conditionDaphnetin, a natural coumarin derivative, is a protein kinase inhibitor, inhibits EGFR, PKA and PKC with IC50 of 7.67 μM, 9.33 μM and 25.01 μM, respectively, also known to exhibit anti-inflammatory and anti-oxidant activities.Extracted from Indigo blue;Suitability:Water,ethanol,glycerol and propylene glycol;Store the product in sealed,cool and dry conditionIsoimperatorin is an anti-inflammatory agent,that also has an effect on proliferation,isolated from the dried roots of Angelicae dahuricae. In bone marrow derived mast cells the compound has been observed to inhibit,at an IC50 24 μM and 10.7 μM,COX-1Tangeretin, a flavonoid from citrus fruit peels, has been proven to play an important role in anti-inflammatory responses and neuroprotective effects in several disease models, and was also selected as a Notch-1 inhibitor.

Asaraldehyde is a natural COX-2 inhibitor, exhibiting 17-fold selectivity over COX-1.

Extracted from synthetic product;Store the product in sealed, cool and dry condition

(S)-10-Hydroxycamptothecin is a clinical therapy agent against hepatoma.

Extracted from Mylabris phqlarata pallas;Store the product in sealed, cool and dry condition.

Betulinic acid is a naturally occurring pentacyclic triterpenoid which has antiretroviral, antimalarial, and anti-inflammatory properties, as well as a more recently discovered potential as an anticancer agent, by inhibition of topoisomerase.ActionsAsiatic acid is commonly used in wound healing. Asiatic acid has antioxidant,anti-inflammatory and neuroprotective properties.Packaging500 mg in glass bottleApplicationStarting material for asiatic acid derivative synthesis for use as: Anticance

General descriptionA highly unsaturared diterpene dicarboxylic acid ester found in saffron. Actions Crocin alleviates some ethanol-induced impairments of learning and prevents ethanol-induced inhibition of hippocampal long-term potentiation (LTP),a form oHovenia dulcis Thunb extract and its ingredient methyl vanillate activate Wnt/β-catenin pathway and increase bone mass in growing or ovariectomized mice.7,8-Dihydroxyflavone (7,8-DHF) is a naturally-occurring flavone found in Godmania aesculifolia, Tridax procumbens, and primula tree leaves.Cryptotanshinone is a STAT3 inhibitor with IC50 of 4.6 μM in a cell-free assay, strongly inhibits phosphorylation of STAT3 Tyr705, with a small effect on STAT3 Ser727, but none against STAT1 nor STAT5.Extracted from Stephania tetrandra S. Moore;Store the product in sealed,cool and dry conditionExtracted from Solidago decurrens,large-fruited Chinese hawthorn;Suitability:Hot water and cold ethanol;Store the product in sealed,cool and dry conditionChlorogenic acid(NSC-407296; 3-O-Caffeoylquinic acid) is one of the most abundant polyphenols in the human diet, has been reported to inhibit cancer cell growth and a major anti-inflammatory constituent of lonicerae flos extract.Extracted from Legume Crotalaria assamica;Suitability:Methanol,ethanol,chloroform;Store the product in sealed,cool and dry conditionNocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM in cell-free assays, respectively.Laetrile is a glycoside initially isolated from the seeds of the tree Prunus dulcis, also known as bitter almonds.

Catharanthine inhibits nicotinic receptor mediated diaphragm contractions with IC50 of 59.6 μM.Baicalin, one the effective compositions of scutellaria baicalensis, possesses multiple properities such as antioxidant, anti-tumor, anti-HIV, treating cardiovascular disease and so on.Extracted from Bupleurum,scorzonerifolium;Suitability:Water,dilute alcohol,especially the hot water,hot alcohol,butanol and pentanol;Store the product in sealed,cool and dry condition

Loganin,an iridoid glucosides,has been reported to be an inhibitor of Cox-1 and also noted to suppress TNF-α formation. This compound also has displayed potent free-radical-scavenging activity and inhibitory effects on melanogenesis. Research has shownMyricitrin, a flavonoid compound isolated from the root bark of Myrica cerifera, which exerts antinociceptive effects.Ginkgolide B, an important active terpenoid from Ginkgo biloba leaves, is reported to increase cell viability and decrease cell apoptosis.Ilomastat (GM6001, Galardin) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-12, MMP-14, and MMP-26 with Ki of 0.4 nM, 0.5 nM, 27 nM, 3.7 nM, 0.1 nM, 0.2 nM, 3.6 nM, 13.4 nM, 0.36 nM, respectively.

Extracted from Puffer fish,salamanders,frogs foot spot; Suitability:Acidic aqueous solution;Store the product in sealed,cool and dry conditionGossypol-acetic acid, a polyphenolic compound isolated from cottonseeds, inhibits Bcl-2 by acting as a BH3 mimetic.TAK-901 is a novel inhibitor of Aurora A/B with IC50 of 21 nM/15 nM. It is not a potent inhibitor of cellular JAK2, c-Src or Abl. Phase 1.SL327 is a selective inhibitor for MEK1/2 with IC50 of 0.18 μM/ 0.22 μM, no activity towards Erk1, MKK3, MKK4, c-JUN, PKC, PKA, or CamKII;capable of transport through the blood-brain barrier.Pifithrin-α is an inhibitor of p53, inhibiting p53-dependent transactivation of p53-responsive genes.Palomid 529 (P529) inhibits both the mTORC1 and mTORC2 complexes, reduces phosphorylation of pAktS473, pGSK3βS9, and pS6 but no effect observed on pMAPK or pAktT308. Phase 1.

MLN0905 is a potent inhibitor of PLK1 with IC50 of 2 nM.

IWP-L6 is a highly potent Porcn inhibitor with EC50 of 0.5 nM.

NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.

AS 602801(Bentamapimod) is a novel, orally active inhibitor of JNK.

GSK0660 is an antagonist and inverse agonist of PPARβ/δ,

VE-822 is an ATR inhibitor with IC50 of 19 nM in HT29 cells

Elacridar (GF120918) is a potent P-gp (MDR-1) and BCRP inhibitor.

Mutant EGFR inhibitor is a selective and potent Mutated EGFR inhibitor(L858R activating mutant, the Exonl9 deletion activating mutant and the T790M resistance mutant).

IWP-2 is an inhibitor of Wnt processing and secretion with IC50 of 27 nM in a cell-free assay, selective blockage of Porcn-mediated Wnt palmitoylation, does not affect Wnt/β-catenin in general and displays no effect against Wnt-stimulated cellular responses.BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, 40-fold more selective for Met-related targets versus Lck, VEGFR-2, and TrkA/B, and more than 500-fold greater selectivity versus all other receptor and non receptor kinases.KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent kinase II (CaMKII), competitively blocking CaM binding to the kinase (Ki = 370 nM).PRT062607 (P505-15, BIIB057) hydrochloride is a novel, highly selective Syk inhibitor with IC50 of 1 nM in cell-free assays, >80-fold selective for Syk than Fgr, Lyn, FAK, Pyk2 and Zap70.TBB(NSC 231634) is a highly selective, ATP/GTP-competitive inhibitor of casein kinase-2 (CK2)with IC50s of 0.9 and 1.6 μM for rat liver and human recombinant CK2 respectively).KN-62 is a potent and specific inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMKII) with Ki of 0.9 μM.KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

BMS-265246 is a potent and selective CDK1/2 inhibitor with IC50 of 6 nM/9 nM in a cell-free assay. It is 25-fold more selective for CDK1/2 than CDK4.Crenolanib (CP-868596) is a potent and selective inhibitor of PDGFRα/β with Kd of 2.1 nM/3.2 nM in CHO cells, also potently inhibits FLT3, sensitive to D842V mutation not V561D mutation, >100-fold more selective for PDGFR than c-Kit, VEGFR-2, TIE-2, FGFR-2, EGFR, erbB2, and Src.PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM in A549 cell line, susceptible to oncogenic mutations (no activity to Y1230C mutant). Phase 1.

TG100-115 is a PI3Kγ/δ inhibitor with IC50 of 83 nM/235 nM, with little effect on PI3Kα/β. Phase 1/2.Regadenoson is an adenosine derivative and selective A2A adenosine receptor agonist with coronary vasodilating activity. Upon administration, regadenoson selectively binds to and activates the A2A adenosine receptor, which induces coronary vasodilation. This leads to an increase in coronary blood flow and enhances myocardial perfusion. Compared to adenosine, ML167 is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor with IC50 of 136 nM, >10-fold selectivity for closely related kinases Clk1-3 and Dyrk1A/1B.

JNK-IN-8 is the first irreversible JNK inhibitor for JNK1, JNK2 and JNK4 with IC50 of 4.7 nM, 18.7 nM and 1 nM, >10-fold selectivity against MNK2, Fms and no inhibition to c-Kit, Met, PDGFRβin A375 cell line.PIK-75 Hydrochloride is a p110α inhibitor with IC50 of 5.8 nM (200-fold more potently than p110β), isoform-specific mutants at Ser773, and also potently inhibits DNA-PK with IC50 of 2 nM in cell-free assays.TGX-221 is a p110β-specific inhibitor with IC50 of 5 nM in a cell-free assay, 1000-fold more selective for p110β than p110α.IC-87114 is a selective PI3Kδ inhibitor with IC50 of 0.5 μM in a cell-free assay, 58-fold more selective for PI3Kδ than PI3Kγ, and over 100-fold more selective than PI3Kα/β.GW2580 is an orally bioavailable inhibitor of c-FMS kinase; completely inhibited human cFMS kinase in vitro at 0.06 microM and was inactive against 26 other kinases.

Fruquintinib (HMPL-013) is a small molecule vascular endothelial growth factor receptors inhibitor.CEP-37440 is a novel potent and selective Dual FAK/ALK inhibitor with IC50 s of 2.3 nM (FAK) and 120 nM(ALK cellular IC50 in 75% human plasma).SB1317/TG02 is a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3)。

MI-2 (Menin-MLL Inhibitor) is a potent menin-MLL interaction inhibitor with IC50 of 446 nM.

MI-3 (Menin-MLL Inhibitor) is a potent menin-MLL interaction inhibitor with IC50 of 648 nM.

RO3280 is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3?nM.

IWR-1(IWR-1-endo) is a novel small-molecule inhibitor of Wnt signaling by stabilizing the Axin destruction complex with an EC50 of 0.2 uM.

IDO-IN-2 is a potent IDO1 inhibitor(IC50=10 nM) with desirable pharmaceutical properties, which is poised to start clinical trials in cancer patients.FK866 (APO866, Daporinad) effectively inhibits nicotinamide phosphoribosyltransferase (NMPRTase) with IC50 of 0.09 nM in a cell-free assay. Phase 1/2.

PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.KRCA-0008 is a potent and selective ALK/Ack1 inhibitor with IC50 of 12 nM/4 nM for ALK and Ack1 respectively; displays drug-like properties without hERG liability.DCC-2036 (Rebastinib) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1.LY2811376 is the first orally available non-peptidic β-secretase(BACE1) inhibitor with IC50 of 239 nM-249 nM, that act to decrease Aβ secretion with EC50 of 300 nM, demonstrated to have 10-fold selectivity towards BACE1 over BACE2, and more than 50-fold inhibition over other aspartic proteases including cathepsin D, pepsin, or renin. Phase 1.LY2784544(gandotinib) is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2V617F(Ki=0.245 nM), 8- and 20-fold selective versus JAK1 and JAK3. Exherin (ADH-1) is a small, cyclic pentapeptide vascular-targeting agent with potential antineoplastic and antiangiogenic activities; selectively and competitively binds to and blocks N-cadherin.Decernotinib(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.

A-1210477 is a potent and selective MCL-1 and Bcl-2 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.Poziotinib(NOV120101; HM781-36B) is an irreversible Pan-HER inhibitor with IC50s of 3/5/23 nM for HER1/HER2/HER4 respectively.Nolatrexed Dihydrochloride is the dihydrochloride salt of nolatrexed, a water-soluble lipophilic quinazoline folate analog with antineoplastic activity. Nolatrexed occupies the folate binding site of thymidylate synthase, resulting in inhibition of thymidylate synthase activity and thymine nucleotide synthesis with subsequent inhibition of DNA replication, DNA damage, S-phase cell MK-0752 is a moderately potent γ-secretase inhibitor, which reduces Aβ40 production with IC50 of 5 nM. Phase 1/2.OSI-930 is a potent inhibitor of Kit, KDR and CSF-1R with IC50 of 80 nM, 9 nM and 15 nM, respectively; also potent to Flt-1, c-Raf and Lck and low activity against PDGFRα/β, Flt-3 and Abl. Phase 1.PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.G-749 is a novel and potent FLT3 inhibitor with IC50 of 0.4 nM, 0.6 nM and 1 nM for FLT3 (WT), FLT3 (D835Y), and Mer, respectively, showing lower potency against other tyrosine kinases.CH5132799 inhibits class I PI3Ks, particularly PI3Kα with IC50 of 14 nM; less potent to PI3Kβδγ, while sensitive in PIK3CA mutations cell lines. Phase 1.LGK-974 is a potent and specific PORCN inhibitor, and inhibits Wnt signaling with IC50 of 0.4 nM in TM3 cells. Phase 1.SNS-314 Mesylate is a potent and selective inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 9 nM, 31 nM, and 3 nM, respectively. It is less potent to Trk A/B, Flt4, Fms, Axl, c-Raf and DDR2. Phase 1.PIK-93 is the first potent, synthetic PI4K (PI4KIIIβ) inhibitor with IC50 of 19 nM; shown to inhibit PI3Kα with IC50 of 39 nM.Flavopiridol hydrochloride competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM.CCT137690 is a highly selective inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 15 nM, 25 nM and 19 nM. It has little effect on hERG ion-channel.AC480 (BMS-599626) is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM, ~8-fold less potent to HER4, >100-fold to VEGFR2, c-Kit, Lck, MET etc. Phase 1.Masitinib is a novel inhibitor for Kit and PDGFRα/β with IC50 of 200 nM and 540 nM/800 nM, weak inhibition to ABL and c-Fms. Phase 3.CHIR-98014 is a selective GSK3 inhibitor with IC50s of 0.65 nM and 0.58 nM for GSK-3α and GSK-3β; potentiate insulin activation of glucose transport and utilization in vitro and in vivo.

Apatinib is an orally bioavailable, selective VEGFR2 inhibitor with IC50 of 1 nM.

Chlorotrianisene is a powerful synthetic, non-steroidal estrogen.

Oxandrolone(SC11585) is a synthetic hormone with anabolic and androgenic properties.

Hesperetin is a bioflavonoid and, to be more specific, a flavanone.

KN-93 Phosphate is a potent and specific inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMKII) with Ki of 0.37 μM, no remarkable inhibitory effects on APK, PKC, MLCK or Ca2+-PDE activities.R788 (Fostamatinib) disodium, a prodrug of the active metabolite R406, is a Syk inhibitor with IC50 of 41 nM in a cell-free assay, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Phase 3.CC-292 (AVL-292) is a covalent, orally active, and highly selective BTK inhibitor with IC50 of <0.5 nM, displaying at least 1400-fold selectivity over the other kinases assayed. Phase 1.Barasertib (AZD1152-HQPA) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.AG-490 (Tyrphostin AG 490) is an inhibitor of EGFR with IC50 of 0.1 μM, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.Synthetic pentapeptide corresponding to the amino acids 32-36 of thymopoietin and exhibiting the full biological activity of the natural hormone. THYMOPENTIN is an immunomodulator which has been studied for possible use in the treatment of rheumatoid arthritis, AIDS, and other primary immunodeficiencies.VX-809 (Lumacaftor) acts to correct CFTR mutations common in cystic fibrosis by increasing mutant CFTR (F508del-CFTR) maturation,EC50 of 0.1 μM in fisher rat thyroid cells. Phase 3.Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.Vismodegib(GDC-0449) is a more potent novel and specific synthetic oral hedgehog pathway inhibitor with an IC50 of 3 nM; also inhibits P-gp with IC50 of 3.0 μM.Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively.Octreotide is a synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, Fluoxymesterone is an Androgen. The mechanism of action of fluoxymesterone is as an Androgen Receptor Agonist. The chemical classification of fluoxymesterone is Androstanes.Brivanib alaninate (BMS-582664) is the prodrug of BMS-540215, an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM.17α-Methyltestosterone has similar binding affinity to AR and similar androgenic and anabolic activities as testosterone.

Cladribine is an adenosine deaminase inhibitor used to treat hairy cell leukemia and multiple sclerosis.Etofenamate is a non-steroidal anti-inflammatory drug used for the treatment joint and muscular pain.Tolmetin is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of tolmetin is as a Cyclooxygenase Inhibitor. The chemical classification of tolmetin is Nonsteroidal Anti-inflammatory CompoundsCabazitaxel(XRP6258; RPR-116258A) is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity.Fingolimod (FTY720) hydrochloride is a S1P antagonist with IC50 of 0.033 nM in K562, and NK cells.Bimatoprost is a prostaglandin analog used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension.Tirofiban hydrochloride monohydrate is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonistEprosartan is a nonpeptide angiotensin II receptor antagonist, [3H]-eprosartan binds to the AT1 receptor with KD of 0.83 nM in rat vascular smooth muscle cells.Ulipristal acetate(CDB2914) is a novel selective progesterone receptor modulator (SPRM) for the treatment of benign gynecological conditions such as uterine myoma.ARRY-380 is a potent and selective HER2 inhibitor with IC50 of 8 nM, equipotent against truncated p95-HER2, 500-fold more selective for HER2 versus EGFR.MK-8776 (SCH 900776) is a selective Chk1 inhibitor with IC50 of 3 nM in a cell-free assay. It shows 500-fold selectivity against Chk2. Phase 2.

LY2157299 is a potent TGFβ receptor I (TβRI) inhibitor with IC50 of 56 nM.

Lomeguatrib is a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase with IC50 of 5 nM.

BAY 87-2243 is a potent and selective hypoxia-inducible factor-1 (HIF-1) inhibitor. Phase 1.

AZD2461 is a novel PARP inhibitor with low affinity for Pgp than Olaparib. Phase 1.

Amuvatinib (MP-470) is a potent and multi-targeted inhibitor of c-Kit, PDGFRα and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively. Phase 2.Linifanib (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFRβ with IC50 of 4 nM, 3 nM, 3 nM/4 nM and 66 nM respectively, mostly effective in mutant kinase-dependent cancer cells (i.e. FLT3). Phase 3.VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.Plinabulin (NPI-2358) is a vascular disrupting agent (VDA) against tubulin-depolymerizing with IC50 of 9.8~18 nM in tumor cells. Phase 1/2.

AZD5438 is a potent inhibitor of CDK1/2/9 with IC50 of 16 nM/6 nM/20 nM in cell-free assays. It is less potent to CDK5/6 and also inhibits GSK3β. Phase 1.S3I-201 shows potent inhibition of STAT3 DNA-binding activity with IC50 of 86 μM in cell-free assays, and low activity towards STAT1 and STAT5.PAC-1 is a potent procaspase-3 activator with EC50 of 0.22 μM and the first small molecule known to directly activate procaspase-3 to caspase-3.Canertinib Dihydrochloride is the hydrochloride salt of an orally bio-available quinazoline with potential antineoplastic and radiosensitizing activities. Canertinib binds to the intracellular domains of epidermal growth factor receptor tyrosine kinases (ErbB family), irreversibly inhibiting their signal transduction functions and resulting in tumor cell apoptosis and Cediranib (AZD2171) is a highly potent VEGFR(KDR) inhibitor with IC50 of <1 nM, also inhibits Flt1/4 with IC50 of 5 nM/≤3 nM, similar activity against c-Kit and PDGFRβ, 36-, 110-fold and >1000-fold selective more for VEGFR than PDGFR-α, CSF-1R and Flt3 in HUVEC cells. Phase 3.Semaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 μM, 20-fold more selective for VEGFR than PDGFRβ, lack of activity against EGFR, InsR and FGFR. Phase 3.

Cilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.AZ5104, the demethylated metabolite of AZD-9291, is a potent EGFR inhibitor with IC50 of <1 nM, 6 nM, 1 nM, and 25 nM for EGFR (L858R/T790M), EGFR (L858R), EGFR (L861Q), and EGFR (wildtype), respectively. Phase 1.AZD9291 is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.Rocilinostat (ACY-1215) is a selective HDAC6 inhibitor with IC50 of 5 nM in a cell-free assay. It is >10-fold more selective for HDAC6 than HDAC1/2/3 (class I HDACs) with slight activity against HDAC8, minimal activity against HDAC4/5/7/9/11, Sirtuin1, and Sirtuin2. Phase 2.

Baricitinib (LY3009104, INCB028050) is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM in cell-free assays, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2. Phase 3.

Dacomitinib(PF299804; PF-00299804) is a potent, orally available, irreversible tyrosine kinase HER 1 (EGFR), HER2 and HER4 inhibitor with IC50 of 6, 45.7 and 73.7 nM for EGFR, ERBB2 and ERBB4, respectively.AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.Tyrphostin 9 is firstly designed as an EGFR inhibitor with IC50 of 460 μM, but is also found to be more potent to PDGFR with IC50 of 0.5 μM.UNBS5162 is a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers; the mean antiproliferative activity IC50 value is 17.9 uM for 9 cancer cell lines; hydrolysis product of UNBS3157.KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.KU-60019 is an improved analogue of KU-55933, with IC50 of 6.3 nM for ATM in cell-free assays, 270- and 1600-fold more selective for ATM than DNA-PK and ATR,and is a highly effective radiosensitizer.PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.CGI1746 is a potent and highly selective small-molecule inhibitor of the Btk with IC50 of 1.9 nM.

CPI-203 is a potent BET bromodomain inhibitor with IC50 of 37 nM for BRD4.

HMN-214(IVX214) is a potent PLK1 inhibitor an average IC50 of 0.12 μM.

LY303511, an inactive analogue of LY294002, is a mTOR inhibitor that did not inhibit PI3-K.

PD 169316 is a potent, cell-permeable and selective p38 MAP kinase inhibitor (IC50 = 89 nM).

CEP-33779 is a novel selective JAK2 inhibitor.

MK-8745 is a potent and selective Aurora A inhibitor with IC50 of 0.6 nM, more than 450-fold selectivity for Aurora A over Aurora B.A-769662 is a potent, reversible AMPK activator with EC50 of 0.8 μM in cell-free assays, little effect on GPPase/FBPase activity.R406 (free base) is a potent Syk inhibitor with IC50 of 41 nM in a cell-free assay, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Phase 1.OSU-03012 (AR-12) is a potent inhibitor of recombinant PDK-1 with IC50 of 5 μM in a cell-free assay and 2-fold increase in potency over OSU-02067.PF-562271 is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM in cell-free assays, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs.NSC319726 is a mutant p53R175 reactivator; inhibits growth of fibroblasts expressing the p53R175 mutation (IC50 = 8 nM); shows no inhibition for p53 wild-type cells.ML141 is a potent, selective and reversible non-competitive inhibitor of Rho family GTPase cdc42 with IC50 of 200 nM.PIK-90 is a PI3Kα/γ/δ inhibitor with IC50 of 11 nM/18 nM/58 nM, respectively, less potent to PI3Kβ(IC50= 350 nM).ZM 39923 hydrochloride is an JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to be sensitive to transglutaminase.IRAK-1-4 Inhibitor I is an inhibitor of both IRAK-1 and IRAK-4 with IC50 values of 0.3μM and 0.2μM , respectively Tivozanib is an orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death. VEGFR LAQ824 (Dacinostat) is a novel HDAC inhibitor with IC50 of 32 nM and is known to activate the p21 promoter.SANT-1 directly binds to Smoothened (Smo) receptor with Kd of 1.2 nM and inhibits Smo agonist effects with IC50 of 20 nM.D 4476 is a potent, selective, and cell-permeant CK1 (casein kinase 1) inhibitor with IC50 of 200 nM and 300 nM in a cell-free assay for CK1 from Schizosaccharomyces pombe and CK1δ, respectively. Also acts as an ALK5 inhibitor with IC50 of 500 nM.Ki8751 is a potent and selective inhibitor of VEGFR2 with IC50 of 0.9 nM, >40-fold selective for VEGFR2 than c-Kit, PDGFRα and FGFR-2, little activity to EGFR, HGFR and InsR.FG-2216 is a potent HIF-prolyl hydroxylase inhibitor with IC50 of 3.9 uM for PDH2 enzyme; orally bioavailable and induced significant and reversible Epo induction in vivo.NK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

TAS-301 is an inhibitor of smooth muscle cell migration and proliferation, inhibits intimal thickening after balloon injury to rat carotid arteriesIC261 is a novel inhibitor of CK1, triggers the mitotic checkpoint control. The IC50 of IC261 for CK1 was 16 μM and for Cdk5 is 4.5 mM.

EPZ011989 is a potent, selective orally bioavailable EZH2 inhibitor with Ki < 3 nM for EZH2 wt and EZH2 Y646; 15-fold selectivity over EZH1 and >3000-fold selectivity over other HMTase.

NU7026 is a potent DNA-PK inhibitor with IC50 of 0.23 μM in cell-free assays, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.

HPOB is a potent, selective HDAC6 inhibitor with IC50 of 56 nM, >30-fold selectivity over other HDACs.GZD824 Dimesylate is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.

KPT-185 is a selective CRM1 inhibitor.

SKLB1002 is a potent and ATP-competitive VEGFR2 inhibitor with IC50 of 32 nM.

FH535 is a Wnt/β-catenin signaling inhibitor and also a dual PPARγ and PPARδ antagonist.

Ostarine(MK-2866; GTX-024)A modulator to human androgen receptor.

Pixantrone dimaleate (BBR 2778 dimaleate) is an experimental antineoplastic drug.

Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs.

P22077 is an inhibitor of ubiquitin-specific protease USP7 with EC50 of 8.6 μM, also inhibits the closely related USP47.

PHT-427 is a dual Akt and PDPK1 inhibitor (high affinity binding for the PH domains of Akt and PDPK1) with Ki of 2.7 μM and 5.2 μM, respectively.BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2 with IC50 of 1.7 nM/15 nM, also inhibits Ron, Axl and Flt3 with IC50 of <3 nM; a prodrug of BMS-817378. Phase 1.A66 is a potent and specific p110α inhibitor with IC50 of 32 nM in a cell-free assay, >100 fold selectivity for p110α over other class-I PI3K isoforms.BIX02189 is a selective inhibitor of MEK5 with IC50 of 1.5 nM, also inhibits ERK5 catalytic activity with IC50 of 59 nM in cell-free assays, and does not inhibit closely related kinases MEK1, MEK2, ERK2, and JNK2.PP-121 is a multi-targeted inhibitor of PDGFR, Hck, mTOR, VEGFR2, Src and Abl with IC50 of 2 nM, 8 nM, 10 nM, 12 nM, 14 nM and 18 nM, also inhibits DNA-PK with IC50 of 60 nM.Torkinib (PP242) is a selective mTOR inhibitor with IC50 of 8 nM in cell-free assays; targets both mTOR complexes with >10- and 100-fold selectivity for mTOR than PI3Kδ or PI3Kα/β/γ, respectively.

SRT1720 hydrochloride is a selective activator of human SIRT1 (EC1.5 = 0.16 μM) versus the closest sirtuin homologues, SIRT2 and SIRT3 (SIRT2: EC1.5 = 37 μM；SIRT3: EC1.5 > 300 μM).Nedaplatin is a derivative of cisplatin and DNA damage agent for tumor colony forming units with IC50 of 94 μM.

Bromfenac Sodium is the sodium salt form of bromfenac, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and anti-inflammatory activities. Upon ophthalmic administration, bromfenac binds to and inhibits the activity of cyclooxygenase II (COX II), an enzyme which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins (PG). By Candesartan Cilexetil is an angiotensin II receptor antagonist with IC50 of 0.26 nM, used in the treatment of hypertension.Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.Tofacitinib citrate (CP-690550 citrate) is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.Ramatroban (BAY u3405) is a thromboxane A(2) (TxA(2)) antagonist marketed for allergic rhinitis.

Camostat is a trypsin-like protease inhibitor, inhibits airway epithelial sodium channel (ENaC) function with IC50 of 50 nM, less potent to trpsin, prostasin and matriptase.Pirfenidone is an inhibitor for?TGF-β?production and TGF-β stimulated collagen production, reduces production of?TNF-α?and IL-1β, and also has anti-fibrotic and anti-inflammatory properties. Phase 3.

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.Vemurafenib (PLX4032, RG7204) is a novel and potent inhibitor of B-RafV600E with IC50 of 31 nM in cell-free assayLY2835219 is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM, respectively.BIBR 1532 is a potent, selective, non-competitive telomerase inhibitor with IC50 of 100 nM in a cell-free assay.RGB-286638 free base is a novel CDK inhibitor with IC50s of 1 nM/2 nM/3 nM/4 nM/5 nM for cyclin T1-CDK9/cyclin B1-CDK1/cyclin E-CDK2/cyclin D1-CDK4/cyclin E-CDK3/p35-CDK5 respectively; less potent against cyclin H-CDK7 and cyclin D3-CDK6.XL147 analogue is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2BX471 is a potent, selective non-peptide CCR1 antagonist (Ki = 1 nM for human CCR1); exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4.

STF-31 is an inhibitor of glucose transporter 1 (GLUT1, IC50 = 1 uM).

UNC0631 is a potent histone methyltransferase G9a inhibitor with IC50 of 4 nM.

Enasidenib is a oral potent, selective, reversible inhibitor of mutant IDH2.

Pelitinib (EKB-569) is a potent irreversible EGFR inhibitor with IC50 of 38.5 nM. Phase2.

HTH-01-015 is a potent and selective NUAK1 inhibitor with IC50 of 100 nM, >100-fold selectivity over NUAK2.Vipadenant(BIIB-014) is an adenosine A2a antagonist with Ki of 1.3 nM; less potent for A1(Ki=69 nM).Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM, respectively.CO-1686 is a novel, irreversible and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M(IC50=21 nM).SKF-86002 is a potent inhibitor of p38 MAP kinase wit IC50 of 0.5-1 uM; inhibits LPS-induced IL-1 and TNF-_alpha_ production in human monocytes (IC50 = 1 _mu_M).Tipiralacil, also known as TPI, is a thymidine phosphorylase inhibitor (TPI). Tipiracil is one of the active components in TAS-102, which is an anticancer drug candidate currently in clinical trialsPilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.Irbinitinib(ARRY-380; ONT-380) is a potent and selective HER2 inhibitor with IC50 of 8 nM, equipotent against truncated p95-HER2, 500-fold more selective for HER2 versus EGFR.

LY2874455 is a pan-FGFR inhibitor with IC50 of 2.8 nM, 2.6 nM, 6.4 nM, and 6 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively, and also inhibits VEGFR2 activity with IC50 of 7 nM. Phase 1.Baricitinib phosphate(INCB 028050; LY 3009104) is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2.ANA-12 is a potent and selective TrkB antagonist with anxiolytic and antidepressant activity in mice.ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold selective for Aurora A than over Aurora B and less potent to VEGFR2/KDR and VEGFR3, FGFR1 and FGFR2 and PDGFRα. Phase 2.GSK1059615 is a dual inhibitor of PI3Kα/β/δ/γ (reversible) and mTOR with IC50 of 0.4 nM/0.6 nM/2 nM/5 nM and 12 nM, respectively.RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

AMI-1 is a potent and specific Histone Methyltransferase (HMT) inhibitor with IC50 of 3.0 μM and 8.8 μM for yeast Hmt1p and human PRMT1, respectively.BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.GSK2334470 is a novel PDK1 inhibitor with IC50 of ~10 nM in a cell-free assay, with no activity at other close related AGC-kinases.BLU9931 is the first selective small molecule inhibitor of FGFR4 with IC50 of 3 nM; less potent for FGFR1/2/3(IC50> 150 nM).

AS601245 is an inhibitor of the c-Jun NH2-terminal kinase (JNK) (hJNK1: IC50=150nM, hJNK2: IC50=220nM and hJNK3: IC50=70 nM), has neuroprotective properties.KW-2449 is a multiple-targeted inhibitor, mostly for Flt3 with IC50 of 6.6 nM, modestly potent to FGFR1, Bcr-Abl and Aurora A; little effect on PDGFRβ, IGF-1R, EGFR.ARN-509 is a selective and competitive androgen receptor inhibitor with IC50 of 16 nM in a cell-free assay, useful for prostate cancer treatment. Phase 3.Radotinib, and sometimes referred to by its investigational name IY5511, is a drug for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML)[1] with resistance or intolerance of other tyrosine kinase Bcr-Abl inhibitorsNeratinib (HKI-272) is an orally available, irreversible tyrosine kinase inhibitor with IC50 of 59 nM and 92 nM for HER2 and EGFR, respectively.Fimasartan(BR-A-657) is a non-peptide angiotensin II receptor antagonist used for the treatment of hypertension and heart failure.LCZ696, consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3.

PF-431396 is a dual PYK2/FAK inhibitor with IC50 of 11 nM and 2 nM, respectively.

HS-173 is a potent inhibitor of PI3Kα with IC50 value of 0.8 nM.

CNX-774 is an irreversible, orally active, and highly selective BTK inhibitor with IC50 of <1 nM.

BMS-833923 is an orally bioavailable Smoothened antagonist. Phase 2.

RPI-1 reduced the phosphorylation of RET, MET, DCDB2, CTND1, and PLCγ

GSK-LSD1 2hydrochloride is an irreversible, and selective LSD1 inhibitor with IC50 of 16 nM, > 1000 fold selective over other closely related FAD utilizing enzymes (i.e. LSD2, MAO-A, MAO-B).

MPI-0479605 is an ATP competitive and selective inhibitor of mitotic kinase Mps1 with IC50 of 1.8 nM, >40-fold selectivity over other kinasesCHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively.Ganetespib(STA-9090) is a unique triazolone-containing Hsp90 inhibitor with an IC50 of 4 nM in OSA 8 cells.

Icotinib hydrochloride(BPI-2009H) is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with an IC(50) of 5 nM, including it's mutants of EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R).SP2509 is a selective histone demethylase LSD1 inhibitor with IC50 of 13?nM, showing no activity against MAO-A, MAO-B, lactate dehydrogenase and glucose oxidase.Afatinib is an orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity. Upon administration, afatinib selectively and irreversibly binds to and inhibits the epidermal growth factor receptors 1 (ErbB1; EGFR), 2 (ErbB2; HER2), and 4 SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.AZD1208 is a novel, orally bioavailable, highly selective PIM kinase inhibitor with single nanomolar potency against all three PIM kinases and is currently undergoing Phase I testing and dose escalation studies in AML. AZD1208 suppresses the growth of MOLM 16 and KG 1 xenograft tumors in vivo in a dosedependent manner. Furthermore, AZD1208 leads to potent PIK-294 is a highly selective p110δ inhibitor with IC50 of 10 nM, 1000-, 49- and 16-fold less potent to PI3Kα/β/γ, respectively.SB590885 is a potent B-Raf inhibitor with Ki of 0.16 nM in a cell-free assay, 11-fold greater selectivity for B-Raf over c-Raf, no inhibition to other human kinases.BG45 is a class I HDAC inhibitor with IC50 of 289 nM, 2.0 ?M, 2.2 ?M and >20 ?M for HDAC3, HDAC1, HDAC2, and HDAC6 in cell-free assays, respectively.SGX-523 is a selective Met inhibitor with IC50 of 4 nM, no activity to BRAFV599E, c-Raf, Abl and p38α. Phase 1.Motesanib Diphosphate (AMG-706) is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50 of 2 nM/3 nM/6 nM, respectively; similar activity against Kit, ~10-fold more selective for VEGFR than PDGFR and Ret. Phase 3.Motesanib is an orally bioavailable receptor tyrosine kinase inhibitor with potential antineoplastic activity. AMG 706 selectively targets and inhibits vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGFR), Kit, and Ret receptors, thereby inhibiting angiogenesis and cellular proliferation.PIK-75 is a p110α inhibitor with IC50 of 5.8 nM (200-fold more potently than p110β), isoform-specific mutants at Ser773, and also potently inhibits DNA-PK with IC50 of 2 nM.BIIB021 is an orally available, fully synthetic small-molecule inhibitor of HSP90 with Ki and EC50 of 1.7 nM and 38 nM, respectively. Phase 2.PX-12(IV-2) is an irreversible inhibitor of Thioredoxin-1(Trx-1) currently in clinical development as an antitumor agent; IC50=7 uM in Hela, MTT assay, 72 h.

A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells.Endoxifen is the most important Tamoxifen metabolite responsible for eliciting the anti-estrogenic effects of this drug in breast cancer cells expressing estrogen receptor-alpha (ER_alpha_). Endoxifen inhibits hERG tail currents at 50 mV in a concentration-dependent manner with IC50 values of 1.6 uM.Losmapimod (GW856553X; SB856553; GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively.SC79 is a unique specific Akt activator that may be used to enhance Akt activity in various physiological and pathological conditions.ITD-1 is an inducer of TGF_beta_ type II receptor degradation-1, is a potent and highly selective TGF_beta_ pathway inhibitor (IC50 = 0.85 uM).BPR1J-097 is a novel small molecule FLT-3 inhibitor(IC50=11±7 nM) with promising in vivo anti-tumour activities; inhibits FLT-3 D835Y with an IC50 of 3 nM.

VER-49009 is a potent HSP90 inhibitor with IC50 of 47 nM for HSP90β.

VER-50589 is a potent HSP90 inhibitor with IC50 of 21 nM for HSP90β.

GW4064 is an agonist of farnesoid X receptor (FXR) with EC50 of 65 nM in CV1 cell line.

Trans-Tranilast is an antiallergic drug, used to treat bronchial asthma, allergic rhinitis and atopic dermatitis.WY 14643 (Pirinixic Acid) is a potent peroxisome proliferator and activator of PPARα with EC50 of 1.5 μM.

BQU57 shows selective inhibition for Ral relative to Ras or Rho and inhibit xenograft tumor growth similar to depletion of Ral by siRNA. The IC50 for BQU57 of 2.0 _mu_M in H2122 and 1.3 _mu_M in H358.Santacruzamate A (CAY10683) is a potent and selective HDAC inhibitor with IC50 of 119 pM for HDAC2, >3600-fold selectivity over other HDACs.PI3K-IN-2 is a PI3K inhibitor, inhibits pPKB and pS6 with "++++/+++(+)" in A2058 melanoma cell.VX-661 is a second F508del CFTR corrector and is believed to help CFTR protein reach the cell surface. Phase 2.CHF5074 is a novel γ-secretase modulator, reduces Aβ42 and Aβ40 secretion, with an IC50 of 3.6 and 18.4 μM, respectively.IM-12 is a potent GSK-3β inhibitor with IC50 of 53 nM; shows a significant activity in several biological tests which was comparable or even outplayed the effects of the known SB-216763.GW9662 is a selective PPAR antagonist for PPARγ with IC50 of 3.3 nM in a cell-free assay, with at least 100 to 1000-fold functional selectivity in cells with PPARγ versus PPARα and PPARδ.CX-4945 (Silmitasertib) is a potent and selective inhibitor of CK2 (casein kinase 2) with IC50 of 1 nM in a cell-free assay, less potent to Flt3, Pim1 and CDK1 (inactive in cell-based assay). Phase 1/2.

SB743921 is a kinesin spindle protein (KSP) inhibitor with Ki of 0.1 nM, almost no affinity to MKLP1, Kin2, Kif1A, Kif15, KHC, Kif4 and CENP-E. Phase 1/2.TCS PIM-1 1(sc-204330) is a potent and selective ATP-competitive Pim-1 kianse inhibitor with IC50 of 50 nM, displays good selectivity over Pim-2 and MEK1/MEK2(IC50s >20,000 nM).DY131(GSK 9089) is a novel selective agonist of ERR_beta_ and ERR_gamma_; displays minimal activity at ERR_alpha_, ER_alpha_ and ER_beta_ at concentrations up to 30 _mu_M.AS-605240 is a potent and selective inhibitor of PI 3-kinase γ (PI3Kγ) (IC50 = 8 nM). AS-605240 displays 30-fold selectivity over PI3Kδ and PI3Kβ and 7.5-fold selectivity over PI3Kα.Kenpaullone, a potent CDK1, CDK2 and CDK5 inhibitor, as new enhancer for iTreg cell differentiation. Kenpaullone promotes iTreg cell differentiation through increased and prolonged transcription of foxp3 gene by enhancing TGFβ-Smad3 signaling pathway. LRRK2-IN-1 is a potent and selective LRRK2 inhibitor with IC50 of 6 nM and 13 nM for LRRK2 (G2019S) and LRRK2 (WT), respectively.CL-387785(EKI785; WAY-EKI 785) is an irreversible inhibitor of EGFR with IC50 of 370+/-120 pM; is able to overcome resistance caused by the T790M mutation on a functional level.Serdemetan(JNJ-26854165) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Wnt-C59(C59) is a very potent and highly selective Wnt signaling antagonist with an IC50 ~ 74 pM in the Wnt signaling reporter assay.Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM; has >200-fold higher selectivity for Aurora A than Aurora B.GSK2578215A is a potent and selective LRRK2 kinase inhibitor with IC50 of 8.9 nM and 10.9 nM for LRRK2 (G2019S) and LRRK2 (WT), respectively.ICG-001 antagonizes Wnt/β-catenin/TCF-mediated transcription and specifically binds to element-binding protein (CREB)-binding protein (CBP) with IC50 of 3 μM, but is not the related transcriptional coactivator p300.RU 58841 is a specific androgen receptor antagonist or anti-androgen; RU 58841 has a dramatic effect on hair regrowth.BEZ235 (NVP-BEZ235, Dactolisib) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3TopBP1-ER cell.TCS JNK 5a(JNK Inhibitor IX) is a selective inhibitor of JNK2 and JNK3 (pIC50 values are 6.7, 6.5, <5.0 and <4.8 for JNK3, JNK2, JNK1 and p38α respectively); displays no significant activity at a range of other protein kinases including EGFR, ErbB2, cdk2, PLK-1 and Src (pIC50 < 5.0).Estradiol dipropionate is a synthetic ester, specifically the 3,17-dipropanoyl ester, of the natural estrogen, estradiol.

Paeoniflorin is a herbal constituent extracted from the root of Paeonia albiflora Pall.

Adrenosterone is a steroid hormone with weak androgenic effect.

2-Chloropyrazine is used in chemical industry.

Apigenin is a potent P450 inhibitor for CYP2C9 with Ki of 2 μM.

It is a CaMKP Inhibitor.

M344 is a potent HDAC inhibitor with IC50 of 100 nM and able to induce cell differentiation.

Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)Uridine, Trisodium Salt is an energy-rich precursor in the enzymatic biosynthesis of RNA, a potent vasodilator, and induces contractile responses in some tissues.2-Methoxyestradiol (2ME2) is a drug that prevents the formation of new blood vessels that tumors need in order to grow (angiogenesis). It has undergone Phase 1 clinical trials against breast cancers. Preclinical models also suggest that 2ME2 could also be effective against inflammatory diseases such as rheumatoid arthritis. Cephalomannine is an active anti-cancer agent obtained from Taxus yunnanensis and has an antineoplastic effect on tumors found in mice.Ferulic Acid is a hydroxycinnamic acid and a type of organic compound found in the Ferula assafoetida L. or Ligusticum chuanxiong.Arecoline is a muscarinic acetylcholine receptor agonist. Arecoline induces ADP ribosylation of histones and chromatid relaxation in spleen and bone marrow cells.

Theophylline-7-acetic acid is a stimulant drug of the xanthine chemical class. It acts as an adenosine receptor antagonist. It is combined with diphenhydramine in the pharmaceutical preparation etanautine to help offset its stimulant effects Lithocholic acid is a toxic secondary bile acid, causes intrahepatic cholestasis, has tumor-promoting activity.ercaptopurine is a widely used antileukemic agent and immunosuppressive drug that inhibits de novo purine synthesis through incorporation of thiopurine methyltransferase metabolites into DNA and RNA.Epiandrosterone is a steroid hormone with weak androgenic activity, is a natural metabolite of DHEA.

Triptolide is a diterpene triepoxide, immunosuppresive agent extracted from the Chinese herb Tripterygium wilfordii.Perifosine (KRX-0401; D-21266; NSC 639966) is a novel Akt inhibitor with IC50 of 4.7 _mu_M, targets pleckstrin homology domain of Akt.

Quercetin, a natural flavonoid present in vegetables, fruit and wine, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC50 of 2.4-5.4 μM. Phase 4.Zebularine is a DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases, also inhibits cytidinedeaminase with Ki of 2 μM in a cell-free assay.2-NP increased the duration of STAT1 tyrosine phosphorylation in response to IFN-gamma, and this may underlie its enhancement of STAT1-dependent transcription. Reflecting the fact that STAT1 can exert tumor-suppressive effects, 2-NP enhanced the ability of IFN-gamma to inhibit the proliferation of human breast cancer and fibrosarcoma cells. TWS119 is a GSK-3β inhibitor with IC50 of 30 nM in a cell-free assay; capable of inducing neuronal differentiation and may be useful to stem cell biology.Suramin sodium salt is a polysulfonated naphthylurea that inhibits the binding of calmodulin to recognition sites on the ryanodine receptor-1 (IC50 = 4.9 μM), blocks G protein coupling to GPCRs, and non-selectively antagonizes P2 purinergic receptors (10-100 μM).

Nutlin-3 is MDM2 antagonist. Nutlin-3 inhibits the MDM2-p53 interaction (IC50 = 0.09 μM) and activates p53. Antiproliferative agent;chemotherapeutic agent; induces apoptosis in cancer cells

WP1066 is a novel inhibitor of JAK2 and STAT3 with IC50 of 2.30 μM and 2.43 μM in HEL cells; shows activity to JAK2, STAT3, STAT5, and ERK1/2 not JAK1 and JAK3. Phase 1.Thiazovivin (Tzv) is a novel ROCK inhibitor with IC50 of 0.5 _mu_M, promotes hESC survival after single-cell dissociation.MG-132 is an inhibitor of proteasome with IC50 of 100 nM, and also inhibits calpain with IC50 of 1.2 _mu_M.1NM-PP1(PP1 Analog II) is a cell-permeable PP1 analog that acts as a potent and selective inhibitor of mutant kinases over their wild-type progenitors(IC50=28 uM vSrc; 4.2 nM v-Src-as1 I338G).Fulvestrant is a drug treatment of hormone receptor-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.

PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Temsirolimus is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the FDA in late May 2007, and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a derivative of sirolimus and is sold as Torisel. Tacrolimus is a macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.(-)-Parthenolide is a sesquiterpene lactone which occurs naturally in the plant feverfew(Tanacetum parthenium) and also promotes the ubiquitination of MDM2 and activates p53 cellular functions.OF-1 is a selective BRPF1B and BRPF2 bromodomain inhibitor with Kd values of 100 nM/500 nM for BRPF1B/BRPF2; 39-fold selectivity over BRD4.Trametinib is an orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MEK MAPK/ERK kinase) with potential antineoplastic activity. Trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity threonine/tyrosine PJ34 hydrochloride is the hydrochloride salt of PJ34, which is a PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2.LY2109761 is a novel selective TGF-β receptor type I/II (TβRI/II) dual inhibitor with Ki of 38 nM and 300 nM, respectively; shown to negatively affect the phosphorylation of Smad2.MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM in cell-free assays, respectively.Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.SC-514 is an orally active, ATP-competitive IKK-2 inhibitor with IC50 of 3-12 μM, blocks NF-κB-dependent gene expression, does not inhibit other IKK isoforms or other serine-threonine and tyrosine kinases.AEE788 (NVP-AEE788) is a potent inhibitor of EGFR and HER2/ErbB2 with IC50 of 2 nM and 6 nM, less potent to VEGFR2/KDR, c-Abl, c-Src, and Flt-1, does not inhibit Ins-R, IGF-1R, PKCα and CDK1. Phase 1/2.Pexidartinib (PLX3397) is an oral, potent mutil-targeted receptor tyrosine kinase inhibitor of CSF-1R, Kit, and Flt3 with IC50 of 20 nM, 10 nM and 160 nM, respectively. Phase 3.NVP-BEP800 is a novel, fully synthetic HSP90β inhibitor with IC50 of 58 nM, exhibits>70-fold selectivity against Hsp90 family members Grp94 and Trap-1.YM155 (Sepantronium bromide) is a novel small molecule survivin suppressant with an IC50 of 0.54 nM for the inhibition of survivin promoter activity.(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.SD-208 is a selective TGF-βRI (ALK5) inhibitor with IC50 of 48 nM, >100-fold selectivity over TGF-βRII.Andarine (S-4) is an investigational selective androgen receptor modulator (SARM) and an active partial agonist.NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.WS6 is a β cell proliferation inducer via modulation of Erb3 binding protein-1 (EBP1) and the IκB kinase pathway.Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.Ispinesib (SB-715992) is a potent, specific and reversible inhibitor of kinesin spindle protein (KSP) with Ki app of 1.7 nM in a cell-free assay, no inhibition to CENP-E, RabK6, MCAK, MKLP1, KHC or Kif1A. Phase 2. ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.CX-5461 is an inhibitor of rRNA synthesis, selectively inhibits Pol I-driven transcription of rRNA with IC50 of 142 nM in HCT-116, A375, and MIA PaCa-2 cells, has no effect on Pol II, and possesses 250- to 300-fold selectivity for inhibition of rRNA transcription versus DNA replication and protein translation.ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.A 77-01 is a potent inhibitor of TGF-(beta) type I receptor superfamily activin-like kinase ALK5 with IC50 of 25 nM.Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. Phase 2.Lexibulin(CYT-997) is a potent tubulin polymerisation inhibitor with IC50 of 10-100 nM in cancer cell lines; with potent cytotoxic and vascular disrupting activity in vitro and in vivo.

ETP-46464 is a potent and selective inhibitor of ATR with IC50 of 25 nM.

CUDC-907 potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes.

LB-100 is a water soluble protein phosphatase 2A (PP2A) inhibitor. Phase 1.

AG-18(RG-50810; Tyrphostin A23) inhibits EGFR with IC50 of 35 μM.

Nimorazole is a nitroimidazole anti-infective.

PI-3065 is a novel potent and selective PI3K p110δ inhibitor with IC50 of 15 nM; exhibits > 100 fold selectivity against p110α, p110β, p110γ, DNA-PK and mTOR.CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50=5.265 uM) respectively.LY2409881 trihydrochloride is a novel selective inhibitor of IKK2 with IC50 of 30 nM; IC50 for IKK1 and other common kinases is at least one log higher.LCL161, a SMAC mimetic, potently binds to and inhibits multiple IAPs (i.e. XIAP, c-IAP). Phase 2.GSK126 is a potent, highly selective EZH2 methyltransferase inhibitor with IC50 of 9.9 nM, >1000-fold selective for EZH2 over 20 other human methyltransferases.

MK-1775 is a potent and selective Wee1 inhibitor with IC50 of 5.2 nM in a cell-free assay; hinders G2 DNA damage checkpoint. Phase 2.B-Raf inhibitor 1 is a potent and selective B-Raf inhibitor with cell IC50s of 0.31 uM and 2 nM for A375 proliferation and A375 p-ERK respectively.GSK2636771 is a potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines. Phase 1/2a.CEP-32496 is a highly potent inhibitor of BRAF(V600E/WT) and c-Raf with Kd of 14 nM/36 nM and 39 nM, also potent to Abl-1, c-Kit, Ret, PDGFRβ and VEGFR2, respectively; insignificant affinity for MEK-1, MEK-2, ERK-1 and ERK-2. Phase 1/2.

Quizartinib (AC220) is a second-generation FLT3 inhibitor for Flt3(ITD/WT) with IC50 of 1.1 nM/4.2 nM in MV4-11 and RS4;11 cells, respectively, 10-fold more selective for Flt3 than KIT, PDGFRα, PDGFRβ, RET, and CSF-1R. Phase 3.Semaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 _mu_M, 20-fold more selective for VEGFR than PDGFR_beta_, lack of activity against EGFR, InsR and FGFR.

Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.2,4-Pyrimidinediamine with linker is a patent compound in WO2013055780A1, Page 71; multikinase inhibitor and has a -NH2 terminal linker for further synthesis.WS3 is a β cell proliferation inducer via modulation of Erb3 binding protein-1 (EBP1) and the IκB kinase pathway.Altiratinib(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with a HGF antagonist in vitro.KY02111 promotes differentiation of hPSCs to cardiomyocytes by inhibiting Wnt signaling, may act downstream of APC and GSK3β.FLT3-IN-1 is a novel potent and selective Flt3 inhibitor with IC50 of 10 nM; against FLT3-ITD-expressing MV4-11 cells with IC50 of 6 nM.PF-06447475 is a highly potent, selective, brain penetrant LRRK2 inhibitor with IC0 of 3 nM/11 nM for Wt LRRK2/G2019S LRRK2 respectively.LY364947 is a potent ATP-competitive inhibitor of TGFβR-I with IC50 of 59 nM in a cell-free assay, shows 7-fold selectivity over TGFβR-II.AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Janex-1 is a cell-permeable, reversible, potent, ATP-competitive, and specific inhibitor of JAK3 (IC50 = 78 _mu_M); has no effect on JAK1, JAK2, or Zap/Syk or SRC tyrosine kinases.PD153035 hydrochloride is a potent and specific inhibitor of EGFR with Ki and IC50 of 5.2 pM and 29 pM in cell-free assays; little effect noted against PGDFR, FGFR, CSF-1, InsR and Src.OAC1 is a Octamer-binding transcription factor 4 (Oct4)-activating compound; enhances the iPSC reprogramming efficiency and accelerated the reprogramming process.GSK923295 is a first-in-class, specific allosteric inhibitor of CENP-E kinesin motor ATPase with Ki of 3.2 nM, and less potent to mutant I182 and T183. Phase 1.

BML-277 (C 3742) is a selective Chk2 (checkpoint kinase 2) inhibitor with an IC50 of 15 nM.

WHI-P180 is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.

Bohemine is a cyclin-dependent kinase inhibitor.

ISX9 was necessary to activate neuron-specific genes as neurogenesis inducer.

Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.

RG108 is an inhibitor of DNA methyltransferase with IC50 of 115 nM in a cell-free assay, does not cause trapping of covalent enzymes.WHI-P258 is a dimethoxyquinazoline inhibitor of JAK3. This compound binds JAK3 weakly and may be used as a JAK binding negative control in the development of new therapeutics.

NG 52 (Compound 52 ) is a potent, cell-permeable, reversible, selective, and ATP-compatible inhibitor of the cell cycle-regulating kinase, Cdc28p (IC50 = 7 _mu_M), and the related Pho85p kinase (IC50 = 2 _mu_M).Chidamide(CS055; HBI-8000) is a class I HDAC inhibitor with IC50s of 95/160/67/733 nM for HDAC1/2/3/8; also inhibits HDAC10/11(IC50=78/432 nM); no inhibition on HDAC4/5/7/9/6(IC50>30 uM).MC1568 is a selective HDAC inhibitor for maize HD1-A with IC50 of 100 nM in a cell-free assay. It is 34-fold more selective for HD1-A than HD1-B.CZC-54252 is a potent inhibitor of LRRK2 with IC50s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2 respectively.OAC2 is an Oct4-activating compound which activates expression through the Oct4 gene promoter; enhances reprogramming efficiency by increasing the rate of production of induced pluripotent stem cells (iPSCs) from embryonic fibroblasts; an analog of OAC1.Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis.MLN9708 immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM, less potent to β1 and little activity to β2. Phase 3.Fexaramine is a small molecule farnesoid X receptor (FXR) agonist with 100-fold increased affinity relative to natural compounds.Oclacitinib(PF03394197) is a potent and selective JAKs inhibitor with IC50 of 10-99 nM; not inhibit a panel of 38 non-JAK kinases (IC50 's > 1000 nM).RKI-1313 was a selective inhibitor for ROCK-dependent signaling, cytoskeletal changes, anchorage-independent colony formation, migration, and invasion.SB-3CT is an effective and selective gelatinase inhibitor with Ki of 13.9 nM and 600 nM for MMP-2 and MMP-9, respectively.LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation.

PF-573228 is an ATP-competitive inhibitor of FAK with IC50 of 4 nM in a cell-free assay, ~50- to 250-fold selective for FAK than Pyk2, CDK1/7 and GSK-3β.AM095 is a potent LPA1 receptor antagonist with IC50 values of 0.98 and 0.73 _mu_M for recombinant human or mouse LPA1 respectively.GDC-0032 is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with IC50 of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.GMX1778(CHS-828) is a potent inhibitor of NAD+ biosynthesis enzyme NAMPT with IC50 <25 nM.

Fedratinib (SAR302503, TG101348) is a selective inhibitor of JAK2 with IC50 of 3 nM in cell-free assays, 35- and 334-fold more selective for JAK2 versus JAK1 and JAK3. Phase 2.Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.Mertansine refers to the thiol-containing maytansinoid, DM1 (N2’-deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) attached to a monoclonal antibody through reaction of the thiol group with the SPP (N-succinimidyl 4-(2-pyridyldithio)) linker to create an antibody-drug conjugate or ADC. Experimental ADCs with the SPP-DM1 design include lorvotuzumab mertansine.ZZZM 323881 hydrochloride is a potent and selective VEGFR2 inhibitor with IC50 of <2 nM, almost no activity on VEGFR1, PDGFRβ, FGFR1, EGFR and ErbB2.AUY922 (NVP-AUY922) is a potent, novel synthetic resorcinylic isoxazole amide inhibitor of heat shock protein 90 (HSP90).[1] It is a small molecular with the formula of C26H31N3O5 and molecular weight of 465.5. It has a much higher af?nity for Hsp90 and can be ound to the ATP binding site of Hsp90 at the N-terminal domain.[2] Heat shock protein 90 (HSP90) is a Duvelisib (IPI-145, INK1197) is a novel and selective PI3K δ/γ inhibitor with Ki and IC50 of 23 pM/243 pM and 1 nM/50 nM in cell-free assays, highly selective for PI3K δ/γ than other protein kinases. Phase 3.

HA14-1 is a non-peptidic ligand of a Bcl-2 surface pocket with IC50 of ~9 μM.

RN486 is a potent and selective BTK inhibitor with IC50 of 4 nM.

ASP3026 is a novel and selective inhibitor for ALK with IC50 of 3.5 nM. Phase 1.

PND-1186 (VS-4718) is a reversible and selective FAK inhibitor with IC50 of 1.5 nM. Phase 1.

Atopaxar Hydrobromide is a reversible protease activated receptor (PAR)-1 thrombin receptor antagonist that interferes with platelet signaling. WHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation.CAY10603 is a potent and selective inhibitor of HDAC6 with IC50 of 2 pM, as compared with 271, 252, 0.42, 6851, and 90.7 nM for HDAC1, 2, 3, 8, and 10, respectively.

AVN-944(VX-944) is a selective, noncompetitive inhibitor of the enzyme directed against human IMPDH with Ki of 6-10 nM for IMPDH1/IMPDH2.Dorsomorphin(Compound C; BML-275) has been shown to act as a potent and selective inhibitor of AMPK (AMP-activated protein kinase; Ki = 109 nM), induced by AICAR and metformin; also inhibits the bone morphogenetic protein type 1 receptors ACTR-I (ALK2), B

BGJ398 (NVP-BGJ398) is a potent and selective FGFR inhibitor for FGFR1/2/3 with IC50 of 0.9 nM/1.4 nM/1 nM in cell-free assays, >40-fold selective for FGFR versus FGFR4 and VEGFR2, and little activity to Abl, Fyn, Kit, Lck, Lyn and Yes. Phase 2.PH-797804 is a novel pyridinone inhibitor of p38α with IC50 of 26 nM in a cell-free assay; 4-fold more selective versus p38β and does not inhibit JNK2. Phase 2.PFI-4 is a potent and selective and cell permeable BRPF1 bromodomain inhibitor (IC50 = 80 nM). Exhibits >100-fold selectivity for BRPF1 over a panel of other bromodomains including BRPF2 (BRD1), BRPF3 and BRD4.GSK-5959 is a potent, selective and cell permeable BRPF1 bromodomain inhibitor with IC50 ~ 80 nM. Exhibits >100-fold selectivity for BRPF1 over a panel of 35 other bromodomains, including BRPF2/3 and BET family bromodomains.WAY-262611 is a wingless (beta)-Catenin agonist that increases bone formation rate; with EC50 of 0.63 uM in TCF-Luciferase assay.AZD3463 is a novel orally bioavailable ALK inhibitor with Ki of 0.75 nM, which also inhibits IGF1R with equivalent potency.Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8.Bikinin(Abrasin) is a potent inhibitor of plant GSK-3/Shaggy-like kinase; activates BR signaling downstream of the BR receptor.Capmatinib (INCB28060) is a novel, ATP-competitive inhibitor of c-MET with IC50 of 0.13 nM in a cell-free assay, inactive against RONβ, as well as EGFR and HER-3. Phase 1.

AZD2014 is a novel mTOR inhibitor with IC50 of 2.8 nM in a cell-free assay; highly selective against multiple PI3K isoforms (α/β/γ/δ). Phase 2.AZ20 is a novel potent and selective inhibitor of ATR kinase with IC50 of 5 nM in a cell-free assay, 8-fold selectivity over mTOR.AZD2858 is a selective GSK-3 inhibitor with an IC50 of 68 nM, inhibits tau phosphorylation at the S396 site, activates Wnt signaling pathway.SB225002 is a potent, and selective CXCR2 antagonist with IC50 of 22 nM for inhibiting interleukin IL-8 binding to CXCR2, > 150-fold selectivity over the other 7-TMRs tested.L-779450 is a potent, ATP-competitive Raf kinase inhibitor (IC50 =10 nM) that displays > 7, > 30 and > 70-fold selectivity over p38α, GSK3β and Lck respectively.MK-2206 2hydrochloride is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2

CZC24832 is a selective inhibitor of PI 3-kinase γ (IC50 = 1.0 μM in a PI 3-Kγ-dependent fMLP-induced neutrophil migration assay); exhibits limited off-target effects in kinome profiling of 154 identified lipid and protein kinases and 922 other proteins.AZD4547 is a novel selective FGFR inhibitor targeting FGFR1/2/3 with IC50 of 0.2 nM/2.5 nM/1.8 nM in cell-free assays, weaker activity against FGFR4, VEGFR2(KDR), and little activity observed against IGFR, CDK2, and p38. Phase 2/3.BS-181 is a highly selective CDK7 inhibitor with IC50 of 21 nM. ; >40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9.GNE-7915 is a highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) inhibitor, with IC50 and Ki of 9 nM and 1 nM, respectively.LDN-214117 is a potent and selective ALK2 inhibitor with IC50 of 22 nM; > 100 fold selectivity for ALK5; also inhibits BMP6(IC50=100 nM).

JSH-23 is an inhibitor of NF-κB transcriptional activity with IC50 of 7.1 μM.

PLX647 is a highly specific dual FMS/KIT kinase inhibitor with IC50 of 28/16 nM respectively.

GSK 525762A (I-BET 762) is an inhibitor for BET proteins with IC50 of ~35 nM.

ML347(DN193719) is a highly selective ALK1/ALK2 inhibitor with IC50s of 46/32 nM; shows >300-fold selectivity for ALK2 vs. ALK3.DMH-1 is a potent and selective BMP inhibitor with IC50s of 27/107.9/<5 nM for ALK1/2/3 respectively; inactive on ALK5, BMPR2, AMPK and VEGFR2.GSK3787 is as a selective and irreversible antagonist of PPARδ with pIC50 of 6.6, with no measurable affinity for hPPARα or hPPARγ.FLT3-IN-2 is a FLT3 inhibitor with IC50 of ＜ 1 μM, detailed information refer to WO 2012158957 A2 and WO 2007013896.Spautin-1 is a novel autophagy inhibitor, IM inhibited the growth of K562 cells with IC50 of 1.03μM. In contrast, co-treatment with Spautin-1 increased IM-induced inhibition of cell viability with IC50 of 0.45 μM.CH5424802(AF 802; Alectinib) is a potent ALK inhibitor with IC50 of 1.9 nM, sensitive to L1196M mutation.LDN193189(DM 3189) is a selective BMP signaling inhibitor, inhibits the transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 of 5 nM and 30 nM, respectively, exhibits 200-fold selectivity for BMP versus TGF-β.BAY 11-7085 is an irreversible inhibitor of TNFα-induced IκBα phosphorylation with IC50 of 10 μM.B-AP15(NSC687852) is a specific inhibitor of the deubiquitinating enzymes UCHL5 and Usp14 of the 26S proteasome. It blocks the deubiquitinating activity of the 26S proteasome.

GLPG0634(filgotinib) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.LDE225 (NVP-LDE225; Erismodegib) is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human), respectively.

LDN-57444 is a reversible, competitive proteasome inhibitor for Uch-L1 with IC50 of 0.88 μM, 28-fold selectivity over isoform Uch-L3.Extracted from Pseudolarix kaempferi Gord. dry root barks or barks near the root;Store the product in sealed, cool and dry conditionAlpelisib (BYL-719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.Tenovin-1 protects against MDM2-mediated p53 degradation, which involves ubiquitination, and acts through inhibition of protein-deacetylating activities of SirT1 and SirT2.NVP-TAE226 is a potent FAK inhibitor with IC50 of 5.5 nM and modestly potent to Pyk2(IC50=3.5 nM); 10- to 100-fold less potent against InsR, IGF-1R, ALK, and c-Met.BIO is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3α/β in a cell-free assay, shows >16-fold selectivity over CDK5, also a pan-JAK inhibitor.Apitolisib (GDC-0980, RG7422) is a potent, class I PI3K inhibitor for PI3Kα/β/δ/γ with IC50 of 5 nM/27 nM/7 nM/14 nM in cell-free assays, respectively. Also a mTOR inhibitor with Ki of 17 nM in a cell-free assay, and highly selective versus other PIKK family kinases. Phase 2.K02288 is a novel small molecule inhibitor of ALK1/2/3/6 with IC50s of 1.8/1.1/34.4/6.3 nM; specific for ALK1,2,3,6 over ALK4,5; inhibitor of BMP signaling.Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM, respectively.Afuresertib (GSK2110183) is a potent pan-AKT inhibitor that demonstrated synergy with bortezomib in preclinical models of multiple myeloma (MM).MHY1485 is a mTOR activator; inhibits the autophagic process by inhibition of fusion between autophagosomes and lysosomes leading to the accumulation of LC3II protein and enlarged autophagosomes.

EPZ005687 is a potent and selective inhibitor of EZH2 with Ki of 24 nM in a cell-free assay, 50-fold selectivity against EZH1 and 500-fold selectivity against 15 other protein methyltransferases.SGI-1027 is a potent and selective inhibitor of DNA methyltransferase (DNMT) with IC50 of 6, 8, 7.5 μM for DNMT1, DNMT3A, and DNMT3B, respectively.Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM in cell-free assays, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively.BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. Also inhibiting components of the ubiquitin system.

Tenovin-3 is a p53 activator, K40Ac Tubulin activator and SirT2 inhibitor.

ZCL278 is a selective Cdc42 GTPase inhibitor with Kd of 11.4 μM.

TG003 is a potent and ATP-competitive Cdc2-like kinase (Clk) inhibitor with IC50 of 20 nM, 200 nM, and 15 nM for Clk1, Clk2, and Clk4, respectively. No inhibitory effect on Clk3, SRPK1, SRPK2, or PKC.LDN-212854 is a novel BMP inhibitor that exhibits substantially greater selectivity for BMP versus the TGF-β type I receptors; possesses a bias towards ALK2(IC50=1.3 nM) versus ALK1 and ALK3 compared to other inhibitors.RKI-1447 is a potent inhibitor of ROCK1 and ROCK2, with IC50 of 14.5 nM and 6.2 nM, respectively, has anti-invasive and antitumor activities.SKLB610, a novel multi-targeted inhibitor, inhibits angiogenesis-related tyrosine kinase VEGFR2, FGFR2 and PDGFR at rate of 97%, 65% and 55%, respectively, at concentration of 10 μM in biochemical kinase assays.CAL-101 (Idelalisib, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.Inhibitor of protease-activated receptor 1 (PAR1)-mediated platelet activation (IC50 = 0.26 μM for the inhibition of platelet P-selectin expression on human platelets). Thought to act allosterically. Also inhibits thrombin-induced platelet activation.NSC 405020 is a noncatalytic inhibitor of MT1-MMP, directly interacts with PEX domain of MT1-MMP, affects PEX homodimerization but not catalytic activity of MT1-MMP.Pracinostat(SB939) is a potent pan-HDAC inhibitor with IC50 of 40-140 nM with exception for HDAC6; has no activity against the class III isoenzyme SIRT I.CI-994 (Tacedinaline) is an anti-cancer drug which inhibits HDAC1 with IC50 of 0.57 μM and causes G1 cell cycle arrest.TAK-632 is a potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.AR-A014418 is an ATP-competitive, and selective GSK3β inhibitor with IC50 and Ki of 104 nM and 38 nM in cell-free assays, without significant inhibition on 26 other kinases tested.3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.XAV-939 selectively inhibits Wnt/β-catenin-mediated transcription through tankyrase1/2 inhibition with IC50 of 11 nM/4 nM in cell-free assays, regulates axin levels and does not affect CRE, NF-κB or TGF-β.LH846 is a selective inhibitor of CK1δ (IC50 values are 290 nM, 1.3 uM and 2.5 uM for CK1δ, ε and α); displays no inhibitory activity at CK2.Kobe0065 is a novel and effective small-molecule compound inhibiting Ras–Raf interaction by SBDD; exhibits potent activity to competitively inhibit the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 46 ± 13 μM.

Fenretinide (4-HPR) is a synthetic retinoid deriverative. 4-HBR is shown to exhibit binding to the retinoic acid receptors (RAR) at concentrations necessary to induce cell death.ATB-346 is a novel hydrogen sulphide-releasing derivative of naproxen with markedly reduced toxicity.PR-619 is a non-selective, reversible inhibitor of the deubiquitinylating enzymes (DUBs) with EC50 of 1-20 μM in a cell-free assay.GSK2126458 is a highly selective and potent inhibitor of PI3K with Ki of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2 , respectively.AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (?1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.TMP269 is a potent, selective class IIa HDAC inhibitor with IC50 of 157 nM, 97 nM, 43 nM and 23 nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.

MS436 is a diazobenzene-based small-molecule inhibitor for the BRD4 bromodomains with a Ki value of 30-50 nM.Belinostat is a novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly ZM 336372 is a potent and selective c-Raf inhibitor with IC50 of 70 nM, 10-fold selectivity over B-RAF, no inhibition to PKA/B/C, AMPK, p70S6, etc.CYT387(momelotinib) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3.Necrostatin-1 is a specific RIP1 inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM.B-Raf IN 1 is a highlt potent and selective B-Raf inhibitor with IC50 of 24 nM; equipotent against c-Raf (IC50= 25 nM).

isoindigotin is used to treat cancer.

CGK 733 is a potent and selective inhibitor of ATM/ATR with IC50 of ~200 nM.

Tenovin-6 is a small molecule activator of p53 transcriptional activity.

KX1-004 is a potent small molecule inhibitor of Src-PTK as a potential protective drug for NIHL.

KPT-330 inhibited proliferation and induced cell cycle arrest and apoptosis-related proteins in 11 NSCLC cells lines. Moreover, the combination of KPT-330 with cisplatin synergistically enhanced the cell kill of the NSCLC cells in vitro. Human NSCLC tumours growing in immunodeficient mice were markedly inhibited by KPT-330. Also, KPT-330 was effective even INK 128 is a potent and selective mTOR inhibitor with IC50 of 1 nM; >200-fold less potent to class I PI3K isoforms.BX-912 is a selective inhibitor of 3-Phosphoinositide-dependent Kinase-1 (PDK1) with IC50 of 12 nM; >10 fold selectivity over PKA, PKC, C-Kit, EGFR etc.AZD2932 is a new series of quinazoline ether inhibitor which potently inhibits VEGFR-2 and PDGFR with IC50s of 4 nM/8 nM/ 7 nM for PDGFRβ/VEGFR-2/Flt-3.PCI-32765(Ibrutinib) is a potent and highly selective Btk inhibitor with IC50 of 0.5 nM, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. CX-6258 is a potent, orally efficacious Pim 1/2/3 kinase(IC50=5 nM/25 nM/16 nM) inhibitor with excellent biochemical potency and kinase selectivityBX795 is a potent and specific PDK1 inhibitor with IC50 of 6 nM, 140- and 1600-fold more selective for PDK1 than PKA and PKC in cell-free assays, respectively. Meanwhile, in comparison to GSK3β more than 100-fold selectivity observed for PDK1.Ruxolitinib(INCB018424) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3.TTP 22 is a high affinity, ATP-competitive casein kinase 2 (CK2) inhibitor with IC50/Ki of 0.1 uM/40 nM; shows selectivity for CK2 over JNK3, ROCK1, and MET(IC50> 10 uM).BKM120 (NVP-BKM120, Buparlisib) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.Voxtalisib (SAR245409, XL765) is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. Phase 1/2.Reversine, a small synthetic purine analogue (2,6-disubstituted purine), is a potent inhibitior of Aurora A/B/C with IC50s of 150-500 nM.

Nexturastat A is a potent and selective HDAC6 inhibitor with IC50 of 5 nM, >190-fold selectivity over other HDACs.

GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl, shows no activity to Flt3-ITD, Tel-PDGFR, TPR-MET and Tel-JAK1 transformed tumor cells.VGX-1027(GIT27) is an isoxazole compound that exhibits various immunomodulatory properties; reduce the secretion of IL-1beta, TNF-alpha and IL-10 from purified murine macrophages.

WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2 nM and 6 nM in cell-free assays, respectively.Purmorphamine, which directly binds and activates Smoothened, blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM in HEK293T cell and also is an inducer of osteoblast differentiation with EC50 of 1 μM.JW 55 is an inhibitor of the PARP domain of tankyrase 1 and 2 (TNKS1/2). JW55 decreased auto-PARsylation of TNKS1/2 in vitro with IC50 values of 1.9 uM and 830 nM respectively.NLG919 is a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor with Ki/EC50 of 7 nM/75 nM in cell-free assays. Phase 1.GNF-5, an analogue of GNF-2 with improved pharmacokinetic properties, is a selective non-ATP competitive inhibitor of Bcr-Abl with an IC50 value of 0.22±0.1 uM (Wild type Abl).SR9243 is a LXR inverse agonist that induces LXR-corepressor interaction; shows anticancer activity and selectively targets the warburg effect and lipogenesisGW788388 is a potent and selective inhibitor of ALK5 with IC50 of 18 nM, also inhibits TGF-(beta) type II receptor and activin type II receptor activities, but does not inhibit BMP type II receptor.RITA(NSC 652287) induced both DNA-protein and DNA-DNA cross-links with no detectable DNA single-strand breaks. RITA, a drug that, like nutlin-3, can disrupt the p53/Mdm2 interaction.Cabozantinib S-malate is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET Carfilzomib is an epoxomicin derivate with potential antineoplastic activity. Carfilzomib irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S catalytic core subunit of the proteasome, a protease complex responsible for degrading a large variety of cellular proteins. Inhibition of proteasome-mediated proteolysis results in an accumulation of

Parecoxib is a potent and selective COX-2 inhibitor.

WZ811 is a novel small molecular and potency CXCR4 antagonist with EC50 of 0.3 nM.

Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.Ceritinib is an orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, ceritinib binds to and inhibits wild-type ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to both the disruption of ALK-mediated signaling and the inhibition of cell growth in INT-747(Obeticholic acid; 6-ECDCA) is a potent and selective FXR agonist(EC50=99 nM) endowed with anticholestatic activity.EPZ-6438 is a potent, and selective EZH2 inhibitor with Ki and IC50 of 2.5 nM and 11 nM in cell-free assays, exhibiting a 35-fold selectivity versus EZH1 and >4,500-fold selectivity relative to 14 other HMTs.Palbociclib (PD-0332991) is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity.Everolimus is a derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. WAY-252623 (LXR-623) is a highly selective and orally bioavailable synthetic modulator of LXR.

SAG is a potent Smoothened (Smo) receptor agonist (Kd = 59 nM); potently activates the Hedgehog signaling pathway in Shh-light 2 cells (EC50 ~ 3 nM).AT7519 hydrochloride is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM; is less potent to CDK3 and little active to CDK7.Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM in cell-free assays. Phase 3.Plerixafor is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM, respectively.Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.Apoptosis Activator 2 is a potent apoptosis activator; increases procaspase-9 processing and subsequent caspase-3 activation.GNE-9605 is a highly potent, selective, and brain-penetrant LRRK2 inhibitor with IC50 of 19 nM.Erastin is a ferroptosis activator by acting on mitochondrial VDAC, exhibiting selectivity for tumor cells bearing oncogenic RAS.SB203580 is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μM in THP-1 cells, 10-fold less sensitive to SAPK3(106T) and SAPK4(106T) and blocks PKB phosphorylation with IC50 of 3-5 μM.SB525334 is a potent and selective inhibitor of TGFβ receptor I (ALK5) with IC50 of 14.3 nM in a cell-free assay, is 4-fold less potent to ALK4 than ALK5 and inactive to ALK2, 3, and 6.RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.PD153035 hydrochloride (ZM 252868; AG 1517) is a potent and specific inhibitor of EGFR with Ki and IC50 of 5.2 pM and 29 pM; little effect against PGDFR, FGFR, CSF-1, InsR and Src.OTSSP167 is an inhibitor of maternal embryonic leucine zipper kinase (MELK) with IC50 value of 0.41nM .ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic sulfonamide agent with IC50 of about 1.5 and 3.4 μM in neuroblastoma and non-neuroblastoma cell lines, respectively.ML323 is a reversible, potent USP1-UAF1 inhibitor with IC50 of 76 nM in a Ub-Rho assay and 174 nM and 820 nM in orthogonal gel-based assays using K63-linked diubiquitin (di-Ub) and monoubiquitinated PCNA (Ub-PCNA) as substrates, respectively.LY2090314 is a potent GSK-3 inhibitor for GSK-3α/β with IC50 of 1.5 nM/0.9 nM; may improve the efficacy of platinum-based chemotherapy regimens. Phase 2.ZM 306416 is a VEGFR (Flt and KDR) inhibitor for VEGFR1 with IC50 of 0.33 μM, but also found to inhibit EGFR with IC50 of <10 nM.D-64131 is a tubulin polymerization inhibitor with an IC50 value of 0.53 μM. The polymerization of bovine brain tubulin as well as binding of [3H] colchicine to biotinylated αβ-tubulin was dose-dependently inhibited by D-64131. Many cancer cells display abnormal microtubule structures, such as fragmented mitotic spindles or multiple spindle poles after treatment with D-64131. Nuclear blebbing and abnormal nuclear structures typical for apoptotic

AZD1080 is a selective, orally active, brain permeable GSK3 inhibitor, inhibits human GSK3α and GSK3β with Ki of 6.9 nM and 31 nM, respectively, shows >14-fold selectivity against CDK2, CDK5, CDK1 and Erk2.

Taxifolin is a flavonoid in many plants such as Taxus chinensis, Siberian larch, Cedrus deodara and so on.

It is an organic compunds with molecular fomula C11H14O4.

Vinblastine sulfate can inhibit the formation of microtubule, it also inhibit nAChR(IC50=8.9 uM).

Melatonin is a MT receptor agonist, used as a dietary supplement.

Ramipril is an Angiotensin Converting Enzyme Inhibitor.

Pazufloxacin (INN) is a fluoroquinolone antibiotic.

Genistein(NPI 031L), a phytoestrogen found in soy products, is a highly specific inhibitor of protein tyrosine kinase (PTK) which blocks the mitogenic effect mediated by EGF on NIH-3T3 cells with IC50 of 12μM or by insulin with IC50 of 19 μM.Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively.SB431542 is a potent and selective inhibitor of ALK5 with IC50 of 94 nM in a cell-free assay, 100-fold more selective for ALK5 than p38 MAPK and other kinases.Y-27632 2hydrochloride is a selective ROCK1 (p160ROCK) inhibitor with Ki of 140 nM in a cell-free assay, exhibits >200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.2'-Deoxyuridine. An antimetabolite that is converted to deoxyuridine triphosphate during DNA synthesis. Laboratory suppression of deoxyuridine is used to diagnose megaloblastic anemias due to vitamin B12 and folate deficiencies. Amfenac Sodium monohydrate is a non-steroidal analgesic anti-inflammatory drug with acetic acid moiety.Diosmetin is an O-methylated flavone, a chemical compound that can be found in the Caucasian vetch[1]It has been found to act as a weak TrkB receptor agonist.LE-SN38 is NeoPharm’s NeoLipid liposomal formulation of SN-38, the active metabolite of irinotecan (Camptosar), a chemotherapeutic pro-drug approved for the treatment of advanced colorectal cancer.

An inactive metabolite of PROGESTERONE by reduction at C5, C3, and C20 position. Pregnanediol has two hydroxyl groups, at 3-alpha and 20-alpha. It is detectable in URINE after OVULATION and is found in great quantities in the pregnancy urine. Aminophylline is a competitive nonselective phosphodiesterase inhibitor that is used to treat airway obstruction from asthma or COPD.Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to ? cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals Crizotinib an inhibitor of receptor tyrosine kinase for the treatment of non-small cell lung cancer (NSCLC). Verification of the presence of ALK fusion gene is done by Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit. This verification is used to select for patients suitable for treatment. FDA approved in August 26, 2011.Vandetanib is an orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth A generic descriptor for all tocopherols and tocotrienols that exhibit alpha-tocopherol activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of isoprenoids. Famciclovir is a guanine analogue antiviral drug used for the treatment of various herpes virus infections, most commonly for herpes zoster (shingles). It is a prodrug form of penciclovir with improved oral bioavailability. Famciclovir is marketed under the trade name Famvir (Novartis).

Penciclovir is a guanine analogue antiviral drug used for the treatment of various herpesvirus infections. It is a nucleoside analogue which exhibits low toxicity and good selectivity. Lenalidomide (initially known as CC-5013 and marketed as Revlimid? by Celgene) is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic modality, but has also shown efficacy in the hematological disorders known as the myelodysplastic syndromes. FDA Ciprofloxacin is a broad-spectrum antimicrobial carboxyfluoroquinoline.

Amlexanox (AA673; CHX3673) is a specific inhibitor of IKKε and TBK1; inhibition of IKKε and TBK1 activity as determined by MBP phosphorylation showing an IC50 of approximately 1–2 μM.β-Carotene is an organic compound and classified as a terpenoid. It is a precursor (inactive form) of vitamin A.Lomefloxacin hydrochloride (Maxaquin) is a hydrochloride salt of lomefloxacin and is a fluoroquinolone antibiotic.Lomefloxacin hydrochloride (Maxaquin) is used to treat bacterial infections including bronchitis and urinary tract infections. Lomefloxacin hydrochloride (Maxaquin) is also used to prevent urinary tract infections prior to surgery.Rosiglitazone maleate is the maleic acid salt form of rosiglitazone, a potent insulin sensitizer, which is used for the treatment of diabetes. Rosiglitazone belongs to a group of compounds, thiazolidinediones (TZDs), which selectively ligate the nuclear transcription factor peroxisome-proliferator-activated receptor-γ (PPARγ). As a TZD, rosiglitazone improves the sensitivity of Imatinib mesylate is a tyrosine kinase inhibitor IC50 value of 100 nM, 100 nM, 600 nM for v-Abl, c-kit, PDGFR, respectively [1].Tyrosine kinase is an enzyme which is a subclass of protein kinase and plays an important role in transferring a phosphate group from ATP to a protein in cells. It is shown that tyrosine kinase plays a pivotal role in the management of disorders in which activation of c-Abl, PDGFR, or c-Kit signaling. Recently, the role of tyrosine kinases in the modulation of growth factor signaling

Glipizide is used to treat high blood sugar levels caused by a type of diabetes mellitus.

Doxifluridine is a Thymidylate synthase inhibitor.

Chlormadinone acetate is a steroidal progestin, with antiandrogen and antiestrogenic effects.

RaloxifeneHcl(LY156758 Hcl) is a second generation selective estrogen receptor antagonist.

Olsalazine Sodium is a mesalamine dimer.

Sirolimus is a mTOR Inhibitor Immunosuppressant.

Irbesartan is an angiotensin receptor blocker (ARB) used mainly for the treatment of hypertension. It competes with angiotensin II for binding at the AT1 receptor subtype. Unlike ACE inhibitors, ARBs do not have the adverse effect of dry cough. The use of ARBs is pending revision due to findings from several clinical trials suggesting that this class of drugs may be Isotretinoin(13-cis-Retinoic acid) is a medication used for the treatment of severe acne. It was first developed to be used as a chemotherapy medication for the treatment of brain cancer, pancreatic cancer and more. Fasudil hydrochloride (INN) is a potent Rho-kinase inhibitor and vasodilator. Since it was discovered, it has been used for the treatment of cerebral vasospasm, which is often due to subarachnoid hemorrhage, as well as to improve the cognitive decline seen in stroke victims. It has been found to be effective for the treatment of pulmonary hypertension.Enalapril is an Angiotensin Converting Enzyme Inhibitor. The mechanism of action of enalapril is as an Angiotensin-converting Enzyme Inhibitor. The physiologic effect of enalapril is by means of Decreased Blood Pressure.

Valproic acid is a HDAC inhibitor by selectively inducing proteasomal degradation of HDAC2, used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.Lomustine is an Alkylating Drug. The mechanism of action of lomustine is as an Alkylating Activity.

Acetohydroxamic Acid, a synthetic drug derived from hydroxylamine and ethyl acetate, is similar in structure to urea. In the urine, it acts as an antagonist of the bacterial enzyme urease. Acetohydroxamic Acid has no direct antimicrobial action and does not acidify urine directly. It is used, in addition to antibiotics or medical procedures, to treat chronic urea-splitting Cyclocytidine is the prodrug of cytarabine, which is a pyrimidine nucleoside analog that inhibits the DNA synthesis and used mainly in the treatment of leukemia.Letrozole (INN, trade name Femara) is an oral non-steroidal aromatase inhibitor that has been introduced for the adjuvant treatment of hormonally-responsive breast cancer Estrogens are produced by the conversion of androgens through the activity of the aromatase enzyme. Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It acts as a false substrate for the aromatase enzyme, and is processed to an intermediate that binds irreversibly to the active site of the enzyme causing Tenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase inhibitors. Naproxen is a COX inhibitor for COX-1 and COX-2 with IC50 of 8.7 μM and 5.2 μM, respectively.Naproxen is a COX inhibitor for COX-1 and COX-2 with IC50 of 8.7 μM and 5.2 μM, respectively.Etoricoxib(MK-0663) selectively inhibited COX-2 in human whole blood assays in vitro, with an IC50 value of 1.1 ± 0.1 μM for COX-2 (LPS-induced prostaglandin E2 synthesis), compared with an IC50 value of 116 ± 8 μM for COX-1 (serum thromboxane B2 generation after clotting of the blood).Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arterial blood Cisplatin is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells.Nifuroxazide is a cell-permeable and orally available nitrofuran-based antidiarrheal agent that effectively suppresses the activation of cellular STAT1/3/5 transcription activity .Resveratrol is a phytoalexin produced naturally by several plants with anti-cancer, anti-inflammatory, blood-sugar-lowering and other beneficial cardiovascular effects.Diclofenac Sodium is a non-selective COX inhibitor with IC50 of 60 and 220 nM for ovine COX-1 and -2, respectively.

Methoxsalen (8-Methoxypsoralen) is a potent tricyclic furocoumarin suicide inhibitor of CYP (cytochrome P-450), is an agent used to treat psoriasis, eczema, vitiligo and some cutaneous Lymphomas in conjunction with exposing the skin to sunlight.

Drospirenone is a synthetic progestin that is an analog to spironolactone. It is found in a number of birth control formulations. Drospirenone differs from other synthetic progestins in that its pharmacological profile in preclinical studies shows it to be closer to the natural progesterone. As such it has anti-mineralocorticoid properties, counteracts the estrogen-Melphalan(Sarcolysin; L-PAM) is a chemotherapy drug belonging to the class of nitrogen mustard alkylating agents; attaches the alkyl group to the guanine base of DNA.

Aliskiren hemifumarate(CGP 60536) is a direct renin inhibitor with IC50 of 1.5 nM.

Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE).

Phenformin, an anti-diabetic drug, has demonstrated antitumor activity both in vitro and in vivo.

Promestriene (INN) is a synthetic estrogen and glucocorticoid used topically in a 1% cream formulation. It is described as a tropic agent and antiseborrheic.Sodium Phenylbutyrate is a transcriptional regulators that act by altering chromatin structure via the modulation of HDAC activity.Gliclazide is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC50 of 184 nM. Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). In June 2006, a Phase I clinical trial found nilotinib has a relatively favorable safety profile and shows activity in cases of CML resistant to treatment with imatinib (Gleevec?), another tyrosine kinase inhibitor currently used Teniposide(VM-26) is a semisynthetic derivative of podophyllotoxin and are increasingly used in cancer medicine; causing breaks in DNA via an interaction with DNA topoisomerase II.An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA topoisomerase, type I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.

Olmesartan is an antihypertensive agent, which belongs to the class of medications called angiotensin II receptor blockers. It is indicated for the treatment of high blood pressure and is marketed under the name Olmetec?. The FDA label includes a black-box warning of injury and death to the fetus, so women of child-bearing age need to be warned and take the necessary Curcumin is a natural phenolic compound with impressive antioxidant properties. Curcumin is recently proved to exert its chemopreventive effects partly through the activation of nuclear factor (erythroid-2 related) factor 2 (Nrf2).Daunorubicin Hcl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 μM.Decitabine is indicated for treatment of patients with myelodysplastic syndrome (MDS). It is a chemical analogue of cytidine, a nucleoside present in DNA and RNA. Cells in the presence of Decitabine incorporate it into DNA during replication and RNA during transcription. The incorporation of Decitabine into DNA or RNA inhibits methyltransferase thereby causing Streptozotocin is a DNA alkylating agent that enters cells exclusively via the GLUT2 glucose transport protein.Vidarabine is an antiviral drug which is active against herpes simplex and varicella zoster viruses.Rifabutin(Mycobutin) is a semisynthetic ansamycin antibiotic with potent antimycobacterial properties.Gemifloxacin mesylate is an oral broad-spectrum quinolone antibacterial agent, used in the treatment of acute bacterial exacerbation of chronic bronchitis, and mild-to-moderate pneumonia. Fosinopril Sodium is the ester prodrug of an angiotensin-converting enzyme (ACE) inhibitor, used for the treatment of hypertension and some types of chronic heart failure.Procarbazine hydrochloride (Matulane) is a hydrochloride salt form of procarbazine which is a polyfunctional alkylating compound used as an antineoplastic agent. Procarbazine is a cytostatic agent, meaning it strands cells midway through cell division, but it does not actively kill them. Procarbazine interferes with cells at a number of sites to prevent DNA and protein Methotrexate, a folate antagonist, is a potent anti-inflammatory agent when used weekly in low concentrations, the anti-phlogistic action of which is due to increased adenosine release at inflamed sites. Studies have demonstrated that methotrexate polyglutamates are active inhibitors of several enzymatic reactions, including dihydrofolate reductase.PERINDOPRIL ERBUMINE is an angiotensin-converting enzyme inhibitor. It is used in patients with hypertension and heart failure.Danazol is a derivative of the synthetic steroid ethisterone, that suppresses the production of gonadotrophins, and has some weak androgenic effects.Acadesine (AICA-riboside) is a purine nucleoside analog with anti-ischemic properties that is currently being studied (Phase 3) for the prevention of adverse cardiovascular outcomes in patients undergoing coronary artery bypass graft (CABG) surgery. It is being developed jointly by PeriCor and Schering-Plough. Acadesine has been granted Orphan Drug Designation for B-Trilostane is an inhibitor of 3 beta-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome. It was withdrawn from the United States market in April 1994. Lornoxicam (chlortenoxicam) is a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties. Lornoxicam differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug. Lornoxicam is approved for use Acemetacin (Emflex) is a non-steroidal anti-inflammatory drug and a glycolic acid ester of indometacin that is a cyclooxygenase inhibitor.Toremifene Citrate(NK 622; FC 1157a) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis.

Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is administered orally as the prodrug, candesartan cilexetil, which is rapidly converted to its active metabolite, candesartan, during absorption in the gastrointestinal tract. Candesartan lowers blood pressure by antagonizing the renin-Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3. Axitinib is marketed under the name Inlyta?, and if one previous systemic therapy for kidney cell cancer has failed, axitinib is indicated.

Fosfosal is used as anti-inflammatory agent with anti-bacterial effect.

It is an organic compunds with molecular fomula C6H6N2S.

Thermographic recording material with improved image tone

Pamidronate disodium, a bisphosphonate drug, can help to strengthen bones.

Levofloxacin hydrate is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery. Phenylbutazone(Butazolidin, Butatron) is used as a non-steroidal anti-inflammatory agent for the treatment of chronic pain, including the symptoms of arthritis. Its use is limited by such severe side effects as suppression of white blood cell production and aplastic anemia. Trifluorothymidine (TFT) and is an inhibitor of thymidine phosphorylase. TFT also inhibits thymidylate synthase (TS), a rate-limiting enzyme of DNA biosynthesis, and is incorporated into DNA.

Ethynyl estradiol is an orally bio-active estrogen used in almost all modern formulations of combined oral contraceptive pills. EE is hormonally effective by activating the estrogen receptor and thus is an estrogen. It finds its most common use in the estrogen-progestin combination preparations of oral contraceptives. The salts or esters of salicylic acids, or salicylate esters of an organic acid. Some of these have analgesic, antipyretic, and anti-inflammatory activities by inhibiting prostaglandin synthesis.Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) analog of Diclofenac. It is used for the relief of pain and inflammation in rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. Diethylcarbamazine citrate is an inhibitor of arachidonic acid metabolism in filarial microfilaria; is highly specific for several parasites and does not contain any toxic metallic elements.Mechlorethamine hydrochloride is a vesicant and necrotizing irritant destructive to mucous membranes.Zidovudine (Azidothymidine, AZT) is a nucleoside analog reverse-transcriptase inhibitor (NRTI), a type of antiretroviral drug used for the treatment of HIV/AIDS infection.Gemfibrozil (Lopid) is an oral drug used to lower lipid levels. It belongs to a group of drugs known as fibrates. Increases activity of Peroxisome proliferator-activated receptor-alpha (PPARα) 'transcription factor ligand' , a receptor that is involved in metabolism of carbohydrates and fats, as well as adipose tissue differentiation. This increase in the synthesis Prodrug of 5-Fluorouracil (5-FU). Selectively activated in tumor cells by thymidine phosphorylase; inhibits DNA synthesis upon conversion to 5-FU. Orally available.Fenofibric acid is a lipid regulating agent available as delayed release capsules for oral administration.Meclofenoxate hydrochloride, an ester of dimethylethanolamine (DMAE) and 4-chlorophenoxyacetic acid (pCPA), has been shown to improve memory, have a mentally stimulating effect, and improve general cognition.Ibuprofen (Motrin) is an anti-inflammatory inhibitor targeting COX-1 and COX-2, of which is used for pain relief, fever reduction and for reducing swelling.Triazole antifungal agent that is used to treat oropharyngeal candidiasis and cryptococcal meningitis in AIDS. Chlorpromazine hydrochloride is a dopamine and potassium channel inhibitor used as the prototypical phenothiazine antipsychotic drug.Griseofulvin, a production from some strains of the mold Penicillium griseofulvumam, is able to inhibit cell mitosis by interfering with microtubule function.Ftorafur is a substance being used in the treatment of some types of cancer. It is a combination of tegafur and uracil. The tegafur is taken up by the cancer cells and breaks down into 5-FU, a substance that kills tumor cells. The uracil causes higher amounts of 5-FU to stay inside the cells and kill them. Ftorafur is a type of antimetabolite.Methyldienedione (estra-4,9-diene-3,17-dione) is an anabolic steroid and a precursor to dienolone.

5-Azacitidine(5-AzaC) is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases.Sucralfate is a cytoprotective agent, an oral gastrointestinal medication primarily indicated for the treatment of active duodenal ulcers.

Acitretin(Ro 10-1670) is a second-generation, systemic retinoid that has been used in the treatment of psoriasis.

4-aminosalicylic acid, commonly known as PAS, is an antibiotic used to treat tuberculosis.

Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone.

Cytarabine (AraC) is an antimetabolic agent and DNA synthesis inhibitor.

Altretamine is an alkylating agent proposed as an antineoplastic.

Lovastatin is a HMG-CoA Reductase Inhibitor.

Carprofen is a non-steroidal anti-inflammatory drug (NSAID) that is used by veterinarians as a supportive treatment for the relief of arthritic symptoms in geriatric dogs. Carprofen was previously used in human medicine for over 10 years (1985-1995). It was generally well tolerated, with the majority of adverse effects being mild, such as gastro-intestinal pain and Carmofur is a derivative of fluorouracil, and is an antineoplastic agent that has been used in the treatment of breast and colorectal cancer. Carmofur has been known to induce leukoencephalopathy. Norfloxacin(Norxacin) is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. It functions by inhibiting DNA gyrase, a type II topoisomerase, and topoisomerase IV, enzymes necessary to separate bacterial DNA, thereby inhibiting cell division. This mechanism can also affect mammalian cell replicationAuranofin is an antirheumatic agent, is used to treat rheumatoid arthritis, improves arthritis symptoms including painful or tender and swollen joints and morning stiffness.Clofibrate (Atromid-S), a fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia.

Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial enzymes DNA gyrase and topoisomerase IV. Bristol-Myers Squibb introduced Gatifloxacin in 1999 under the proprietary name Tequin? for the treatment of respiratory tract infections, having licensed the medication from Kyorin Oxiconazole nitrate (U.S.: Oxistat, Canada: Oxizole) is an antifungal medication typically administered in a cream or lotion to treat skin infections such as athlete's foot, jock itch and ringworm. TTNPB (Arotinoid Acid; AGN191183; Ro 13-7410)is a potent RAR agonist, and inhibits binding of [3H]tRA with IC50 of 5.1 nM, 4.5 nM, and 9.3 nM for human RARα, β, and γ, respectively.

Anethole trithione is a drug used in the treatment of dry mouth， being studied in the treatment of cancer.Nepafenac(AHR 9434; AL 6515; Nevanac) is a selective COX-2 inhibitor; is prodrug of Amfenac.

Vincristine (sulfate) is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM.Medroxyprogesterone acetate is a progestin, a synthetic variant of the human hormone progesterone and a potent progesterone receptor agonist.Nabumetone(BRL14777) is a non-steroidal anti-inflammatory drug and its active metabolite inhibits the COX.Bestatin (Ubenimex) is a competitive aminopeptidase inhibitor, which is studied for use in the treatment of acute myelocytic leukemia.A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine's most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes SMOOTH MUSCLE, stimulates CARDIAC MUSCLE, stimulates DIURESIS, and appears to be useful in the treatment of some Thio-TEPA(Thioplex; Tiofosfamid) is an alkylating agent used to treat cancer, this molecule features tetrahedral phosphorus and is structurally akin to phosphate.A cardioselective beta-1 adrenergic antagonist that has intrinsic symopathomimetic activity. It is used in the management of ANGINA PECTORIS and HYPERTENSION.

Oxolinic acid is a potent inhibitor of DNA gyrase and DNA synthesis, lead to DNA cleavage when extracted chromosomes are incubated with sodium dodecyl sulfate.Diethylstilbestrol, a synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. Ketorolac (Ketorolac tromethamine, Toradol) is a non-selective COX inhibitor with strong analgesic activity.A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover. Flunixin Meglumin is a potent inhibitor of the enzyme cyclooxygenase used as analgesic agent with anti-inflammatory and antipyretic activity.

Amsacrine (mAMSA) an antineoplastic agent which can intercalate into the DNA of tumor cells. Amsacrine also expresses topoisomerase inhibitor activity, specifically inhibiting topoisomerase II.Mitotane(2,4′-DDD), an isomer of DDD and derivative of DDT, is an antineoplastic medication used in the treatment of adrenocortical carcinoma.

Clomifene Citrate is a selective estrogen receptor modulator.

Temozolomide, an alkylating agent, is a DNA damage inducer.

Protoporphyrin IX, in the metabolism of porphyrin, is created by the enzyme protoporphyrinogen oxidase.A drug that has analgesic, anti-inflammatory, and antipyretic properties. It is the sodium sulfonate of AMINOPYRINE. Because of the risk of serious adverse effects its use is justified only in serious situations where no alternative is available or suitable. Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. Topotecan HCl (SKF 104864A; NSC 609669) is the first topoisomerase I-directed cytotoxic agent to enter clinical trials in the United States. Cyproterone acetate is an androgen receptor (AR) antagonist with IC50 of 7.1 nM, as well as a weak progesterone receptor agonist with weak pro-gestational and glucocorticoid activity.Ellipticine is a potent antineoplastic agent exhibiting multiple mechanisms of action, IC50 of 1.25±0.13, 0.67±0.06, 1.25±0.13, 0.67±0.06, 0.27±0.02, 0.44±0.03, 0.49±0.04, and 1.48±0.62 μM for Breast adenocarcinoma MCF-7, Leukemia HL-60, Breast adenocarcinoma MCF-7, Leukemia HL-60, Neuroblastoma IMR-32, Neuroblastoma UKF-NB-3, Neuroblastoma UKF-NB-Phenoxybenzamine HCl is a non-specific, irreversible alpha antagonist with long duration of action.Mebendazole is a highly effective, broad-spectrum antihelmintic indicated for the treatment of nematode infestations; has been found as a hedgehog inhibitor.Fenofibrate is a Peroxisome Proliferator Receptor alpha Agonist. The mechanism of action of fenofibrate is as a Peroxisome Proliferator-activated Receptor alpha Agonist. The chemical classification of fenofibrate is PPAR alpha.Lidocaine, an amide local anesthetic, has anti-inflammatory properties in vitro and in vivo, possibly due to an attenuation of pro-inflammatory cytokines, intracellular adhesion molecule-1 (ICAM-1), and reduction of neutrophils influx.Doxycycline Hydrochloride is a synthetic tetracycline derivative with similar antimicrobial activity.Doxycycline is a tetracycline antibiotic which is commonly used to treat a variety of infections. Nimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old. Due to concerns about the risk of hepatotoxicity, nimesulide has An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity. Podophyllotoxin is a lignan (LIGNANS) found in PODOPHYLLIN resin from the roots of PODOPHYLLUM plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic. It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do Dacarbazine(DTIC-Dome) is an antineoplastic chemotherapy drug used in the treatment of various cancers, among them malignant melanoma, Hodgkin lymphoma, sarcoma, and islet cell carcinoma of the pancreas.Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.Aminoglutethimide is an aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.Formestane was the first selective, type I, steroidal aromatase inhibitor used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women. Formestane suppresses estrogen production from anabolic steroids or prohormones. It also acts as a prohormone to 4-hydroxytestosterone, an active steroid which displays weak androgenic activity in addition to Sparfloxacin is a fluoroquinolone antibiotic used in the treatment of bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription.Adapalene is a topical retinoid primarily used in the treatment of acne and is also used (off-label) to treat keratosis pilaris as well as other skin conditions. It is currently marketed by Galderma under the trade names Differin in some countries, and Adaferin in India. Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to ? cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose Valaciclovir hydrochloride is an antiviral drug used in the management of herpes simplex, herpes zoster, and herpes B.Vitamin D2 has a strong inhibitory effect against bladder tumor promotion by sodium saccharin and induces cell differentiation in leukemia cells. Vitamin D2 is an inhibitor of DNA Polymerase.A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under several brand names such as Uniphyl and Theochron, and it is Theophylline is a methylated xanthine derivative; competitive nonselective phosphodiesterase inhibitor and nonselective adenosine receptor antagonist.

Cysteamine is an agent for the treatment of nephropathic cystinosis and an antioxidant.

L-Epinephrine(L-Adrenaline) is a hormone and a neurotransmitter.

Ifosfamide is a nitrogen mustard alkylating agent used in the treatment of cancer.

L-Epinephrine Bitartrate is alpha- and beta-adrenergic receptor stimulator.

Luteolin is a falconoid compound, which exhibits anticancer properties.

Itraconazole is a triazole antifungal agent.

Nifenazone is a drug that has been used as an analgesic for a number of rheumatic conditions

Dequalinium Chloride is a selective blocker of apamin-sensitive K+ channels.

Novobiocin Sodium is an antibiotic compound derived from Streptomyces niveus.

Metronidazole is a nitroimidazole antibiotic medication used particularly for anaerobic bacteria and protozoa.

Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections.Carboplatin is a chemotherapy drug by binding to DNA and interfering with the cell's repair mechanism.Azilsartan(TAK-536) is a specific and potent angiotensin II type 1 receptor antagonist with IC50 of 2.6 nM.Isoprenaline Hydrochloride is a non-selective beta-adrenergic agonist and structurally similar to adrenaline.

An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other Estradiol (E2) is a potent mammalian estrogenic hormone that is produced in the ovaries (by the granulosa cells), placenta, testis and possibly the adrenal cortex.

Fludarabine(NSC 118218), a DNA synthesis inhibitor, is a chemotherapy drug used in the treatment of hematological malignancies.Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.Tranylcypromine is a drug of the substituted phenethylamine and amphetamine classes which acts as a monoamine oxidase inhibitor (MAOI)—it is a nonselective and irreversible inhibitor of the enzyme monoamine oxidase (MAO).Doxorubicin (Adriamycin) is an antibiotic agent that inhibits DNA topoisomerase II and induces DNA damage and apoptosis.

Etodolac is a non-steroidal anti-inflammatory compound that is a non-selective inhibitor of COX (IC50=53.5 nM)Gimeracil is an inhibitor of dihydropyrimidine dehydrogenase, which inhibits the early step in homologous recombination for double strand breaks repair.Flucytosine is a Nucleoside Analog Antifungal. The chemical classification of flucytosine is Nucleoside Analog.5-Fluorouracil is a potent antitumor agent that affects pyrimidine synthesis by inhibiting thymidylate synthetase thus depleting intracellular dTTP pools.A naturally occurring opium alkaloid that is a centrally acting antitussive agent.

Chlorambucil(WR-139013; CB-1348) is a chemotherapy drug that has been mainly used in the treatment of chronic lymphocytic leukemia.

Paclitaxel is a novel antineoplastic agent, which was discovered in a screen of extracts of thousands of plants and natural products for antineoplastic activity by a National Cancer Institute program. Alought it functions as a mitotic inhibitor like vinca alkaloids, paclitaxel promotes the polymerization of tubulin instead of inducing the disassembly of microtubules, Floxuridine (5-fluorodeoxyuridine) is an oncology drug that belongs to the class known as antimetabolites with an GI50 of 5.1 μM for the inhibition of PEPT1.Methyl 4-acetamido-2-ethoxybenzoate is an inhibitor of folate metabolism. It is used as a coccidiostat in poultry.

Busulfan is a bifunctional alkylating agent.

Bufexamac is a COX inhibitor for IFN-α release.

Fenbufen is a non-steroidal anti-inflammatory drug in the propionic acid derivatives class.

Flufenamic Acid is an anti-inflammatory agent, and also acts as an ion channel modulator.

Dehydroepiandrosterone acetate is a major C19 steroid produced by the adrenal cortex.

Bezafibrate(BM15075) is the first clinically tested dual and pan-PPAR co-agonism.

Propranolol Hydrochloride is a widely used non-cardioselective beta-adrenergic antagonist.

Tranexamic acid is an Antifibrinolytic Agent. The physiologic effect of tranexamic acid is by means of Decreased Fibrinolysis.An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2..Thiabendazole is an Antihelminthic. Hiabendazole is a benzimidazole compound that acts as a fungicide and is reported to have aneugenic effects. Amidopyrine is a white crystalline substance used as an analgesic and antipyretic.A pyrazolone with analgesic, anti-inflammatory, and antipyretic properties but has risk of agranulocytosis. A breath test with 13C-labeled aminopyrine has been used as a non-invasive measure of cytochrome P-450 metabolic activity in liver function tests.Azelaic acid is a saturated dicarboxylic acid found naturally in wheat, rye, and barley. It is a natural substance that is produced by Malassezia furfur (also known as Pityrosporum ovale), a yeast that lives on normal skin. It is effective against a number of skin conditions, such as mild to moderate acne, when applied topically in a cream formulation of 20%. It works in part by A synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA GYRASE. Nalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum.Sulfasalazine, a sulfa agent and a derivative of mesalazine, is used primarily as an anti-inflammatory agent. Target: Others Sulfasalazine (Azulfidine), used to treat pain and swelling in arthritis, belongs to a class of drugs called sulfa drugs.Ofloxacin is a fluoroquinolone whose primary mechanism of action is inhibition of bacterial DNA gyrase.Mefenamic acid is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of mefenamic acid is as a Cyclooxygenase Inhibitor. The chemical classification of mefenamic acid is Nonsteroidal Anti-inflammatory Compounds.Felbinac (INN, or biphenylylacetic acid) is a topical medicine, belonging to the family of medicines known as non-steroidal anti-inflammatory drugs (NSAIDs) of the arylpropionic acid class, which is used to treat muscle inflammation and arthritis. It is an active metabolite of fenbufen.6-Aminocaproic acid is an antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.Acetylcysteine is a derivative of cysteine; an acetyl group that is attached to the nitrogen atom. This compound is sold as a dietary supplement commonly claiming antioxidant and liver protecting effects.Acetylcysteine (also known as N-acetylcysteine or N-acetyl-L-cysteine or NAC) is primarily used as a mucolytic agent and in the management of acetaminophen

DHEA (Dehydroisoandrosterone) is an important endogenous steroid hormone; DHEA also has a variety of potential biological effects in its own right, binding to an array of nuclear and cell surface receptors and acting as a neurosteroid.

An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.

Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.Ketoprofen is a non-selective NSAID with IC50 of 0.5 μM and 2.33 μM for human recombinant COX-1 and COX-2, respectively.Triclabendazole is a benzimidazole, it binds to tubulin impairing intracellular transport mechanisms and interferes with protein synthesis.Tamoxifen(ICI-46474) is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen.Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve the symptoms of arthritis (juvenile rheumatoid arthritis, osteoarthritis, and rheumatoid arthritis), such as inflammation, swelling, stiffness, and joint pain. However, this medicine does not cure arthritis and will only help you as long as you continue to take it. Ebselen is a mimic of glutathione peroxidase and can also react with peroxynitrite. It is being investigated as a possible treatment for reperfusion injury and stroke, hearing loss and tinnitus, and bipolar disorder.Nonoxynol-9 (N-9) is a typical surfactant used as a vaginal spermicide. Spermicides are locally acting non-hormonal contraceptives. When present in the vagina during intercourse, they immobilize/inactivate/damage and/or kill sperms without eliciting systemic effects. N-9 has been in use for more than 30 years as an over-the-counter (OTC) drug in creams, gels, foams

Triamcinolone is a long-acting synthetic corticosteroid.

Piroxicam is a non-selective COX inhibitor

Brivudine is an antiviral drug used in the treatment of herpes zoster.

Enoxacin is a broad-spectrum 6-fluoronaphthyridinone antibacterial agent.

Enoxacin is a broad-spectrum 6-fluoronaphthyridinone antibacterial agent.

Cyanoacetohydrazide is an anti-TB drug.

Ganciclovir is an antiviral drug for feline herpesvirus type-1 with IC50 of 5.2 μM.

Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin Quinapril hydrochloride (Accupril) used in the treatment of hypertension and congestive heart failure. Quinapril is a prodrug. Quinapril is converted to its active metabolite, quinaprilat, in the liver. Quinapril inhibits angiotensin converting enzyme, an enzyme which catalyses the formation of angiotensin II from its precursor, angiotensin I. Angiotensin II is a powerful Dantron (INN), also known as chrysazin or 1,8-dihydroxyanthraquinone, is used in some countries as a stimulant laxative. Withdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.

Rutin, a flavonol glycoside found in many plants including buckwheat; tobacco; forsythia; hydrangea; viola, etc., which possesses healthy effects for human.Tolfenamic acid (TA) is one of the class of non-steroidal anti-inflammatory drugs (NSAIDs).Tolfenamic acid is a NSAID. Tolfenamic acid treatment inhibited cell growth and induced apoptosis as measured by caspase activity and bioelectric impedance.Phenacetin is a non-opioid analgesic without anti-inflammatory properties. Its analgesic effects are due to its actions on the sensory tracts of the spinal cord. In addition, phenacetin has a depressant action on the heart, where it acts as a negative inotrope. Phenacetin is an antipyretic, acting on the brain to decrease the temperature set point. Phenacetin is also used A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids.L-ornithine has an antifatigue effect in increasing the efficiency of energy consumption and promoting the excretion of ammonia.Antipyrine is an analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver.Benzydamine hydrochloride is a locally-acting nonsteroidal anti-inflammatory drug with local anaesthetic and analgesic properties; selectively binds to prostaglandin synthetase and has notable in vitro antibacterial activity.Formononetin is a phytoestrogen from the root of Astragalus membranaceus and an O-methylated isoflavone.Ursolic acid(Bungeolic acid) is a natural pentacyclic triterpenoid carboxylic acid, exerts anti-tumor effects and is an effective compound for cancer prevention and therapy.

Oxfendazole is a broad spectrum benzimidazole anthelmintic. Its main use is for protecting livestock against roundworm, strongyles and pinworms. Oxfendazole is the sulfoxide metabolite of fenbendazole,Suloctidil is a new drug that is currently being evaluated in many clinical trials for use in dementia and thrombotic disorders.Niclosamide(BAY2353) is used for the treatment of most tapeworm infections by inhibiting DNA replication.Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID) used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and Lisinopril Dihydrate is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks.Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a drug of the salicylate family but it is not a derivative of acetylsalicylic acid (ASA). Gabapentin (brand name Neurontin) is a medication originally developed for the treatment of epilepsy. Presently, gabapentin is widely used to relieve pain, especially neuropathic pain. Gabapentin is well tolerated in most patients, has a relatively mild side-effect profile, and passes through the body unmetabolized. Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens. Niflumic acid, a Ca2+-activated Cl- channel blocker, is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.

Rifampicin is a bactericidal antibiotic drug of the rifamycin group.

Ketoconazole is an imidazole anti-fungal agent, a CYP3A4 inhibitor.

2-Methoxy Phenothiazine is Light yellow or light gray solid.

Used in the manufacture of acetophenetidin.

fluorescent pH indicator

Flutamide is an antiandrogen drug, with its active metablolite binding at androgen receptor.

Irinotecan Hcl(CPT-11 Hcl) prevents DNA from unwinding by inhibition of topoisomerase 1.

Irinotecan Hcl-trihydrate prevents DNA from unwinding by inhibition of topoisomerase 1.

Loxoprofen is a non-steroidal anti-inflammatory drug.

Simvastatin is an HMGCR (HMG-CoA reductase) inhibitor with anti-proliferative properties. This compound has been shown to modulate purified bovine pituitary 20 S proteasome via mild stimulation of chymotrypsin-like activity and inhibition of peptidylglutamylpeptide hydrolyzing activity.

Hydroxyurea is an antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.A series of benzylaniline hydrochlorides as potential cytotoxic and antimitotic agents acting by inhibition of tubulin polymerizationSalicylic acid is a natural product extract from Willow bark, well known as an antiinflammatory inhibitor of cyclooxygenase activity.5-aminosalicylic acid (5-ASA), also known as mesalamine or Mesalazine is an anti-inflammatory drug used to treat inflammatory bowel disease, such as ulcerative colitis and mild-to-moderate Crohn's disease.

3,7-Dimethylxanthine. The principle alkaloid in Theobroma cacao (the cacao bean) and other plants. A xanthine alkaloid that is used as a bronchodilator and as a vasodilator. It has a weaker diuretic activity than THEOPHYLLINE and is also a less powerful stimulant of smooth muscle. It has practically no stimulant effect on the central nervous system. It was formerly Nicotinamide N - oxide is niacin related compounds, used in the study of nicotinic acid related granulocyte differentiation mechanismAnti-inflammatory, immunomodulatory and antiproliferative agent. Inhibits p56lck and syk protein tyrosine kinases and inhibits TNF-induced NF-κB activation and gene expression. Synthesis results from conversion of resveratrol by cytochrome P450 1B1.

Lenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β in cell-free assays. Phase 3.Clotrimazole is an imidazole derivative, an antifungal compound and is a CYP (cytochrome P450) inhibitor.Salsalate is a nonsteroidal anti-inflammatory agent for oral administration. Salsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins. The usefulness of salicylic acid, the active in vivo product of salsalate, in the treatment of arthritic disorders has been established. In contrast to aspirin, Dimethyl fumarate is an anti-inflammatory. It is indicated for multiple sclerosis patients with relapsing forms and is also being investigated for the treatment of psoriasis. The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MMF

Deracoxib, a selective cyclooxygenase-2 inhibitor, is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID). IC50 Value: 70 to 150 uM(inhibition of 3 osteosarcoma cell lines).Zileuton (A-64077) is a selective and potent 5-LO inhibitor, and thus inhibits leukotrienes (LTB4, LTC4, LTD4, and LTE4) formation.A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Lidocaine, an amide local anesthetic, has anti-inflammatory properties in vitro and in vivo, possibly due to an attenuation of pro-inflammatory cytokines, intracellular adhesion molecule-1 (ICAM-1), and reduction of neutrophils influx.Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer under the brand name Celebrex. In some countries, it is Ellagic Acid is a cell permeable and strong casein kinase 2 (CK2) inhibitor (Ki = 20 nM) which acts as a potent antioxidant and anti-mutagenic.

Sulindac is a nonsteroidal anti-inflammatory agent (NSAIA) of the arylalkanoic acid class that is marketed in the U.S. by Merck as Clinoril. Like other NSAIAs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted in vivo to an active sulfide compound by liver enzymes. The sulfide metabolite Indomethacin is a non-steroidal antiinflammatory agent (NSAIA) with antiinflammatory, analgesic and antipyretic activity. Its pharmacological effect is thought to be mediated through inhibition of the enzyme cyclooxygenase (COX), the enzyme responsible for catalyzes the rate-limiting step in prostaglandin synthesis via the arachidonic acid pathway.

Cinchophen is an analgesic drug that is frequently used to treat gout.

Minoxidil(U 10858) is an antihypertensive vasodilator medication.

Menadione, a synthetic naphthoquinone, can be converted to active vitamin K2 in vivo.

Econazole nitrate (Spectazole) is an imidazole class antifungal medication.

Econazole is an antifungal compound of the imidazole class.

Salicin is a phenol β-glycosid produced from willow bark that shows anti-inflammatory effects.

Pasiniazid is an anti-TB and anti-leprosy drug, used to treat various types of TB and leprosy.

6-Acetamidohexanoic acid is a kind of amino acids deriviate.

Miconazole (Monistat) is an imidazole antifungal agent.

S(+)-Ibuprofen is capable of inhibiting cyclooxygenase (COX) at clinically relevant concentrations, R(-)-ibuprofen is not a COX inhibitor.

Proflavine Hemisulfate is a topical antiseptic by interchelating DNA, thereby disrupting DNA synthesis and leading to high levels of mutation in the copied DNA strands.

PCI-24781 (Abexinostat) is a novel pan-HDAC inhibitor mostly targeting HDAC1 with Ki of 7 nM, modest potent to HDACs 2, 3, 6, and 10 and greater than 40-fold selectivity against HDAC8. Phase 1/2.Glucosamine is commonly used as a treatment for osteoarthritis, although its acceptance as a medical therapy varies. It is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids. Since glucosamine is a precursor for glycosaminoglycans, and glycosaminoglycans are a major component of joint cartilage, Pefloxacin mesylate dehydrate is a an antibacterial agent and prevents bacterial DNA replication by inhibiting DNA gyrase (topoisomerse).Pefloxacin is a an antibacterial agent and prevents bacterial DNA replication by inhibiting DNA gyrase (topoisomerse).Bismuth subsalicylate is used to treat diarrhea in adults and teenagers. It is also used to relieve the symptoms of an upset stomach, such as heartburn, indigestion, and nausea in adults and teenagers.Ethylenediaminetetraacetic acid (EDTA) trisodium salt is used to bind metal ions in the practice of chelation therapy, for treating mercury and lead poisoning, used in a similar manner to remove excess iron from the body, for treating the complication of repeated blood transfusions, as would be applied to treat thalassaemia.An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium. Testosterone Propionate is an efficient androgenic hormone for the treatment of low testosterone.Anastrozole(ZD1033) is a potent and highly selective aromatase (CYP19) inhibitor (IC50 = 15 nM) that has no discernible effect on adrenocorticoid hormone synthesis. Dabigatran etexilate is an oral prodrug that is metabolized by a serum esterase to dabigatran. It is a synthetic, competitive and reversible direct thrombin inhibitor. Inhibition of thrombin disrupts the coagulation cascade and inhibits the formation of clots. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients who have Estradiol benzoate is an estradiol analog which binds to the human, murine and chicken ERα with IC50 of 22-28 nM.Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It binds to the androgen receptor.Sunitinib is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit.Potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor. Also inhibits cellular receptor phosphorylation of FLT3, RET and CSF-1R. Exhibits antiangiogenic and antitumor activity in multiple xenograft models.Erlotinib is a directly acting inhibitor of human EGFR tyrosine kinase with an IC50 of 2 nM. Erlotinib hydrochloride (trade name Tarceva) is a drug used to treat non-small cell lung cancer, pancreatic cancerand several other types of cancer.Erlotinib (OSI-744; NSC 718781; R1415) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.Estropipate is a form of estrogen. It has several uses such as: Alleviate symptoms of menopause as hormone replacement therapy, treatment some types of infertility, treatment of some conditions leading to underdevelopment of female sexual characteristics,treatment of vaginal atrophy,treatment of some types of breast cancer (particularly in men and Prednisolone 21-acetate is an adrenal cortico hormones, with anti-inflammatory, anti-allergic and immune suppressive effects.

Moxifloxacin (Hydrochloride) is a synthetic fluoroquinolone antibiotic agent.

Etidronate (Didronel) is a human protein tyrosine phosphatase inhibitor.

Hydrocortisone 17-butyrate is an adrenocortico hormone.

A broad-spectrum antimicrobial carboxyfluoroquinoline.

Lonidamine is an orally administered small molecule hexokinase inactivator.

Thioproline, used as antioxidants.

Thalidomide can directly inhibit angiogenesis induced by bFGF or VEGF in vivo.

Sodium salicylate is a metabolite of acetylsalicylic acid, and functions by inhibiting NF-kB and reduces oxidative stress.Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellular Indoprofen is a non-steroidal anti-inflammatory drug. It was withdrawn worldwide in the 1980s after postmarketing reports of severe gastrointestinal bleeding. A 2004 study using high-throughput screening found indoprofen to increase production of the survival of motor neuron protein, suggesting it may provide insight into treatments for spinal muscular atrophies. Colchicine is a tubulin inhibitor, it blocks polymerization of microtubules by binding to tubulin (IC50 = 3.2 μM).Suxibuzone is a drug used for joint and muscular pain. It is a prodrug of the non steroidal anti inflammatory drug phenylbutazone, and is commonly used in horses.

Clofarabine(Clolar; Clofarex) inhibits the enzymatic activities of ribonucleotide reductase (IC50 = 65 nM) and DNA polymerase.Flurbiprofen is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity.9-Aminoacridine is a highly fluorescent dye used clinically as a topical antiseptic and experimentally as a mutagen, an intracellular pH indicator.Procodazole is a non-specific active immunoprotective agent against viral and bacterial infections, used as a potentiator.Isoxicam is a novel and long-acting, non-steroidal anti-inflammatory drugs, used to treat arthritis.Cinoxacin was an older synthetic antimicrobial related to the quinolone class of antibiotics with activity similar to oxolinic acid and nalidixic acid. Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of Zomepirac, formerly marketed as Zomax tablets, was associated with fatal and near-fatal anaphylactoid reactions. The manufacturer voluntarily removed Zomax tablets from the Canadian, US, and UK markets in March 1983.Chloropyramine is a first generation antihistamine drug approved in some Eastern European countries for the treatment of allergic conjunctivitis, allergic rhinitis, bronchial asthma, and other atopic (allergic) conditions. Related indications for clinical use include Quincke’s edema, allergic reactions to insect bites, food and drug allergies, and anaphylactic shock.A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.Lithium Citrate is the active component of Lithium which is a drug used in treatment of psychiatric disease. Lithium Citrate has shown the effects on metabolic and signaling pathways in the brain based on the specific clinical condition and disease model. Lithium Citrate has been reported to use as a mood stabilizer when treating bipolar mood disorders (BD) and Gemcitabine(LY-188011; NSC 613327) is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

Methyl Hesperidin is a flavanone glycoside (flavonoid) (C28H34O15) found abundantly in citrus fruits. Its aglycone form is called hesperetin.

Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about possible increased risk of heart attack and stroke. Losartan is an angiotensin II receptor antagonist, competes with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM. IC50 Value: 20 nM [1] Target: Angiotensin Receptor in vitro: Pre-incubation with losartan (LOS), an antagonist of Pioglitazone hydrochloride can increase both insulin-stimulated glucose uptake in peripheral tissues and insulin sensitivity in hepatic and adipose tissue. It is treated for hyperglycemia and Type 2 diabetes (T2D). Pioglitazone needs insulin as a co-factor for PPAR agonism so it is not effect when being treated to late stages of T2D with developed insulinopenia. In clinical trials, Seratrodast (INN) is a thromboxane A2 (TXA2) receptor (TP receptor) antagonist used primarily in the treatment of asthma. It was the first TP receptor antagonist that was developed as an anti-asthmatic drug and received marketing approval in Japan in 1997.

Amiloride hydrochloride is a potent epithelial sodium channel blocker.

Vinpocetine is a selective inhibitor of cyclic GMP phosphodiesterase (PDE).

Oxaliplatin inhibits DNA synthesis by conforming DNA adducts.

Leucovorin Calcium is a reduced folic acid.

Sanguinarine-containing mouthwashes are marketed as anti-plaque and anti-malodor.

Bergenin, a polyphenol, is a potent antinarcotic agent with antioxidant action.

Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) taken or applied to reduce inflammation and as an analgesic reducing pain in certain conditions. It is supplied as or contained in medications under a variety of trade names.Chloroquine diphosphate is used as an antimalarial drug and also functions to increase sensitivity of tumor cells to radiation and chemotherapy via inducing autophagy [1]. Chloroquine diphosphate has been reported as an adjuvant for radiation and chemotherapy for inducing cell autophagy to anti-cancer cells proliferation or metastasis [2]. The mechanism of Vinorelbine (Navelbine®) is an anti-mitotic chemotherapy drug that is given as a treatment for some types of cancer, including breast cancer and non-small cell lung cancer. Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma as well as non-small cell lung cancer. Pemetrexed is a Folate Analog Metabolic Inhibitor. The mechanism of action of pemetrexed is as a Folic Acid Metabolism Inhibitor.Docetaxel trihydrate(Taxotere trihydrate), an analog of taxol, is an inhibitor of depolymerisation of microtubules through binding to stabilized microtubules.An anti-inflammatory analgesic and antipyretic highly bound to plasma proteins. It is pharmacologically similar to ASPIRIN, but causes less gastrointestinal bleeding. Benazepril, brand name Lotensin, is a medication used to treat high blood pressure (hypertension), congestive heart failure, and chronic renal failure. Upon cleavage of its ester group by the liver, benazepril is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor.

Mitoxantrone Dihydrochloride, a type II topoisomerase inhibitor, is an anthracenedione-derived antineoplastic agent.Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant shown to both normalize platelet count Oltipraz is an organosulfur compound belonging to the dithiolethione class.[1] It acts as a schistosomicide and has been shown in rodent models to inhibit the formation of cancers in the bladder, blood, colon, kidney, liver, lung, pancreas, stomach, and trachea, skin, and mammary tissue. Clinical trials of oltipraz have failed to demonstrate efficacy and have shown significant Bosutinib is a Bcr-Abl kinase inhibitor for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Compared to other tyrosine kinase inhibitors, it has a more favourable hematologic toxicity profile. FDA approved on September 4, 2012.

Tioconazole is an antifungal medication of the Imidazole class used to treat infections caused by a fungus or yeast. Tioconazole topical (skin) preparations are also available for ringworm, jock itch, athlete's foot, and tinea versicolor or "sun fungus". Tioconazole interacts with 14-alpha demethylase, a cytochrome P-450 enzyme that converts lanosterol to ergosterol, an Toremifene (NK 622; FC 1157a) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis.β-estradiol 17-valerate (EV) is a synthetic estrogen widely used in combination with other steroid hormones in hormone replacement therapy drugs.Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.Cepharanthine is a biscoclaurine alkaloid inhibiting tumor necrosis factor (TNF)-α-mediated NFκB stimulation, plasma membrane lipid peroxidation and platelet aggregation and suppressing cytokine production.

Voriconazole is an Azole Antifungal. Voriconazole is a new triazole derivative similar to fluconazole and itraconazole that acts by inhibiting fungal cytochrome P-450-dependent, 14-alpha-sterol demethylase-mediated synthesis of ergosterol.Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are Bendamustine hydrochloride is an alkylating agent associated with DNA damage with IC50 of 50 μMSorafenib (rINN), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer). It has also received "Fast Track" designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials. Sorafenib is a small molecular Sorafenib tosylate (BAY 43-9006) is a potent inhibitor of Raf-1 with IC50 values of 6 nM, 22 nM and 90 nM for Raf-1, B-Raf, and VEGFR2 respectively, BAY 43-9006 suppresses both wild-type and V599E mutant BRAF activity in vitro.

Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor.

Clofibric acid is a PPARα agonist and hypolipidemic agent.

An anti-inflammatory agent.

Taurine is an organic acid widely distributed in animal tissues.

Mercaptopurine (6-mercaptopurine; 6-MP) is an immunosuppressive drug; is a thiopurine.

Stanozolol is a synthetic anabolic steroid derived from dihydrotestosterone, has been approved by the FDA for human use.Lapatinib ditosylate is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer.Lapatinib(GW-572016) is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively.Uracil is one of the four nucleobases in the nucleic acid of RNA can be used for drug delivery and as a pharmaceutical.

2-Ethoxybenzamide is widely used as an antipyretic anodyne.

Famprofazone (Gewodin, Gewolen) is a non-steroidal anti-inflammatory agent (NSAID) of the pyrazolone series . It has analgesic, anti-inflammatory, and antipyretic effects.

Glafenine is a non-steroidal anti-inflammatory drug (NSAID), is a non-narcotic analgesic agent, widely used for the treatment of pains of various origins.. Disulfiram is a specific inhibitor of aldehyde-dehydrogenase (ALDH1), used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol.4-Aminoantipyrine is a reagent for glucose determination in the presence of peroxidase and phenol.Arsenic trioxide is a chemOthersaputic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. Due to the toxic nature of arsenic, this drug carries significant health risks. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide. Quinestrol is a synthetic estrogen, used in hormone replacement therapy, and occasionally to treat breast cancer and prostate cancerDienestrol is a synthetic, non-steroidal estrogen. It is an estrogen receptor agonist. Estrogens work partly by increasing a normal clear discharge from the vagina and making the vulva and urethra healthy.Miltefosine is used for the treatment of visceral and cutaneous leishmaniasis, and is undergoing clinical trials for this use in several other countries. Several medical agents have some efficacy against visceral or cutaneous leishmaniasis, however a 2005 survey concluded that miltefosine is the only effective oral treatment for both forms of leishmaniasis.Sodium 4-Aminosalicylate is an antibiotic used to treat tuberculosis via NF-κB inhibition and free radical scavenging.Procainamide hydrochloride is a class Ia antiarrhythmic drug that is structurally-related to PROCAINE.Anethole is a type of aromatic compound that occurs widely in nature, widely used as a flavoring substance.A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia.

Flubendazole is an anthelmintic that is used to treat worm infection in humans. It is available OTC in Europe.Aspirin (Acetylsalicylic acid) is a potent and selective inhibitor of cyclooxygenase (COX) with a broad range of pharmacological activities including anti-inflammation and pain relief. Multiple studies have accumulated sufficient evidence to establish the association between the use of aspirin and a reduced risk of cancers including prostate cancer, breast cancer, colorectal Salicylamide is the common name for the substance o-hydroxybenzamide, or amide of salicyl. Salicylamide is a non-prescription drug with analgesic and antipyretic properties. Its medicinal uses are similar to those of aspirin. Salicylamide is used in combination with both aspirin and caffeine in the over-the-counter pain remedies Ethamsylate is a haemostatic drug, which inhibits biosynthesis and action of prostaglandins, and increases capillary endothelial resistance as and platelet adhesion

Reference1. Jagdev SP, et al. Br J Cancer, 2001, 84(8), 1126-1134.1. Tang HB, et al. Neuropharmacology, 2005, 48(7), 1035-1042.1. Sanda T, et al. Leukemia, 2005, 19(6), 901-909.1. Tamaoki T, et al. Biochem Biophys Res Commun, 1986, 135(2), 397-402.1. Grozinger CM, et al. J Biol Chem, 2001, 276(42), 38837-38843.1. Haftchenary S, et al. ACS Med Chem Lett. 2013, 4(11), 1102-1107. 1. Soares LM,et al.Neuroscience. 2016 Apr 4. pii: S0306-4522(16)30049-5. 1. Wilkinson SE, et al. Biochem J. 1993, 294 ( Pt 2), 335-337.1.Constantine GD, Kagan R, Miller PD.Menopause. 2016 Mar 29. [Epub ahead of print]

1. Chung LC, et al. Am J Physiol Cell Physiol. 2012, 302(4), C676-685.1. Takayuki Nakashima, et al. Clin Cancer Res, 2010, 16(10), 2792-2802.1. Selvendiran K, et al. Cancer Biol Ther. 2011, 12(9), 837-845. 1. Handratta VD, et al. J Med Chem, 2005, 48(8), 2972-2984.1. Huang P, et al, J Biol Chem, 1990, 265(27), 16617-16625.1. Nikolovska-Coleska Z, et al. J Med Chem, 2004, 47(10), 2430-2440.1. Shutes A, et al. J Biol Chem. 2007, 282(49), 35666-35678.1.Tyagi S, Sharma S, Budhiraja RD.Can J Physiol Pharmacol. 2012 Jul;90(7):881-5.1. Zhang C, et al. Clin Cancer Res, 2002, 8(5), 1234-1240.1. Gergely P, et al. Br J Pharmacol, 2012, 167(5), 1035-1047. 1. Roe SM, et al, J Med Chem, 1999, 42(2), 260-266.1. Gellibert F, et al. J Med Chem, 2004, 47(18), 4494-4506.1. Brock WA, et al. Cancer Lett. 2004, 205(2), 155-160.1. Tatake RJ, et al. Biochem Biophys Res Commun, 2008, 377(1), 120-125.1. Changelian PS, et al, Science, 2003, 302(5646), 875-878.1. Manfredi MG, et al. Proc Natl Acad Sci U S A, 2007, 104(10), 4106-4111.1. Gozgit JM, et al. J Biol Chem. 2008, 283(47), 32334-32343.1. Chandarlapaty S, et al, Clin Cancer Res, 2008, 14(1), 240-248.1. Bartholomeusz GA, et al. Blood, 2007, 109(8), 3470-3478.

1. Evenou JP, et al. J Pharmacol Exp Ther, 2009, 330(3), 792-801.1. Leahy JJ, et al. Bioorg Med Chem Lett, 2004, 14(24), 6083-6087.1. Nguyen M, et al. Proc Natl Acad Sci, 2007, 104(49), 19512-191517. 1. Margolin KA, et al. Clin Cancer Res. 2012, 18(4), 1129-1137.1. Vigushin DM, et al. Clin Cancer Res, 2001, 7(4), 971-976.1. Hanke JH, et al. J Biol Chem, 1996, 271(2), 695-701.1. Ding Q, et al. J Med Chem. 2013, 56(14), 5979-5983.1. Fry DW, et al. Mol Cancer Ther, 2004, 3(11), 1427-1438.1. Fry DW, et al. Mol Cancer Ther, 2004, 3(11), 1427-1438. 1. Rusnak DW, et al. Mol Cancer Ther, 2001, 1(2), 85-94.1. Saito A, et al. Proc Natl Acad Sci U S A, 1999, 96(8), 4592-4597. 1. Buchdunger E, et al. Proc Natl Acad Sci USA. 1995, 92(7), 2558–2562.1. Pavillard V, et al. Cancer ChemOthers Pharmacol. 2002, 49(4), 329-335.1. Chang YM, Oncogene, 2008, 27(49), 6365-6375.1. Shih C, et al. Cancer Res. 1997, 57(6), 1116-1123.1. Silwal P, et al. Mol Immunol. 2015 Jun;65(2):242-9. 1. Mendeleyev J, et al. Biochem Pharmacol, 1995, 50(5), 705-714.1. Duncia JV, et al. Bioorg Med Chem Lett. 1998, 8(20), 2839-2844.1. Huynh H, et al, Mol Cancer Therapy, 2007, 6 (1), 138-1461. Mahajan S, et al. J Biol Chem. 1999, 274(14), 9587-9599.1. Attard G, et al. J Clin Oncol. 2008, 26(28), 4563-4571.1. Pinto-Bazurco Mendieta MA, et al. J Med Chem. 2008, 51(16), 5009-5018.1. Zheng S, et al. J Med Chem. 2014, 57(8), 3369-3381.1. Dovey HF, et al. J Neurochem. 2001, 76(1), 173-181.1. Rader J, et al. Clin Cancer Res. 2013, 19(22), 6173-6182. 1. Garcia Soriano F, et al. Nat Med, 2001, 7(1), 108-113.1. Barrett SD, et al. Bioorg Med Chem Lett, 2008, 18(24), 6501-6504.1. Martinez A, et al. J Med Chem, 2002, 45(6), 1292-1299. 1. Zhai D, et al. Mol Cancer Ther, 2008, 7(6), 1639-1646.

1. Laird AD, et al. Cancer Res, 2000, 60(15), 4152-4160.1. Steegmaier M, et al. Curr Biol, 2007, 17(4), 316-322.1. Kirshner JR, et al. Mol Cancer Ther, 2008, 7(8), 2319-2327.1. Yaguchi S, et al. J Natl Cancer Inst, 2006, 98(8), 545-556.1. Honda T, et al. J Med Chem. 2000, 43(22), 4233-4246.1. Wang X, et al. Mol Cancer Ther, 2003, 2(11):1085-1092.1. Smaill JB et al. J Med Chem. 2000; 43(7): 1380-1397. 1. Kim K, et al. Br J Haematol, 2010, 149(4), 537-549.1. Nagasawa J, et al. Int J Urol, 2006, 13(5), 587-592.;1. Munshi N, et al. Mol Cancer Ther. 2010, 9(6), 1544-1553.1. Jääskelä-Saari HA, et al. Acta Otolaryngol Suppl. 1997, 529, 241-244.1. Jefferies HB, et al. EMBO Rep, 2008, 9(2), 164-170.1. Ohta H, et al, Mol Pharmacol, 2003, 64(4), 994-1005. 1. Liu Q, et al. J Med Chem, 2011, 54(5), 1473-1480.1. Hickinson DM, et al. Clin Cancer Res, 2010, 16(4), 1159-1169.1. Wannamaker W, et al. J Pharmacol Exp Ther. 2007, 321(2), 509-516.1. Dai Y, et al. Clin Cancer Res, 2010, 16(2), 376-383.1.Bono F, et al. Cancer Cell. 2013, 23(4), 477-488.1. Chang YM, Oncogene, 2008, 27(49), 6365-6375.1. Penebre et al. Epizyme, Inc.1. Regueiro-Ren A , et al. Org Lett, 2001, 3(17), 2693-2696.1. Gumireddy K, et al. Cancer Cell, 2005, 7(3), 275-286.1. Morris EJ, et al. Cancer Discov, 2013 Apr 29.1. Marek L, et al. J Med Chem. 2013, 56(2), 427-436.1. Verma SK, et al. ACS Med Chem Lett. 2012, 3, 1091-1096.1. Goodfellow VS, et al. J Med Chem. 2013, 56(20), 8032-8048.1. Wood ER, et al. Bioorg Med Chem Lett, 2004, 14(4), 953-957.1. Mader M, et al. Bioorg Med Chem Lett, 2008, 18(1), 179-183.1. Thoreen CC, et al, J Biol Chem, 2009, 284(12), 8023-8032.

1. Matsumoto K, et al. Biopolymers. 1999, 51(1), 99-107.1. Nicole Miller, et al. Mol Cancer Ther, 2009, 8(12 Suppl):B146.1. Blasina A, et al. Mol Cancer Ther, 2008, 7(8), 2394-2404.1. Piva R,et al. Blood. 2008,111(5),2765-2775.1. Nakanishi Y, et al. Mol Cancer Ther. 2014, 13(11), 2547-2558.1. Tovar C, et al. Proc Natl Acad Sci U S A, 2006, 103(6), 1888-1893.1. Rudolph D, et al. Clin Cancer Res, 2009, 15(9), 3094-3102.1. Mulvihill MJ, et al. Future Med Chem, 2009, 1(6), 1153-1171.1. Dorr P, et al. Antimicrob Agents ChemOthers. 2005, 49(11), 4721-4732.1. Licciulli S, et al. J Biol Chem. 2013, 288(4), 29105-29114.1. Slee EA, et al. Biochem J, 1996, 315 (Pt 1), 21-24.1. Allensworth JL, et al. Breast Cancer Res Treat, 2013, 137(2), 359-371.1. Furumai R, et al. Cancer Res, 2002, 62(17), 4916-4921.1.Rickers A, et al. Eur J Immunol. 1998, (1), 296-304.1. Tran C, et al, Science, 2009, 324 (5928), 787-790.1. Seelmeier S, et al. Proc Natl Acad Sci U S A. 1988, 85(18), 6612-6616.1. Rolfo C, et al. Expert Opin Investig Drugs. 2015, 24(11), 1493-1500.1. Mohammad HP, et al. Cancer Cell. 2015, 28(1), 57-69.1. Kwiatkowski N, et al. Nature. 2014 Jul 31;511(7511):616-20.;Nilson KA, et al. Mol 1. Ruben N, et al. Blood. 2015, 126:3040;1. Zeng Q, et al. J Med Chem. 2015, 58(20), 8200-8215.1. Nukatsuka M, et al. Anticancer Res. 2015 Sep;35(9):4605-15.1. Hino T, et al. Biochim Biophys Acta. 1998 Sep 16;1425(1):47-60.1. DiMaio MA, et al. Mol Cancer Ther. 2009 Mar;8(3):592-601.1. Patent WO 2013014448 A1: 2 - (2, 4, 5 - substituted -anilino) pyrimidine 1. Warren JP. Discovery of a Novel Notch Inhibitor. The 8th SCI-RSC Symposium 1. MacLean DB et al. J Clin Endocrinol Metab. 2015 Dec;100(12):4579-87. 1. Maly J, et al. Curr Hematol Malig Rep. 2016 Feb;11(1):52-60.1. Hoeflich KP, et al. Cancer Res. 2012, 72(1), 210-219.;Baudy AR, et al. EJNMMI Res.

N/A

1. Zhang S, et al. Clin Cancer Res. 2016 Oct 25.;1.Li Shengrong,et al. Biological Trace Element Research (2010), 136(3), 294-1. Kim SH, et al. Exp Biol Med (Maywood). 2015 Jan;240(1):26-33.1. Caccese M, et al. Expert Opin Pharmacother. 2016 Dec;17(17):2253-2266. 1. Patrick R. Hagner, et al. Blood. 2015 Aug 6; 126(6): 779–789.1. Vacchelli E, et al. Oncoimmunology. 2014 Dec 15;3(10):e957994.1. Yongkun Sun, et al. J Hematol Oncol. 2016; 9: 105.1. Toma S, et al. Xenobiotica. 1987 Oct;17(10):1195-202.1. Chan SL, et al. J Biol Chem. 2003 Jun 6;278(23):20453-6.1. Liu SL et al. Eur J Drug Metab Pharmacokinet. 2014 Jun;39(2):99-102.1. Zhu S, et al. Oncotarget. 2015 Apr 30;6(12):10460-72.

1. Jin J, et al. Lancet Oncol. 2013 Jun;14(7):599-608. 1. Ulrich H. Chem. Rev., 1974, 74 (6), pp 625–6521. Wang L, et al. Invest New Drugs. 2012, 30(6):2113-20.1. Koltun ES, et al. Bioorg Med Chem Lett. 2012 Jun 1;22(11):3727-31. 1. Li X, et al. Bioorg Med Chem Lett. 2011, 21(18):5251-4.1. Vendetti FP, et al. Oncotarget. 2015. doi: 10.18632/oncotarget.6247.1. Tsai JH et al. Toxicol Appl Pharmacol. 2013 Nov 1;272(3):746-561. Hui KM, et al. Biochem. Pharmacol. 2012, 64 (9): 1415–24. 1. Ripple GH. Clin Cancer Res 2000;6:390-6.1. Melissa KB, et al. Cancer Biol Ther. 2012 Jul 1; 13(9): 804–811.1. Kouvaris JR. Oncologist. 12 (6): 738–471. Pennanen, Niina et al. Pharmaceutical Research. 12 (6): 916–922.1. Burbridge MF, et al. Mol Cancer Ther. 2013 Sep;12(9):1749-62.1. Shultz MD, et al. J Med Chem. 2013, 56(16), 6495-6511.1. Clem B, et al. Mol Cancer Ther. 2008 Jan;7(1):110-20. 1. Piali L, et al. J Pharmacol Exp Ther. 2011 May;337(2):547-56.1. Vedadi M, et al.Nat Chem Biol. 2011 Jul 10;7(8):566-74.

N/A

N/A

1. Tai, Y. T.Blood. 123 (20): 3128–38.

1. Li Y, et al. Proc Natl Acad Sci U S A. 2015, 112(6), 1839-1844.1.Kim J, et al. COX-2 inhibitor NS-398 suppresses doxorubicin-induced 1.Fabbro D, et al. Pharmacol Ther, 1999, 82(2-3), 293-301.1.Bola BM, et al. Mol Cancer Ther. 2014 Dec;13(12):2805-16.1. Paul E. Hughes, et al. Cancer Res October 1, 2014 74; 7281. Neel Jasani, et al. DOI: 10.1158/1538-7445.1. Wang Y, et al. Chem Biol. 2015 Feb 19;22(2):273-84.1. Jayathilaka N, et al. Nucleic Acids Res. 2012 Jul;40(12):5378-88.1. Senisterra G, et al. Biochem J. 2013 Jan 1;449(1):151-9.1. Liu M, et al. Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72.1. Suzuki T, et al. J Med Chem. 2005 Feb 24;48(4):1019-32.1. Liang X, et al. J Med Chem. 2016 Mar 10;59(5):1984-2004.1. Brooks EE, et al. J Biol Chem. 1997 Nov 14;272(46):29207-11.1. Chou CJ, et al. J Biol Chem. 2008 Dec 19;283(51):35402-9.1. Saw S,et al. Eur J Pharmacol. 2016 Apr 5;776:176-84.1. Zhang H, et al. Biomed PharmacOthers. 2008 Feb;62(2):65-9.1. Rigas AC, et al. Oncogene. 2007 Dec 6;26(55):7611-9. 1. Rossi AB, et al. J Allergy Clin Immunol. 2006 Sep;118(3):749-55.1. Zubovych IO, et al. Mol Cancer Ther. 2016 Jan;15(1):23-36. 1. Narwal M, et al. J Med Chem. 2013 Oct 24;56(20):7880-9.1. Zhou B, et al. Cancer Res. 2013 Nov 1;73(21):6484-93. 1. Yap TA, et al. Curr Opin Pharmacol. 2015 Aug;23:98-107.1. Qin JD, et al. Pharm Biol. 2014 Nov;52(11):1460-1466.1. Lu J, et al. J Mass Spectrom. 2015 Jan;50(1):153-9. 1. Oda SS, El-Ashmawy IM. Int J Exp Pathol. 2012 Jun;93(3):172-8.1. Jakubovic A, Cekan Z. Acta Endocrinol (Copenh). 1967 Oct;56(2):197-202.

1. Camozzi V, et al. J Endocrinol Invest. 2015 Apr;38(4):389-97.1. Guo B, et al. J Drug Target. 2015 Apr;23(3):266-74. 1. Voermans M, et al. J Vet Pharmacol Ther, 2006, 29(6), 555-560.1. Qian F, et al. Cancer Res, 2009, 69(20), 8009-8016.1. Sanchez-Martinez et al. Mol Cancer Ther, 2011,10(11 Suppl), Abstract nr B234.1. Bennett BL, et al. Proc Natl Acad Sci U S A, 2001, 98(24), 13681-13686.1. Cai X, et al. J Med Chem, 2010, 53(5), 2000-2009.1. Rebecca Redman, et al. Cancer Res August 1, 2015 75; CT206.1. Kruidenier L, et al. Nature, 2012, 488(7411), 404-408.1. Robert A. Protein methyltransferases in cancer. AACR Annual Meeting, 2013.1. Hideshima T, et al. J Biol Chem. 2002, 277(19), 16639-16647.1. Jeon Y, et al. Exp Dermatol. 2015 Feb;24(2):140-5. 1. Krynetskaia NF, et al. FASEB J,2000, 14(14), 2339-2344.1. Yu W, et al. Nat Commun. 2012;3:1288. 1. Daigle SR, et al. Cancer Cell. 2011, 20(1), 53-65.1. Nakagawa R, et al. J Immunol. 2011 Nov 1;187(9):4611-20.1. Sabbatini P, et al. Mol Cancer Ther. 2009, 8(10), 2811-2820.1. Chen LS, et al. Blood, 2011, 118(3), 693-702.1. Coghlan MP, et al. Chem Biol, 2000, 7(10), 793-803.1. Van Rompaey L, et al. J Immunol. 2013, 191(7), 3568-3577.1. Krämer A, et al. Nat Chem Biol. 2013, 9(11), 731-738.1. Ring DB,et al. Diabetes. 2003, 52(3), 588-595.1. Daniel I Perez, et al. Med Res Rev.2011,31(6): 924-954.1. Forsyth T, et al. Bioorg Med Chem Lett, 2012, 22(24), 7653-7658.1. Ren X, et al. J Med Chem. 2013, 56(3), 879-894.1. Lauth M, et al. Proc Natl Acad Sci, 2007, 104(20), 8455-85601. Domínguez JM, et al. J Biol Chem, 2012, 287(2), 893-901. Quintas-Cardama A, et al. Blood, 2010, 115(15), 3109-3117.1. Wisniewski D, et al. Cancer Res. 2002, 62(15), 4244-4255.

N/A

1. James RG, et al. PLoS One. 2012, 7(12), e50457.1. Johnson TW, et al. J Med Chem. 2014, 57(11), 4720-4744.1. Ono-Saito N, et al. Pharmacol Ther, 1999, 82(2-3), 123-131.1. Sen Zhang, et al. Cancer Research: April 15, 2010; Volume 70, Issue 8, Supplement 11. Beharry Z, et al. Mol Cancer Ther, 2009, 8(6), 1473-1483.1. Konze KD, et al. ACS Chem. Biol. 2013, 8 (6), 1324–1334.1. Lin CP, et al. Anticancer Drugs. 2007 Feb;18(2):161-70.

1. Yuta Komoike, et al. Archives of Toxicology.2012, 86(1): 37-44.1. Quintas-Cardama A, et al. Blood, 2010, 115(15), 3109-3117.1. Jacqueline Sayyah, et al. Mol Cancer Ther 2008;7(8):2308-18.1. A Dose Finding Study With Oral LDK378 in Patients With Tumors 1. Philip M Reaper, et al. Nature Chemical Biology, 7, 428-430 (2011)1. Tojo M, et al. Cancer Sci. 2005 Nov;96(11):791-800.1. Luo Y, et al. Mol Med Rep. 2015 Dec;12(6):8294-300.1. Xu X, et al. Mol Cancer Ther. 2016 Nov;15(11):2586-2597. 1. Forsgren KL, et al. Gen Comp Endocrinol. 2014 Jun 1;202:1-7.1. Menear KA, et al. J Med Chem, 2008, 51(20), 6581-6591.1. Ong JY, et al. Life Sci. 2015 Aug 15;135:158-64.1. Seo MS, et al. Toxicol Appl Pharmacol. 2015 Apr 15;284(2):113-24.1. Li M, et al. Cancer Sci. 2015 Oct;106(10):1341-50. 1. Wang G, et al. Pflugers Arch, 1992, 421(6), 558-565.1. Lee MS, et al. PhytOthers Res, 2011, 25(6), 833-837.1. Wu N, et al. Tumour Biol. 2015 Jul 7.1. Yang J, et al. Int J Immunopathol Pharmacol. 2015 Sep;28(3):296-307.1. Saad MA, et al. Pharmacol Rep. 2015 Feb;67(1):115-22. 1. Huang TH, et al. Eur J Pharmacol. 2007 Jun 22;565(1-3):158-65. 1. Feng Y, et al. J Neurochem. 2015 Aug;134(4):668-76. 1. Shih DM, et al. FASEB J. 2013 Sep;27(9):3805-17.

1. Zhang H, et al. Int J Clin Exp Pathol. 2015 May 1;8(5):4444-56. 1. Wu X, et al. Biochem Pharmacol. 2015 Aug 15;96(4):323-36. 1. Lin H, et al. Biochem Biophys Res Commun. 2015 May 1;460(2):422-7. 1. Insel PA, et al. Cell Mol Neurobiol, 2003, 23(3), 305-314.1. Xiao L, et al. Eur J Med Chem. 2014 Jun 10;80:267-77. 1. Bunel V, et al. J Appl Toxicol. 2014 Dec;34(12):1311-9. 1. Man HW, et al. J Med Chem, 2009,52(6), 1522-1524.1. Song L, et al. Biochem Biophys Res Commun. 2015 Aug 28;464(3):705-10.1. Reisman SA, et al. J Am Soc Nephrol. 2012 Oct;23(10):1663-73. 1. Wang T, et al. Int Immunopharmacol. 2014 Sep;22(1):192-9.1. Li GF, Qin YH, Du PQ. Life Sci. 2015 Sep 1;136:67-72. 1. Zhao Q, et al. Int J Cancer. 2015 Sep 15;137(6):1446-56.1. Liu Y, et al. Technol Cancer Res Treat. 2015 Oct 6. pii: 1533034615609014. 1. Wang GY, Wang N, Liao HN. Cell Mol Neurobiol. 2015 Nov;35(8):1105-15. 1. Kim SC, et al. Biochem Biophys Res Commun. 2015 Nov 27;467(4):638-44. 1. Cho YS, et al. Korean J Physiol Pharmacol. 2013 Apr;17(2):133-7.1. Ren H, et al. Acta Biochim Biophys Sin (Shanghai). 2014 Dec;46(12):1049-55.1. Cha TL, et al. Mol Carcinog. 2015 Mar;54(3):167-77. 1. Liu J, J Ethnopharmacol, 1995, 49(2), 57-68.1. Grainger EM, et al. Br J Nutr. 2015 Aug 28;114(4):596-607. 1. Dang YJ, Zhu CY. J Food Sci. 2015 Mar;80(3):C504-9. 1. Akiyama T, et al. J Biol Chem, 1987, 262(12), 5592-5595.1. Pan X, et al. Inflamm Res. 2014 Jul;63(7):597-608. 1. Zhang W, et al. Med Oncol, 2011, 28(1), 307-314.1. Yang EB, et al. Biochem Biophys Res Commun, 1999, 260(3), 682-685.1. Margetis K, et al. J Neurosurg. 2015 Jan;122(1):40-8.1. Chen TL, et al. Fitoterapia. 2014 Mar;93:88-97.1. Hirano T, et al. Br J Cancer, 1995, 72(6), 1380-1388.1. Murakami A, et al. Cancer Res, 2000, 60(18), 5059-5066.

1. Fujioka T, et al. J Nat Prod, 1994, 57(2), 243-247.1. Bunbupha S, et al. Clin Exp Pharmacol Physiol. 2015 Nov;42(11):1189-97. 1. Ni G, Yu DQ. Zhongguo Zhong Yao Za Zhi. 2013 Feb;38(4):569-73.1. Sapanidou V, et al. Theriogenology. 2015 Nov;84(8):1273-82.1. Cha PH, et al. PLoS One. 2014 Jan 22;9(1):e85546.1. Lee RH, et al. Oncol Rep. 2015 Feb;33(2):631-8. 1. Shin DS, et al. Cancer Res, 2009, 69(1), 193-202.1. Guo B, et al. J Drug Target. 2015 Apr;23(3):266-74. 1. Pradhananga S, Shim WS. Eur J Pharmacol. 2015 Sep 5;762:313-21. 1. Illing EA, et al. Otolaryngol Head Neck Surg. 2015 Aug;153(2):291-7.1. Ahmed LA, et al. Eur J Pharmacol. 2014 Oct 5;740:379-87.1. Park H, et al. ChemMedChem. 2012, 7(1), 53-56.1. Milazzo S, Horneber M. Cochrane Database Syst Rev. 2015 Apr 28;4:CD005476.1. Mavrogonatou E, Angelopoulou MT, Kletsas D. J Orthop Res. 2014 1. Pereira DM, et al. Phytomedicine, 2010, 17(8-9), 646-652.1. Chen JG, et al. J Steroid Biochem Mol Biol. 2015 May;149:11-6. 1. Zhao H, et al. Exp Ther Med. 2015 Aug;10(2):823-827.1. Teicher BA. Biochem Pharmacol. 2007 Oct 22;.1. Liu K, et al. Life Sci. 2015 Feb 15;123:78-85.1. Meotti FC, et al. J Pharmacol Exp Ther, 2006, 316(2), 789-796.1. Liu X, et al. Thromb Res. 2014 Nov;134(5):1066-73. 1. Grobelny D, et al. Biochemistry, 1992, 31(31), 7152-714.1. Goldstein P, Leshem M. Appetite. 2014 Aug;79:83-901. Chen YC, et al. Life Sci. 2009 Jun 19;84(25-26):915-22. 1. Deng S, et al. J Vet Sci, 2013. 14(3): p. 281-9.1. Pamela Farrell, et al, AACR, 2009, Abstract B2701. Scherle PA, wt al. J Biol Chem. 2000, 275(47), 37086-37092.1. Komarov PG, et al. Science, 1999, 285(5434), 1733-1737.1. Xue Q, et al. Cancer Res, 2008, 68(22), 9551-9557.

N/A

1. Duffey MO, et al. J Med Chem, 2012, 55(1), 197-208.1. Chen B, et al. Nat Chem Biol, 2009, 5(2), 100-107.1. Schroeder GM, et al. J Med Chem, 2009, 52(5), 1251-1254.1. Tombes RM, et al. Cell Growth Differ. 1995 Sep;6(9):1063-70.1. Coffey G, et al. J Pharmacol Exp Ther, 2012, 340(2), 350-359.1. Orzechowska E, et al. Oncol Rep. 2012 Jan;27(1):281-5.1. Tokumitsu H, et al. J Biol Chem. 1990, 265(8), 4315-4320.1. Hickson I, et al. Cancer Res. 2004, 64(24), 9152-9159.1. Wang X, et al. J Med Chem. 2013, 56(6), 2700-2704.1. Tiedt R, et al. Cancer Res. 2011, 71(15), 5255-5264.1. Misra RN, et al. Bioorg Med Chem Lett. 2003, 13(14), 2405-2408.1. Heinrich MC, et al, Clin Cancer Res, 2012, Jun 27.1. Timofeevski SL, et al. Biochemistry, 2009, 48(23), 5339-5349.1. Ferrandi C, et al. Mult Scler. 2011 Jan;17(1):43-56.1. Savage SR, et al. Mol Vis. 2015 May 20;21:568-76.1. Doukas J, et al. Proc Natl Acad Sci U S A, 2006, 103(52), 19866-19871.1. Zoghbi GJ, Iskandrian AE. J Nucl Cardiol. 2012 Feb;19(1):126-41. 1. Rosenthal AS, et al. Probe Reports from the NIH Molecular Libraries Program. 2010.1. Fokas E, et al. Cell Death Dis, 2012, 3, e441.1. Zhang T, et al. Chem Biol, 2012, 19(1), 140-154.1. Zheng Z, et al. Mol Pharmacol. 2011, 80(4), 657-664.1. Chaussade C, et al. Biochem J. 2007, 404(3), 449-458.1. Wen PJ, et al. Nat Commun, 2011, doi:10.1038/ncomms1500.1. Conway JG, et al. Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16078-83.1. Tang SC, et al. Int J Cancer. 2014, 134(6), 1484-1494.1. Gu Y, et al. Cancer ChemOthers Pharmacol. 2014 Jul;74(1):95-115.1. Iragavarapu C, et al. J Hematol Oncol. 2015 Feb 27;8(1):17. 1. Poulsen A, et al. J Mol Model. 2013 Jan;19(1):119-30.

1. Lu J, et al. Bioorg Med Chem Lett, 2009, 19(14), 3825-3827.1. Grembecka J, et al. Nat Chem Biol. 2012, 8(3), 277-284.1. Yue EW, et al. J Med Chem. 2009, 52(23), 7364-7367.1. Nahimana A, et al. Blood, 2009, 113(14), 3276-3286.1. Grembecka J, et al. Nat Chem Biol. 2012, 8(3), 277-284.1. Mohammadi M, et al. EMBO J, 1998, 17(20), 5896-5904.1. Park CH, et al. Bioorg Med Chem Lett. 2013 Nov 15;23(22):6192-6.1. Chan WW, et al. Cancer Cell. 2011, 19(4), 556-568.1. May P, et al. J Neurosci, 2011, 31(46), 16507-16516.1. Ma L, et al. 53rd ASH Annual Meeting and Exposition, 2011, Abstract 4087.1. Perotti A, et al. Ann Oncol. 2009 Apr;20(4):741-5.1. Mahajan S, et al. J Pharmacol Exp Ther. 2015 Mar 11. pii: jpet.114.221176.1. Chen S, et al. Bioorg Med Chem Lett, 2012, 22(2), 1247-1250.1. Bruncko M, et al. J Med Chem. 2015 Mar 12;58(5):2180-2194.1. Nam HJ, et al. Cancer Lett. 2011 Mar 28;302(2):155-65.1. Hughes AN, et al. Br J Cancer. 2000 May;82(9):1519-27.1. Cook JJ, et al. J Neurosci, 2010, 30(19), 6743-6750.1. Garton AJ, et al. Cancer Res. 2006, 66(2):1015-1024.1. Dudley DT, et al. Proc Natl Acad Sci U S A, 1995, 92(17), 7686-7689.1. Lee HK, et al. Blood. 2014, 123(14), 2209-2219.1. Tanaka H, et al, Clin Cancer Res, 2011, 17(10), 3272-3281.1. Liu J, et al. Proc Natl Acad Sci U S A. 2013, 110(50), 20224-20229.1. Oslob JD, et al. Bioorg Med Chem Lett, 2008, 18(17), 4880-4884.1. Knight ZA, Cell, 2006, 125(4), 733-747.1. Caracciolo V, et al, Cell Cycle, 2012, 11(6), 1202-1216.1. Bavetsias V, et al. J Med Chem, 2010, 53(14), 5213-5228.1. Wong TW, et al. Clin Cancer Res, 2006, 12(20 Pt 1), 6186-6193.1. Dubreuil P, et al. PLoS One, 2009, 4(9), e7258.1. Ring DB,et al. Diabetes. 2003, 52(3), 588-595.

1. Sumi M, et al. Biochem Biophys Res Commun. 1991, 181(3), 968-975.1. Braselmann S, et al. J Pharmacol Exp Ther, 2006, 319(3), 998-1008.1. Evans E, et al. ASH Annual Meeting, 2011 San Diego, CA.1. Yang J, et al. Blood, 2007, 110(6), 2034-2040.1. Samanta AK, et al. Cancer Res, 2006, 66(13), 6468-6472.1. Zhu MX, et al. Exp Cell Res. 2015 Feb 15;331(2):387-98. 1. Van Goor F, et al. Proc Natl Acad Sci U S A, 2011, 108(46), 18843-18848.1. Albert JM, et al, Clin Cancer Res, 2007, 13(10), 3033-3042. 1. Tian F, et al. Anticancer Res. 2012, 32(1), 89-94.1. You WK, et al. Cancer Res, 2011, 71(14), 4758-4768.1. Bronstein MD. Front Horm Res. 2006;35:129-34.1. Tian S, et al. Cancer Sci, 2011, 102(7), 1374-1380.1. Fernandez L, et al. Endocrinology. 1994 Mar;134(3):1401-8. 1. Bhide RS, et al. J Med Chem, 2006, 49(7), 2143-2146.1. Gao J, et al. Environ Toxicol Pharmacol. 2014 May;37(3):1157-68. 1. Kupfer D, Bulger WH. FEBS Lett. 1990 Feb 12;261(1):59-62.1. Zhao J, et al. Steroids, 2004. 69(5): p. 357-66.1. Palit S, et al. J Cell Physiol. 2015 Aug;230(8):1729-39. 1. Kopadze T, et al. Eur J Neurol. 2009, 16(3), 409-412.1. Bender T, et al. Arzneimittelforschung. 2001;51(6):489-92.1. Burdan F, et al. Pharmacol Res. 2004 Nov;50(5):533-43. 1. Pal SK, et al. Clin Interv Aging, 2010, 5, 395-402.1. Rolin J, et al. Cancer Immunol ImmunOthers. 2010, 59(4), 575-586.1. Liang Y, et al. J Biol Chem, 2003, 278(29), 27267-27277.1. Winter JP, Juergens CP. Cardiovasc Hematol Disord Drug Targets. 2008 1. Plosker GL, et al. Drugs, 2000, 60(1), 177-201.1. Pohl O, et al. Int J Clin Pharmacol Ther. 2013 Jan;51(1):26-33.1. Madala SK, et al. Am J Respir Cell Mol Biol. 2012 Mar;46(3):380-8.1. Guzi TJ, et al. Mol Cancer Ther, 2011, 10(4), 591-602.

1. Mahadevan D, et al. Oncogene, 2007, 26(27), 3909-3919.1. Albert DH, et al. Mol Cancer Ther, 2006, 5(4), 995-1006.1. Kuliopulos A, et al. Thromb Haemost, 2004, 92(6), 1387-1393.1. Fournel M, et al. Mol Cancer Ther. 2008, 7(4), 759-768.1. Nicholson B, et al. Anticancer Drugs, 2006, 17(1), 25-31.1. Yingling JM, et al. Proc Am Assoc Cancer Res. 2006, 47, abstract 250.1. Byth KF, et al. Mol Cancer Ther. 2009, 8(7), 1856-1866.1. Siddiquee K, et al. Proc Natl Acad Sci U S A, 2007, 104(18), 7391-7396.1. Putt KS, et al. Nat Chem Biol, 2006, 2(10), 543-550.1. Smaill JB et al. J Med Chem. 2000; 43(7): 1380-1397.1. Wedge SR, et al. Cancer Res. 2005 May 15; 65(10):4389-400.1. Fong TA, et al. Cancer Res, 1999, 59(1), 99-106.1. McElhinney RS, et al. J Med Chem, 1998, 41(26), 5265-5271.1. Reardon DA, et al. Genes Cancer, 2011, 2(12):1159-1165.1. Vyomesh Patel, et al. Cancer Res, 2002, 62(5), 1401-14091. Cross DA, et al. Cancer Discov. 2014, 4(9), 1046-1061.1. Patent. 2013, WO2013014448 A1.1. Santo L, et al. Blood, 2012, 119(11), 2579-2589.1. Ellinghaus P, et al. Cancer Med. 2013, 2(5), 611-624.1. Norman P, et al. Expert Opin Ther Pat, 2012, 22(10), 1233-1249.1. Jaspers JE, et al. Cancer Discov, 2013, 3(1), 68-81.1. Engelman JA, et al, Cancer Res, 2007, 67(24), 11924-11932.1. Yap TA, et al. Clin Cancer Res. 2012, 18(14), 3912-3923.1. Gazit A, et al. J Med Chem, 1989, 32(10), 2344-2352.1. Mijatovic T, et al. Neoplasia. 2008 Jun;10(6):573-86.1. García-Martínez JM, et al. Biochem J, 2009, 421(1), 291. Golding SE, et al. Mol Cancer Ther, 2009, 8(10), 2894-2902.1. Tsai J, et al. Proc Natl Acad Sci U S A, 2008, 105(8), 3041-3046.1. Di Paolo JA, et al. Nat Chem Biol, 2011, 7(1):41-50.

1. Chowdhury A, et al. Leuk Lymphoma. 2012, 53(3), 462-471.1. Pevton KJ, et al, J Pharmacol Exp Ther, 2012, Jun 13.1. Braselmann S, et al. J Pharmacol Exp Ther, 2006, 319(3), 998-1008.1. Zhu J, et al. Cancer Res, 2004, 64(12), 4309-4318.1. Roberts WG, et al. Cancer Res, 2008, 68(6), 1935-1944.1. Yu X, et al. Cancer Cell. 2012 May 15;21(5):614-25.1. Chen HY, et al. EMBO Mol Med. 2013, 5(5), 723-736.1. Van Keymeulen A, et al. J Cell Biol. 2006, 174(3), 437-445.1. Brown GR, et al. Bioorg Med Chem Lett. 2000, 10(6), 575-579.1. Powers JP, et al. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2842-5.1. Nakamura K, et al. Cancer Res, 2006, 66(18), 9134-9142.1. Atadja P, et al. Cancer Res, 2004, 64(2), 689-695.1. James K. Chen, et al. Proc Natl Acad Sci U S A, 2002, 99(22), 14071-14076.1. Rena G, et al. EMBO Rep. 2004, 5(1), 60-65.1. Kubo K, et al. J Med Chem, 2005, 48(5), 1359-1366.1. Hong YR, et al. Bioorg Med Chem Lett. 2013 Nov 1;23(21):5953-7.1. Yokota S, et al. Cancer Res. 2000, 60(11), 2942-2948.1. Sebolt-Leopold JS, et al. Nat Med, 1999, 5(7), 810-816.1. Devaiah BN, et al. Proc Natl Acad Sci U S A. 2012, 109(18), 6927-6932.1. Muranaka Y, et al. J Pharmacol Exp Ther. 1998 Jun;285(3):1280-1286.1. Behrend L, et al. Oncogene. 2000 Nov 9;19(47):5303-5313.1. Garland LL, et al. Clin Cancer Res. 2006 Sep 1;12(17):5182-9.1. Campbell JE, et al. ACS Med Chem Lett. 2015 Mar 4;6(5):491-495.1. Kristof AS, et al. J Pharmacol Exp Ther. 2005 Sep;314(3):1134-43.1. Veuger SJ, et al. Cancer Res, 2003, 63(18), 6008-6015.1. Fu Y, et al. Biochem Biophys Res Commun. 2003 Oct 17;310(2):391-7.1. Lee JH, et al. Proc Natl Acad Sci U S A. 2013, 110(39), 15704-157099.1. Ren X, et al. J Med Chem. 2013, 56(3), 879-894.1. Seavey MM, et al. Mol Cancer Ther. 2012 Apr;11(4):984-93.

1. WO2009094417A1

1. Ranganathan P, et al. Blood. 2012, 120(9), 1765-1773.1. Tian X, et al. Assay Drug Dev Technol, 2011, 9(2), 165-173.1. Zhang S, et al. Clin Cancer Res. 2011, 17(13), 4439-4450.1. Meuillet EJ, et al. Mol Cancer Ther, 2010, 9(3), 706-717.

1. Jamieson S, et al. Biochem J, 2011, 438(1), 53-62.1. Tatake RJ, et al. Biochem Biophys Res Commun, 2008, 377(1), 120-125.1. Apsel B, et al. Nat Chem Biol, 2008, 4(11), 691-699.1. Apsel B, et al. Nat Chem Biol, 2008, 4(11), 691-699.1. Handeli S, et al. Mol Cancer Ther. 2008, 7(3), 521-529.1. Milne JC, et al. Nature. 2007, 450(7170), 712-716.1. Alberts DS, et al. Cancer ChemOthers Pharmacol, 1997, 39(6), 493-497.1. Kim J, et al. J Pharmacol Exp Ther, 2005, 315(1), 230-239.1. Shimura M, Yasuda K. Br J Ophthalmol. 2015 Feb;99(2):215-9. 1. See S, et al. Am J Health Syst Pharm,?000,?7(8), 739-746.1. Adams J, et al. Cancer Res, 1999, 59(11), 2615-2622.1. Changelian PS, et al, Science, 2003, 302(5646), 875-878.1. Sugimoto H., et al. J Pharmacol Exp Ther, 2003. 305(1): p. 347-52.1. Cavalletti E., et al. Invest New Drugs, 2007. 25(3): p. 187-95.1. Coote K, et al. J Pharmacol Exp Ther, 2009, 329(2), 764-774.1. Nakazato H, et al. Eur J Pharmacol, 2002, 446(1-3), 177-185.1. Muller GW, et al. Bioorg Med Chem Lett, 1999, 9(11), 1625-1630.1. Scuto A, et al. Blood. 2008, 111(10), 5093-5100.1. Bollag G, et al. Nature, 2010, 467(7315), 596-599.1. Patrick J. Roberts, et al. JNCI J Natl Cancer Inst (2012) 104 (6): 476-487.1. Pascolo E, et al. J Biol Chem. 2002, 277(18), 15566-15572.1. Cirstea D, et al. Leukemia. 2013 Dec;27(12):2366-75.1. Chakrabarty A, et al. Proc Natl Acad Sci U S A, 2011, 1-6.1. Liang M, et al. J Biol Chem. 2000 Jun 23;275(25):19000-8.

N/A

1. Banerjee S, et al. Biochem J. 2014, 457(1), 215-225.1. Brooks DJ, et al. Clin Neuropharmacol. 2010 Mar-Apr;33(2):55-60.1. O'Hare T, et al. Cancer Cell, 2009, 16(5), 401-412.1. Walter AO, et al. Cancer Discov. 2013 Sep 25.1. Griswold DE, et al. Biochem Pharmacol. 1987 Oct 15;36(20):3463-70.1. Yoshino T, et al. Lancet Oncol. 2012 Oct;13(10):993-1001.1. Foster P, et al. Mol Cancer Ther. 2015, 14(4), 931-940.

1. Chan DA, et al. Sci Transl Med. 2011 Aug 3;3(94):94ra70.1. Zhao G, et al. Mol Cancer Ther. 2011, 10(11), 2200-2210.1. Fridman JS, et al. J Immunol, 2010, 184(9), 5298-5307.1. Cazorla M, et al. J Clin Invest. 2011, 121(5), 1846-1857.1. Fletcher GC, et al, Mol Cancer Ther, 2011, 10(1), 126-137.1. Maira SM, et al. Curr Top Microbiol Immunol, 2010, 347, 209-239.1. Vassilev LT, et al. Proc Natl Acad Sci U S A. 2006, 103(28), 10660-10665.1. Liu F, et al. J Med Chem. 2011, 54(17), 6139-6150.1. Cheng D, et al. J Biol Chem. 2004, 279(23), 23892-23899.1. Carboni JM, et al. Mol Cancer Ther, 2009, 8(12), 3341-3349.1. Najafov A, et al. Biochem J, 2011, 433(2), 357-369.1. Hagel M, et al. Cancer Discov. 2015 Apr;5(4):424-37.1. Stein EM, et al. ASH Annual Meeting. Abstract 115. Presented December 7, 1. Carboni S, et al. Br J Pharmacol. 2008 Jan;153(1):157-163.1. Shiotsu Y, et al. Blood, 2009, 114(8), 1607-17.1. Clegg NJ, et al. Cancer Res, 2012, 72(6), 1494-1503.1. Heo SK, et al. PLoS One. 2015 Jun 12;10(6):e0129853.1. Torrance CJ, et al. Nat Med, 2000, 6(9), 1024-1028.1. Schwab CL, et al. Gynecol Oncol. 2014 Oct;135(1):142-8.1. Ryu S, et al. Biol Pharm Bull. 2013;36(3):467-74.1. Gu J, et al. J Clin Pharmacol. 2010, 50(4), 401-414.2. von Lueder TG, et al. Circ

1. Structural Genomics Consortium.1. Han S, et al. J Biol Chem. 2009, 284(19), 13193-13201.1.Tardif K D. et al. Molecular cancer therapeutics, 2011, 10(12): 2267-2275.1. Naujok O, et al. BMC Res Notes. 2014 Apr 29;7:273. 2. Besing RC, et al. J Biol Rhythms. 1. Wang Y, et al. Curr Opin Investig Drugs. 2010 Dec;11(12):1466-76. 2. Proia DA, et al. 1. Yun SM, et al. Cancer Lett. 2013 May 1;331(2):250-61.1. Tan F, et al. Lung Cancer. 2012 May;76(2):177-82.1. Fiskus W, et al. Leukemia. 2014, 28(11), 2155-2164.1. Prim N, et al. Rev Pneumol Clin. 2014 Oct;70(5):279-85.1. Labenski M. 17th North Am Meet Int Soc Study Xenobiot (ISSX) 2011. Abst. P211.1. Davies SP, et al. Biochem J, 2000, 351(Pt 1), 95-105.2. Nemoto S, et al. J Biol 1. Kirschner AN, et al. J Natl Cancer Inst. 2014 Dec 13;107(2) 2. Keeton EK, et al.1. Tang JY, et al. Semin Cutan Med Surg. 2011, 30(4 Suppl), S14-18.2. Zaidi AH, et al. Cancer 1. Knight ZA, et al. Cell. 2006, 125(4), 733-747.2. Bobrovnikova-Marjon E, et al. Mol Cell 1. King AJ, et al. Cancer Res, 2006, 66(23), 11100-11105.2. Takle AK, et al. Bioorg 1. Minami J, et al. Leukemia. 2014, 28(3), 680-689.1. Buchanan SG, et al. Mol Cancer Ther, 2009, 8(12), 3181-3190.1. Polverino A, et al. Cancer Res, 2006, 66(17), 8715-8721.1. Polverino A, et al.Cancer Res, 2006, 66(17), 8715-8721.1. Zheng Z, et al. Mol Pharmacol. 2011, 80(4), 657-664.1. Lundgren, et al. Molecular Cancer Therapeutics (2009), 8(4), 921-929.2. 1. Shin HR, et al. Oncol Lett. 2013 Dec;6(6):1804-1810.2. Baker AF, et al.J Lab 1. Petrangolini G, et al. Biochem Pharmacol. 2006 Aug 14;72(4):405-14. 2. Caccia D, et al. 1. Zhang J, et al. Cell Cycle. 2014;13(19):3143-9.1. Chae YJ, et al. Eur J Pharmacol. 2015 Apr 5;752:1-7.2. Wu X, et al. Breast Cancer Res. 1. Willette RN, et al. J Pharmacol Exp Ther. 2009 Sep;330(3):964-70.2. Ostenfeld T, et al. 1. Jo H, et al. Proc Natl Acad Sci U S A. 2012, 109(26), 10581-10586.2. So EY, et al. 1. Willems E, et al. Cell Stem Cell. 2012 Aug 3;11(2):242-252.1. Lin WH, et al. Br J Cancer. 2012 Jan 31;106(3):475-81.

N/A

1. Rogosnitzky, MR, et al. Anticancer Res, 2012. 32(7): p. 2471-8.2. Swiderski, K, et al. 1. Issemann I, et al. Nature. 1990, 347(6294), 645-650.2. Staels B, et al. Nature. 1. Sharp SY, et al. Mol Cancer Ther. 2007, 6(4), 1198-1211.1. Yan C, et al. Nature. 2014 Nov 20; 515(7527): 443-447.1. Pavlik CM, et al. J Nat Prod. 2013, 76(11), 2026-2033.

1. Pettit RS, Fellner C. P T. 2014 Jul;39(7):500-11.2. Veit G, et al. Sci Transl 1. Imbimbo BP, et al. J Pharmacol Exp Ther. 2007 Dec;323(3):822-30. 2. Ronsisvalle N, et 1. Schmole AC, et al. Bioorg Med Chem. 2010 Sep 15;18(18):6785-95.1. Collino M, et al. Kidney Int, 2005, 68(2), 529-536.2. Seargent JM, et al. Br J 1. Siddiqui-Jain A, et al. Cancer Res, 2010, 70(24), 10288-10298.2. Pierre F, et al. J Med 1. Sharp SY, et al. Mol Cancer Ther. 2007, 6(4), 1198-1211.1. Jackson JR, et al. AACR, 2006, Abst 0906.2. Sakowicz R, et al. Cancer Res, 2004, 1. Cheney IW, et al. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1679-83.1.Wang Y, et al. ACS Chem Biol. 2012,15;7(6):1040-8.2. Kumar P, et al. Mol 1. Camps M, et al. Nat Med, 2005, 11(9), 936-943.2. Kim JI, et al. Nat Neurosci, 2011, 14(11), 1. Gu H, et al. Cell Immunol. 2014 Jul;290(1) :138-44. 2. Yoshida H, et al. 1. Deng X, et al. Nat Chem Biol. 2011, 7(4), 203-205.2. Yao C, et al. Hum Mol Genet. 2013, 1. Discafani CM, et al. Biochem Pharmacol. 1999 Apr 15;57(8):917-25.2. Sweeney WE, et 1. Kojima K, et al. Mol Cancer Ther. 2010, 9(9), 2545-2557.2. Yuan Y, et al. J 1. Proffitt KD, et al. Cancer Res. 2013 Jan 15;73(2):502-7.1. Sehdev V, et al. Mol Cancer Ther, 2012, 11(3), 763-774.1. Reith AD, et al. Bioorg Med Chem Lett. 2012, 22(17), 5625-5629.2. Saez-Atienzar 1. Emami KH, et al, Proc Natl Acad Sci USA, 2004, 101(34), 12682-12687.2. Teo JL, 1. Battmann T, et al. J Steroid Biochem Mol Biol. 1994 Jan;48(1):55-60.2. Münster U, et al. 1. Maira SM, et al. Mol Cancer Ther, 2008, 7(7), 1851-1863.2. Roper J, et al. PLoS 1. Angell RM, et al. Bioorg Med Chem Lett. 2007, 17(5), 1296-1301.2. Rudolf E, et al. 1. Akwabi-Ameyaw A et al., Bioorg Med Chem Lett, 2008, 18(15), 4339-4343. 2. Maloney 1. Noguchi M, et al.J Vet Med Sci. 2013; 75(3):343-8.

N/A

1. Cao BY, et al. J Ethnopharmacol, 2010. 131(1): p. 122-9.1. Brune K, Neubert A. Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S51-7. 1. Imming P, et al. Nat Rev Drug Discov. 2006, 5(10):821-34.1. Rao PN, et al. Steroids. 2002, 67(13-14), 1079-1089.1. Helson L. Int J Oncol. 1993 Feb;2(2):297-9.1. Yang GW, et al. Int J Mol Sci. 2015 Oct 12;16(10):24011-31.1. Zhao XY, et al. Chin Med J (Engl). 2012 Mar;125(6):1068-75.1. Blasco M, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 May 1. Voynikov Y, et al. Bioorg Med Chem Lett. 2014 Jul 15; 24(14):3043-5. 1. Kozoni V, et al. Carcinogenesis. 2000 May;21(5):999-1005.1. Sahasranaman S, et al. Eur J Clin Pharmacol, 2008, 64(8), 753-767.1. Gupte SA, et al. J Pharmacol Exp Ther, 2002, 301(1), 299-305.1. Bégouin JM, Gosmini C. J Org Chem. 2009 Apr 17;74(8):3221-4.1. Qiu D, et al. J Biol Chem, 1999, 274(19), 13443-13450.1. Vyomesh Patel, et al. Cancer Res, 2002, 62(5), 1401-14091. Lin JK, et al. J Cell Biochem Suppl, 1997, 28-29, 39-48.1. Navarro-Nunez L, et al. Fitoterapia, 2010, 81(2):75-80.1. Zhou L, et al. J Mol Biol, 2002, 321(4), 591-599.1. Lynch RA, et al. Cancer Res. 2007 Feb 1;67(3):1254-61.1. Ding S, et al, Pro Natl Acad Sci U S A, 2003, 100(13), 7632-7637.1. Klinger M, et al. Biochem J. 2001 May 1;355(Pt 3):827-33.

1. Stéphane Supiot, et al. Molecular Cancer Therapeutics (2008), 7(4), 993-999.1. Jung M, et al. J Med Chem. 1999, 42(22), 4669-4679.1. Verstovsek S, et al. Clin Cancer Res, 2008, (3), 788-796.1. Yue Xu, et al. PNAS, May 4, 2010 vol. 107 no. 18 8129-81341. Tsubuki S, et al. J Biochem, 1996, 119(3), 572-576.1. Papa FR, et al. Science. 2003 Nov 28;302(5650):1533-7.1. Wakeling AE, et al. Cancer Res, 1991, 51(15), 3867-3873.

N/A

1. Shor B, et al. Cancer Res, 2008, 68(8), 2934-2943.1. Flanagan WM, et al. Nature, 1991, 352(6338), 803-807.

1. Yamaguchi T, et al. Int J Oncol, 2011, 39(1), 23-31.1. Garcia Soriano F, et al. Nat Med, 2001, 7(1), 108-113.1. Melisi D, et al. Mol Cancer Ther, 2008, 7(4), 829-840.1. Kupperman E, et al. Cancer Res, 2010, 70(5), 1970-801. Dawson MA, et al. Nature, 2011, 478(7370), 529-533.1. Souers AJ, et al. Nat Med, 2013, 19(2), 202-208.1. Kishore N, et al. J Biol Chem, 2003, 278(35), 32861-32871.1. Traxler P, et al. Cancer Res, 2004, 64(14), 4931-4941.1. DeNardo DG, et al. Cancer Discov. 2011, 1(1), 54-67.1. Massey AJ, et al. Mol Cancer Ther, 2010, 9(4), 906-919.1. Iwasa, et al. Clinical Cancer Research (2008), 14(20), 6496-65041. Filippakopoulos P, et al. Nature, 2010, 468(7327), 1067-1073.1. Uhl M, et al. Cancer Res. 2004, 64(21), 7954-7961.1. Yin D, et al. J Pharmacol Exp Ther. 2003, 304(3), 1334-1340.1. Mitsiades CS, et al. Cancer Cell, 2004, 5(3), 221-230.1. Shen W, et al. J Am Chem Soc. 2013, 135(5), 1669-1672.1. Albert JM, et al, Clin Cancer Res, 2007, 13(10), 3033-3042. 1. Lad L, et al. Biochemistry, 2008, 47(11), 3576-3585.1. Tse C, et al. Cancer Res. 2008, 68(9), 3421-3428.1. Drygin D, et al, Cancer Res, 2011, 71(4), 1418-1430.1. Konopleva M, et al. Cancer Cell, 2006, 10(5), 375-388.1. Tojo M, et al. Cancer Sci. 2005 Nov;96(11):791-800.1. Carpinelli P, et al. Mol Cancer Ther, 2007, 12 Pt 1, 3158-3168.1. Burns CJ, et al. Mol Cancer Ther, 2009, 8(11), 3036-3045.1. Gable KL, et al. Mol Cancer Ther, 2006, 5(4), 1079-1086.

1. Toledo LI, et al. Nat Struct Mol Biol, 2011, 18(6), 721-727.1. Ali K, et al. Nature. 2014 Jun 19;509(7505):407-11.1. Cho YS, et al. J Med Chem. 2010 Nov 25;53(22):7938-57.1. Deng C, et al. Clin Cancer Res. 2015, 21(1):134-145.1. Weisberg E, et al. Leukemia, 2010, 24(12), 2100-2109.1. McCabe MT, et al. Nature. 2012, 492(7427), 108-112.1. Qian C, et al. Clin Cancer Res. 2012 Aug 1;18(15):4104-13.1. Hirai H, et al. Mol Cancer Ther, 2009, 8(11), 2992-3000.1. Wang X, et al. J Med Chem. 2012 Sep 13;55(17): 7332-41.1. Macauley D, et al. Drugs Fut, 2012, 37(6), 451.1. Rowbottom MW, et al. J Med Chem, 2012, 55(3), 1082-1105.1. Bai X, et al. Cancer Lett. 2014, 355(2), 281-287.1. Zarrinkar PP, et al. Blood, 2009, 114(14), 2984-2992.1. Fong TA, et al. Cancer Res, 1999, 59(1), 99-106.1. Gazit A, et al. J Med Chem, 1989, 32(10), 2344-2352.1. Gray NS, et al. Science. 1998, 281(5376), 533-538.1. MULTIPLEXED KINASE INHIBITOR BEADS AND USES THEREOF. Patent 1. Shen W, et al. J Am Chem Soc. 2013, 135(5), 1669-1672.1. Kwon Y, et al. Oncogene. 2015 Jan 8;34(2):144-53.1. Liu F, et al. J Pharmacol Exp Ther, 2008, 327(3), 827-839.1. Li WW, et al. J Med Chem. 2012 Apr 26;55(8):3852-66.1. Henderson JL, et al. J Med Chem. 2014 Nov 17.1. Li HY, et al. J Med Chem, 2006, 49(6), 2138-2142.1. Levitzki A, et al. Science, 1995, 267(5205), 1782-1788.1. Overgaard J, et al. RadiOthers Oncol, 1998. 46(2): p. 135-46.1. Sudbeck EA, et al. Clin Cancer Res. 1999 Jun;5(6): 1569-82.1. Fry DW, et al. Science. 1994, 265(5175), 1093-1095.1. Li W, et al. Proc Natl Acad Sci U S A, 2012, 109(51), 20853-20858.1. Wood KW, et al. Proc Natl Acad Sci U S A, 2010, 107(13), 5839-5844.

1. Brueckner B, et al, Cancer Res, 2005, 65(14), 6305-6311.1. Fry DW, et al. Science. 1994, 265(5175), 1093-1095.1. Arienti KL, et al. J Med Chem. 2005 Mar 24; 48(6): 1873-85.1. An R, et al. Pharm Res. 2009 Feb;26(2):449-58.1. Liskova B, et al. Chem Res Toxicol. 2012 Feb 20;25(2):500-9. 1. ray NS, et al. Science. 1998 Jul 24;281(5376):533-8.1. Liu L, et al. Biochem Biophys Res Commun. 2010 Feb 5;392(2):190-5.1. Mai A, et al. J Med Chem, 2005, 48(9), 3344-3353.1. Liu F, et al. J Pharmacol Exp Ther, 2008, 327(3), 827-839.1. Li W, et al. Proc Natl Acad Sci U S A, 2012, 109(51), 20853-20858.1. Wada Y, et al. PLoS One. 2012;7(4):e35069.1. Kupperman E, et al. Cancer Res, 2010, 70(5), 1970-80.1. Lam IP, et al. Am J Physiol Gastrointest Liver Physiol. 2009 Jul;297(1): G90-7.1. Gonzales AJ, et al. J Vet Pharmacol Ther. 2014 Aug;37(4):317-24.1. Patel RA, et al. Cancer Res. 2012 Oct 1;72(19): 5025-34.1. Brown S, et al. J Am Chem Soc. 2000, 122 (28), 6799–6800.1. Ohmi M, et al. Bioorg Med Chem Lett. 2014 Dec 1;24(23):5364-8.1. Li X, et al. Cell Stem Cell. 2015 Aug 6;17(2): 195-203.1. Slack-Davis JK, et al. J Biol Chem, 2007, 282(20), 14845-14852.1. Swaney JS,et al. Journal of Pharmacology and Experimental 1. Ndubaku CO, et al. J Med Chem. 2013 Jun 13; 56(11): 4597-610.1. Watson M, et al. Mol Cell Biol. 2009 Nov;29(21):5872-88.1. Kang Y, et al. J Natl Cancer Inst. 2013, 105(19), 1485-1495.1. Wernig G, et al. Cancer Cell, 2008, 13(4), 311-320.1. Folkes AJ, et al. J Med Chem, 2008, 51(18), 5522-5532.1. Whiteman KR, et al. MAbs. 2014 Mar-Apr;6(2): 556-66. 1. Whittles CE, et al. Microcirculation, 2002, 9(6), 513-522.1. Wainberg ZA, et al. Mol Cancer Ther. 2013 Apr;12(4):509-19. 1. Vito Palombella, Targeting PI3K- δ and PI3K-γ in Inflammation, 2012.

N/A

1. Changelian PS, et al. Blood. 2008 Feb 15;111(4):2155-7.1. O'Donoghue ML, et al. J Thromb Thrombolysis. 2012 Jul;34(1):36-43. 1. Kozikowski AP, et al. J Med Chem. 2008 Aug 14;51(15):4370-3.1. Wang JL, et al. Proc Natl Acad Sci, 2000, 97(13), 7124-7129.1. Zimmermann AG, et al. Prog Nucleic Acid Res Mol Biol. 1998;61:181-209.1. Yu PB, et al. Nat Chem Biol. 2008, 4(1), 33-41.1. Xu D, et al. J Pharmacol Exp Ther, 2012, 341(1), 90-103.1. Guagnano V, et al. J Med Chem. 2011, 54(20), 7066-7083.1. Hope HR, et al, J Pharmacol Exp Ther, 2009, 331(3), 882-895.1. Demont EH, et al. ACS Med Chem Lett. 5(11):1190-1195.1. Demont EH, et al. ACS Med Chem Lett. 5(11):1190-1195.1. Pelletier JC, et al. J Med Chem. 2009 Nov 26;52(22):6962-5.

1. Butler KV, et al. J Am Chem Soc, 2010, 132(31), 10842-10846.1. De Rybel B, et al. Chem Biol. 2009, 16(6), 594-604.1. Liu X, et al, Clin Cancer Res, 2011, 17(227). 7127-7138.1. Sadao Kuromitsu, et al. AACR 102nd Annual Meeting, 2011.1. Sylvie M. Guichard, et al. Cancer Research: April 15, 2012; Volume 72, Issue 8, 1. Xavier Jacq, et al. Cancer Res 2012;72(8 Suppl):Abstract nr 1823.1. Sisask G, et al. Bone, 2013, 54(1), 126-132.1. White JR, et al. J Biol Chem. 1998, 273(17), 10095-10098.1. Shelton JG, et al. Leukemia. 2003 Sep;17(9):1765-82.1. Cheng Y, et al, Cancer Res, 2011, 71(7), 2654-2663.1. Tanjoni I, et al. Cancer Biol Ther. 2010, 9(10), 764-777.1. Bergamini G, et al. Nat Chem Biol, 2012, 8(6), 576-582.1. Gavine PR, et al. Cancer Res, 2012, 72(8), 2045-2056.1. Ali S, et al. Cancer Res. 2009 Aug 1;69(15): 6208-15.1. Estrada AA, et al. J Med Chem. 2012, 55(22), 9416-9433.1. Mohedas AH, et al. J Med Chem. 2014 Oct 9; 57(19): 7900-15.

1. Engers DW, et al. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.1. Engers DW, et al. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.1. Shearer BG, et al. J Med Chem, 2010, 53(4), 1857-1861.1.Zhang Chao, et al.. From PCT Int. Appl. (2012), WO 2012158957 A2 1. Shao S, et al. Int J Oncol. 2014 May;44(5):1661-1668.1. Sakamoto H, et al. Cancer Cell. 2011, 19(5), 679-690.1. Lee YC, et al. Cancer Res, 2011, 71(15), 5194-5203.1. Pierce JW, et al. J Biol Chem. 1997, 272(34), 21096-21103.1. D'Arcy P, et al. Nat Med. 2011 Nov 6;17(12):1636-40.1. Kasparkova J, et al. FEBS J. 2014, doi: 10.1111/febs.12711.1. Van Rompaey L, et al. J Immunol. 2013, 191(7), 3568-3577.1. Fendrich V, et al. Ann Surg, 2011, 254(5), 818-23.1. Zhang C, et al. Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5689-94.1. Cartier AE, et al. PLoS One, 2012, 7(4), e34713.1. Li T, et al. Life Sci. 2015 Jan 15;121:88-96. 1. Dejan Juric, et al. 2012, AACR 103rd Annual Meeting. Abst CT-01.1. Lain S, et al. Cancer Cell, 2008, 13(5), 454-463.1. Liu TJ, et al. Mol Cancer Ther, 2007, 6(4), 1357-1367.1. Tseng AS, et al. Chem Biol, 2006, 13(9), 957-963.1. Sutherlin DP, et al. J Med Chem, 2011, 54(21), 7579-7587.1. Sanvitale CE, et al. PLoS One. 2013, 8(4), e62721.1. Wei Fu, et al. Molecular Cancer Therapeutics (2011), 10(6), 1018-1027.1. Spencer A, et al. Blood. 2014 Jul 29. pii: blood-2014-03-559963.1. Choi YJ, et al. PLoS One. 2012, 7(8), e43418.1. Nicodeme E, et al. Nature, 2010, 468(7327), 1119-1123.1. Knutson SK, et al. Nat Chem Biol, 2012, 8(11), 890-896.1. Datta J, et al. Cancer Res. 2009, 69(10), 4277-4285.1. Sylvie Laquerre, et al. 2009, EORTC International Conference. Abst B88.1. Melisi D, et al. Expert Opin Ther Targets, 2007, 11(2), 133-144.

1. Muraki M, et al. J Biol Chem. 2004, 279(23), 24246-24254.1. Mohedas AH, et al. ACS Chem Biol. 2013;8(6):1291-302.1. Patel RA, et al. Cancer Res, 2012, 72(19), 5025-5034.1. Shah A, Mangaonkar A. Ann PharmacOthers. 2015 Jul 16. 1. Lannutti BJ, et al. Blood, 2011, 117(2), 591-594.1. Dockendorff C, et al. ACS Med Chem Lett, 2012, 3(3), 232-237.1. Remacle AG, et al. Cancer Res. 2012 May 1;72(9):2339-49.1. Novotny-Diermayr V, et al. Mol Cancer Ther, 2010, 9(3), 642-652.1. Methot JL, et al. Bioorg Med Chem Lett, 2008, 18(3), 973-978.1. Zhang Q, et al. EMBO Mol Med. 2012 Apr; 4(4): 298-312.1. Carter YM, et al. Cancer Biol Ther. 2014, 15(5).1. Miller S, et al. Autophagy. 2010, 6(6), 805-807. 1. Dregalla RC, et al. Aging, 2010, 2(10), 691-708.1. Lee JW, et al. Angew Chem Int Ed Engl. 2011 Nov 4;50(45):10608-11.1. Shima F, et al. Enzymes. 2013;34 Pt. B:1-23. 1. Ma L, et al. Cell Death Dis. 2014 Oct 23;5:e1483. 1. Manzano VM, et al. J Pharmacol Exp Ther, 1999, 289(1), 123-132.1. Wallace JL, et al. Br J Pharmacol. 2010 Mar;159(6):1236-46.1. Altun M, et al. Chem Biol, 2011, 18(11), 1401-1412.1. Knight SD, et al. ACS Med. Chem. Lett. 2010, 1 (1), 39–43.1. Chresta CM, et al. Cancer Res, 2010, 70(1), 288-298.1. Lobera M, et al. Nat Chem Biol. 2013, 9(5), 319-325.1. Friesland A, et al. Proc Natl Acad Sci U S A. 2013, 110(4), 1261-1266.1. Zhang G, et al. J Med Chem. 2013 Nov 27;56(22):9251-64.1. Savickiene J, et al. Anticancer Drugs. 2014 Sep;25(8):938-49. 1. Hall-Jackson CA, et al. Chem Biol, 1999, 6(8), 559-568.1. Pardanani A, et al. Leukemia, 2009, 23(8), 1441-1445.1. Han W, et al. Apoptosis. 2009 May;14(5):674-86.1. Berger DM, et al. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6519-23.

1. Christopher J. Walker,et al. Blood. 2013 Oct 24; 122(17): 3034–3044.1. Zhao P, et al. Eur J Med Chem. 2014 Oct 30;86:165-74. 1. Hsieh AC, et al. Nature. 2012, 485(7396), 55-61.1. Feldman RI, et al. J Biol Chem. 2005, 280(20), 19867-19874.1. Plé PA, et al. Bioorg Med Chem Lett. 2012 Jan 1;22(1):262-6.1. Burger JA1, Buggy JJ. Leuk Lymphoma. 2013 Nov;54(11):2385-91.1. Mustapha Haddach, et al. ACS Med. Chem. Lett., 2012, 3 (2), pp 135-139 1. Feldman RI, et al. J Biol Chem. 2005, 280(20), 19867-19874.1. Quintas-Cardama A, et al. Blood, 2010, 115(15), 3109-3117.1. Golub AG, et al. Eur J Med Chem. 2011 Mar;46(3): 870-6.1. Burger MT, et al. ACS Med Chem Lett, 2011, 2 (10), 774–779.1. Garcia-Echeverria C, et al. Oncogene, 2008, 27(41), 5511-5526.1. D'Alise AM, et al. Mol Cancer Ther. 2008, 7(5), 1140-1149.1. Won J, et al. Nat Chem Biol, 2006, 2(7), 369-374.1. Bergman JA, et al. J Med Chem. 2012, 55(22), 9891-9899.1. Lain S, et al. Cancer Cell, 2008, 13(5), 454-463.1. Adrián FJ, et al. Nat Chem Biol, 2006, 2(2), 95-1021. Stosic-Grujicic S, et al. J Pharmacol Exp Ther. 2007, 320(3), 1038-1049.1. Harris KC, et al. Hear Res. 2005 Oct;208(1-2):14-25.1. Martin MW, et al. J Med Chem. 2006 Aug 10;49(16): 4981-91.1. Faghihi F, Biomed PharmacOthers, 2012, 3322(12).1. Waaler J, et al. Cancer Res. 2012 Jun 1;72(11):2822-32.1. AACR Meeting, Poster 491, 2013.1. Zhang J, et al. Nature. 2010 Jan 28;463(7280):501-6.1. Flaveny CA, et al. Cancer Cell. 2015 Jun 24. pii: S1535-6108(15)00183-X.1. Gellibert F, et al. J Med Chem. 2006, 49(7), 2210-2221.1. Ma T, et al. Biochem Biophys Res Commun. 2012, 417(3), 931-937.1. You WK, et al. Cancer Res, 2011, 71(14), 4758-4768.1. Kortuem KM, Stewart AK. Blood. 2013 Feb 7;121(6):893-7.

1. Wilhelm SM, et al. Int J Cancer, 2011, 129(1), 245-255.1. Marsilje TH, et al. J Med Chem. 2013, Jun 6.1. Pellicciari R, et al. J Med Chem. 2002, 45(17), 3569-3572.1. Knutson SK, et al. Proc Natl Acad Sci U S A. 2013, 110(19), 7922-7927.1. Fry DW, et al. Mol Cancer Ther, 2004, 3(11), 1427-1438.1. Zhu Y, et al. Tumour Biol. 2012 Apr 11. Doi: 10.1007/s13277-012-0383-6.1. Quinet EM, et al. J Lipid Res. 2009 Dec;50(12):2358-70.1. Ye Z, et al. Neurochem Res. 2012 Feb;37(2):321-9.1. Chen JK, et al. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14071-6.1. Squires MS, et al. Mol Cancer Ther, 2009, 8(2), 324-332.1. Hilberg F, et al. Cancer Res, 2008, 68(12), 4774-4782.1. Nishimura Y, et al. J Invest Dermatol. 2012, 132(3 Pt 1), 711-720.1. D Li, et al. Oncogene (2008) 27, 4702-47111. Nguyen JT, et al. Proc Natl Acad Sci U S A, 2003, 100(13), 7533-7538.1. Estrada AA , et al. J Med Chem. 2014, 57(3), 921-936.1. Dolma S, et al. Cancer Cell. 2003, 3(3), 285-296.1.Ferdinand V. Lali, et al. J Biol Chem, 2000, 275(10), 7395-402.1. Grygielko ET, et al. J Pharmacol Exp Ther, 2005, 313(3), 943-951.1. Malvaez M, et al. PNAS, 2013, 110(7), 2647-2652.1. Fry DW, et al. Science. 1994, 265(5175), 1093-1095.1. Chung S, et al. Oncotarget, 2012, 3(12), 1629-1640.1. Meany HJ, et al. Pediatr Blood Cancer. 2010, 54(1), 47-54.1. Liang Q, et al. Nat Chem Biol. 2014 , 10(4), 298-304.1. Brail LH, et al. J Clin Oncol, 2011, 29, abstr 3030.1. Antczak C, et al. J Biomol Screen, 2012, 17(7), 885-899.1. Beckers T, et al. Cancer Res. 2002 Jun 1;62(11):3113-9.1. Georgievska B, et al. J Neurochem, 2013, 125(3), 446-456.1. Zhan W, et al. J Med Chem, 2007, 50(23), 5655-5664.1. Makena PS, et al. Environ Mol Mutagen, 2009, 50(6), 451-459.

1. Akiyama T, et al. J Biol Chem, 1987, 262(12), 5592-5595.1. Pinto DJ, et al. J Med Chem. 2007, 50(22), 5339-5356.1.Callahan JF, et al. J Med Chem, 2002, 45(5), 999-1001.1. Uehata M, et al. Nature, 1997, 389(6654), 990-994.1. Choi JH, et al. J Stroke Cerebrovasc Dis. 2014 Mar;23(3):e215-20. 1. Honeywell RJ, et al. Int J Biochem Cell Biol. 2015 Mar;60:73-81. 1. Gamache DA, et al. Inflammation, 2000, 24(4), 357-370.1. Jang SW, et al. Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2687-92. 1. Goldwirt L, et al. J Pharm Biomed Anal. 2012 Jul;66:325-33.1. Overington JP, et al. Nat Rev Drug Discov. 2006 Dec;5(12):993-6.1. Blackwell LF, et al. Hum Reprod. 2013 Dec;28(12):3306-15. 1. Hirota K, et al. Acta Anaesthesiol Scand. 2002 Mar;46(3):297-302. 1. Hu S, et al. J Pharmacol Exp Ther. 2000 May;293(2):444-52. 1. Gigant B, et al. Nature, 2005, 435(7041), 519-522.1. Zou HY, et al. Cancer Res. 2007, 67(9), 4408-4417.1. Reiter RJ, et al. J Biomed Sci, 2000, 7(6), 444-458.1. Wedge SR, et al. Cancer Res. 2002, 62(16), 4645-4655.1. Ralat LA, Colman RF. Biochemistry. 2006 Oct 17;45(41):12491-9. 1. Schmid-Wendtner MH, Korting HC. Skin Pharmacol Physiol. 2004 Sep-1. Stevens BR, et al. Comp Biochem Physiol C, 1988, 91(2), 493-497.1. Scott GM, et al. J Gen Virol. 2005 Aug;86(Pt 8):2141-51.1. Muller GW, et al. Bioorg Med Chem Lett, 1999, 9(11), 1625-1630.1. Wise R, et al. Antimicrob Agents ChemOthers, 1983, 23(4), 559-564.1. Shishibori T, et al. Biochem J. 1999 Mar 15;338 ( Pt 3):583-9.1. Kasperczyk S, et al. Toxicol Appl Pharmacol. 2014 Oct 1;280(1):36-41. 1. Takenouchi T, et al. Antimicrob Agents ChemOthers. 1995 Jul;39(7):1414-8. 1. Pfützner A, et al. Vasc Health Risk Manag. 2007; 3(2):211-20.1. Niu CC, et al. Leuk Res. 2013 Nov;37(11):1532-7. 1. Rubinstein E, et al. ChemOthersapy. 2001;47 Suppl 3:3-8; discussion 44-8.

1. Bernhart CA, et al. J Med Chem, 1993, 36(22), 3371-3380.1. Webster WS, et al. J Craniofac Genet Dev Biol, 1986, 6(3), 211-222.1. Hu H, et al. Exp Mol Pathol. 2015 Apr;98(2):277-85.1. Andujar-Sanchez M, et al. FEBS Lett. 2007 Jul 24;581(18):3449-54. 1. Gribble FM, Ashcroft FM. Metabolism. 2000 Oct;49(10 Suppl 2):3-6. 1. Kramer OH, et al. EMBO J. 2003 Jul 1; 22(13): 3411-20. 1. Rassnick KM, et al. J Vet Intern Med, 1999, 13(6), 601-605.1. Kang YK, et al. Br J Cancer. 2013 Apr 2;108(6):1245-51.1. Kim JM, et al. Eur J Pharmacol. 2014 Mar 5;726:1-8.1. Palinska KA, et al. Microbiology. 2000 Dec;146 Pt 12:3099-107.1. Kirsch LE, et al. J Pharm Sci, 1984, 73(7), 896-902.1. Haynes BP, et al. J Steroid Biochem Mol Biol, 2003, 87(1), 35-45.1. Wang X, et al. Cancer Res, 2006, 66(21), 10281-10286.1. Yamada M, et al. J Pharmacol Exp Ther. 1997 May;281(2):1005-12.1. Xu WS, et al. Oncogene. 2007 Aug 13; 26(37): 5541-52. 1. Mitchell JA, et al. Proc Natl Acad Sci, 1993, 90(24), 11693-11697.1. Albertini R, et al. Inflamm Res. 2007 Jun;56(6):228-9. 1. Capone ML, et al. Prostaglandins Others Lipid Mediat. 2007 Jan;82(1-4):85-94.1. Benson SC, et al. Hypertension, 2004, 43(5), 993-1002.1. Siddik ZH. Oncogene, 2003, 22(47), 7265-7279.1. Nelson EA, et al. Blood, 2008, 112(13), 5095-5102.1. Pirola L, et al. IUBMB Life, 2008, 60(5), 323-332.1. Kirchheiner J, et al. Br J Clin Pharmacol. 2003 Jan;55(1):51-61.1. Obach RS, et al. Drug Metab Dispos, 2004, 32(1), 89-97.1. Smith SI, et al. Analyst. 2010 May; 135(5):943-52.1. Wadworth AN, et al. Drugs, 1991, 41(4), 647-664.1. Bray JD, et al. J Steroid Biochem Mol Biol. 2005 Dec;97(4):328-41.1. Monahan SD, et al. Chem Biol. 2007 Sep; 14(9): 1065-77.1. Dowling RJ, et al. Biochim Biophys Acta. 2010 Mar;1804(3):433-9.

1. Del Pup L, et al. Anticancer Drugs. 2013 Nov;24(10):989-98. 1. Burrage LC, et al. Mol Genet Metab. 2014 Sep-Oct;113(1-2):131-5. 1. Mamputu JC, Renier G. J Diabetes Complications. 2002 Jul-Aug;16(4):284-93. 1. Maekawa T, et al. Int J Clin Oncol. 2007 Oct;12(5):327-40.1. de Lucio B, et al. Cancer Sci. 2005 Nov;96(11):774-83. 1. Zhang S, et al. Anticancer Drugs. 2014 Jul;25(6):614-23. 1. Nakamura Y, et al. ACS Med Chem Lett, 2012, 3(9), 754–758.1. Koike H, et al. J Hypertens Suppl. 2001 Jun;19(1):S3-14.1. Zanotto-Filho A, et al. Cancer Lett. 2015 Mar 28;358(2):220-31. 1. Fu Y, et al. Thromb Haemost, 2010, 104(6), 1235-1241.1. Shaker S, et al. Leuk Res, 2003, 27(5), 437-444.1. Arison RN, et al. Diabetes, 1967, 16(1), 51-56.1. Suzuki M, et al. Antiviral Res. 2006 Nov; 72(2):157-61. 1. Schnaider T, et al. Cell Stress Chaperones. 2000 Jan;5(1):52-61. 1. Ruiz J, et al. Int J Antimicrob Agents. 2003 Jul;22(1):73-6. 1. Sharma S, et al. Fosinopril Hemodynamics Study Group. Am J Ther. 1. Ogawa K, et al. Mutat Res. 2003 Aug 5;539(1-2):145-55. 1. Al-Rashood ST, et al. Bioorg Med Chem. 2006 Dec 15;14(24):8608-21. 1. Ceconi C, et al. Eur J Pharmacol, 2007, 577(1-3), 1-6.1. Fujimoto J, et al. Gen Pharmacol. 1995 May;26(3):507-16. 1. Corton JM, et al. Eur J Biochem, 1995, 229(2), 558-565.1. Puddefoot JR, et al. Expert Opin PharmacOthers. 2006 Dec;7(17):2413-9. 1. Renner RM, et al. Contraception. 2010 May;81(5):372-88. 1. Chávez-Piña AE, et al. Br J Pharmacol, 2008, 155(6), 857-864.1. Locci P, et al. J Interferon Cytokine Res. 2001 Nov;21(11):961-70. 1. Andujar-Sanchez M, et al. FEBS Lett. 2007 Jul 24;581(18):3449-54.1. Fierens F, et al. Eur J Pharmacol, 1999, 367(2-3), 413-422.1. Sakamoto K, et al. Am J Physiol Endocrinol Metab, 2004, 287(2), E310-1. Hu-Lowe DD, et al. Clin Cancer Res, 2008, 14(22), 7272-7283.

1. Schmitz FJ, et al. J Antimicrob ChemOthers. 1998 Apr;41(4):481-4. 1. O'Hare T, et al. Cancer Res. 2005, 65(11), 4500-4505.1. O'Hare T, et al. Cancer Res. 2005, 65(11), 4500-4505.1. Takenouchi T, et al. Antimicrob Agents ChemOthers. 1995 Jul;39(7):1414-81. Arifah AK, Lees P. J Vet Pharmacol Ther. 2002 Aug;25(4):299-309. 1. Shintani M, et al. Oncol Rep. 2010 May; 23(5):1345-50. 1. Gómez LA, et al. Eur J Pharmacol. 1988 Mar 15;147(3):459-63.1. Micevych PE, et al. Endocrinology. 2007, 148(2):782-9. 1. Cummings AJ, Martin BK. Br J Pharmacol ChemOthers. 1965 Oct;25(2):470-80.1. Ganesh M, et al. Int J Biol Macromol. 2015 Mar;74:310-7. 1. Bach MK, Brashler JR. Biochem Pharmacol. 1986 Feb 1;35(3):425-33.1. Khan S, et al. Biochem Pharmacol, 1992, 43(9), 1963-1967.1. Barry M, et al. Clin Pharmacokinet. 1997 Mar;32(3):194-209.1. Clavey V, et al. Cell Physiol Biochem. 1999;9(3):139-49. 1. Lv H, et al. Chin J Cancer Res. 2014 Dec; 26(6):692-7. 1. Clavey V, et al. Cell Physiol Biochem. 1999;9(3):139-49. 1. Perez-Vizcaino F, et al. Am J Physiol Lung Cell Mol Physiol. 2002 Oct;283(4):L839-48. 1. Noreen Y, et al. J Nat Prod, 1998, 61(1), 2-7.1. Uppuluri P, et al. Antimicrob Agents ChemOthers, 2008, 52(3), 1127-1132.1. Oades RD, et al. Behav Pharmacol. 2000 Jun;11(3-4):317-30.1. De Carli L, et al. Mutat Res, 1988, 195(2), 91-126.1. Sotaro Sadahiro, et al. Cancer ChemOthersapy and Pharmacology. 2012, 1. Scarth JP, et al. Steroids. 2010 Oct;75(10):643-52.1. Tani N, et al. Eur J Med Chem. 2012 Jan;47(1):270-7. 1. Zhang Z, et al. Neuroreport. 2015 Apr 15;26(6):367-73.1. Kiziltepe T, et al. Mol Cancer Ther. 2007 Jun;6(6):1718-27.1. Terao N, et al. Arzneimittelforschung. 1980;30(1):76-8. 1. Bergstrom JD, et al. Arch Biochem Biophys. 2000 Jan 1;373(1):231-41. 1. Orfanos CE, et al. Drugs. 1997 Mar;53(3):358-88.

1. Kay-Mugford P, et al. Am J Vet Res. 2000 Jul; 61(7): 802-10.1. Miyazaki N, Tabata Y. J Nanosci Nanotechnol. 2009 Aug; 9(8):4797-804. 1. Preissner S, et al. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43.1. Rigobello MP, et al. Free Radic Res. 2005 Jul; 39(7):687-95. 1. Casas F, et al. FEBS Lett. 2000, 478(1-2):4-8. 1. Mifflin RC, et al. Mol Pharmacol. 2004 Feb;65(2):470-8.1. Hussy P, et al. Antimicrob Agents ChemOthers. 1986 Jun;29(6):1073-8. 1. Rafii F, et al. Antimicrob Agents ChemOthers. 2005 Feb;49(2):488-92. 1. Carrillo-Munoz AJ, et al. Rev Esp Quimioter. 2006 Jun;19(2):130-9. 1. Pignatello MA, et al. Toxicol Appl Pharmacol. 1997, 142(2), 319-327.1. Ukai Y, et al. Arzneimittelforschung. 1988 Oct; 38(10):1460-5.1. Gamache DA, et al. Inflammation. 2000 Aug;24(4):357-70.1. Prakasha Gowda AS, et al. Biochemistry. 2010 Jun 15;49(23):4833-40. 1. Jordan MA, et al. Cancer Res, 1985, 45(6), 2741-2747.1. Risch HA, et al. Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1738-41. 1. Hedner T, et al. Drugs, 2004, 64(20), 2315-2343.1. Sekine K, et al. Leukemia, 1999, 13(5), 729-734.1. Daly JW, et al. Cell Mol Life Sci. 2007 Aug;64(16):2153-69.1. Gor PP, et al. Breast Cancer Res. 2010;12(3):R26.1. Abdelkrim MA, et al. Can J Physiol Pharmacol. 2013 Oct;91(10):791-6. 1. Keldsen N, et al. Gynecol Oncol. 2003 Feb;88(2):118-22.1. Jariyawat S, et al. J Pharmacol Exp Ther. 1999 Aug;290(2):672-7. 1. Greschik H, et al. J Biol Chem. 2004 Aug 6;279(32):33639-46. 1. Hocherl K, et al. Am J Physiol Renal Physiol. 2002 Aug;283(2):F294-301. 1. Grases F, et al. Circ J. 2007 Jul; 71(7):1152-6. 1. Duz M, et al. Am J Vet Res. 2015 Mar;76(3):208-15. 1. Pahan K, et al. J Clin Invest, 1997, 100(11), 2671-2679.1. Thomas D, et al. Br J Pharmacol. 2004 Jun;142(3):485-94.1. Kandul SV, et al. Fiziol Zh. 1986 Sep-Oct;32(5):579-84.

1. Batra S, et al. Cancer Chemother Pharmacol,?990, 26(4), 310-312.1. ALAN R., et al. Nature 285, 17 - 21 (01 May 1980); 1. Jage J, et al. Anaesthesist. 2008 Apr;57(4):382-90.1. Ehrich EW, et al. J Rheumatol. 1999 Nov; 26(11):2438-47.1. Perzborn E, et al. J Thromb Haemost, 2005, 3(3), 514–521.1. Ciardiello F, et al. Clin Cancer Res. 2000 May;6(5):2053-63. 1. Dinca EB, et al. J Neurosurg. 2007 Sep;107(3):610-6. 1. Caceres G, et al. Anticancer Drugs. 2003, 14(7), 569-574.1. Sonneveld E, et al. Toxicol Sci. 2005, 83(1), 136-148.1. Savorani C, et al. Leuk Lymphoma. 2015 Mar;56(3):739-47.1. Stam WB, et al. Br J Pharmacol. 1999 Jun; 127(3):661-70. 1. Lubega GW, et al. Mol Biochem Parasitol. 1993 Dec;62(2):281-92. 1. Clavey V, et al. Cell Physiol Biochem. 1999;9(3):139-49. 1. Sheets PL, et al. J Physiol. 2007 Jun 15;581(Pt 3):1019-31. 1. Hanemaaijer R, et al. J Biol Chem, 1997, 272(50), 31504-31509.1. Rainsford KD. Curr Med Res Opin. 2006 Jun;22(6):1161-70. 1. Teicher BA. Biochem Pharmacol. 2007 Oct 22;.1. Zhang YL, et al. J Nat Prod. 1992 Aug; 55(8):1100-11. 1. Lonn U, Lohn S. Cancer Res. 1987 Jan 1;47(1):26-30. 1. Naoi M, Maruyama W. Expert Rev NeurOthers. 2009 Aug;9(8):1233-50. 1. Neves MA, et al. Eur J Med Chem, 2009, 44(10), 4121-4127.1. Wiseman LR, Goa KL. Drugs Aging. 1996 Oct;9(4):292-306.1. Schmitz FJ, et al. J Antimicrob ChemOthers. 1998 Apr;41(4):481-4. 1. Brogden RN, et al. Drugs, 1997, 53(3), 511-519.1. Hansen AM, et al. Br J Pharmacol, 2005, 144(4), 551-557.1. Teh BS, et al. Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1520-9.1. Mizushina Y, et al. J Pharmacol Sci. 2003 Jul;92(3):283-90.1. Nantwi KD, et al. J Spinal Cord Med. 2003 Winter;26(4):364-71.1. Philipp S, et al. Cardiovasc Res. 2006 May 1;70(2):308-14.

1. Omran Z, et al. Bioorg Med Chem Lett. 2011 Jan 1;21(1):45-7.1. Sisson G, et al. J Bacteriol. 2000 Sep;182(18):5091-6.1. Sanbe A, et al. Br J Pharmacol. 2007 Oct;152(3):332-40. 1. Kashida Y, et al. Toxicol Sci, 2002, 69(2), 317-321.1. Sharma S, et al. J Mol Biol. 2007 Aug 23;.1. Ojima M, et al. J Pharmacol Exp Ther, 2011, 336(3), 801-808.1. Degerman E, et al. Proc Natl Acad Sci U S A, 1990, 87(2), 533-537.1. Hartley JM, et al. Clin Cancer Res. 1999 Mar;5(3):507-12.1. Manzano VM, et al. J Pharmacol Exp Ther, 1999, 289(1), 123-132.1. Takabe K, et al. J Biol Chem, 2010, 285(14), 10477-10486.1. Sanbe A, et al. Br J Pharmacol. 2007 Oct;152(3):332-40. 1. Fernández-Calotti P, et al. Int Immunopharmacol. 2006, 6(5), 715-721. Matesanz R, et al. Chem Biol. 2008 Jun;15(6):573-85. 1. Yu MC, et al. Eur J Pharmacol, 2010, 627(1-3), 269-275.1. Taavitsainen P, et al. Drug Metab Dispos, 2001, 29(3), 217-222.1. Sun W, et al. Cancer Res, 2009, 69(10), 4294-4300.1. Gachotte D, et al. Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11173-8.1. Glaser K, et al. Eur J Pharmacol. 1995 Jul 25;281(1):107-11. 1. Prescrire Int. 2013 May;22(138):122.1. Osterman DG, et al. Biochemistry. 1988 Jul 12;27(14):5204-10.1. Longley DB, et al. Nat Rev Cancer, 2003, 3(5), 330-338.1. Chen X, Facchini PJ. Plant J. 2014 Jan;77(2):173-84.1. Bani-Yaseen AD, Al-Balawi M. Phys Chem Chem Phys. 2014 Aug 7;16(29):15519-26. 1. Manetta A, et al. Gynecol Oncol, 1993, 50(1), 38-44.1. Kashiwazaki G, et al. Bioorg Med Chem. 2010 Apr 15;18(8):2887-93. 1. Gormley NA, et al. Biochemistry. 1996 Apr 16;35(15):5083-92. 1. Wang J, et al. Anticancer Drugs. 2003, 14(1), 13-19.1. Ferguson PJ, et al. Br J Pharmacol. 1999 Aug; 127(8):1777-86. 1. El-Kosasy AM, et al. Spectrochim Acta A Mol Biomol Spectrosc. 2015 Nov 5;150:430-9.

1. Dunn CJ, Goa KL. Drugs. 1999 Jun, 57(6):1005-32. 1. Nuttle LC, et al. Am J Physiol. 1999 Apr;276(4 Pt 2):H1289-94. 1. Cha, HJ, et al. PLoS Biology, 2012, Aug, 10 (8).1. Ochsenfahrt H, et al. Naunyn Schmiedebergs Arch Pharmacol, 1974, 281(2), 175-196.1. Stamatiadis D, et al. Br J Dermatol. 1988 Nov;119(5):627-32. 1. Meng A, et al. Cancer Res, 2003, 63(17), 5414-5419.1. Jain A, Rajeswari MR. J Biomol Struct Dyn. 2002 Oct;20(2):291-9.1. Emmerson AM, Jones AM. J Antimicrob ChemOthers. 2003 May;51 Suppl 1:13-20.1. Weber CK, et al. Gastroenterology. 2000 Nov;119(5):1209-18. 1. Divo AA, et al. Antimicrob Agents ChemOthers. 1988 Aug;32(8):1182-6.1. Bhat AS, et al. Eur J Pharmacol. 2007 Feb 5; 556(1-3):190-9.1. Kohler C, et al. Arzneimittelforschung. 1980;30(4A):702-7.1. Mochalkin I, et al. Biochemistry. 1999 Feb 16;38(7):1990-8.1. Alvirez-Freites EJ, et al. Antimicrob Agents ChemOthers, 2002, 46(4), 1022-1025.1. Kränke B, et al. Contact Dermatitis. 1997 Apr;36(4):212-5.1. Yang Y, Gao H. Spectrochim Acta A Mol Biomol Spectrosc. 2013 Jan 15;101:119-26. 1. White MM, et al. Mol Pharmacol, 1990, 37(5), 720-724.1. Chen F, et al. Endocrinology. 2005 Nov; 146(11):4568-76.1. Stárka L, et al. J Steroid Biochem Mol Biol. 2015 Jan;145:254-60. 1. Albertini R, et al. Inflamm Res. 2007, 56(6):228-9. 1. Tenenbaum A, et al. Cardiovasc Diabetol. 2005 Sep 16;4:14. 1. Pelligand L, et al. J Vet Pharmacol Ther. 2014 Aug;37(4):354-66. 1. Parsadaniantz SM, et al. J Neuroendocrinol. 2000 Aug; 12(8):766-73.1. Moll L, et al. Vet Parasitol, 2000 Jul 24, 91(1-2), 153-158. 1. Sasson S. Pathol Biol (Paris). 1991, 39(1):59-69. 1. Poulsen Nautrup B, et al. Dtsch Tierarztl Wochenschr. 1999 Mar;106(3):94-100.1. Schewe T. Gen Pharmacol, 2009, 26 (6): 1153–69. 1. Zalenskaya IA, et al. Am J Reprod Immunol. 2011, 65(6):569-77.1. Rouget C, et al. Biol Reprod. 2006 Jan;74(1):209-16.

1. Jeske AH. J Gt Houst Dent Soc. 1999, 71(4):39-40. 1. Watson AM, et al. Atherosclerosis. 2014 Aug;235(2):444-8.1. Zhou R, et al. Acta Pharmacol Sin. 2013 Aug; 34(8):1061-9. 1. Schaefer EC, et al. Am J Vet Res. 2009 Dec;70(12):1494-501.1. Navarro-Nunez L, et al. J Agric Food Chem, 2008, 56(9), 2970-2976.1. Adwan L, et al. J Neurochem. 2015 Apr;133(2):266-72.1. Brix AE. Toxicol Pathol. 2002 Nov-Dec;30(6):672-4.1. Blanco FJ, et al. J Rheumatol. 1999 Jun;26(6):1366-73.1. Shen S, et al. Environ Sci Pollut Res Int. 2014 Nov;21(21):12563-8.1. Kristiansen RG, et al. Am J Physiol Gastrointest Liver Physiol. 2014 Nov 1. Brune K, et al. Clin Exp Rheumatol. 2001, 19(6 Suppl 25):S51-7. 1. Epstein JB, et al. Int J Radiat Oncol Biol Phys, 1989, 16(6), 1571-1575.1. Liu XJ, et al. Asian Pac J Cancer Prev. 2014;15(6):2835-9.1. Kim M, et al. Int J Mol Med. 2015 Mar;35(3):755-62.1. Wilhelmus KR. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD002898.1. Snyder RD, Cooper CS. Photochem Photobiol. 1999 Mar;69(3):288-93.1. Preissner S, et al. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. 1. Ortiz P, et al. Acta Trop. 2014 Aug;136:10-3. 1. Ishibashi A, et al. Nihon Yakurigaku Zasshi. 1983 Nov;82(5):361-73.1. Ren X, et al. ACS Med Chem Lett, 2010, 1(9), 454-459.1. Yood MU, et al. Pharmacoepidemiol Drug Saf. 2006 Dec;15(12):852-60. 1. Ketolainen J, et al. Pharm Res. 1995 Feb;12(2):299-304.1. Andujar-Sanchez M, et al. FEBS Lett. 2007 Jul 24;581(18):3449-54.1. Acta Crystallographica Section A, 49 ( Pt 1), 10-22 (1993)1. X M He and B M Craven. Acta Crystallographica Section A, 49 ( Pt 1), 1. Hota D, et al. Methods Find Exp Clin Pharmacol. 2007 Sep;29(7):443-6.1. Yoo SH, et al. Respirology. 2001 Mar;6(1):15-21. 1. Jabeen T, et al. Acta Crystallogr D Biol Crystallogr. 2005 Dec;61(Pt 12):1579-86.1. Champness JN, et al. Proteins. 1998 Aug 15;32(3):350-61.

1. Slater EE, et al. Drugs. 1988, 36 Suppl 3, 72-82.1. Villain-Guillot P, et al. Drug Discov Today. 2007 Mar;12(5-6):200-8. 1. Eil C. Horm Metab Res. 1992 Aug;24(8):367-70. 1. Culligan K, et al. Plant Cell. 2004 May;16(5):1091-104.1. Cushman M, et al. J Med Chem. 1993 Sep 17;36(19):2817-21.1. Moon C, et al. Neurosci Lett. 2004 Feb 12; 356(2):123-6. 1. Mifflin RC, et al. Mol Pharmacol. 2004 Feb;65(2):470-8.1. NIESCHULZ O, et al. Arzneimittelforschung. 1960 Mar;10:156-65.1. Larsson R, et al. J Pharmacol Exp Ther. 1985 Nov;235(2):475-80.1. Chou CC, Vickroy TW. Am J Vet Res. 2003 Feb;64(2):216-24. 1. Tian YJ, et al. Br J Nutr. 2014 May;111(9):1594-601. 1. Oliver JM, et al. J Biol Chem, 1994, 269(47), 29697-29703.1. Mitra P, et al. Int J Pharm. 2014 Oct 1;473(1-2):636-43. 1. Matsui J, et al. Int J Cancer. 2008, 122(3), 664-671.1. Warrilow AG, et al. Antimicrob Agents ChemOthers. 2010 Oct;54(10):4235-45.1. Stichtenoth DO, et al. Med Klin (Munich). 1998 Jul 15;93(7):407-15.1. Oh CJ, et al. PLoS One. 2012;7(10):e45870. 1. Chang HC, et al. Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11173-7. 1. Yoshikawa M, et al. Int J Cancer. 2004 Jul 20;110(6):921-7. 1. Tsuruo T, et al. Cancer ChemOthers Pharmacol. 1988;21(1):71-4.1. Ustün Alkan F, et al. ScientificWorldJournal. 2012;2012:976740. 1. Rossi A1, et al. Br J Pharmacol, 2010, 161(3), 555-570.1. Ye P, et al. Horm Metab Res. 2009 Jan;41(1):35-9. 1. Sheets PL, et al. J Physiol. 2007 Jun 15;581(Pt 3):1019-31. 1. Sigthorsson G, et al. Gastroenterology. 2002 Jun; 122(7):1913-23. 1. Sekiguchi Y, et al. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2920-3. 1. Fukiya Y, et al. Biomed Res. 2014; 35(1):17-23. 1. Kamath-Rayne BD, et al. Am J Obstet Gynecol. 2015 Jan; 212(1):96.e1-7. 1. Mitchell JA, et al. Proc Natl Acad Sci U S A. 1993, 90(24), 11693-11697.

1. Cutrín Prieto C, et al. Med Clin (Barc). 1991 Jun 15; 97(3):104-6.1. Evans JM, et al. J Exp Biol. 2005 Oct; 208(Pt 19):3771-83.1. Wang Z, et al. Hepatology. 1995 Sep; 22(3):876-82. 1. Sanchez-Fidalgo S, et al. Eur J Pharmacol. 2004 Nov 28; 505(1-3):187-94. 1. Ge S, et al. Int J Pharm. 2014 Apr 25; 465(1-2):120-31.1. Ge S, et al. Int J Pharm. 2014 Apr 25; 465(1-2):120-31.1. Wei W, et al. J Asian Nat Prod Res. 2015 Apr 23:1-6. 1. Pym AS, et al. Mol Microbiol. 2001 May;40(4):879-89. 1. Stokowa K, et al. J Inorg Biochem, 2012, 106(1), 111-116.1. Lee U, et al. Xenobiotica. 2012 Mar;42(3):310-5. 1. Buggy JJ, et al. Mol Cancer Ther, 2006, 5(5), 1309-1317.1. Fenton JI, et al. Equine Vet J Suppl. 2002 Sep;(34):219-23. 1. Bergogne-Bérézin E, et al. Int J Antimicrob Agents. 1991;1(1):29-46.1. Vila J, et al. Int J Antimicrob Agents. 2006 Jul;28(1):19-24.1. Pitz AM, et al. Gut Microbes. 2015 Mar 4; 6(2):93-100. 1. Stowers JM, et al. Lancet. 1967 Jan 21;1(7482):124-7.1. Gi M, et al. Antimicrob Agents ChemOthers. 2014 Dec; 58(12):7205-14. 1. Small EJ, Ryan CJ. J Urol. 2006 Dec; 176(6 Pt 2):S66-71.1. Dukes M, et al. J Steroid Biochem Mol Biol, 1996, 58(4), 439-445.1. Squizzato A, et al. Intern Emerg Med. 2009 Dec;4(6):479-84. 1. Matthews J, et al. J Steroid Biochem Mol Biol, 2000, 74(4), 223-234.1. Wang LG, et al. Biochem Pharmacol. 1998 May 1; 55(9):1427-33.1. Sun L, et al. J Med Chem, 2003, 46(7), 1116-1119.1. Sun L, et al. J Med Chem, 2003, 46(7), 1116-1119.1. Moyer JD, et al. Cancer Res. 1997, 57(21), 4838-4848.1. Moyer JD, et al. Cancer Res. 1997, 57(21), 4838-4848.1. Brama M, et al. Mol Cell Endocrinol. 2007 Jan 29;264(1-2):102-8. 1. White TC, et al. Clin Microbiol Rev. 1998 Apr;11(2):382-402. 1. Ikonomidis I, et al. Heart. 2009 Sep;95(18):1502-7.

N/A

1. Kopp E, et al. Science, 1994, 265(5174), 956-959.1. Pfützner A, et al. Vasc Health Risk Manag. 2007; 3(2):211-20.1. Reuveni D, et al. Int J Oncol. 2010 Aug; 37(2):463-71. 1. Lunn MR, et al. Chem Biol. 2004 Nov;11(11):1489-93.1. Yee KW, et al. Clin Cancer Res. 2005 Sep 15;11(18):6615-24.1. Andrews FM, et al. Vet Ther. 2009 Fall;10(3):113-20.1. Grases F, et al. Circ J. 2007 Jul;71(7):1152-6.1. Bonate PL, et al. Nat Rev Drug Discov, 2006, 5(10), 855-863.1. Rieke CJ, et al. J Biol Chem. 1999 Jun 11; 274(24):17109-14. 1. Ju W, et al. Retrovirology. 2014 Jun 2;11:43.

1. Burch FX. Am J Med. 1985 Oct 18;79(4B):28-32.1. Jariyawat S, et al. J Pharmacol Exp Ther. 1999 Aug;290(2):672-7. 1. Raynaud JP. Am J Clin Oncol. 1988;11 Suppl 2:S132-47.1. Grossman R, et al. Ann N Y Acad Sci. 2006 Jul;1071:410-21.1. Hata AN, et al. Mol Pharmacol. 2005 Mar;67(3):640-7.1. Budihna M, et al. Pflugers Arch. 1996;431(6 Suppl 2):R217-8.1. Soriano-Hernández AD, et al. Int Urol Nephrol. 2012 Apr;44(2):471-7.1. Oruch R, et al. Eur J Pharmacol. 2014 Jun 30. pii: S0014-2999(14)00493-21. Hertel LW, et al. Cancer Res, 1990, 50(14), 4417-4422.1. Lee JK, et al. Microbiol Immunol. 2005;49(7):647-53. 1. Floridi A, et al. J Natl Cancer Inst, 1981, 66(3), 497-499.1. Nizamutdinova IT, et al. Int Immunopharmacol, 2008, 8(5), 670-678.1. Barba-Espin G, et al. Plant Physiol Biochem. 2012 Oct;59:30-6.1. Talley JJ, et al. J Med Chem. 2000 Mar 9;43(5):775-7. 1. Burnier M, et al. Circulation, 2001, 103, 904-912.1. Saad S, et al. Nephrol Dial Transplant. 2009 Apr; 24(4):1130-41.1. Zhu YX, et al. Leuk Lymphoma. 2013 Apr;54(4):683-7. 1. Endo S, Akiyama K. Nihon Rinsho. 1996 Nov;54(11):3045-8.

1. Prokkola JM, et al. Aquat Toxicol. 2015 Jan;158:116-24. 1. Gewirtz, D.A. Biochem Pharmacol, 2014. 90(3): 208-11.1. Fellous A, et al. Semin Oncol. 1989, 16(2 Suppl 4), 9-14.1. Teicher BA, et al. Clin Cancer Res. 2000 Mar;6(3):1016-23.1. Shih C, et al. Cancer Res. 1997, 57(6), 1116-1123.1. Matesanz R, et al. Chem Biol. 2008 Jun;15(6):573-85.1. Poggi JC, et al. J Clin Pharmacol. 2006 Nov;46(11):1328-36.1. Song JC, White CM. Clin Pharmacokinet. 2002;41(3):207-24. 1. Kelly O, et al. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1279-90. 1. Medina AE, et al. Proc Natl Acad Sci U S A. 2010 Jun 1; 107(22):9921-2.1. Ehrsson H, et al. Med Oncol. 2002;19(4):261-5.1. Seitz M. Curr Opin Rheumatol, 1999, 11(3), 226-232.1. Kawada T, et al. Jpn J Thorac Cardiovasc Surg. 1999 Mar;47(3):104-9.1. Zhang Y, Gordon GB. Mol Cancer Ther. 2004 Jul;3(7):885-93.1. Remsing Rix LL, et al. Leukemia. 2009 Mar;23(3):477-85. . 1. Aschele C, et al. Ann Oncol. 2002 Dec; 13(12):1882-92.1. Ballard SA, et al. Biochem Pharmacol. 1988 Dec 15;37(24):4643-51.1. Locci P, et al. J Interferon Cytokine Res. 2001 Nov;21(11):961-70. 1. Takabe K, et al. J Biol Chem, 2010, 285(14), 10477-10486.1. Gibson SJ, et al. Cell Immunol. 2002 Jul-Aug;218(1-2):74-86. 1. Berman HM, et al. Nucleic Acids Res. 2000 Jan 1; 28(1):235-42. 1. Huang H, et al. Inflammation. 2014 Feb;37(1):235-46. 1. Han MH, et al.Toxicol Lett. 2013 Jul 4;220(2):157-66. 1. Gao XJ, et al. Inflammation. 2015 Jun;38(3):1142-50. 1. Espinel-Ingroff A, et al. J Clin Microbiol, 1998, 36(1), 198-202.1. Harris PA, et al. J Med Chem. 2008, 51(15), 4632-4640.1. Leoni LM, et al. Clin Cancer Res. 2008, 14(1), 309-317.1.Wilhelm SM, et al. Cancer Res. 2004 Oct 1;64(19):7099-109.1. Wilhelm SM, et al. Cancer Res, 2004, 64(19), 7099-7109.

1. Luzardo OP, et al. Endocrinology. 2000 Sep;141(9):3377-87.1. Rusnak DW, et al. Mol Cancer Ther, 2001, 1(2), 85-94.1. Rusnak DW, et al. Mol Cancer Ther, 2001, 1(2), 85-94.1. Imming P, et al. Nat Rev Drug Discov. 2006 Oct; 5(10):821-34. 1. Botting R, Ayoub SS. Prostaglandins Leukot Essent Fatty Acids. 2005 Feb;72(2):85-7. 1. Richert L, et al. Toxicol Appl Pharmacol, 2003, 191(2), 130-146.1. Darias V, et al. Arch Pharm (Weinheim). 1992 Feb;325(2):83-7.1. Chan KH, et al. J Anal Toxicol. 2010 Jul-Aug;34(6):347-53.1. Goldsmith JR, et al. Dis Model Mech. 2013 Jan;6(1):146-59. 1. Kleinknecht D, et al. Clin Nephrol. 1986 Jun;25(6):275-81.1. Mackenzie IS, et al. Arterioscler Thromb Vasc Biol. 2005 Sep; 25(9):1891-5. 1. Brune K, Neubert A. Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S51-7.1. Babaeivelni K, et al. J Environ Sci Health A Tox Hazard Subst Environ Eng. 1. Shyu C, et al. Toxicol Appl Pharmacol. 2010 Nov 12. 1. Juriansz RL, et al. Cancer Res. 1988 Jan 1;48(1):14-8. 1. Uberall F, et al. Cancer Res, 1991, 51(3), 807-812.1. Huxtable RJ. Prog Neurobiol, 1989, 32(6), 471-533.1. Dinis TC, et al. Arch Biochem Biophys, 1994, 315(1), 161-169.1. Wojnarowska Z, et al. J Chem Phys. 2012 Apr 28;136(16):164507. 1. Shimoni E, et al. J Biol Chem. 2002 Apr 5;277(14):11866-72.1. Oka M, et al. Eur J Pharmacol. 2002 Oct 4;452(2):175-81.1. Dubinsky MC, et al. Clin Gastroenterol Hepatol. 2004 Sep;2(9):731-43. 1. Hou ZJ, et al. Oncotarget. 2015 Jan 21;6(8):6326-40.1. Kopp E, et al. Science, 1994, 265(5174), 956-959.1. Manin AN, et al. J Phys Chem B. 2014 Jun 19;118(24):6803-14. 1. Garay RP, et al. Am J Ther, 2006, 13(3), 236-247.

Documents

[XLS] · Web viewWang X, et al. J Med Chem. 2013, 56(6), 2700-2704. T2001 PF 573228 869288-64-2 C22H20F3N5O3S PF-573228 is an ATP-competitive inhibitor of FAK with IC50 of 4 nM in